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PREFACE 
 
Neurodegenerative diseases are linked to altered splicing mechanisms (Mills et 
al., 2012). Fronto temporal dementia and parkinsonism linked to chromosome 
17 (FTDP-17) is one such disease that stems from the differential splicing caused 
due to mutations in Microtubule associated protein tau (MAPT) gene (Esther et 
al., 2002). 
This PhD thesis focuses on developing RNA-based therapeutic approaches to 
address FTDP-17. 
 
CHAPTER 1 introduces a broad range of topics such as splicing mechanism, 
neurodegenerative diseases associated with splice defects, therapeutic tools to 
modulate such splice defects in the context of neurogenetic diseases and possible 
applications of available tools for FTDP-17. 
 
CHAPTER 2 explores an exon skipping strategy to modulate splice defects in the 
context of FTD-17 using small nuclear RNAs (snRNAs). 
 
CHAPTER 3 is based on a short interfering RNA (siRNA) approach to modulate 
post-transcriptional gene silencing of specific isoform associated to FTDP-17. 
 
CHAPTER 4 employs long non coding RNA (lncRNA) to mediate post 
transcriptional repression of tau protein associated to FTDP-17 and deciphers its 
auxiliary role in splicing of exon 10  
 
CHAPTER 5 elaborates on the future perspectives of all the above mentioned 
approaches to find a cure for FTDP-17. 
  
6 
 
CHAPTER 1. INTRODUCTION 
 
1.1. RNA processing and gene expression                                                                   8 
 
        1.1.1. 5’end capping                                                                                                        10 
        1.1.2. 3’end capping                                                                                                        10 
        1.1.3. Splicing                                                                                                                    11 
                   1.1.3 (i) Evolution of alternative splicing                                                      11 
                   1.1.3 (ii) Pre-mRNA splicing                                                                              16 
 
1.2. The splicing machinery                                                                                              17 
 
         1.2.1. U snRNPs                                                                                                               20 
         1.2.2. Canonical cis-acting elements in splice site selection                              22 
                    1.2.2 (i) 5’ splice site                                                                                           23 
                    1.2.2 (ii) 3’ splice site                                                                                          23 
        1.2.3. Auxilliary cis-acting sequences                                                                         25 
                   1.2.3 (i) Splicing enhancers                                                                                26 
                   1.2.3 (ii) Splicing silencers                                                                                  27 
       1.2.4. Trans-acting factors                                                                                              27 
                  1.2.4 (i) Heterogenous ribonuclear proteins (hnRNPs)                             27 
                  1.2.4 (ii) Serine-arginine rich proteins (SRs)                                                 28 
 
1.3. Impact of splice defects in neurodegeneration                                               29 
 
        1.3.1. Neurodegenerative diseases                                                                             29 
        1.3.2. Fronto temporal lobar degeneration (FTLD)                                               30 
  
7 
 
 
1.4. Fronto temporal dementia and Parkinsonism linked to chromosome 
        17 (FTDP-17)                                                                                                         33 
1.4.1. Microtubule associated protein tau (MAPT) gene                                              34 
         1.4.2. Tau protein: Localisation, Structure and Function                                    35 
         1.4.3. Tau Pathology: Causes and consequences in the context  
                     of FTDP-17                                                                                                            39 
 
1.5. Tools for manipulation of splice defects in neurodegeneration             44 
 
         1.5.1. Exon skipping approaches                                                                               44 
                    1.5.1. (i). Antisense oligonucleotides (AONs)                                             44 
                    1.5.1.(ii). Chimeric small nuclear RNAs (snRNAs)                                    44 
                                       U1 snRNAs                                                                                          45 
                                       U7 snRNAs                                                                                          48 
       1.5.2. Post -transcriptional gene silencing (PTGS)                                                 50 
                  1.5.2.(i). Small interfering RNAs (siRNAs)                                                     50 
                 1.5.2.(ii). Long non coding RNAs (lncRNAs)                                                   54 
  
8 
 
1.1. RNA processing and gene expression 
 
In 1958, Francis Crick stated that; 
"In its simplest form the sequence hypothesis assumes that the specificity of a 
piece of nucleic acid is expressed solely by the sequence of its bases, and that this 
sequence is a (simple) code for the amino acid sequence of a particular protein. 
 
According to this sequence hypothesis, which is well known as the “Central 
dogma” of molecular biology, a segment of DNA, called gene, is transcribed into 
RNA (precisely messenger-RNA, mRNA) that is then converted through a process 
called translation, into a protein (Crick F, 1970). The intermediate mRNA carries 
the essential information to form the functional protein (Fig.1). 
 
 
Fig. 1 | Schematic representation of the central dogma of life in which DNA is transcribed in to 
RNA which is translated to form proteins 
 
The steps followed by the mRNA to allow expression of its gene are a highly 
complex and regulated process. Differential gene expression is crucial for 
growth, differentiation, development and cell survival in various situations, 
including environmental stress. It is therefore very important that all these 
processes are tightly controlled to minimise cell energy, and reduce errors that 
might affect survival of the cells.  
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Transcription is the process by which a template strand of DNA is utilized by 
specific RNA polymerases to generate one of the following distinct classifications 
of RNA (Lodish et al., 2000, Cooper et al., 2003, Wita et al., 2006, Gueneau de 
Novoa, et al., 2004, Vazquez, et al., 2004, Watanabe, et al., 2008, Amarlal et al., 
2008). 
 
1. Messenger RNAs (mRNAs): A class of RNAs templates used by the translational 
machinery to determine the order of amino acids which forms the protein 
through translation.  
 
2. Transfer RNAs (tRNAs): A class of small RNAs that interacts with the mRNAs 
to allow correct insertion of amino acids into the elongating polypeptide chain. 
 
3. Ribosomal RNAs (rRNAs): A class of RNAs that cluster together with numerous 
ribosomal proteins, to form the ribosomes. Ribosomes attach to the mRNAs and 
form a catalytic domain into which the tRNAs enter with their attached amino 
acids.  
 
4. Small RNAs: A class of RNAs that includes the small nuclear RNAs (snRNAs) 
and small nucleolar RNAs involved in RNA splicing, microRNAs (miRNAs) and 
short interfering RNAs (siRNAs) involved in the modulation of gene expression. 
 
5. Long non coding RNAs (lncRNAs) involved in regulation of gene expression. 
 
How is a functional mRNA formed? The precursor mRNAs (pre-mRNAs) are 
transcribed by RNA Pol II in the nucleus and undergoes various post-
transcriptional modifications to form stable mature mRNAs. Along with that, the 
mRNAs undergo co-transcriptional events composed of: 5’-capping, 3’end-
processing, splicing and RNA editing, which lead to the formation of mature 
transcripts (Maniatis et al., 2002) (Fig.2). 
The matured mRNA transcript is then exported from the nucleus in to the 
cytoplasm where it begins to serve as a template for protein synthesis.  
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Fig. 2 | Schematic representation of RNA processing in which the primary transcript undergoes 
5’ end capping and 3’ end processing followed by polyadenylation to form the functional mRNA. 
 
1.1.1. 5’end capping 
 
The capping event is comprised of the addition of 7-methylguanosine (m7G) to 
the 5’ end of the nascent pre-mRNA. This step protects the 5’-3’ exonuclease 
mediated degradation of the pre-mRNA (Beelman et al., 1995). The 5’cap further 
mediates export from the nucleus to the cytoplasm, thus promoting translation 
of the mRNA (Gross et al., 2003). 
 
1.1.2. 3’end processing 
The 3’ end processing is a two step reaction that comprises the following sub-
steps: 
 
(i) The pre -mRNA cleavage is mediated by the binding of the enzyme cleavage 
and polyadenylation specific factor (CPSF) to the AAUAAA consensus sequence 
(Beaudoing et al., 2000) thus initiating cleavage at the 5’-CA-3’ dinucleotide 
located 10-35 bases downstream its binding site. 
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(ii) Polyadenylation at the 3’ end of the transcript which is initiated after the 
cleavage through the polymerase A enzyme that adds a polyA tail (composed of 
200-250 adenine residues). PABII (Poly A binding protein) binds to the nascent 
poly A tail and stabilizes the pre-mRNA through protection from exonuclease 
digestion (Gromak et al., 2004). 
 
1.1.3. Splicing 
 
In 1977, Nobel laureates, Dr. Richard Roberts and Dr. Phillip Sharp 
independently discovered that the genes were present in the genetic material as 
distinct and separate segments in the viral genome. They also hypothesised that 
a specific gene regulation mechanism is required for the production of proteins 
from the split genes. 
Within half a year after the description of split genes and RNA splicing in the 
context of viral genome, such similarities in containing discontinuous fragments 
of genes were observed in eukaryotic cells as well (Rabbits et al., 1978). 
The majority of eukaryotic genes contain several introns and during the process 
of RNA synthesis, both introns and exons are transcribed from the DNA template. 
Before the export of mature mRNA from the nucleus to the cytoplasm, the 
introns need to be excised from the primary transcript followed by the joining of 
flanking exons. This process is called splicing in which the intervening introns 
are removed and the coding exons are joined together to form the correct 
protein reading frame (Roca et al., 2013). 
Splicing is mediated and regulated by the different regulatory elements located 
both within the exons and introns, guiding the splicing complex and auxiliary 
RNA binding proteins (Ward AJ et al., 2010). A detailed description on pre-mRNA 
splicing is described in the following section. 
 
1.1.3 (i) Evolution of alternative splicing 
How did alternatively spliced exons evolve and enter in to genomes? Human-
mouse comparative analyses revealed that a recent creation and/or loss of an 
exon is associated with alternative splice event (Maor et al., 2003, Thanaraj et al., 
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2003, Nurtdinov et al., 2003). There are three known evolutionary mechanisms 
known to be involved in splicing (Keren et al., 2013): 
 Exon shuffling 
 Exonisation of intronic sequences 
 Transition of constitutive exon to an alternative exon. 
 
Exon shuffling 
The exon shuffling theory was proposed by Walter Gilbert in 1978 and he 
suggested the creation of a new chimeric protein as a result of shuffled exons 
provides an evolutionary advantage to the organism (Gilbert et al., 1978) 
(Fig.3). Although many studies have proved or disproved this theory, increasing 
evidences suggest a correlation between exon borders and protein domains 
(Dodlittle et al., 1995, Kolkman et al., 2001, Liu et al., 2004). Recent analysis on 
exons of human and mice suggests that newly duplicated exons tend to retain 
the splicing status of their original exons (Peng et al., 2009). The process of exon 
shuffling increases in proportion to the evolution of complex genome (Keren H 
et al., 2010). 
 
 
Fig. 3 | Schematic representation of exon shuffling in which the constitutive exons are 
represented as blue blocks, alternative exons as purple blocks and introns as solid lines. 
(Keren H et al., 2010). 
 
Exonisation  
This process involves the transition of genomic sequence to exons. It was first 
suggested as a mechanism involving acquisition of 5’ region in bovine 
thyroglobulin (TG) gene. This was further supported through many other studies 
in human and other vertebrate genomes. 
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About half of the human genome stems from the repeat forming transposable 
elements (TE) and are prone to exonisation. The random mutations in intronic 
sequences and RNA editing, both account for the creation of a true 3’ or 5’ splice 
site thus enabling spliceosome recognition and leading to exonisation of TE. This 
process has been extensively studied in special type of TE called Alu elements 
(Keren H et al., 2010). 
 
 
Transition  
In the transition process, alternative cassette exons are derived from 
constitutively spliced exons (Fig. 4). This can be accomplished through the 
following ways: 
 Accumulation of mutations in splice sites leading to exon skipping 
 Formation of a dsRNA secondary structure from 2 Alu exons in opposite 
orientations to each other thus influencing all the altered splice events in 
the downstream exon. 
Although conserved exons maintain a specific splice pattern, reconstruction of 
evolution has imposed a shift from constitutive to alternative splicing. This shift 
arises due to mutations in the splice site that blocks binding of U1 snRNA to its 
proximity. Mutations in splice site also lead to creation of new splice site signals 
that competes with the original splice site (Keren H et al., 2010). 
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Fig. 4 | Process of conversion from constitutive to alternative splicing 
A | Mutations that lead to insufficient recognition of the exon resulting in exon skipping. A.a| 
Mutations that lead to a new alternative 5′ splice site (5′ SS) or 3′ SS. A. b| Mutations that lead to 
insufficient recognition of the 5′ SS. A. c| Mutations in exons (or introns) that can disrupt an 
exonic splicing enhancer (ESE) or intronic splicing enhancer (ISE) or may create an exonic 
splicing silencer (ESS) or intronic silencing silencer (ISS).  
B | A secondary structure, usually formed between two Alu elements in opposite orientation, 
thus interrupting the exon recognition. (The resulting isoforms are represented for each 
pathway. Constitutive exons are shown in blue, alternatively spliced regions are shown in purple, 
and introns are represented as solid lines) (Keren H et al., 2010). 
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1.2.5. Alternative splicing 
Splicing is a ubiquitous process in eukaryotes and the importance of alternative 
splicing (AS) can be inferred from interrogating its prevalence throughout the 
eukaryotic evolutionary tree. The process of AS is more abundant in higher 
eukaryotes than in lower eukaryotes, and the percentage of genes and exons that 
undergo AS is higher in vertebrates than in invertebrates (Keren et al., 2010). 
There are several types of AS (Fig 5) as described by Keren et al., 2010. 
 
 
 
Fig. 5 | Types of alternative splicing events 
a. Exon skipping in which, the cassette exon is spliced out of the transcript along with its flanking 
introns.  
b. Alternative 3’ splice site and 5’ splice site selection events occur in the presence of two or more 
splice sites in the end of an exon. 
c. Intron retention involves the inclusion of an intronic region in to the mature mRNA transcript  
d. Production of an alternative transcript variant lead to the formation of mutually exclusive 
exons, alternative promoter usage or alternative polyadenylation. 
The prevalence of exon skipping gradually increases further up the eukaryotic tree, suggesting 
that exon skipping is the type of AS that majorly contributes to the phenotypic complexity. 
Alternative 5′ and 3′ splice sites are believed to be sub-families of exon skipping  
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1.1.3. (ii) Pre-mRNA splicing 
The splicing reaction involves a rapid mechanism through which the intervening 
introns or the non-coding regions are excised to attach the exons or the coding 
regions to form the correct protein reading frame (Krainer et al., 2013). 
 
Splicing occurs via two TRANSESTERIFICATION steps (Fig.6). 
 
Step 1. 
The 2′-hydroxyl group of the A residue at the branch site attacks the phosphate 
at the GU 5′-splice site. This reaction leads to the cleavage of 5’ exon from the 
intron and formation of a lariat intermediate. 
 
Step 2. 
The phosphate (p) at the 3′ end of the intron and the 3′-hydroxyl group of the 
detached exon, enables ligation of the two exons. This reaction further allows 
release of the lariat intron. 
 
 
Fig. 6 | Schematic representation of splicing in two transesterfication steps. 
a.| The pre-mRNA containing exons (orange boxes) and introns ( lines) and the splice site signals; 
A= adenine residue of branch point, (Py)n = polypyrimidine tract, Splice site signals = GU and AG. 
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b.| In the first transesterification step, an adenine residue of the branch point attacks the 
phosphodiester bond at the 5’ss of exon 1.This generates two intermediates: free exon 1 and 
lariat –exon 2.(Modified from Pagani F et al., 2004). 
c.| In the second esterfication step, the 3’ OH of the detached exon attacks the phosphate at the 
AG 3’ end of intron  
d.| Splicing results in two products; The two exons joined together through a phosphodiester 
bond and the intron in the form of a lariat 
 
1.2. The splicing machinery 
 
Splicing reaction is mediated by the spliceosome- a macro-molecular machinery 
that assembles on to the nascent pre-mRNA transcripts. It catalyses the splicing 
reaction and gets released upon completion of the process. 
 
This complex is composed of the following (Cooper A.T et al., 2009); 
 
a. Five uridine-rich (U) small nuclear ribonucleoproteins (snRNPs), each 
containing one or two snRNAs U1, U2, U4/U6 and U5)  
b. A common set of Smith (Sm) proteins 
c. Different number of complex specific protein factors including RNA binding 
factors (e.g.U2AF, SF1 and SRFs) 
d. Enzymes such as helicases/RNPases, kinases and phosphatases. 
 
The above mentioned factors help in modulation of structure and conformational 
transitions of the pre-mRNA, snRNA and protein complexes to enable splicing 
reaction, proof-reading and release of substrates (Nilsen et al., 2003; Staley et al., 
1998; Will and Luhrmann et al., 2001). 
The spliceosome is also known to interact with several (150-300) non-snRNP 
proteins, such as hnRNPs and serine–arginine (SR) rich proteins (Wahl, Will et 
al., 2009). The spliceosome assembles in a sequential manner leading to the 
assembly/disassembly of different snRNP and non-snRNP splicing factors on the 
pre-mRNA (Nilsenn TW et al., 2003). The formation of mature mRNA involves 
several interactions such as RNA-RNA base pair, RNA-protein base-pair and 
protein-protein-interactions (Malca et al., 2003). 
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The interaction between the spliceosome and the crucial motifs occurs through 
the following steps (Bonnal S et al., 2012) (Fig.7): 
 
 The first step begins with the assembly of U1snRNP to the pre-mRNA. 
This step is mediated through an RNA-RNA base pairing between the 5’ 
tail of the U1 snRNA and 5’ ss of the intron. The complex thus formed is 
termed as the “early” complex (E) which is also known as the 
commitment complex interacts with the pre-mRNA through RNA-RNA 
base pairing and RNA- protein interaction. 
 
 The branch point nucleotide A located 20-40 nucleotides upstream the 
acceptor splice site is bound by the branch point binding protein 
(BBP/SF1) (Gaur et al., 1996.,Richie et al., 2008). 
 
 The second step in the spliceosome assembly is the formation of the 
complex A in which the BBP/SF1 is replaced by the U2 snRNP at the 
branch point.  
 
 The third step involves transition from complex A to complex B in which 
the U4/U5 and U6 snRNPs are assembled to form the complex. 
 
 The complex B contains all the necessary snRNPs to promote splicing. 
However, the activation of spliceosome is mediated through intricate 
RNA-RNA interactions, which causes a conformational change and 
promotes formation of activated B* complex (Reed et al., 2000, Makarov 
et al., 2004). 
  The first step of transesterification reactions occurs in the B* complex 
generating two intermediates: 
 
 The free 5’ end of exon  
 The lariat 3’ of the exon 
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 This is followed by the formation of C complex in which the second 
esterification reaction takes place. 
 
Fig. 7 | Represented at the top is a typical precursor mRNA (pre-mRNA) with intronic 
sequences (thin line) and exonic sequences (coloured boxes), with the consensus 
sequences at the intron 5′ and 3′ ends (Y = pyrimidines, N = any nucleotide and (n) = 
undefined number of pyrimidines). The branch point adenosine is represented in bold. 
The splicing factors represented in the box assemble on the pre-mRNA in a sequential 
manner, forming the indicated complexes (E, A and B).  
Conformational rearrangements within the assembled spliceosome (complexes Bact and 
C) lead to splicing catalysis, generating a mature mRNA and releasing the intron in a 
lariat configuration. U2 small nuclear ribonucleoprotein (snRNP) binding involves base-
pairing interactions between U2 small nuclear RNA (snRNA) and nucleotides flanking 
the branch point, as well as contacts between the U2 snRNP proteins splicing factor 3B 
subunit 1 (SF3B1) and p14 and the pre-mRNA. BPRS, branch point recognition 
sequence; SF1, splicing factor 1; ss, splice site; U2AF, U2 snRNP auxiliary factor. (Bonnal 
S et al., 2012). 
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1.2.1. U snRNPs 
 
UsnRNPs 
The U snRNPs (Uridine rich small ribonucleo particles) are the constitutive 
elements of the splicing machinery and play an important role in the 
identification of the consensus signals (Will et al., 2001). They contain a small 
nuclear U-rich RNA (U-snRNA) and different protein factors (Cooper et al., 2009). 
The biogenesis of snRNPS is a highly complex process that involves export of the 
nascent pre-UsnRNAs to the cytoplasm ,where the Sm proteins assembles with 
the RNA and re-imported to the nucleus to aid splicing reactions (Neuenkirchen 
et al., 2008 ;Yong et al.,2004). 
 
The U1 snRNP is the first element that is involved in spliceosome assembly upon 
its recognition of the 5’ss in the pre-mRNA (Sperling et al., 2008). 
In humans, the U1 snRNP (Fig.8) is composed of the following: 
 A 164-nucleotide long RNA molecule, U1 snRNA that recruits ten different 
proteins (Starke et al., 2001). 
 Seven of these proteins are called Sm proteins and they are common to 
all UsnRNPs. They are termed as Sm B, D1, D2, D3, E, F and G. 
 Three other proteins are U1 specific and are termed as U1-70K, U1-A, 
and U1-C.  
 
Fig.8 | Secondary structure of U1 small nuclear ribonucleic acid (snRNA) (black) and 
general location of the seven Sm proteins (cyan), U1-70k (peachy brown), U1-A (green), 
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and U1-C (maroon). A consensus 5′ splice-site is indicated, base-pairing to the single-
stranded 5′ end of U1 snRNA (Krummel et al., 2009). 
 
The secondary structure of U1 snRNA is depicted by the presence of four stem 
loops (I, II, III, IV) and two single stranded regions. The 5’ protruding tail of the 
U1 snRNA single strand, base-pairs with the nine bases at the 5’ss consensus 
motif in the pre-mRNA (Mount et al., 1983). The other single stranded region 
between stem loops II and IV is the conserved Sm-binding site (AAUUUGUGGG). 
It is bound by the heteroheptameric ring composed of Sm proteins in the 
cytoplasm (Riker et al., 1999). 
The U1 specific proteins U1-70 K and U1-A interact with stem loop I and II 
respectively (Surowy et al., 1989) U1-C enters in the U1 complex through 
protein-protein interaction and contributes to the following aspects (Du et al., 
2002): a) mediates 5’ ss recognition b) stabilizes base-pairing between the 5’tail 
of the U1 snRNA and the donor site, thus promoting formation of the E complex. 
The U1 snRNP complex forms a stable interaction with nucleotides +1 to +6 of 
the intron at the 5’ splice site promoting a suitable site for spliceosome 
assembly (Stakins et al., 1994). U1 snRNP plays a vital role in recognition of 
donor splice site (Mount et al., 1998), studies have also shown that recognition 
of 5’ss can still occur for some exons in the absence of U1 complex with a less 
efficient splicing process (Du et al., 2002). 
The U1 snRNP is also involved in targeting the U2AF to promote the 
polypyrimidine tract (Hoffman and Grabowski 1992), where it promotes the 
association of U2 snRNP complex with the branch site region (Barabino et al., 
1990). Although U2 snRNP can bind to the pre-mRNAs in the absence of U1 
snRNP, this reaction is inefficient and seeks the assistance of U1 snRNP to 
establish successful binding to the pre-mRNA (Query et al., 1997). 
U2 snRNP interacts with the branch site at the 3’ splice site with the aid of 
additional splice factors such as U2AF (Ruskin et al., 1988), SF1 (Arning et al., 
1996) SF3a and SF3b, components of U2 snRNP binds upstream the branchsite 
of pre-mRNA and stabilizes the U2 snRNP (Gozani et al., 1994). This active 
binding of the U2 snRNP to the branch site sequence generates the pre-
spliceosome complex A. 
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The U5 snRNP binds to the spliceosomal complex in the form of U4/U6-U5 tri 
snRNP complex. 
An invariant loop sequence in the U5 snRNA attaches to the nucleotide at 
position -1 of the first exon, before and after splice site cleavage. This loop 
additionally interacts with the nucleotide at position +1 of the second exon that 
is within the lariat intron-exon 2 intermediate. 
It helps in holding the free exon 1 and intermediate in the spliceosome and 
aligns it with the 3’ splice site for the second catalytic reaction (Sontheimer et 
al., 1993). 
The U4 and U6 snRNAs are present within a single snRNP and are associated 
with each other through extensive base pairing (Black et al., 1986).The U4/U6 
snRNP binds to U5 snRNP forming a 17S tri-snRNPs particle before binding to 
the complex A. 
The addition of tri snRNP particle to complex A leads to the formation of 
spliceosomal complex or (complex B). Conformational changes further assists 
the formation of complex C (active spliceosome ) 
Thus, the base pairing between 5’ splice site and U1 snRNP is disrupted and 
replaced by the base pairing of U6 with this region (Kandels-Lewis et al., 1993) 
A simultaneous disruption of base pairing occurs between U4 and U6, wherein 
the U6 now interacts with U2 via base pairing (Madhani et al., 1994). The U5 
and U6 snRNAs cooperate to align the two splice sites to facilitate exon-exon 
ligation (Kandels-Lewis et al., 1993) (Fig.6 and 7). 
 
1.2.2. Canonical cis-acting elements in splice site selection 
Three consensus sequences are found at all exon-intron junctions: the 5’ splice 
site and 3’ splice site located at the 5’ and 3’ ends of the introns. and the branch 
point sequence (BPS)that is located upstream of 3’ splice site. 
They recruit the spliceosome machinery through RNA-RNA and RNA-protein 
interactions (Cooper et al., 2009, Barash et al., 2010). 
 
The following nucleotides in the consensus sequence (Fig.9) play a vital role in 
splicing: 
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1. The GU dinucleotide at the 5’ end of splice site (5’ss)(Mount M.S et al.,2000). 
2. The AG dinucleotide at the 3’ end of splice site (3’ss)( Mount M.S et al.,2000). 
3. A polypyrimidine tract (Py)n and the A nucleotide at the branch point both 
located upstream of 3’ ss (Shapiro et al.,1987). 
 
 
 
Fig. 9 | Splicing consensus sequences and its interactions.  
A. Location of splice site consensus sequences. Exons are indicated by red boxes, introns by a 
black line. Invariant nucleotides from consensus sequences are shown in black beneath the 
introns. B. Interaction between the sequence elements in RNA and corresponding proteins. Grey 
and black arrows indicate protein-protein interactions promoting splicing, red indicates 
inhibitory interactions (Pettigrew et al., 2008). 
1.2.2. (i) The 5’ splice site 
 
The 5’ splice site comprises of MAG/GURAGU (M indicates A or C and R indicates 
purines). An invariant dinucleotide GU located in the intron is highly conserved 
in eukaryotes (Baralle et al., 1990; Pettigrew et al., 2008).  
The 5’ss is recognised by the U1 snRNA which binds through complementarity.  
 
1.2.2. (ii). The 3’ splice site 
The consensus sequence at the 3′ splice site is defined by three separate 
elements (Baralle et al., 2005):  
 The branch site (Branch point sequence)  
 The polypyrimidine tract  
 The 3′ splice site dinucleotide AG 
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Studies have also shown that the conserved dinucleotide AG of the 3' splice site 
may be recognized twice during in vitro splicing of mammalian mRNA 
precursors. (Weiner et al., 1990). 
 
The Branch point sequence (BPS) 
The mammalian branch site consensus is composed of YURAC (R = purine; Y = 
pyrimidine) and it is located 20-50 nucleotides downstream the 3’ss (Zhuang Y 
et al., 1990).The U2 snRNP binds to the branch site via the U2 snRNA base 
pairing through RNA: RNA interaction (Will LC et al., 2011). 
 
The polypyrimidine tract 
This region is located between the BPS and the AG dinucleotide at the 
intron/exon border. Although multiple interactions contribute to the recognition 
of the BPS. In metazoans, the branch adenosine is initially recognized by SF1 
/mBBP, which binds along with the heteromeric dimer U2AF. The two subunits 
of U2AF executes the following steps (Will et al., 2011): 
 The 65-kDa subunit of U2AF binds to the adjacent polypyrimidine tract. 
 The 35 kDa subunit contacts the 3’ ss and plays a role in 3′ss recognition. 
In the next step of the spliceosome assembly, the bound U2AF65 and U2AF35 
facilitate substitution of SF1 for U2snRNP at the branch point to form complex A. 
(Fu et al., 2011). 
Although the effect of mutations on the classical splicing signals upstream of the 
3’ splice site, the polypyrimidine tract and the branch point, is less certain, many 
studies have shown their effect on leading to an incorrect splicing (Baralle et al., 
2005).  
 
The AG dinucleotide  
The AG dinucleotide located on the terminal part of the intron at the junction 
between intron/exon is comprised of a consensus sequence YAG/G 
(Y=pyrimidine) in which the AG is invariant and highly conserved. The U2AF 
interacts with this region through it 35 kDa subunit and assists in the formation 
of E complex (Wu et al., 1999). 
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1.2.3. Auxilliary cis-acting sequences 
 
In its most basic form an exon can be identified by a few cis-acting elements, thus 
recognising exons may seem a straightforward linear process. However, the 
sequences used as 5′ and 3′ splice sites are so diverse that many potential and 
similar candidates can be found in a typical mammalian transcript that match 
these consensus sequences as well as, and in some cases better than, the 
sequences at real splice sites. Therefore, raising an intriguing question in 
mammalian pre-mRNA splicing: how are real splice sites recognised? (Baralle et 
al., 2005). 
Evidences on literature provided so far elucidates the importance of the splice 
sites on mediating splicing. However, these sequences are not sufficient to define 
exon-intron boundaries. 
Therefore additional sequences are present in the introns and exons that are 
known to be involved in splice site recognition and they are termed as splicing 
enhancers and splicing silencers (Fig.10) (Baralle et al., 2005). 
 
 
 
Fig. 10 | Regulatory elements in pre-mRNA splicing a | The essential splicing signals that define 
the exon boundaries are the GU and the AG dinucleotides that directly flank the exon (at the 3′ 
and 5′ ends, respectively) and the branch-point adenosine (all in red) are always conserved. 
(Pagani F et al., 2004). 
 
Regulatory elements in the pre-mRNA splicing are reported in Fig. 10. In most 
cases, there is also a polypyrimidine tract of variable length (the consensus 
symbol ‘y’ represents a pyrimidine base — cytosine or thymine) upstream of the 
3′-splice site. The branch point is typically located 18–40 nucleotides upstream 
from the polypyrimidine tract. Components of the basal splicing machinery bind 
to the consensus sequences and promote assembly of the splicing complex. This 
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multiprotein complex, known as a spliceosome, performs the correct 
identification of the splicing signals and catalysis of the cut-and-paste reactions 
Five small nuclear ribonucleoproteins (snRNPs) and more than 100 proteins 
make up the spliceosome. The U1 snRNP binds to the 5′-splice site, and the U2 
snRNP binds the branch site through RNA–RNA interactions. Additional 
enhancer and silencer elements in the exons (exon splicing enhancer (ESE); exon 
splicing silencer (ESS)) and/or introns (intron splicing enhancer (ISE); intron 
splicing silencer (ISS)) allow the correct splice sites to be distinguished from the 
many cryptic splice sites that have identical signal sequences. Trans-acting 
splicing factors can interact with enhancers and silencers and can accordingly be 
subdivided into two main groups: members of the serine arginine (SR) family of 
proteins and of the heterogeneous nuclear ribonucleoprotein particles 
(hnRNPs). In general, SR protein binding at ESE facilitates exon recognition 
whereas hnRNPs are inhibitory. Protein–protein interactions in the spliceosome 
that modulate the recognition of the splice sites are the probable cause of 
splicing inhibition or activation (Pagani F et al., 2004). 
 
1.2.3 (i) Splicing enhancers  
 
Splicing enhancer include the exonic splicing enhancer (ESE) and intronic 
splicing enhancer (ISE) that mediate their effects by increasing the recognition of 
an exon. 
Most of them are recognized by proteins of the Serine-rich (SR) family. Studies 
on functional systematic evolution of ligands by exponential enrichment (SELEX) 
have identified that A/C rich enhancers play an important role in exon definition. 
SR proteins bind to these elements through their RNA binding domains and 
promote splicing by recruiting the spliceosome. However, these elements are 
also known to bind to other trans-acting factors apart from SR proteins. Studies 
have shown that GT repeat could be a possible strong intronic splicing enhancer 
(Gabellini et al., 2001). 
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1.2.3 (ii) Splicing silencers  
 
Splicing enhancer include the exonic splicing silencers (ESS) and intronic 
splicing silencers (ISS) and mediates their effects by decreasing the recognition 
of an exon. 
The factors that bind to these regions have not been well characterized, however 
hnRNPs have been known to interact with these elements (Baralle et al., 2005). 
Silencers are known to regulate both constitutive and alternative splicing events 
in mammals (Pozzuoli et al., 2005).  
Several studies have suggested that silencers could pose a fundamental role in 
preventing pseudoexon inclusion into the matured transcripts and refining the 
selection of constitutive exons by suppressing fake splice sites. Additionally they 
enable recruitment of regulatory factors to the alternatively spliced exons thus 
participating in regulation of alternative splicing (Pozzuoli et al., 2005).  
 
1.2.4. Trans-acting factors 
 
1.2.4 (i) hnRNPs 
 
The heterogenous nuclear ribonucleoproteins (hnRNPs) constitute a family of 
RNA binding proteins. They are involved in processing of heterogenous nuclear 
RNAs into mRNAs and act as trans-acting factors in regulation of gene 
expression. Studies on Hela have revealed the protein composition of hnRNP 
complexes. They are known to contain at-least 20 abundant major hnRNP 
proteins and are designated as hnRNPA1 through hnRNP U1 with varied 
molecular weights ranging from 34 kDa to 120 kDa. hnRNP proteins A1, A2, B1, 
B2, C1 and C2 were identified to be associated with nascent transcripts and were 
termed as “core hnRNPs” (Beyer et al., 1977; Dreyfus et al., 2002). 
These proteins are ubiquitiously expressed in all tissues, however they show a 
stage-specific expression pattern. 
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1.2.4 (ii) SR proteins 
 
The serine -arginine rich proteins are a highly conserved set of splicing 
regulators (Bradley et al., 2014). They contain one or two N-terminal RNA 
recognition motifs (RRM) and a C terminal (RS) domain enriched in arginine and 
serine dipeptides. Their primary function is the regulation of splice-site 
selection. In alternative splicing events, these proteins function in the following 
ways: 
 As activators facilitated by binding to the splicing enhancers (ESEs) 
through the RRM domain. 
 Recruiting the splicing machinery to splice site via RS-domain–protein 
interactions. 
The binding sites for SR proteins and other splice regulators are located in close 
proximities on the pre-mRNA suggestive of an inter-play between activation and 
repression that modulates exon inclusion. SELEX based techniques have 
identified the protein binding motifs for these proteins and ascertained 
degenerate purine rich sequences that resemble identified ESEs or 5’ splice sites. 
A recent study on the regulation of alternative splicing mediated through SR 
proteins was performed in Drosophila (Bradley et al., 2014). This study revealed 
that a majority of SR-regulated splice events are controlled by multiple SR 
proteins, wherein they can be involved in both exon inclusion and exon skipping. 
The binding location on the target RNA determines the positive or negative effect 
imposed by the SR protein. Although these proteins are known to mediate their 
effects by recruitment and/or stabilization of core spliceosome, they are also 
known to pose an effect on alternative splicing as activators/repressors (Bradley 
et al., 2014). 
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1.3. Impact of splice defects in neurodegeneration 
 
Around 50 % of human genetic diseases are linked to mutations that affect 
alternative splicing processes (Matlin et al., 2005). Since brain has the greatest 
amount of alternative splicing of all tissues, the effect of altered splice events 
have been linked to neurodegenerative brain diseases (NBDs) that has been an 
important area of study in the past decade (Mills et al., 2012).  
 
1.3.1. Neurodegenerative diseases  
 
Neurodegenerative diseases arise due to various factors including functional loss 
of neurons, inability of neurons to respond to changes in their internal and 
external environments, loss of connection in neuronal projections, all of which 
lead to neuronal degeneration (Courtney et al., 2010).  
The commonly studied neurodegenerative diseases include Alzheimers disease 
(AD), Parkinson’s disease (PD), Huntington’s disease (HD), progressive 
supranuclear palsy (PSP), corticobasal degeneration (CBD) and Pick’s disease 
(PiD). The PSP, CBD and PiD are collectively classified as Fronto temporal 
dementia (FTD) as they share the common features of an intracellular tau-
positive pathology (Mills et al., 2012; Betram et al., 2005) (Fig.11). 
 
 
Fig. 11 | Types of neurodegeneration and the anatomical location (in brain) of macroscopic and 
microscopic characteristic changes involved in neurodegeneratives diseases (Betram et al., 
2005). 
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In fact, a handful of alternatively spliced genes are known to associate with the 
onset of these diseases (Mills et al., 2012). A detailed review on association of 
these genes to the above mentioned diseases can be referred from Mills et al., 
2012 (Table 1). 
 
 
Table 1 | Alternatively spliced genes in the human brain associated to neurodegenerative brain 
disorders (Mills et al., 2012). 
 
1.3.2. Fronto temporal lobar degeneration (FTLD) 
 
Fronto temporal lobar degeneration (FTLD) refers to a group of progressive 
brain diseases that share a common feature of atrophy of frontal and temporal 
cortex but are heterogeneous in etiology and neuropathology. The onset of 
symptoms occurs before 60 years of age and the mean survival after diagnosis 
varies between 3 to 10 years. The prevalance is estimated to be 15 in 100,000 in 
the population of people in the age group between 45 and 60 years (Riedl et al., 
2014). 
FTLD has been included in the list of orphan diseases. (Orphanet number 
ORPHA282 of http://www.orpha.net). 
The clinical syndrome is characterized by progressive deterioration of either 
language or behavior. In 1892, Arnold Pick described the first patient with 
clinical syndrome of Pick’s disease which was used interchangeably with FTLD 
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over a decade from then. However, now this term is referred to only a subset of 
FTLD with specific histopathological features. 
FTLD is classified based on two functions: clinical syndromes and 
neuropathology. 
The clinical syndromes include behavioural-variant fronto temporal dementia 
(bvFTD) and primary progressive aphasia (PPA). 
 
Behavioural-variant fronto temporal dementia (bvFTD) 
It is the most common clinical syndrome of FTLD and is characterized by the 
atrophy of mesofrontal, orbitofrontal and anterior insular cortex of the frontal 
lobes .It leads to progressive personality changes and behavioural disturbances. 
While behavioural changes dominate the initial stages, cognitive deficits appear 
on disease progression. 
 
Primary progressive aphasia (PPA). 
The language variants of FTLD include: a) semantic variant PPA (svPPA); also 
termed as semantic dementia or temporal variant dementia. b) non fluent 
variant PPA (nfvPPA) also referred to as progressive nonfluent aphasia (Johnson 
et al., 2005). 
 
Semantic variant PPA (svPPA) 
It accounts for 19% of all FTLD cases and is characterized by difficulties in 
understanding of sensory stimuli. Loss of verbal and non-verbal skills in a 
progressive manner. 
 
Non fluent variant PPA (nfvPPA)  
It accounts for 24% of all FTLD cases and is characterized by reduction of speech 
in a progressive manner which leads to complete loss of speech in the later 
stages. The pathological hallmark of this disease is the atrophy of the left 
cerebral hemisphere. 
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The neuropathological subtypes are characterized as follows: 
 
FTLD- tau 
The best studied FTLD subgroups are known to contain hyperphosphorylated 
tau proteins in the neuron and glial cells. They represent 40 % of FTLD cases and 
include neuropathology observed in Pick’s disease, PSP, CBD and cases of familial 
FTLD caused due to mutations in MAPT. Though these diseases share a common 
tau-positive pathology, each condition is characterised by an additional inclusion 
that enables pathological classification; Pick bodies in Pick’s disease, Neuro 
fibrillary tangles (NFT) and tufted astrocytes in PSP and astrocytic plaques in 
CBD. 
 
FTLD-U 
The tau negative cases are characterized by neuronal cytoplasmic inclusions and 
dystrophic neurites in the layers of frontotemporal neocortex and dentate 
granule cells of hippocampus that were detected with ubiquitin immuno 
histochemistry, hence termed FTLD-U. 
However, TDP-43 was identified as the ubiquitinated pathological protein hence 
leading to a subsequent change in the name as FTLD-TDP. The pathological form 
of TDP-43 consists of abnormal C-terminal fragments that are 
hyperphosphorylated and ubiquitinated. Around 10-20% of cases that were 
considered as FTLD-U did not respond to staining for either tau or TDP-43. 
However, discovery of FUS mutations in ALS (Amyotrophic lateral sclerosis) 
later led to the identification of FUS positive inclusions in this subset of tau /TDP 
43 negative inclusions, hence this new group was classified and termed as FTLD-
FUS. Further studies in 2004 to 2006 revealed the involvement of other genes 
such as Valosin containing protein (VCP), Chromatin modifying protein 2B 
(CHMP-2B) and Progranulin (PGRN) to be associated with the FTLD-U disorders 
(Watts et al., 2004; Skbinski et al., 2005; Cruts and Van Broeckhoven et al., 2008). 
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1.4. Fronto temporal dementia and Parkinsonism linked to chromosome 
17 (FTDP-17) 
 
In 1994, the familial disease called disinhibition-dementia–parkinsonism-
amyotrophy complex (DDPAC) was linked to chromosome 17q21-22 
(Wilhelsmsen 1994). 
This study was further followed by other reports that showed a link between 
number of dementing diseases and to the same region of chromosome 17. 
(Goedert et al., 2000). In 1996, these group of diseases were termed as Fronto 
temporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) by a 
consensus conference. (Foster et al., 1997). 
The major clinical features include behavioral disturbances, cognitive 
impairment and parkinsonism (Foster et al., 1997).The age for onset of disease 
varies between 45-65 years. (Snowden et al., 1996). 
A study on the Dutch population estimated its prevalence to be 1 over 1000,000 
people, however clinical manifestations could account for an underestimated 
prevalence rate (Rosso et al., 2003). 
The neuropathological features include atrophy of the fronto temporal lobes of 
the brain accompanied by neuronal loss, gliosis and spongiosis (Pookraj et al., 
1998) with additional presence of proteinaceous inclusions containing 
hyperphosphorylated tau protein called neurofibrillary tangles (NFTs). 
The behavioral changes include the following: disinhibition, apathy, compulsive 
behavior, negligence of personal hygiene, verbal and physical aggressiveness. 
As the disease progresses, it leads to cognitive and memory deficits. 
Due to the presence of motor symptoms, patients with this disease could be 
misdiagnosed with Parkinson’s disease or progressive supra nuclear palsy (PSP). 
Although a majority of FTDP-17 cases are sporadic in nature,10% to 50% of the 
patients have been reported to have a positive family history of the disease. 
A subset of familial cases, however exhibit an autosomal dominant pattern of 
inheritance indicating a significant contribution to the disease onset.(Neary et 
al.,1998; Poorkaj et al.,1998). 
Since tau gene maps to the critical interval region on chromosome 17 and 
hyperphosphorylated tau proteins have been characterized as neuropathological 
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hall-marks in in the familial fronto temporal dementia cases (Wilhelsen et al., 
1997), tau gene was considered a strong candidate for the FTDP-17 locus. 
Further studies have led to the discovery of many mutations in tau gene and 
established the effect of tau dysfunction in neurodegeneration. However, it 
became very clear that MAPT gene was a candidate target gene only for FTDP-17 
cases containing tau positive histopathology. 
 
1.4.1. Microtubule associated protein tau (MAPT) gene  
The Microtubule associated protein tau (MAPT) spans about 100 kb on the long 
arm of chromosome 17 at band position 17q21.1 (ch17q21.1). It consists of 
sixteen exons and has the following features (Kolarova M et al., 2012): 
 Exon 1 is part of the promoter and is transcribed but not translated; 
 Exons 1, 4, 5, 7, 9, 11, 12 and 13 are constitutive in nature; 
 Exons 2, 3 and 10 are alternatively spliced. 
Alternative splicing of these exons leads to the formation of six different 
isoforms that are 353 to 441 amino acids long (Fig.12) and differentially 
expressed during the development of the brain. (Zhou et al., 2008; Kolarova et 
al., 2005). 
 
 
Fig.12 | Human tau gene and the six isoforms expressed in the CNS .The tau gene is composed of 
16 exons of which 11 are used in the CNS (Highlighted in purple and green boxes).The 
alternatively spliced exons includes exons 2, 3 and 10 (purple) leads to the formation of six 
isoforms.The microtubule binding domain is encoded by exons 9 to 12 and labelled as R1 to R4 
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respectively (black bars). The isoforms are represented based on the number of repeats attained 
from each terminal (Esther et al., 2002). 
 
1.4.2. Tau protein: Localisation, Structure and Function 
MAPT gene codes for tau protein a member of microtubule associated proteins 
(MAPs) family that comprises MAP 1 and MAP 2. 
 
Localisation 
Tau is localized in several parts of tissues and organs. However, it is particularly 
abundant in neurons of the CNS especially in their axons. A lower amount is 
detectable in the axons of peripheral neurons and in oligodendrocytes of glial 
cells. Tau expression varies in different regions of the adult brain with the frontal 
cortex bearing the highest level of tau followed by occipital cortex, white matter, 
putamen and cerebellum (Traozuni et al., 2012). 
 
Structure  
Previous studies have revealed tau as a “natively unfolded” protein (Von Bergen 
et al., 2005, Gamblin et al., 2005, Jeganathan et al., 2008). Since disordered 
proteins undergo variable conformational changes they have not been subjected 
to crystallographic analyses. However, nuclear magnetic resonance 
spectroscopic studies have enabled recovery of complete assignment of the 441 
amino acid residues of the longest isoform (Fig.13) (Kalarova et al., 2012). 
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Fig. 13 | Amino acid sequence of the longest tau isoform (441 amino acids). (N1 and N2 = 
polypeptide sequences encoded by exons 2 and 3) (P1 and P2= proline-rich regions) (R1–R4 = 
microtubule-binding domains encoded by exons 9–12) (275VQIINK280 and 
306VQIVYK311=sequences with β-structure) (Kalarova et al., 2012). 
 
Six isoforms of tau differ according to the contents of tubulin binding domains (R 
or repeats) in the C terminal designated as 4R or 3R and the number of inserts of 
29 amino acids each in N-terminal portion designated as 1N, 2N or 0N.  
The varied size of amino acids arises as a result of presence or absence of 
sequences encoded by exons 2, 3 or 10. Inclusion of exon 10 lead to the 
expression of tau with four repeats (4R tau) while exclusion results in 
expression of the alternative isoform with three repeats (3R tau) (Lee et al., 
2012). Skipping of both exons 2 and 3 leads to the expression of 0N isoform, 
inclusion of exon 2 but not exon 3 leads to the expression of 1N isoform and 
inclusion of exons 2 and 3 leads to the expression of 2N isoform (Baker et al., 
2006). 
The primary sequence analysis of tau shows that it consists of a half N-terminal 
acidic portion followed by a proline rich region and a C terminal tail. Exons 2 and 
3 accounts for the acidic nature of tau protein and Exon 10 (encodes a positively 
charged sequence) contributes to the basic nature. 
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Thus, tau is a dipolar protein with both positive and negative charges and can be 
modulated by post translational modifications. 
The N terminal domain is referred to as the projection domain as it projects from 
the microtubule surface to interact with other cytoskeletal elements and the 
neuronal plasma membrane. The two 29 amino acid domains encoded by exons 
2 and 3 provide different lengths to the N terminal part of the tau protein. This 
region of tau protein is known to interact with the following molecules (Kolarova 
M et al., 2012): 
 Spectrin and actin filaments- Allows tau-stabilized microtubules to 
interconnect with neurofilaments 
 Peptidyl-prolyl cis/trans isomerase Pin 1 – Triggers conformational 
changes that lead to tau dephosphorylation. Pin 1 is involved in regulation 
of tau and protein and protects against degeneration as a result of ageing 
 Intracellular membranous elements such as mitochondria and plasma 
membrane  
 Kinases and proteases – Helps in the maintenanace of equilibrium of both 
phosphorylated or dephosphorylated forms of tau protein 
 
The proline-rich region is known to bind to Src-homology 3 (SH3) domains of 
several proteins. Fyn, a tyrosine kinase belongs to the class of Src-family. Studies 
have shown that association of tau with Fyn regulates the outgrowth of 
cytoplasmic processes in oligodendrocytes. Imapired interaction of Fyn kinase 
and hyperphosphorylated tau causes hypomyelination leading to demyelination 
of axons. 
The repeated domains R1 to R4 encoded by exons 9-12 located in the C terminal 
domain enable binding of tau protein to microtubules. 
Studies in vitro have demonstrated that tau protein increases the rate of 
microtubule polymerization and in parallel inhibits their rate of 
depolymerisation (Dreschel et al., 1992). 
Microtubule polymerization is stimulated by the interregion between repeats 1 
and 2 (R1-R2 interregion) that codes for the peptide 275KVQIINKK280 
(Sergeant et al., 2005; Goode et al., 1994). This is the most unique region for 4R 
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tau and accounts for the major difference in binding affinities between 3R and 4R 
tau (Sergeant et al., 2005; Brandt et al., 1993). 
In the adult brain, the ratio of 4R and 3R is expected to be 1:1. Although the 
necessity for such balance between the isoforms is universally accepted, the 
mechanism by which an alteration causes the onset of FTDP-17 remains unclear. 
One of the main hypothesis is that the 4R isoform binds to different sites on 
microtubules as compared to its 3R counterparts. Hence, an excessive 
production of 4R leads to a saturation of the binding sites with a simultaneous 
aggregation of the unbound 4R isoforms. However, an accurate determination of 
the mechanism involved in the onset of FTDP-17 upon disruption of the ratios 
will be necessary to address potential therapeutic strategies for the treatment of 
tauopathies (Liu et al., 2008). 
The main function of tau being a promoter of tubulin polymerization depends 
majorly on the R domain (R). Recent studies have suggested a possible role for 
the R domain the modulation of phosphorylation of tau protein, wherein a direct 
and competitive binding has been observed between this region and microtubule 
on one side and the same region with PP2A (protein phosphatase 2 A) on the 
other side. As a result, the activity of PP2A is halted by microtubules by binding 
to tau protein (Sontag et al., 1999).  
 
Function 
Tau functions include promotion of microtubule assembly and their stabilization, 
morphogenesis, axonal extension, mitosis and axonal transport (Buee et al., 
2000). 
Microtubules are involved in diverse cellular processes such as cell 
morphogenesis, cell division, and intracellular trafficking (Drubin et al., 1996; 
Goodson et al., 1997). They mediate organelle transport with the help of motor 
proteins such as kinesin or motor dynein. These motor proteins are involved in 
transport of their cargoes such as mitochondria (Morris et al., 1993; Tanaka et 
al., 1998), lysosomes (Hollenback et al., 1990), peroxisomes (Weimer et al., 
1997) towards the cell periphery or towards the microtubule organizing center 
(MTOC). 
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The tau protein is known to tightly bind to the microtubules, thus leading to 
intracellular trafficking, this might arise as a result of detachment of the cargoes 
from kinesin (Kolarova et al., 2012). 
 
1.4.3. Tau Pathology: Causes and consequences in the context of FTDP-17 
 
Intracellular tau deposits have been observed in a number of neurodegenerative 
diseases (Goedert et al., 2005). However, it was quite unclear whether the 
dysfunction of tau protein was a cause or a consequence of the disease. Studies 
on mutations in MAPT gene in 1998, however unraveled the role of tau protein 
and its causative role in FTDP-17. At present about 40 different mutations have 
been found in the gene and are known to be associated with FTDP-17 (Wszolek 
et al., 2006). 
Most of the mutations in MAPT gene (Fig.13) are missense, deletions or silent in 
nature. They are either located in the coding region of Exons 9 to 13 or in the 
first portion of the intron following exon 10.(Table 2) (Esther et al., 2002). 
 
Further, these mutations can be classified according to their functionality; 
leading to primary effects at the RNA splicing or protein levels. Mutations in exon 
1 (R5H and R5L), exon 9 (K257T, L226V, and G272V), exon 11 (S320F), exon 12 
(V337M, E342V and K369I) and exon 13 (G389R and R406W) have an effect on 
all six isoforms. Mutations in exon 10 (N279K, K280, L284L, N296, N296H, 
N296N, P301L, P301S, S305N and S305S) however, poses their effect on the 4R 
isoform. 
Mutations in the coding regions of exons 9, 10 (P301L and P301S), 11, 12, and 13 
of MAPT gene is reported to disrupt its interactions with microtubules, hence 
causing an improper microtubule assembly. A reduction of microtubule 
assembly has also been observed in R5H and R5L mutations in exon 1(Hayashi et 
al., 2002; Poorkaj et al., 2002). 
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Fig. 14 | a. Mutations associated with tau gene leading to FTDP-17 are shown for exons 1 to 13. 
Exonic mutations are depicted according to codon number and intronic mutations according to 
nucleotide number. b. An enlarged version of the predicted stem loop structure located between 
exons 10 and 11.Exonic and intronic mutations that lead to the instability of this structure thus 
excessively including exon 10 are depicted in uppercase and lowercase respectively (Esther et al., 
2002). 
Mutations that alter splicing of MAPT mRNA 
The two types of mutations known to pose their effects on pre-mRNA splicing 
include: 
a. Mutations within coding regions of exon 10 (N279K, 280K, N296H/N, and 
N296N/S305N/S). 
b. Mutations in introns close to 5’ splice site of exon 10 in positions +3, +11, 
+12,+13,+14, +16 and +19. 
All of these mutations are known to increase the inclusion of exon 10 in MAPT 
mRNA, thus altering the ratios of the two isoforms of 4R and 3R. However, 
mutations Δ280K in exonic and +19 and +29 intronic regions lead to an opposing 
effect of increasing the 3R isoform (D’Souza et al., 1999) (Table 2.). 
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Table 2 | Mutations that affect splicing of exon 10 are located both in the intronic and exonic 
region. (Abbreviations 4R: four repeat tau, 3R: three repeat tau, ND: Not determined, PHF: Paired 
helical filaments) (Modified from Esther et al., 2002). 
 
 
Fig. 15 | Structure of exon 10 and intron 10 of the tau gene with its regulatory elements. Exon 10 
is depicted in capital letters and part of the flanking introns 9 and 10 are shown in lower case. 
There are three ESE (SC35-like enhancer, PPE, and ACE) at the 5’ end of exon 10 and bipartite cis 
elements (an ESS and an ESE) at its 3' end. Intron 10 elements include an ISS and an ISM. There is 
a stem-loop structure at the interface between exon 10 and intron 10. Mutations that cause an 
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increase (red), decrease (dark green), or a not yet known change (black) in the 4R-tau: 3R-tau 
ratio are indicated. Triangles indicate deletion mutations. ACE, A/C-rich enhancer; ESE, exonic 
splicing enhancer; ESS, exonic splicing silencer; ISM, intronic splicing modulator; ISS, intronic 
splicing silencer; PPE, polypurine enhancer (Qian et al.,2010). 
 
The N279K misense and L284L silent mutations strengthen one of the two exon 
splicing enhancer elements (ESEs) located at the 5’ region of exon 10, thus 
causing an excessive accumulation of RNA containing exon 10 hence forming 
insoluble 4R isoforms. (D’Souza et al.,1999; D’Souza et al.,2000; Clark et al., 1998, 
Hasegawa et al., 1999). Another silent mutation N296N causes a similar effect in 
producing 4R transcripts that is thought to result from disruption of an existing 
exon splicing silencer (ESS)(Spillantini et al., 2000) or through creation of an 
exon splicing enhancer element (ESE)(Grover et al., 2002). In vitro studies have 
shown that S305N mutation changes the last amino acid of exon 10 and reduces 
the thermodynamic stability of a stem-loop structure (Varani et al., 1999; Iijima 
et al., 1999). Additionally, this mutation is also known to increase the binding of 
U1 snRNP to the 5’ splice site thus causing an increased splicing of exon 10. The 
silent S305 mutation however is thought to disrupt the stem-loop structure 
without affecting the binding of U1 snRNP (Stanford et al., 2000). 
Mutations Delta 280, Delta 296 and N296H pose their effects at both RNA and 
protein levels. Like the other mutations, located in the coding regions, these 
reduce the ability of tau to promote MT assembly (Grover et al., 2002; Yoshida et 
al., 2002) N296H and N296N leads to excessive production of exon 10 by 
modulating splicing (Grover et al., 2002; Yoshida et al., 2002) and the K280 leads 
to reduced splicing in of exon 10.suggesting its primary effect on over production 
of 3R tau (Esther et al., 2002). 
Lack of available tissues however has limited the biochemical analyses of the 
mutations that affect splicing. 
The exon-intron interface at the 3’ end of exon 10 in tau pre-mRNA, (which is 
also a splice site junction) has been predicted to contain a stem-loop RNA 
structure. The two groups involved in the theoretical prediction of tau pre-mRNA 
for such a structure have also proposed that several tau mutations pose an effect 
through destabilization of the stem-loop, thereby exposing this splice site to the 
U1 snRNP and subsequently leading to the increased inclusion of exon 10. This 
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theoretical prediction has been confirmed through an indirect analysis of stem-
loop in mice models: all MAPT mRNAs in the rodent adult brain contain exon 10, 
thus producing pre-dominant 4R isoforms. This enhanced inclusion of exon 10 is 
predicted to arise as a result of destabilization of the stem loop structure relative 
to the human sequence caused by a naturally occurring G at position +13 in 
MAPT intron 10 (D’Souza et al., 2005) (Fig 15). 
As previously discussed, alternative splicing is a highly regulated process 
therefore mutations in the essential cis acting splice regulatory elements are 
highly likely to induce an alteration in the splicing pattern.  
Mutational studies on the region spanning Exon 10 and its adjacent introns on 
MAPT gene have shown the presence of atleast seven non redundant regulatory 
elements.  
The first 45 nucleotides of exon 10 contain a multipartite exonic splicing 
enhancer (ESE) composed of the following: 
 An SC35 –like sequence that resembles degenerate binding consensus for 
the SR protein SC35 
 A polypurine enhancer (PPE), an exonic enhancer with a high purine 
content 
 An AC rich enhancer (ACE), an exonic splicing enhancer rich in As and Cs. 
 
Additionally, the sequence between the SC35-like element and the PPE element 
consists of a potential inhibitory element for splicing. Although the PPE element 
is fundamental for splicing of exon 10, additionally the other regulatory elements 
play a vital role in regulation of splicing. A central splicing silencer (ESS) is 
located between the above mentioned ESE (located at the 5’ end of exon 10) and 
another ESE (located at the 3’ end of exon 10). The downstream intron 10 
sequence adjacent to the 5’ splice junction is composed of a bipartite inhibitory 
sequence followed by an intronic splicing modulator (ISM). These regulatory 
elements are involved in a complex interaction to regulate splicing of exon 10, 
thus determining the balance between the two alternatively spliced transcripts 
(4R:3R) (Gao et al., 2000;D’Souza et al., 2005)(Fig 15). 
Despite increasing evidences in unraveling molecular mechanisms involved in 
FTDP-17, there is no available cure for this disease. 
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1.5. Tools for manipulation of splice defects in neurodegeneration 
 
1.5.1. Exon skipping approaches 
 
Since exon 10 inclusion leads to FTDP-17, by posing an alteration in the balance 
between the two isoforms 4R and 3R, strategies to induce exon skipping or 
selective depletion of isoforms containing exon 10 can be utilized to recuperate 
the ideal equilibrium of these two isoforms.  
 
1.5.1 (i) Antisense oligo nucleotides 
 
The most widely studied gene therapeutic approach for correction of splice 
defects is through the application of antisense oligonucleotides (AONs) that 
target the pre-mRNA (Siva et al., 2013). Antisense oligonucleotides (ASOs) with 
their diverse functionality, high target specificity, and relative ease of delivery in 
the central nervous system (CNS) are uniquely considered as potential therapies 
for neurological diseases (Southwell et al., 2012). 
 
Please refer to attachment for a detailed review on the use of antisense oligonucleotides in the 
context of neurodegenerative diseases with the following title: 
Exon-skipping antisense oligonucleotides to correct missplicing in neurogenetic 
diseases. 
Siva K, Covello G, Denti MA Nucleic acid therapeutics (2014). 
There has been no improvement or modification in the state of the art since the 
above mentioned review was published. 
 
1.5.1 (ii) Chimeric small nuclear RNA (snRNA) molecules 
 
Although antisense oligonucleotides are used to induce exon skipping, an 
alternative approach is the use of suitable DNA vectors. The UsnRNPs involved in 
several processing of splicing appear to be attractive carriers for the antisense 
sequences (Wood et al., 2010). They are considered to be advantageous when 
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compared to naked synthetic antisense oligo ribonucleotides for a number of 
following reasons (Glaus et al., 2011);  
1. They are resistant to degradation with a decreased risk of being attacked by 
RNA interference as they are engulfed by the RNP particles. 
2. Their accumulation is specifically centred in the nucleus, the active location of 
splicing  
3. They are continuously expressed thus avoiding repeated administrations  
4. The short length of U snRNA genes (500 bp) allows their incorporation into 
any transfer vector. 
5. An endogenous transcriptional control of the target gene is maintained such 
that the protein expression is controlled by cellular regulatory elements. 
6. It has the potential to rescue normal splice pattern, thus reducing the amount 
of mutated proteins, which is specifically relevant for the treatment of dominant 
diseases caused by gain of function mutations. 
The most commonly used antisense molecules in this category are U1 snRNAs 
and U7 snRNAs (Muller et al., 1997). 
 
U1 snRNA 
 
The U1 snRNP is composed of a 164 bp long U1 snRNA and is known to associate 
to many protein factors to initiate splicing processes through Watson and crick 
base pairing. 
In humans, the U1 snRNA gene RNU1-1 (also known as RNU1) is located on the 
short arm of chromosome 1, 1p36 (Naylor et al., 1984).  
RNAU1 is a TATA-less promoter gene which contains a) an enhancer like distal 
sequence element (DSE) and b) a fundamental proximal sequence (PSE) that is 
recognized by the snRNA gene-specific factor PTF (PSE-binding transcription 
factor) or SNAPc (snRNA activator protein complex) (Sadowski et al.,1993). 
In addition, several U1 snRNA pseudogenes are present throughout the genome. 
There are three distinct classes of the U1 snRNA pseudogenes, that have been 
generated by both DNA and RNA mediated mechanisms (Denison and Weiner 
1982; Bernstein et al., 1985). The U1 snRNA class II and class III pseudogenes are 
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dispersed throughout the genome and have no homology in their flanking 
regions, to each other or to the U1 snRNA gene.  
 
The U1 snRNA class I pseudogenes, in contrast, have considerable 5′ and 3′ 
flanking sequence homology with the U1 snRNA genes and retain good homology 
with the two essential promoter elements, the distal sequence element (DSE), 
and proximal sequence element (PSE) (Denison and Weiner 1982). Since the U1 
snRNA is not translated into a protein, active pseudogenes could possibly 
generate variant functional snRNAs. It has been known for some time that minor 
U1-like snRNAs, with variation to the human U1 snRNA exist, but to date, their 
function remains elusive (Patton et al., 1987; Lund et al., 1988; Kyriakopoulou et 
al., 2006).  
 
RNU1 is polymerase II dependent and needs TBP, TFIIB, TFIIA, TFIIE and TFIIF 
proteins (Kuhlman et al., 1999) for its transcription. 
 
The transcription of snRNA gene follows the below mentioned pattern, (Egloff et 
al., 2008): 
• snRNA gene promoters recruit gene-type-specific pre-initiation 
complexes; 
• There are several cis acting factors and transacting factors involved in the 
pre-initiation complex; 
• It includes, a TATA box, at –25 relative to the transcription start site, USEs 
(upstream sequence elements), generally located within approximately 200 bp 
of the start site and an Enhancer, which can be far upstream or downstream of 
the start site; 
• TATA box is recognized by the general factor TFIID. USEs and Enhancers 
bind a range of sequence-specific DNA-binding factors; 
• Transcription initiation may also require interaction of the pol II CTD. 
 
The 3’ end of the U1 snRNA (Hernandez A et al., 1992) is transcribed by pol II 
and occurs in several steps initiated by recognition of the cis-acting 3′ -box that 
is a 13–16-nt-long element which directs the production of a 3′ extended pre-
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snRNA. It is a specific substrate for subsequent processing that generates the 
mature 3′-end after transport to the cytoplasm (Kiss T et al., 2004, Mougun A et 
al., 2002, Huang Q et al., 1997). 
 
The RNU1 transcript is not spliced and its 3’ end is not polyadenylated, thus 
preventing its association to the translation machinery (Hernandez et al., 2001). 
The use of U1 snRNA as an antisense agent for modulation of splicing is justified 
as it is involved in the initiation of splicing and there are thirty functional U1 
genes in human genome versus only one U7 gene. This dis-equlibrium leads to 
the production of 1x106 U1 snRNA molecules per cell  compared to only 5X103 
copies of U7 snRNA, suggesting that the expression of U1 snRNA per gene copy is 
6 fold higher than that of U7 making U1 a more feasible carrier than the U7 
snRNA (Gorman et al.,2000). 
The U1 snRNA engineered (Fig.16) through the replacement of an 8 nucleotide 
long sequence with a complementarity to specific splicing regulatory elements 
was demonstrated to show an efficient expression in vivo and to accumulate 
stably as a small ribonucleoprotein (snRNP), hence acting as a suitable backbone 
for the expression of antisense sequences that induces exon skipping (De Angelis 
et al., 2002). Antisense derivatives of U1 snRNA have been employed to induce 
skipping of exons in the human beta-globin pre-mRNA and (Gorman et al., 2000) 
and in mutated dystrophin pre-mRNA (De Angelis et al., 2002; Denti et al., 2006a, 
b, 2008). 
A U1 snRNA modified to target mouse dystrophin gene exon 23 was systemically 
delivered using adeno-associated virus (AAV) vectors to the dystrophin-deficient 
mouse model of Duschenne muscular dystrophy (DMD) mdx (Denti et al., 2006 a 
and b 2008). It was observed that the treated mice successfully skipped the 
targeted pre-mature termination codon (PTC) containing exon 23. Although, 
body-wide dystrophin restoration was evident, the effect was heterogeneous 
throughout the skeletal muscles (Denti et al., 2006). Further to this, U1 snRNA 
was used to correct splicing through exon skipping in human DMD pre-mRNA in 
primary patient fibroblasts (Incitti et al., 2010). The most efficient exon skipping 
was achieved from targeting splice site as well as exonic regulatory regions of 
exon 51. 
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Recent work has also shown that a single chromosome-integrated copy of ExSpe 
U1 induced a significant correction splicing of endogenous SMN2 E7 and resulted 
in the restoration of the corresponding SMN protein levels (Dal Mas et al., 2015). 
 
Fig.16 | Schematic representation of of U1 snRNA (black) along with its modifiable arm is shown 
to interact with exon 1 (red) and intron (blue) of pre mRNA at the 5’ss. 
 
U7 snRNAs  
 
The U7 snRNAs are involved in 3’ end processing of the histone pre-mRNA 
(Goyanvalle A et al., 2012) and is normally expressed in low levels. However they 
can be converted in to a versatile tool by engineering thus changing their 
properties and target specificities. A minor conversion of the wild type Sm 
binding site (AAUUUGUCUAG) into the consensus Sm-binding sequence derived 
from the major spliceosomal snRNPs (smOPT) was found to have beneficial 
effects on the U7 snRNA molecules as it increased the expression levels and 
enabled an efficient localization within the nucleus. 
The innate 18 nt-long sequence of the modified U7snRNA (complementary to the 
3’ processing sites of histones) can be replaced with antisense sequences 
complementary to specific splicing regulatory elements, thus masking them 
(Fig.17). 
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Fig. 17 | Shematic representation of modifiable U7 snRNA in which the antisense sequence 
(red) is embededed to target the specific sequence in the pre-mRNA to modulate splicing.The 
modification of wild type Sm binding site to consensus Sm binding site derived from smOPT 
is shown in red letters  
(Website:http://www.izb.unibe.ch/content/groups/schuemperli/gene_therapy_ii/index_en
g.html). 
 
In the last decade, many groups have shown that U7 snRNAs are appropriate to 
shuttle antisense sequences within them to correct aberrantly spliced exons in 
several pathologies. U7 snRNA-mediated modulation of splicing was achieved in 
CyPA (Cyclophillin A) that resulted in exon skipping effects and reduction of 
protein levels of cyclophillin A (Liu et al., 2004). 
 
It has also been applied for the dystrophin gene involved in Duchenne Muscular 
Dystrophy (DMD), wherein splice correction was achieved through exon 
skipping effects. These effects remained consistent both upon transduction in to 
mammalian cells and injection in to the mdx mouse model (Denti et al., 2006). 
A similar strategy was then successfully adapted to dystrophic immortalized 
mdx muscle cells wherein exon-23-skipped dystrophin mRNA rescued 
dystrophin protein synthesis (Brun et al., 2003). 
Similar effects were achieved for the SMN2 gene exon 7 implicated in Spinal 
Muscular Atrophy (SMA) in SMA patient-derived fibroblasts wherein the 
modified U7 snRNAs were able to induce exon 7 inclusion in up to 80% of 
transcripts (Geib et al., 2009). A bifunctional U7 based snRNA was used to treat 
SMA mice with the modified construct through transgenic expression (Marquis 
et al., 2007) or by lentiviral injection in to the CNS (Meyer et al., 2009) both of 
which enabled prolonged survival in a dose dependent manner. 
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Recent studies have also demonstrated that U7 snRNAs can be effective in 
skipping of multiple exons (Goyanvalle et al., 2012) in the context of Duchenne 
Muscular Dystrophy (DMD).  
 
These observations prove that the antisense snRNAs embedded within AAV 
(Adeno-associated virus) vectors represents a promising form of gene therapy 
with persistent expression for treatment of several neurological disorders in the 
years to come (Uchikawa et al., 2007). 
 
1.5.2. Post transcriptional gene silencing (PTGS) 
Only 1.5% of the mammalian genome encodes proteins (Tan L et al., 2013). A 
significant proportion of the transcriptome that is unable to form proteins is 
classified as ncRNAs. They remain to be the largest class of transcripts known in 
the mouse and human. Based on the length, these molecules are classified as: 
small (<400 nucleotides) and long (>400 nucleotides) (Kornienko A.E et al 
.2013). The small ncRNAs are further divided in to: 
 Infrastructural RNAs (rRNA, tRNA, and snRNA) 
 Regulatory RNAs (miRNAs, siRNAs and snoRNAs) 
Long noncoding RNAs can exceed 10,000 nucleotides and covers a range of 
regulatory molecules. This class includes Natural antisense transcripts (NATs) 
and RNA expansion repeats.  
Transcriptional gene silencing can be achieved through both siRNAs and long 
noncoding RNAs (Malecova B et al., 2010) thus, paving way to utilize these 
molecules to target diseased genes. 
 
1.5.2 (i) siRNAs 
RNA interference (RNAi) was first discovered in Caenorhabditis elegans by 
Andrew Fire and Craig Mello in 1998 (Fire et al., 1998), for which they were 
awarded the Nobel prize in Physiology and Medicine (Chen S et al., 2013). 
It is a physiological gene specific silencing mechanism that is mediated by double 
stranded RNAs (dsRNAs) and can operate at transcriptional and post 
transcriptional events. (Dykxhoorn et al., 2003; Meister et al., 2004; Zamore et 
al., 2005; Chapman et al., 2007). 
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This process is initiated by an endogenous double stranded RNA (dsRNA) 
molecule, which is processed in the nucleus by an endonuclease, Drosha and 
exported in to the cytoplasm for a further processing by a second endonuclease 
Dicer to generate RNA duplexes that are 21-23 nucleotides in length with 2 
nucleotide overhangs at the 3’ termini (Miller et al., 2005; Seyhan et al., 2011). 
These duplexes now termed as siRNAs are recognized and bound by a multi-
protein complex known as RNA-induced silencing complex (RISC). The RISC 
unwinds the siRNA duplex; one strand termed as the “guide” / “antisense” strand 
hybridizes to complementary target sequence of a messenger RNA leading to its 
degradation (Meister et al., 2004) and the other strand termed as “passenger” / 
“sense” strand is cut by an enzyme argonaute 2 (Ago 2) present within the RISC 
complex (Miller et al., 2005; Seyhan et al., 2011). 
The guide strand directs a RISC-mediated endonucleolytic cleavage of the mRNA. 
This process occurs at a single phosphate across nucleotides 10 and 11 from the 
5’ end of the guide strand, thus triggering degradation of mRNA eventually 
preventing its translation in to a protein (Hamilton et al., 1999; Hammond et al., 
2000; Zamore et al., 2000; Elbashir et al., 2001) (Fig.18). 
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Fig. 18 | Schematic representation of the fate of double stranded siRNA a) Entry in to the cell via 
transfection b) The duplex binds to DICER leaving a two nucleotide long 3’ overhang c)This 
primes binding of the dsRNA for binding to the RNA induced silencing complex (RISC) d) Binding 
of the RISC complex to dsRNA leads to the activation of Ago 2 enzyme and the RNAse component 
of RISC destroys one of the strands e) The other strand binds to the target mRNA and mediates 
its cleavage f) Cleaved target mRNA (Modified from Santa cruz biotechnology) 
 
RNAi can also be triggered by exogenous delivery of dsRNAs in to cells. Once a 
potent and selective siRNA is identified, it can be incorporated in to short hairpin 
RNA (shRNA) to be expressed from plasmids or viral vectors (Seyhan et al., 
2011) and injected in to the cells through transfection or transduction 
respectively. 
RNAi has been successfully used in in vitro and in vivo studies thus 
demonstrating its potential as a therapeutic molecule in the context of 
neurogenetic diseases (Seyhan A. et al., 2011). 
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 Amyotrophic lateral sclerosis (ALS) is caused due to mutations in 
Superoxide dismutase 1 (SOD1) that leads to toxic gain of function 
phenotype. Selective suppression of mutant SOD1 allele using siRNAs has 
been shown in Drosophila lysate using reporter assays (Schwarz et al., 
2006).This was followed by a viral RNAi delivery in to a transgenic mouse 
model of ALS wherein a therapeutic benefit was observed through 
improved motor neuron survival, delayed disease onset and increased life 
span of animals (Ralph et al., 2005; Raoul et al., 2005). 
 Spinocerebellar ataxia type 3 (SCA 3) is caused by a dominant 
expression of CAG repeats in the ataxin-3 gene (Paulson et al., 2000). 
Researches have shown that these mutations can be targeted using an 
AAV1 expressing shRNAs in a transgenic mouse model expressing high 
levels of pathogenic form of ataxin -1 with 82 CAG repeats in cerebellar 
cells (Burright et al., 1995). Upon treatment, an improved motor 
coordination and cerebellar morphology was observed in the animals. 
Similar studies were also shown in ataxin-7 disease model (Scholefield et 
al., 2009). 
 Huntington’s disease (HD) characterized by the poly Q proteins 
encoded by CAG repeats within the HTT (Huntingtin) gene was targeted 
with an RNAi approach using an AAV expressing shRNA, which resulted in 
an improvement of disease pathology and life span extension (Harper et 
al., 2005). 
 Alzheimer’s disease (AD) caused due to mutations in the Amyloid 
precursor protein (APP) gene. Allele specific silencing has been 
demonstrated in a transgenic APP mutant mouse model, in which an AAV 
5 vector based delivery lead to decrease of mutant protein accumulation 
and an increase of psychometric performance (Rodriguez –Lebron et al., 
2009). 
 FTDP-17 is caused due to various mutations in MAPT gene and an siRNA 
approach has been used to selectively target the mutant allele containing 
the V337M mutation in exon 12 of MAPT gene. 
 Parkinson’s disease (PD) is characterized by an over expression of 
alpha synuclein protein as a result of mutations such as A53T and A30P. 
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Lentiviral based shRNA approach was successfully employed in a rat 
model, in which selective suppression of the mutant allele was observed. 
 Similar studies were also carried out in the Slow channel congenital 
myasthenic syndrome disease (SCCMS), in which a selective 
suppression of mutant acetyl choline receptor (AChR) subunits 
(containing an AS226F mutation) was achieved in mammalian cells. using 
siRNAs and shRNAs (Croxen et al., 2002). 
 
Likewise, siRNAs have also been used as therapeutic molecules to target splice 
defects wherein, it is employed to specifically target and degrade disease linked 
mRNA isoform (Zhu et al., 2005). Therefore RNAi is emerging as a valuable tool 
for clinical applications in the context of neurogenetic diseases. This justifies a 
possible approach to target the 4R isoform containing exon 10 in FTDP-17. 
 
1.5.2 (ii) Long non coding RNAs (lncRNAs) 
 
Long non-coding RNAs are transcripts with a varied size between 200-100,000 
bases. They have little or no protein coding capacity (Schonrock et al., 2012). 
They may or may not be spliced, or polyadenylated, they might be nuclear or 
cytoplasmic, and are transcribed by RNA polymerase II or III (Amaral P.P et al., 
2011).  
Those ncRNAs engaging in RNA-RNA, RNA-DNA, and RNA-protein interactions 
can thus regulate processes such as chromatin remodeling, transcription, mRNA 
processing, stability and localization, translation and protein stability 
(Schonrock N et al., 2012). 
 
Long noncoding RNAs (lncRNAs) can regulate gene expression through a variety 
of mechanisms (Mercer, T.R. et al., 2009; Korneinko et al., 2013) (Fig.19). 
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Fig. 19| Long non-protein-coding RNAs (lncRNAs) act at different levels to regulate protein 
coding gene expression. lncRNAs can inhibit general protein-coding (pc) gene expression in trans 
(a) by preventing transcription factor (TF) activity (e.g. 7SK lncRNA) or (b) by inhibiting RNAPII 
binding to DNA (e.g: B2 lncRNA). Xist lncRNA is transcribed from the X inactivation center (XIC) 
and inactivates a whole chromosome in cis (c) by recruiting epigenetic modifiers (EM). lncRNAs 
can regulate specific genes, acting in trans (d) or in cis (e) by directly recruiting epigenetic 
modifiers to certain genomic loci. In both cases the lncRNA binds EMs via a specific sequence or 
structure and targets them to promoter regions via DNA/RNA interaction elements to influence 
expression of the respective pc gene. Transcription of a lncRNA through a pc gene promoter or a 
cis-regulatory element (RE) affects pc gene expression in cis independent of the lncRNA product. 
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Both DNA strands are shown as separate boxes to indicate lncRNA transcription over the pc gene 
promoter in the antisense orientation (Kornienko et al., 2013). 
 
In fact, ncRNAs have been regarded as significant regulators in orchestrating 
neural gene expression and function (Brosius et al., 2005). Implications of 
ncRNAs in mediating complex biological functions such as neurogenesis, 
neurotransmission, neuronal patterning, synaptic plasticity, stress responses 
and aging of brain have been observed.  
Knock out studies in mice models have shown that ncRNAs are active players in 
the development of nervous sytem (Guttman, M et al., 2009; Mercer et al., 2010; 
Gordon et al., 2010; Bond et al., 2009; Lewejohann et al., 2004) 
This validates the function of ncRNAs in the Central nervous system (CNS) (Cao 
et al., 2006; Mehler et al., 2007; Mercer T.R et al., 2008; Tsurdome K et al., 2010; 
Gao F.B et al., 2010; Qureshi et al., 2011). Thus their dysregulation could be 
central to the development of debilitating neurodegenerative diseases. NATs are 
a class of abundant ncRNAs located in the nervous system. They are transcribed 
from the opposite strand of either protein or non-protein coding genes and often 
partially overlap with the protein-coding genes thus sharing a sequence 
complementarity with the corresponding sense mRNA (Schonrock et al., 2012). 
LncRNAs have also been shown to be associated to AD, which is caused due to an 
accumulation of extracellular amyloid protein (Aβ42). This diseased state is 
thought to be associated with an elevated level of secretase enzyme, termed as β-
secretase cleaving enzyme 1 (BACE1). A lncRNA, known as BACE1 antisense 
transcript (BACE1-AS) is known to regulate the expression of BACE1 mRNA and 
the protein both in vitro and in vivo (Faghihi et al., 2008). 
Upon exposure to Aβ42, the expression of BACE1-AS becomes elevated wherein 
it increases the stability of BACE1 mRNA and generates more Aβ42 through a 
post-transcriptional feed-forward mechanism (Faghihi et al., 2008). The 
increased amounts of BACE1-AS was confirmed in both subjects with AD and 
transgenic mouse, thus proving the direct implication of lncRNA in accumulation 
of APP linked to AD (Massone et al . 2011). 
Other Long ncRNAs include NEAT1and 2 that has been shown to contribute to 
the development of amyotrophic lateral sclerosis (ALS) (Nishimoto et al., 2013). 
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TAR DNA-binding protein-43 (TDP-43) and fused in sarcoma/translocated in 
liposarcoma (FUS/TLS) (Lagier-Tourenne and Cleveland, 2009) contribute to the 
development of ALS. Recent studies showed that both TDP-43 and FUS/TLS are 
bound by and are co-localized with the long ncRNA NEAT1 and 2. This long 
ncRNA is vital for the formation of nuclear bodies called paraspeckles and was 
shown to be up-regulated in human motor neurons in early stage of ALS 
(Nishimoto et al., 2013). Thus, NEAT1 and 2 might contribute to the 
development of early stage of ALS through their interaction with TDP-43 and 
FUS/TLS (Vucicevic et al., 2014). 
 
Long ncRNAs could also be possibly involved in the development of HD, in which 
long ncRNAs HAR1F and HAR1R are affected (Pollard et al., 2006). Human 
accelerated regions (HARs) are fast evolving non-coding sequences in the human 
brain and are often found close to the neurodevelopmental genes like GATA3. It 
was postulated that they might potentially participate in unique human brain 
functions (Pollard et al., 2006). Of these regions, the most dramatic changes were 
found in the HAR1 locus that codes for the two long ncRNAs HAR1F and HAR1R 
(Pollard et al., 2006). The expression of both can be repressed by the RE-1-
silencing transcriptional factor (REST) that pathologically (in HD) trans-locates 
to the nucleus and mediates repression of important neuronal genes in neuronal 
cells (Johnson et al., 2010). Future studies are essential to shed light on the 
mechanism of HAR1 long ncRNAs and their role in development of HD (Vucicevic 
et al., 2014). 
Another lncRNA BC200 is known to exhibit abnormal sub-cellular localization 
and expression levels in brain regions of AD patients (Mus et al., 2007). 
Hence, these studies open a possible new avenue of research focusing on 
regulation of MAPT through lncRNAs for a therapeutic benefit.  
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Abstract 
 
This chapter focuses on evaluating the feasibility of a gene therapy approach 
using antisense sequences embedded in U1 and U7 snRNAs to modulate splicing. 
Since mutations in exon 10 of MAPT gene have been reported to cause an 
impairment of splicing leading to an altered proportion of 4R and 3R isoforms in 
FTDP-17, this work has been dedicated to explore modulation of splicing so as to 
induce skipping of exon 10 thus restoring the balance of 1:1 of the two isoforms 
(4R:3R). 
Previous work by Covello G et al., (unpublished data) has demonstrated that 
antisense oligonucleotides are capable of inducing exon 10 skipping in the 
context of rat pheochromocytoma (PC12) cells. These oligonucleotides were 
further embedded in to the U1 and U7 snRNA cassettes and available in the lab 
prior to the beginning of sections explained below. 
The first part of this project was dedicated to produce chimeric scramble 
constructs which were used as controls for all the following experiments. 
The second part was dedicated to test the efficacy of thirteen different chimeric 
constructs embedded in the U1 / U7 snRNA cassette to check for their effect on 
regulation of MAPT exon 10 splicing. 
The results were checked after 48 hours of transfection in PC12 cells using semi-
quantitative Real-Time PCR assays. 
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2.1. Materials and methods 
 
All the primers were synthesized by the Eurofins mwg/ operon company. 
The following constructs were available in the Laboratory of RNA Biology and 
Biotechnology, CIBIO: 
-pAAV2.1.-CMV eGFP3 vector, an adeno associated vector recombinant vector 
containing the following parts: 
a. A Strong CMV promoter, that allows an high expression of foreign genes; 
b. Ampicillin resistance for a positive selection of the recombined colonies and 
the GFP cassette for the visualization of transfected cells (Auricchio et al., 2001). 
 
-Six different chimeric constructs, composed of the U1 snRNA cassette, coupled 
to specific antisense oligonucleotides, embedded in to the pAAV2.1 CMV eGFP 
vector (Table 1). 
-Six different chimeric constructs, composed of the U7 snRNA cassette, coupled 
to specific antisense oligonucleotides, embedded in to the pAAV2.1 CMV eGFP 
vector (Table 1). 
 
U1 Chimeric constructs U7 Chimeric constructs 
 
pAAV_GFP_U1#10_α 
 
pAAV_GFP_U7#10_α 
 
pAAV_GFP_U1#10_β 
 
pAAV_GFP_U7#10_β 
 
pAAV_GFP_U1#10_rβ 
 
pAAV_GFP_U7#10_rβ 
 
pAAV_GFP_U1#10_ α β 
 
pAAV_GFP_U7#10_ α β 
 
pAAV_GFP_U1#10_ α rβ 
 
pAAV_GFP_U7#10_ α rβ 
 
pAAV_GFP_U1#10_γ 
 
pAAV_GFP_U7#10_γ 
Table 1 | List of available chimeric constructs in the Lab of RNA Biology and Biotechnology 
(prior to 2011). 
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2.1.1. Construction of U snRNA chimeric scramble molecules 
 
2.1.1.(i) Oligonucleotides phosphorylation  
 
100 pmol of forward and reverse primers were phosphorylated in a final volume 
of 100 μL by using T4 polynucleotide kinase (Fermentas). 
 
Reagent [C]i [C]f 
Primers 100 pmol/μL 100 pmol/ 100 μL 
T4 polynucleotide kinase (Fermentas) 10 U/ μL 50 U/ 100 μL 
Buffer A (Fermentas) 10X 1X 
ATP (Fermentas) 100 μM 1 μM 
Water - - 
Final volume: 100 μL 
 
After an incubation of 30 minutes at 37°C, the reaction was stopped by the 
addition of 1 μL of EDTA 0.5M pH=8. Oligonucleotides were purified by the 
addition of 100 μLof chloroform, and centrifuged for 2 minutes at 13000 rpm. 
The resulting supernatant containing the phosphorylated oligonucleotides was 
transferred in a new eppendorf. 
The phosphorylated primers with a final concentration of 1 pmol/μL thus 
obtained were then used for the first PCR amplification reaction and /or stored 
at -20 °C. 
 
2.1.1. (ii) First polymerase chain reaction 
The fragments of U1#10_α scramble, U1#10_ƴ scramble, and U1#10_universal 
were obtained via three distinctive PCRs using the pAAV2.1.-CMV eGFP PBS U1 
plasmid containing the U1 snRNA gene. Similarly, the U7#10_α scramble, and 
U7#10_universal were obtained via two distinctive PCRs using the pU7 smOPT 
containing the U7 snRNA gene. 
Each individual set of PCR was carried out such that; 
 100ng of template was used with the following set of primers; 
 a. U1#10_α scramble (Forward primer: U1 casup and Reverse primer: U1 
antisense (α) scramble). 
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 b. U1#10_ƴ scramble (Forward primer: U1 casup and Reverse primer: 
U1 ace antisense (ƴ) scramble). 
 c. U1#10 universal (Forward primer: U1 universal and Reverse primer: 
U1 cas down). 
 d. U7#10_α scramble (Forward primer: U7 casup and Reverse primer: U7 
antisense (α) scramble). 
 e. U7#10 universal (Forward primer: U1 universal and Reverse primer: 
U7 cas down). 
 
2.1.1. (iii) Ligation of the U1 fragments 
 
The fragments were ligated such that: 
 U1#10 α scramble and U1#10 universal to generate the full length U1#10 
α scramble. 
 U1#10 ƴ scramble and U1#10 universal to generate the full length U1#10 
ƴ scramble. 
 U7#10 α scramble and U7#10 universal to generate the full length U7#10 
α scramble. 
The ligation was performed in a final volume of 20 μL with a molar ratio of 1:2 
for the U1/ U7 #10 α/ ƴ scramble and U1/ U7 #10 universal respectively. The 
reaction was incubated at 16 °C for 3 hours, according to the following protocol. 
The result of the ligation was checked on a 1.2% agarose gel (EtBr 5%), and 
subsequently used as a template for the II PCR reaction that follows. 
 
Reagent [C]i [C]f 
U1/ U7#10 α/ ƴ scramble - 440 ng/20 µl 
U1/ U7 #10 universal - 100 ng/20 µl 
T4 DNA Ligase Buffer (NEB) 10X 1X 
T4 DNA Ligase  
(NEB) 
5U/µl 3U/20 µl 
Water - - 
Final Volume = 20 µl 
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2.1.1. (iv) Second polymerase chain reaction 
 
Each of the three fragments obtained from the ligation reaction was used as a 
template (20ng) for a II PCR reaction, with the external U1 Cas up and U1 cas 
down primers to generate the full length chimeric U1 and U7 antisense scramble 
constructs. This reaction was performed in a final volume of 50 μL with a single 
series of 30 cycles, preceded by a 1 minute long pre-denaturation step, according 
to the below mentioned protocol: 
 
Reagent [C]i [C]f 
Ligation product - 20 ng/50 μL 
Cloned pfu DNA polymerase reaction 
buffer (Agilent) 
10X 1X 
dNTPs mix (Euroclone) 10 mM 0.2mM 
Cloned pfu DNA polymerase (Agilent) 2U/ μL 2.5U/ 50 μL 
U1 Cas up For 10 μM 0.2 μM 
U1 Cas down Rev 10 μM 0.2 μM 
Water - - 
Final volume: 50 μL 
 
5 μL of the amplification product were loaded on a 1.2% TBE 1X agarose gel 
(EtBr=5%) with 1 kb plus DNA ladder (Fermentas). The electrophoresis was 
allowed to run for 30 minutes at 80 V. DNA products (575 bp) were purified with 
the QIAquick PCR purification kit (Qiagen) following manufacturer’s protocol 
and quantified with Nanodrop ND-1000 spectrophotometer (Thermo scientific). 
 
2.1.1. (v) Cloning in the pAAV2.1-CMV-eGFP vector 
 
Digestion and dephosphorylation of pAAV-2.1 CMV-eGFP3 vector 
 
The amplified product was purified using the QIAquick PCR purification kit 
(Qiagen). The total amount of U1/U7 #10 scrambles (α/ƴ) and 10 μg of pAAV2.1 
CMV eGFP3 vector were digested with NheI restriction enzyme for 3 hours at 37⁰ 
C in a final volume of 50 μL, according to the protocol described in the below 
mentioned table. 
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Reagent [C]i [C]f 
PCR sample - - 
NEBuffer (NEB) 10x 1x 
NheI (NEB) 2U/ μL 2U/50 μL 
Water - - 
Final volume: 50 μL 
 
Following this, the U1 / U7 #10 scramble fragments were purified with QIAquick 
PCR purification kit (Qiagen), according to manufacturer’s instructions. This 
protocol is based on an ionic exchange of columns in order to bind to DNA and 
elution of the sample in a final volume of 30 μL of water after a couple of washing 
steps, performed with appropriate buffer containing isopropanol. 
In order to prevent re-circularisation of the plasmid, the digested pAAV2.1 CMV 
eGFP3 vector was dephosphorylated with Calf Intestine Alkaline Phosphatase 
(CIAP, Fermentas) at 37°C for 30 minutes, following the below mentioned 
protocol in table. 
 
Reagent [C]i [C]f 
pAAV2.1 CMV eGFP3 - 10 μg/ 100 μL 
CIAP (Fermentas) 1U/ μL 0.4U/100 μL 
Buffer CIAP (Fermentas) 10X 1X 
Water - - 
Final volume: 100 μL 
 
The dephosphorylated Nhe I- pAAV2.1 CMV eGFP3 vector was separated on 1% 
TAE 1X agarose gel (2.5% EtBr) in addition to 40% W/V 6X sucrose loading dye. 
DNA was recovered by the QIAquick Gel extraction Kit (Qiagen) according to 
manufacturer’s instructions and quantified with Nanodrop ND-1000 
Spectrophotometer (Thermo scientific). 
 
Ligation of chimeric fragments in to the pAAV2.1 CMV eGFP3 vector 
The ligation reaction was performed for three hours at 16 °C in a final volume of 
20 μL by using T4 DNA ligase (NEB) and using a molar ratio of 1:3 for the vector 
(Nhe I- pAAV2.1 CMV eGFP3) and the chimeric scramble fragments (Nhe I- U1 / 
U7 #10 (α/ƴ)) respectively. 
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 The exact quantity of insert to use in this reaction for 100 ng of vector was 
calculated with the below mentioned formula: 
 
ng of insert = vector (ng) x insert dimension (kb) x molar ratio (insert/vector) 
vector dimension (kb) 
The protocol used for the ligation is reported in the below mentioned table. 
 
Reagent [C]i [C]f 
Nhe I- pAAV2.1 CMV eGFP3 vector - 100 ng/20 μL 
Nhe I- U1#10 chimeric scramble - 35 ng/20 μL 
T4 DNA Ligase Buffer (NEB) 10X 1X 
T4 DNA Ligase Enzyme (NEB) 5U/ μL 5U/20 μL 
Water - - 
Final volume: 20 μL 
 
The result of the ligation reaction was transformed in to E.coli DH5 α competent 
cells. 
 
2.1.1. (vi) Preparation of E.coli DH5α competent cells and transformation 
Preparation of competent cells 
 
An aliquot of E.coli DH5 α competent cells was grown in LB (25g/L, Sigma) at 37 
°C until it reached the exponential growth phase, with an OD600 of 0.6. 1mL of 
the culture was then inoculated in 50 mL of LB (25g/L, Sigma) containing 50 
μg/mL ampicillin, and incubated for 2 hours in agitation at 37 °C. DH5 α cells 
were then centrifuged for 5 minutes at 4000 rpm at 4°C. The pellet thus obtained 
was resuspended in 1/20 volume of a solution containing 25g/L LB (Sigma), 
10% PEG3350, 5% DMSO, 10mM MgCl2 and 10mM MgSO4. 10% glycerol was 
added to this solution and stored at -80°C. 
 
Transformation  
 
Competent cells prepared as described above were thawed in ice for 10 minutes. 
Meanwhile, 10μL of the ligation products were mixed with 100μL of KCM 
solution (100mM KCL, 20 mM Cacl2, 50 mM MgCl2) and incubated for 5 minutes 
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in ice. 100μL of DH5α competent cells were hence added to DNA-KCM, and the 
resulting solution was gently mixed and incubated in ice for 20 minutes. At the 
end of the incubation step, DH5α cells were heat-shocked for 1 minute at a 
temperature of 42°C, and incubated for in ice for another minute. 800μL of LB 
(25g/L, Sigma) without ampicillin was added to the transformed cells, and the 
resulting solution was incubated for 1 hour at 37°C in agitation at 350 rpm. 
Finally, they were plated on a LB agar plate (35 g/L, Sigma) with ampicillin 
(50μg/mL) and incubated overnight at 37°C. 
 
The colonies grown during the overnight incubation were picked and grown 
overnight in agitation at 37°C in 5 mL of 25 g/L LB (Sigma) with ampicillin 
(50μg/mL). On the following day, the plasmid DNA was extracted using the 
QIAprep Spin Miniprep Kit (Quiagen) following manufacturer’s protocol, and its 
concentration was measured with Nanodrop ND1000 spectrophotometer 
(Thermo scientific). 
 
Analysis of the transformed colonies 
 
The exact sequence and the orientation of the inserts within the PAAV-
2.1CMVeGFP3 vector were confirmed by automated DNA sequencing (BMR 
Genomics, Padua) using the AAV Rev primer (5’ -
CCATATATGGGCTATGAACTAATG-3’). 
 
2.1.2. Selection of cell line 
 
2.1.2. (i). PC12 cell line 
 
Rat pheochromocytoma cells (PC12) was used as the system to study the effects 
of chimeric constructs on exon 10 of MAPT gene. This system has been employed 
as a model system to study due to its pre-dominant content of exon 10 and 
ability to stop division and terminally differentiate upon treatment with nerve 
growth factor (NGF) (Greene and Tischle, 1976). The cells were maintained in 
Dulbecco’s Modified Eagle’s Medium (DMEM) with 4.5% g/L glucose and phenol 
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red, supplemented with 5% Fetal Bovine serum (FBS) and 10% Horse serum 
(HS).Cells were plated in monolayer in a T-25 flask coated with 0.05% poly-D-
lysine. They were allowed to grow until reaching a confluency of 70% after 
which they were transiently transfected with the chimeric constructs. 
 
2.1.2. (ii) Optimisation of transfection efficiency  
 
In order to optimize the best transfection efficiency, two transfection methods 
were adapted; 
 
a. Lipid based transfection 
b. Electroporation 
 
These methods were optimized for transfection of DNA in PC12 cells and have 
been included in the manuscript with the following title: 
 
Covello G, Siva K, Adami V, Denti MA. (2014) “An electroporation protocol for 
efficient DNA transfection in PC12 cells” Cytotechnology 66(4):543-53. 
 
a. Lipid based transfection 
 
The transfection reagents used in this study were: TransIT-LT1 Transfection 
Reagent (Mirus, Madison, WI, USA), Lipofectamine 2000 and Lipofectamine LTX 
(Invitrogen). 4 x 104 cells/well were seeded on poly-D-lysine- coated 24-well 
plates (Corning) a day prior to transfection and grown in supplemented DMEM 
at 37 °C supplied with 5 % CO2. PC12 cells which were grown upto a 70 % 
confluency were then transfected with the mammalian expression vector pEGFP-
C1 (Empty vector with GFP). Transfection procedures were performed as 
indicated by manufacturer. The ratio DNA (ng) : transfection reagent (μL) was 
1:3 with all three transfection reagents.  
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b. Electroporation 
 
Electroporation in PC12 cells were optimized using the pEGFP-C1 (Empty vector 
with GFP) as described by Covello G et al., 2014 (Refer to attachment). 
The above mentioned optimized method was used as a standard protocol to 
perform transfections in PC12 cells as described below. 
2.1.2. (iii) Transfection experiments in PC12 cell line 
 
The transfection of PC12 cells with chimeric constructs was performed using the 
Neon transfection system MPK5000 (Invitrogen). Cells with 70% confuency 
were washed twice with 5mL of PBS (1X) (Lonza). 1mL of 1X Trypsin (Lonza) 
was added and incubated for 2 minutes at 37 °C. Trypsin was deactivated using 
9mL of DMEM and cells were transferred in a 15 mL falcon and centrifuged at 
400g for 5 minutes. The pellet thus obtained was re-suspended in 10 mL PBS 
.The number of cells were counted using the Burker chamber. Trypan blue stain 
exclusion test was used to determine cell viability. 10 μL of cell solution was 
mixed with an equal volume of 0.4% trypan blue stain and counted with the 
Burker chamber, using the below mentioned formula: 
 
Cell concentration (cells/ml) =mean of the readings x titration factor x10000 
 
Cells were further resuspended in Buffer R to reach a concentration of 108 cells/ 
mL. 10 μL of cell solution (containing ~ 106 cells) plus 0.5 μg of each chimeric 
construct were added to 500 μL of DMEM in every well of the plate coated with 
poly-D-lysine.   
The transient transfections of PC12 cells with chimeric constructs were 
performed with the following conditions: 1x106 cells / well, three 10ms-long 
pulses each with 1500 V. 
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Evaluation of transfection efficiency  
 
Images of the transfected cells were acquired using Operetta High Content 
Imaging System (Perkin Elmer, Monza, Italy). After 48 hours of transfection, cells 
were washed with PBS 1X (Lonza). They were incubated for 20 minutes at 37 °C 
in 500 μL of supplemeted DMEM with 1mg/mL of Hoechst 3342 fluorescent dye 
(Sigma) to enable nuclei counterstain and subsequent total cell count. Cells were 
washed again with PBS 1X and replaced with supplemented medium (without 
red phenol). 
The transfection efficiency was analysed using the Harmony High Content 
Imaging Software (Perkin Elmer). The ‘Select Population’ feature of Harmony 
software allowed to set a threshold of fluorescence intensity in order to identify 
the sub-population of transfected cells. 
Images were obtained with a 20X LWD objective, with two different filter sets; 
1. Filter for Hoechst 3342 stain (excitation filter: 360-400 nm, emission filter: 
410-480 nm) to visualise total viable cells. 
2. Filter for Alexa Fluor 488 (excitation filter 460-490 nm, emission filter: 500-
550 nm) was used to count the number of transfected cells. The laser autofocus 
was applied and 12 image fieds were acquired for each well. 
 
2.1.3. Semi-quantitative reverse transcriptase analysis on PC12 cell line 
 
2.1.3. (i) RNA extraction 
RNA extraction was performed using Trizol reagent (Life technologies). After the 
addition of 200 μL of Trizol reagent, 60 μL of chloroform was added to added to 
each sample and vortexed vigorously. This was followed by an incubation of 3 
minutes at room temperature. The solution was then centrifuged at 12000 g for 
15 minutes at 4°C. 150 μL of isopropanol was added to the mix and incubated at 
room temperature for 10 minutes followed by a centrifugation at 12000 g for 10 
minutes at 4°C. The supernatant was discarded while the pellet was washed with 
300 μL of 75% ethanol. The sample was briefly vortexed, centrifuged at 7500 g 
for 5 minutes at 4 °C and air-dried for 5 minutes. 
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The RNA was resuspended in 30 μL of RNAse free water and quantified by 
Nanodrop ND-1000 (Thermo scientific) spectrophotometer.  
In order to remove traces of DNA, the extracted RNA was treated with DNAse by 
using Turbo-DNAse Kit (Ambion) following manufacturer’s instructions. 
 
2.1.3. (ii) cDNA preparation 
 
500ng of the RNA extracted from each sample with Trizol reagent (Life 
Technologies) was reverse-transcribed to cDNA with the RevertAidTM First 
Strand cDNA Synthesis Kit (Fermentas) by using both random primers and dT18 
oligonucleotides, following manufacturer’s protocol. The obtained cDNA was 
used as template for semi-quantitative Real-Time PCR reactions, in order to 
evaluate the levels of the expression of the U1 chimeric molecules snRNAs and 
isoforms of MAPT transcripts. 
 
2.1.3. (iii). Semi quantitative RT-PCR assay to evaluate expression of RNA of  
U1snRNA constructs 
 
The expression levels of U1 snRNA chimeric constructs and their integrity was 
analysed using semi-quantitative reverse transcription polymerase chain 
reaction with appropriate primers using 5 μL of the cDNA synthesized with 
random primers. The amplification reaction was carried out using 35 cycles 
preceded by a pre-denaturation step of incubation for 1 minute at 95 °C, using 
the below mentioned protocol in a final volume of 25 μL. ß actin was used as a 
house keeping control. The dimensions of amplified U1 and U7 products are 
reported in the table below. 
 
Sample Product dimension (bp) 
U1/U7 α 98 
U1/U7 β 97 
U1/U7 α β 130 
U1/U7 αrβ 130 
U1/U7 γ 98 
U1/U7 α scr 98 
U1 γ scr 98 
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The above mentioned forward primers were used in a combination with the U7 
Reverse primer U7rev ggg AGG GGT TTT CCG ACC GAA G for the 
amplification of U7 small nuclear RNAs. The primer pairs used for the 
amplification of the house keeping gene (HK) ß-actin is as follows: 
 
Amplified products were allowed to run with 1 Kb plus DNA ladder (Fermentas) 
on a 2 % agarose gel electrophoresis (EtBr=5%) at 90 Volts in TBE 1X running 
buffer for about 40 minutes. 
Images were acquired using the BioDoc-It Imaging (UVP) and densitometric 
analyses were performed on the images using Image J software.  
  
Chimeric 
construct 
Forward primer Reverse primer 
U1 α r/h Anti 3F   ATT ATC TGC ACC TTT GGT AGC C 
 
 
U1+130rev   gtc AGC ACA TCC GGA GTG CAA TG 
 
U1 β r/h Anti5F     GAA GGT ACT CAC ACT GCC GCC TC 
 
U1+130rev   gtc AGC ACA TCC GGA GTG CAA TG 
 
U1 α β r/h Anti 3F   ATT ATC TGC ACC TTT GGT AGC C 
 
 
U1+130rev   gtc AGC ACA TCC GGA GTG CAA TG 
 
U1 αrβ r/h Anti 3F   ATT ATC TGC ACC TTT GGT AGC C 
 
U1+130rev   gtc AGC ACA TCC GGA GTG CAA TG 
 
U1 γ r/h Anti ACEF CAC TTG GAC TGG ACG TTG CTA AG 
 
 
U1+130rev   gtc AGC ACA TCC GGA GTG CAA TG 
 
U1 α 
scramble 
r/h Anti 3F   ATT ATC TGC ACC TTT GGT AGC C 
 
 
U1+130rev   gtc AGC ACA TCC GGA GTG CAA TG 
 
U1 γ 
scramble 
r/hAnti ACEF CAC TTG GAC TGG ACG TTG CTA AG 
 
U1+130rev   gtc AGC ACA TCC GGA GTG CAA TG 
 
House 
keeping 
gene 
Forward primer Reverse primer Product length 
 
ß actin 
 
bACTINrt_r/mFor GAT CAA GAT 
CAT TGC TCC TCC TG 
 
 
bACTINrt_r/mRev AGG GTG 
TAA AAC GCA GCT 
 
200bp 
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2.1.3. (iv) Semi quantitative RT-PCR assay to evaluate expression of RNA of 
MAPT transcript isoforms 
 
A semiquantitative RT-PCR amplification was performed to analyse the 
expression levels of MAPT and HK gene β-actin. This analysis was performed to 
evaluate the effects of chimeric constructs on regulation of splicing events of 
MAPT exon 10. The cDNA was prepared using oligo dT oligonucleotides and 
amplification reaction was performed in a final volume of 25 μL, with a single 
series of 35 cycles preceded by a 1 minute long pre-denaturation step of 
incubation at 95 °C, using the below mentioned protocol. 
 
Reagent [C]i [C]f 
cDNA - - 
RBC reaction buffer 10X 1X 
dNTPs mix (Euroclone) 10 mM 0.2 mM 
RBC Taq polymerase 5U/ μL 1U /25 μL 
Forward primer (Tau) 10 μM 1 μM 
Reverse primer (Tau) 10 μM 1 μM 
Water - - 
Final volume: 25 μL 
 
Reagent [C]i [C]f 
cDNA - - 
RBC reaction buffer 10X 1X 
dNTPs mix (Euroclone) 10 mM 0.2 mM 
RBC Taq polymerase 5U/ μL 1U /25 μL 
Forward primer (ß actin)  10 μM 0.5 μM 
Reverse primer (ß actin) 10 μM 0.5 μM 
Water - - 
Final volume: 25 μL 
 
  
74 
 
Primers used for amplification of MAPT and ß-actin gene and the PCR protocol 
are described as follows: 
 
 
 
PCR METHOD : 35 CYCLES (BIORAD) 
Temperature Time 
95 °C 10 minutes 
95 °C 30 seconds 
60 °C 40 seconds 
72°C 1 minute 
72°C 10 minutes 
4°C ∞ 
 
The amplified products were allowed to run with 1 Kb plus DNA ladder 
(Fermentas) on a 2 % agarose gel electrophoresis (EtBr=5%) at 90 Volts in TBE 
1X running buffer for about 40 minutes. 
 
Images were acquired using the BioDoc-It Imaging (UVP) and densitometric 
analyses were performed on the images using Image J software. 
  
Gene Forward primer Reverse primer Product 
dimension 
(bp) 
 
Exon 10+ 
/ Exon 10- 
 
TAUR9F CTGAAGCACCACCAGCCGGGAGG             
 
 
TAU13R TGGTCTGTCTTGGCTTTGGC 
 
368 / 275 
 
 
ß-actin 
 
ACTIN FOR 
AGACGGGGTCACCCACACTGTGCCCATCTA 
 
 
ACTIN REV 
CTAGAAGCATTTGCGGTGCACGATGGAGGG 
 
 
650 
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2.2. Results  
 
2.2.1. Screening of Exon specific U1 constructs (ExSpe U1s) on MAPT 
exon10 in the endogenous content of PC12 cell line. 
A total of twelve different U1 and U7 chimeric constructs were produced and 
readily available in the Laboratory of RNA Biology and Biotechnology prior to my 
arrival. 
I had produced U1 (α / ƴ) and U7 (α) scramble constructs. These are essential 
controls to validate the possible potent target specific effects of the U1 and U7 
constructs on exon 10 of MAPT gene. 
 
2.2.1. (i) Construction of U snRNA scramble chimeric molecule  
For generating the U1 snRNA scramble (α / ƴ) constructs, as a first step, two 
different PCR reactions were performed using the PBS 1 plasmid as a template 
For the U7 snRNA scramble (ƴ) construct, the smOPT plasmid was used as a 
template (Fig 2.1 ). 
 
 
 
Fig. 2.1 | Schematic representation of distinct PCR reactions to amplify specific products such as 
U1 snRNA scramble (α / ƴ) constructs and the U7 snRNA scramble (ƴ) construct and the 
universal fragments for each U1 and U7 snRNA construct.(Figure is not drawn to scale). 
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First PCR reaction  
The five different fragments obtained via distinct PCR reactions are as follows; 
 
U1 snRNA scramble (α) fragment  
A PCR reaction was set up using the PBS U1 plasmid, for which a (i) forward 
primer that annealed with the 5’ end of the U1 snRNA promoter (U1 cas up For) 
with an overhanging tail coding for the NheI endonuclease site and (ii) reverse 
primer that annealed with the 3’ end of the U1 snRNA promoter carrying 
additional scramble sequences specific to the 3’ splice site of the Exon 10 (α 
scramble Rev) was used yielding a product of 360 base pairs. 
 
U1 snRNA scramble (ƴ) fragment  
A PCR reaction was set up using the PBS U1 plasmid, for which a (i) forward 
primer that annealed with the 5’ end of the U1 snRNA promoter (U1 cas up For) 
with an overhanging tail coding for the NheI endonuclease site and a (ii) reverse 
primer that annealed with the 3’ end of the U1 snRNA promoter carrying 
additional scramble sequences specific to the ACE rich region of the Exon 10 (ƴ 
scramble Rev) was used yielding a product of 362 base pairs 
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U7 snRNA scramble (α) fragment 
A PCR reaction was set up using the smOPT plasmid, for which a (i) forward 
primer that annealed with the 5’ end of the U7 snRNA promoter (U7 cas up For) 
with an overhanging tail coding for the NheI endonuclease site and a (ii) reverse 
primer that annealed with the 3’ end of the U7 snRNA promoter carrying 
additional scramble sequences specific to the 3’ splice site of the Exon 10 (α 
scramble Rev) was used yielding a product of 364 base pairs  
 
 
U1 universal fragment (U1 Univ fragment) 
A PCR reaction was set up using the PBS U1 plasmid, for which a forward primer 
that annealed with the 5’ end of the U1 snRNA (U1 Univ For) and a reverse 
primer that annealed with the 3’ end of the U1 snRNA (U1 cas down Rev) with an 
overhanging tail coding for the NheI endonuclease site yielding a product of 210 
base pairs. 
 
U7 universal fragment (U7 Univ fragment) 
A PCR reaction was set up using the smOPT plasmid, for which a forward primer 
that annealed with the 5’ end of the U7 snRNA (U7 Univ For) and a reverse 
primer that annealed with the 3’ end of the U7 snRNA (U7 cas down Rev) with an 
overhanging tail coding for the NheI endonuclease site yielding a product of 210 
base pairs. 
 
Ligation of constructs 
The distinct products obtained via the first PCR reaction were ligated via 
treatment with T4 DNA ligase such that (Fig 2.3 and Fig.2.4): 
(i) U1 snRNA scramble (α) fragment + U1 universal fragment  
(ii) U1 snRNA scramble (ƴ) fragment + U1 universal fragment 
(iii) U7 snRNA scramble (α) fragment + U7 universal fragment 
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Fig. 2.2 | Schematic representation of the ligation of specific products obtained from the first PCR  
 
 
Fig.2.3 | Result of ligated products as loaded on a 1% TBE gel (Gene Ruler 1 Kb plus DNA ladder 
Fermentas) 
 
Second PCR reaction  
The ligated products were used as templates to initiate the second PCR reaction 
with the Casup forward and Casdown reverse primers (Fig.2.4) to generate the 
three scramble chimeric antisense constructs (U1 α scr / ƴ scr and U7 ƴ scr ) 
(Fig.2.5 and Fig.2.6). 
 
 
Fig. 2.4 | Schematic representation of the second PCR set up and the location of forward and 
reverse primers to amplify the chimeric scramble fragments. 
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Fig. 2.5 | Schematic representation of the expected chimeric scramble fragments.after the second 
PCR on ligated products 
 
 
 
Fig. 2.6 | Result of the products after the second PCR reaction as loaded on a 1% TBE gel. Lanes 1 
= U1α scramble, 2 =U1ƴ scramble and 3 = U7α scramble. (Gene Ruler 1 Kb plus DNA ladder 
Fermentas). 
 
 
Ligation of the vector with the antisense scramble constructs  
The chimeric scramble constructs thus obtained were successfully ligated with 
the NheI-pAAV2-2.1-CMV eGFP3 vector generating the following complete 
constructs (Fig.7).  
 Two of the U1 constructs - pAAV_GFP_U1 α and ƴ scr composed of the U1 
snRNA gene, modified with the substitution of its endogenous 5’ sequence 
responsible for recognition of the splicing donor site with an antisense 
scramble  
 One of the U7 construct - pAAV_GFP_U7 α scr composed of the U7 snRNA 
gene modified with the substitution of its endogenous 5’ sequence with an 
antisense scramble.  
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Fig. 2.7 | Schematic representation of the pAAV CMV eGFP3 vector back bone 
 
 
Fig. 2.8 | Schematic representation of the pAAV_GFP_U1 snRNA construct containing the 
modified arm with the antisense embedded within the AAV backbone. 
 
Transformation  
In order to obtain a sufficient amount of DNA (of antisense scramble constructs), 
the pAAV_GFP_U1 and U7 chimeric scramble construct was transformed within 
E.Coli DH5α competent cells, following which colonies were picked and 
inoculated in suitable volume of LB and grown overnight in agitation. 
81 
 
Bacterial DNA was extracted using QIAprep Spin Miniprep Kit protocol (Qiagen) 
and samples were digested using the NheI enzyme to check for the insertion of 
modified U1and U7 snRNA cassette. 
 
Sequence analysis of the scramble constructs  
 
The positive samples were sent for sequencing by the BMR Genomics company 
(Padua) using the AAV Rev primer (5’ -CCATATATGGGCTATGAACTAATG-3’). 
The sequencing results confirmed the right nucleotide composition and correct 
orientation of the inserts within the pAAV2.1-CMV-eGFP3 vector. 
 
2.2.1. (ii) PC12 cell line transfection and analysis  
 
PC12 cells are derived from the pheochromocytoma of the adrenal medulla of rat 
cells. They are small cells with a limited cytoplasm and a long doubling time. 
They are also known to grow in culture as undifferentiated neuroblasts (Greene 
and Tischler 1976). It is a widely used model system for the studies on neuronal 
differentiation, neurotransmission and neurodegenerative disorders, as they 
develop in to sympathetic neuron like cells upon treatment with nerve growth 
factor (NGF). Additional properties such as, electrical excitability and 
development of synapses with muscle cells in culture makes them attractive 
cellular models (Grau and Greene et al., 2012). However, they posses limitations 
such as sensitivity to physical stress and alterations in temperature and pH. 
PC12, was one of the few cells known to express 80% of Exon 10+ (4R) tau 
isoform, thus recapitulating the FTDP-17 pathological condition. 
Since these cells are known to have limited transfection efficiency, the first 
experimental set up was focused on optimizing an efficient transfection protocol 
for introducing the pAAV_GFP_U1 and U7 chimeric constructs within the cell. 
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Optimisation of transfection efficiency 
 
Lipid based transfection 
 
 
 
Fig. 2.9 | Transfection optimisation in PC12 cells using liposoluble agents PC12 cells were 
transfected using the following liposoluble agents: TransIT-LT1 Transfection Reagent (Mirus), 
Lipofectamine LTX (L_LTX) and Lipofectamine 2000 (L_2000) with different concentrations of 
plasmid encoding EGFP. Fluorescence images of transfected PC12 cells were analyzed by High-
Content screening system (Operetta) after 48 h of transfection.  
 
 
Fig 2.10 | A) Percentage of transfection efficiency in PC12 cells. The percentage of 
transfected cells was calculated by dividing the number of EGFP positive cells by the total 
population of cells. The best result was obtained by using 1 μg of plasmid and Lipofectamine 
2000 (transfection efficiency of 45.9 %) (Data represent mean ± SEM obtained from triplicates). 
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Fig 2.10 | B) Percentage of cell viability in transfected PC12 cells The percentage of viable 
cells after transfection was measured by the Trypan Blue assay. The optimal cell viability (93.6 
%) was observed in cells transfected with 0.5 μg of plasmid and Lipofectamine 2000. (Data 
represent mean ± SEM obtained from triplicates). 
 
As shown in Fig.2.9 and 2.10 the TransIT-LT1 Transfection Reagent (Mirus) was 
not effective in facilitating transfection of DNA in to PC12 cells, even when a 
higher concentration of DNA was used (However, experiments were performed 
in parallel on the HEY4 ovarian cancer cell line using TransIT-LT1 that showed a 
transfection efficiency of approximately 35 % (data not shown) thus clearly 
indicating that trend of efficiency depends on the cell type). 
On the contrary, transfection experiments using Lipofectamine LTX and 
Lipofectamine 2000 enabled transfection of DNA into PC12 cells, with the 
respective efficiencies of 15% and 7 %, with 0.25 μg DNA; 27% and 20% with 
0.5µg DNA; 30% and 40% with 0.75 µg DNA;35% and 46% with 1 µg DNA. 
As expected, transfection efficiency for both reagents correlates to the amounts 
of DNA used. However, on comparing the transfection efficiency of the two 
cationic lipids, Lipofectamine LTX indicates to perform better than 
Lipofectamine 2000 at low DNA amounts between 0.25 – 0.5 µg, while 
Lipofectamine 2000 outperforms Lipofectamine LTX at higher DNA amounts 
between 0.5 – 1.0 µg. 
On comparison of our results with those by Lee and colleagues (2008), it can be 
observed that upon transfection using Lipofectamine 2000 we attained 21 % 
transfection efficiency (with 0.5 μg of DNA in a 24-well plate) while Lee and 
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collaborators reported 14 % efficiency in similar conditions (1 μg of DNA in a 12-
well plate). 
Cell viability was measured by Trypan Blue Staining after 48 hours of 
transfection (Fig.2.10 B). In all cases, viability decreased as the DNA amounts 
increased. However, as clearly indicated there is a variation of trend for different 
reagents. TransIT-LT1 had a milder impact on cell viability, reaching 92 % when 
1 μg of DNA was used. On the contrary, Lipofectamine 2000 and Lipofectamine 
LTX reached 87–88 % viability in those conditions. 
 
Electroporation 
We additionally employed optimization of transfection using the electroporation  
with the Neon Transfection system MPK5000 (Invitrogen) following which the 
most suitable condition yielding 90% of efficiency was obtained (Covello G et al., 
2013). The following conditions were identified as optimal for each reaction: 3 
pulses of 1500 voltage with 10 milliseconds to transfect 1X106 cells / well with 
0.5 µg of each chimeric construct. 
All the thirteen different constructs (Ten of the already available constructs plus 
three new scrambles) were transfected in a 24-well format. The experiments 
were performed in biological duplicate and technical duplicate. As the vector 
backbone containing the chimeric constructs contained the GFP transcriptional 
cassette, measure of GFP served adequate to measure efficiency of transfection.  
 
 
 
 
 
 
 
 
Fig 2.11 | Percentage of transfection efficiency in PC12 cells. The percentage of transfected 
cells was calculated by dividing the number of EGFP positive cells by the total population of cells. 
The best condition (99 %) was obtained by 0.5 µg of plasmid, 1x105 cells/well, and 3 pulses of 
1,300 Volt and 10 ms. (Data represent mean ± SEM obtained from triplicates).(Refer to  
manuscript attached). 
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S2.2.1. (iii).Semi quantitative RT-PCR analysis 
 
2.2.1. (iii) a. U1 snRNA chimeric molecule: RNA anlaysis 
 
Following the transfection experiments, the expression of the U1 and U7 snRNA 
constructs in the PC12 was analysed using the RT-PCR method  
RNA was extracted from each well containing cells transfected with the 
constructs and reverse transcribed to cDNA using both random and oligo dT-18 
primers. These reactions were carried out along with the set of controls as 
specified by the manufacturer. 
5µl of cDNA was amplified with a semi quantitative RT-PCR reaction using a 
forward and reverse primer designed to bind to the cDNA region of the 3’ end of 
UsnRNA. Therefore, the cells sufficiently transfected with the chimeric 
constructs and enabling their expression were expected to yield amplified 
products. The controls such as cells with empty vector or non transfected cells 
were not expected to produce amplified products. ß actin served as a gene for 
normalization and was expected to show an endogenous expression in the all the 
cells (Transfected and non-transfected). 
 
Fig 2.12 | Schematic representation of the location of forward and reverse primers used for the 
amplification of modified U snRNA (the figure is not drawn to scale). 
 
Results of the semi-quantitative RT-PCR analysis on the samples containing cells 
transfected with the U1 snRNA constructs was checked on a 2% agarose gel. 
Representative results of one of the experiments are shown in Figure 2.13. 
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Fig 2.13 | Results of the RT-PCR amplification of the U1 snRNAs. The bands represent a) 
amplified product of U1 snRNA cassette possessing ~90 bp (α, β, λ, αscr and λscr) and 130 bp (αβ 
and αrβ) b) amplified product of ß actin used as a house keeping gene. 
 
 
 
Fig 2.14 | Relative expression level of each U1 snRNA construct normalized using the ß actin as a 
house keeping gene.Data represent mean ± SEM obtained from biological duplicate experiments. 
 
As expected, the samples transfected with the AAV2.1-CMV-eGFP3 vector with 
scramble sequences showed expression of the U1 snRNAs and corresponding 
amplified products of the ß actin RNA. The samples with the empty vector and 
non treated cells showed no bands corresponding to the amplification of U1 
snRNAs but expressed ß actin. The bands of U1 αβ and αrβ appeared slightly 
higher than α, β, λ, αscr and λscr as they are long constructs containing double 
sequences. Hence, indicating a successful transfection of the constructs and their 
expression within the PC12 cells. 
The expression analysis based on the density of each band was performed, 
wherein the ampflication signal from each modified U1snRNA was normalized 
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against that of ß actin.Means and standard deviations of the signals from the 
intensities are reported in Figure 2.14. 
 
Results of the semi-quantitative RT-PCR analysis on the samples containing cells 
transfected with the U7 snRNA constructs was checked on a 2% agarose gel. 
Representative results of one of the experiments are shown in Figure 2.15. 
 
 
Fig 2.15 | Results of the RT-PCR amplification of the U7 snRNAs. The bands represent a) 
amplified product of U7 snRNA cassette cassette possessing ~ 90 bp (α, β, λ, αscr and λscr) and 
130 bp (αβ and αrβ) b) amplified product of ß actin used as a house keeping gene. 
 
 
Fig 2.16 | Relative expression level of each U7 snRNA construct normalized using the ß actin as a 
house keeping gene. Data represent mean ± SEM obtained from biological duplicate experiments. 
 
As expected, the samples transfected with the AAV2.1-CMV-eGFP3 vector 
containing scramble sequences showed expression of the U7 snRNAs and 
corresponding amplified products of the ß-actin RNA. The samples with the 
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empty vector and non treated cells showed no bands corresponding to the 
amplification of U7 snRNAs but expressed ß actin. The bands of U7 αβ and αrβ 
appeared slightly higher than α, β, λ, αscr as they are long constructs containing 
double sequences. Hence, indicating a successful transfection of the U7 
constructs and their expression within the PC12 cells. 
The expression analysis based on the density of each band was performed, 
wherein the ampflication signal from each modified U7snRNA was normalized 
against that of ß-actin. Means and standard deviations of the signals from the 
intensities are reported in Figure 2.16. 
 
Both the U1 and U7 snRNA constructs have shown sufficient expression within 
the cells indicating their ability to be transcribed and expressed.  
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2.2.1. (iii) b. MAPT mRNA levels in the endogenous condition of PC12 cells 
after transfection of U1 snRNA chimeric molecule  
 
 
Fig 2.17 | RT-PCR analysis of MAPT cDNA of samples transfected with the U1 constructs A) The 
upper band corresponds to the 4R tau isoform with a length of 368 bp, whereas the lower band 
corresponds to the 3R tau isoforms  with a length of 275 bp. B) amplified product of ß actin used 
as a house keeping gene. 
 
 
Fig 2.18 | Relative expression levels of the two different isoforms of MAPT mRNA of each sample 
transfected with U1 constructs Data represent mean ± SEM obtained from biological duplicate 
experiments. 
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Fig 2.19 | RT-PCR analysis of MAPT cDNA of samples transfected with the U7 constructs A) The 
upper band corresponds to the 4R tau isoform with a length of 368 bp, whereas the lower band 
corresponds to the 3R tau isoforms  with a length of 275 bp. B) amplified product of ß-actin is 
used as a house keeping gene. 
 
 
 
Fig.2.20 | Relative expression levels of the two different isoforms of MAPT mRNA of each sample 
transfected with U7 constructs Data represent mean ± SEM obtained from biological duplicate 
experiments. 
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The U1 and U7 chimeric molecules were expected to mask different cis-acting 
elements that were known to enhance inclusion of exon 10 in the MAPT 
transcript. Such masking was expected to induce skipping of exon 10 by 
inhibiting the spliceosome machinery from detecting the exon. 
This would enable reduction of 4R isoforms that is known to be elevated in 
FTDP-17. 
Although it has been demonstrated that the modified U1 and U7 snRNAs have 
been sufficiently expressed in the PC12 cells (Fig.2.13-2.16), the graphs 
represent that there is no variation between the two isoforms upon treatment 
with the chimeric constructs. This is evident by comparison between the two 
isoforms of cells treated with chimeric constructs versus that of the scramble 
constructs or the non treated cells. 
The above mentioned data indicates that the U1 and U7 chimeric constructs 
were not able to pose an effect of skipping on exon 10, thus did not contribute to 
modulating alternative splicing decisions in the context of PC12 cells. 
 
Discussion  
 
Design of chimeric constructs embedded in the U1 and U7 snRNA cassette 
The rat neuronal pheochromocytoma PC12 cells were selected to analyse the 
effect of chimeric constructs on inducing skipping of exon 10. These cells 
predominantly express exon 10 which is most likely due to the changes in three 
nucleotides in the 5’ splice site that resembles stem-loop-disrupting mutations in 
human tau. 
A total of fourteen different constructs were tested for their efficiency to induce 
skipping of exon 10 in the context of rat PC 12 cells. 
The chimeric constructs were designed and produced such that: 
 Three active cis-acting elements in exon 10 were selected. 
 Different oligonucleotides were designed to base pair with 
complementarities to the cis acting elements. This enables masking of the 
splice site thus preventing the assembly of the spliceosome and as a 
consequence, inducing skipping of exon 10. 
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 AON α is complementary to the 3’ exon / intron junction , AON ß is 
complementary to the 5’ exon / intron junction, AON rß is 
complementary to the 5’ exon / intron junction with three nucleotide 
changes to make it completely complementary to the rat sequence. The 
U1 constructs harboring these sequences are expected to induce skipping 
of exon 10 as these are antisense to the canonical cis-acting elements in 
the splice site selection and will inhibit the recruitment of spliceosome 
machinery. AON ƴ is complementary to the ACE region of exon 10. AON α 
ß is a couplet formed by α and ß thus complementary to both 5’ and 3’ 
exon /intron junction. AON α rß is similar to AON α ß excepting the 
difference of the three nucleotides changes to make it complementary to 
the rat sequence.  
 Non targeting oligonucleotides were designed to ensure the specificity of 
each oligonucleotide. They were composed of same nucleic acid bases in a 
random order and hence designated as scrambled 
 The oligonucleotides were then embedded in to the U1 / U7 cassette to 
enable stable expression within the cells. 
 
 
Fig 2.21 | Schematic representation of A) Modified U1 snRNA chimeric construct with specific 
oligonucleotides that are complementary to the cis acting splice sites of Exon 10 embedded in to 
the U1 casette. B) Exon 10 containing its specific regulatory elements involved in splicing and the 
location of binding of modified U1 constructs (coloured lines represents corresponding 
constructs). 
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Previous work by Covello G et al., (unpublished data) has shown that all the four 
oligonucleotides have induced exon 10 skipping in rat PC12 cells when 
transfected alone or in combination. 
Therefore these oligos were embedded in the U1 and U7 snRNA cassettes for the 
following reasons; 
The U1 snRNA is one of the prime factors involved in splice site recognition 
hence its utility as a vector for delivering therapeutic antisense RNA sequence is 
highly desirable. Since both the U1 snRNA and tau pre-mRNA co-localises within 
the same region (i.e: the nucleus), it should increase the effectiveness of 
therapeutic molecule. 
Upon masking the 5’ splice site, the base pairing interaction between the 5’ splice 
site and the U1 snRNA must be shunt, thus favoring its interaction with U6 
snRNA. Therefore the spliceosome’s catalytic core is not formed and leads to 
skipping of exon 10. 
Additionally, the strong pol II dependent promoter of the U1 snRNA genes 
ensures high levels of expression of the chimeric constructs. 
These modified exon specific U1 snRNAs can also be used specifically to target 
the mutated splice sites by incorporating sequences complementary to the 
mutated region thus leaving the wild-type site unaffected. This approach offers 
the following advantages; (i) they do not bind directly to normal 5′ ss and (ii) 
they are capable of correcting different types of splicing defects associated to 
exon skipping (Alanis et al., 2012).   
The U7 snRNA functions as natural antisense sequence by hybridizing with the 
spacer element of histone pre-mRNA during its 3’ processing. Modification of the 
U7 vector by converting the wild type U7 Sm binding site to the consensus Sm 
binding site derived from snRNPs (smOPT) provides two benefits; 
The target RNA will not be cleaved by the histone 3’ end processing machinery  
and inability of U7 smOPT particles to bind one or more U7 specific proteins 
prevents the RNA from binding to endogenous U7 snRNPs. 
The embedded chimeric constructs are designated as U1 (α, ß, rß, ƴ, αß, αrß, 
αscr and ƴscr) and U7 (α, ß, rß, ƴ, αß, αrß, αscr and ƴscr). 
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2.3.2. Transfection efficiency was optimized for PC12 cell line 
 
Although PC12 cells represent an important model system to study a variety of 
neuronal functions, they proved relatively difficult to transfect (Covello G et al., 
2013). There are three different types of transfection methods; biological, 
chemical and physical. The biological methods include virus mediated gene 
delivery, Chemical method includes employment of cationic lipids, cationic 
polymers or calcium phosphate based delivery. The physical methods include a 
wide range of tools such as direct injection, biolistic particle delivery, 
electroporation, laser irradiation, sonoporation and magnetic nano particle. 
Although different methods of transfection have been developed, their 
applications are highly dependent on the cell type and purpose of investigation. 
(Kim et al., 2010). 
Various methods of transfection have been attempted in PC12 cells; cationic 
lipids formulations have been employed to increase transfection efficiency. 
Using Lipofectamine 2000 (Invitrogen) the transfection efficiency was about 14 
% and was similar to the efficiency obtained with polyethyleneimine (PEI) (15 
%) (Lee et al., 2008). A higher efficiency (30%) was reported with Metafectene 
Pro (Biontex) (Cogli et al., 2010). An increase in the transfection efficiency 
(40%–50 %) was observed by simultaneous treatment with Lipofectamine and 
0.1 μM GALA, a pH-sensitive fusogenic peptide which accelerates the endosomal 
escape of the plasmid/liposome complexes to the cytosol (Futaki et al., 2005). 
However, this method has not encountered wide popularity thereafter. 
 
We have compared the efficiency of three different chemical transfection 
reagents (Lipofectamine 2000, Lipofectamine LTX and TransIT-LT1) and of two 
electroporation systems (Neon and Gene Pulser Xcell) in transiently transfecting 
undifferentiated PC12 cells. By comparing efficiencies from replicate 
experiments, we conclude that electroporation (in particular Neon) is the 
method of choice. By optimizing different parameters (voltage, pulse width and 
number of pulses) we attained a high efficiency of transfection (90 %) and 
viability (99 %). We also demonstrated that, upon electroporation, cells do not 
alter and maintain their ability to differentiate. 
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On the process of optimization of transfection efficiency, I had contributed to the 
experiments on chemical transfection using three different cationic lipid 
reagents. 
Refer to the manuscript as an attachment M.2. 
 
2.3.3. The U1 and U7 ExSpe UsnRNAs did not pose an effect on skipping of 
exon 10 in PC12 cell line 
 
The U1 and U7 chimeric constructs were designed to modulate splicing of exon 
10 by masking the cis-acting elements. Although the constructs were expressed 
in the PC12 cells, they were unable to modulate splicing of exon 10.  
 
2.3.4. Molecular mechanisms involved in inefficient exon skipping. 
 
Possible hypotheses that attribute to inefficient exon skipping are described 
below (Fig.2.21). 
 
Inadequate expression of the chimeric constructs  
 
A total of 0.5 µg of each construct was used. This might be too less an amount of 
DNA to be transcribed and produce enough amounts of transcripts to be able to 
mask the splice sites of exon 10. It could also be possible that the 48 hours of 
time after transfection was not sufficient to induce formation of enough 
transcripts. However, since previous studies have validated the use of chimeric 
small nuclear RNAs in mice, it is difficult to compare such dose and time related 
strategies.It could be possible that the effect might be linked to the cis acting 
regions in exon 10 that is prohibiting the effect of such therapeutic invention in 
the context of PC12 cells. 
 
Contribution of cis acting and trans acting elements in regulation of 
splicing in PC12 cells 
 
Previous studies by Freund and colleagues have reported that protein 
interaction between the U1 snRNP and 5’ splice site is essential for splice donor 
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recognition (Freund et al., 2003). Additionally, experiments have demonstrated 
that the binding of U1 snRNA to the 5'-splice site is required, but not sufficient, to 
begin spliceosome assembly (Robert et al., 2005). This indicates the additional 
essential role of other proteins involved in the formation of U1 snRNP to initiate 
splicing process. It could be possible that the modified U1 snRNA constructs 
were not able to enter in to the integral complex due to a) insufficient expression 
b) complexities in their secondary structure .Thus, being unable to modulate 
splicing. 
 
In vitro studies by Yamashita and colleagues have demonstrated that a new 
element is located in the intronic sequence that is known to possess a unique 
secondary structure in rodents. This element is expected to play a universal role 
in regulation of splicing.of exon 10. They used DNA analyzing software package 
ver.5 (GENETYX) to analyse the DNA sequences and secondary structures of 
mouse tau genes (Yamashita T et al., 2005). 
In order to confirm the predicted structure, they synthesized oligo RNAs. 
Experiments revealed that there were two stem loop structures juxtaposed with 
each other suggesting a cooperative action in regulation of splicing of exon 10, 
thus causing an increase in the 4R isoform. In its denatured form, the mutant 
RNAs containing mouse intronic stem loop structure sequence was shown to 
move slower than its wild type counterpart (preserved set of sequence with the 
same A, U, G, C content as that of the mutant RNA oligo but avoiding the 
formation of hair pin structure). These studies indicate the existence of a 
possible complex secondary structure of tau mRNA containing exon 10 in PC12 
cells might lead to an inaccessibility of the U1 and U7 chimeric constructs to bind 
to it. 
 
Studies on antisense mediated exon skipping on exon 10 has revealed that 
although this strategy is successful in providing a potential therapy, the 
regulation of exon 10 in cells predominantly expressing 4R tau mRNA may differ 
from the regulation in cells expressing its alternative 3R isoform. (Sud et al., 
2014). This indicates cell specific regulation and variation of dynamics involved 
in splicing of exon 10. Since other studies using U1 and U7 snRNAs have been 
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employed in different cell lines, a successful strategy to induce exon skipping 
was established. 
An interesting work by Du and colleagues in 2002 has shown that that the U1 
snRNP lacking the 5’ end of its snRNA retains the 5’ splice-site sequence 
specificity. They also propose that U1 C protein, (a component of U1 snRNP 
involved in splicing of mammalian sytems and known to directly interact with 
the 5’ splice site) binds first to the pre-mRNA thus being the earliest step in 
splicing process followed by the canonical U1 snRNA/5’ splice-site base pairing 
(Du et al., 2002). 
Therefore, it could also be possible that there are other proteins like U1C 
involved in initiating the splice site recognition, hence an inability of the 
chimeric constructs to mask specific sites. 
Another hypothesis could also result from the binding of the chimeric constructs 
to non specific / uncharacterized proteins thus blocking its action on the specific 
target on cis acting elements of exon 10. 
 
Two other additional hypotheses may support the reasons why the antisense 
oligos had an effect on inducing exon skipping and not the U1 snRNAs; U1 
constructs might rather enable and direct the recruitment of splicing machinery 
than blocking it, whereas the antisense oligos blocks the splice sites or PC12 cells 
might undergo a U1-independent splicing mechanism in MAPT gene thus not 
reacting to the U1 constructs. Previous studies have suggested that U1-
independent splicing mechanisms could occur in cells (Raponi et al., 2008).    
Having discussed the above mentioned possible suggestions leading to the 
ineffective exon 10 skipping in the context of PC12 cells, it is noteworthy to 
mention that these constructs have not been tested on other cell lines. Therefore, 
it would be irrational to discard the potentiality of the U1 and U7 constructs in 
inducing skipping of exon 10 in other cell lines.  
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Fig 2.22 | Schematic illustration of the possible hypothesis for the inability of A) U1 and B) 
constructs to induce exon skipping in the context of rat PC12 cells. a) Unstable binding between 
the cis acting elements of exon 10 and the modified chimeric constructs may lead to a further 
dissociation of binding between them. b) Inability of the constructs to bind to active regions may 
be associated to a complex secondary structure arising due to the double stem loop of the intron 
10 region observed in rodents. c) Pre-occupied cis-acting target sequences by binding to other 
splice regulatory elements leading to inability of the constructs to bind to the target region d) 
Binding of the constructs to either splice repressors or non specific targets may result in inability 
to bind to their targets. (The red and green circles indicate possible target elements known to 
interact with the cis acting elements and chimeric constructs respectively) e) Recruitment of 
splice machinery facilitated by the U1 construct may enhance splicing and inclusion of exon 10. 
A 
 B 
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Abstract  
 
Abnormalities of microtubule associated protein tau have been shown to be 
linked to pathogenesis of neurodegenerative disease collectively termed as 
“Tauopathies. Gene mutations in tau lead to perturbation of gene splicing and tau 
fibrillization leading to formation of tau aggregates. A missense mutation in exon 
10 at codon 279, results in an asparagine to lysine substitution (N279K). This 
impinges alternative splicing of exon 10 in the tau mRNA, and disturbs the 
normal ratio of 4R tau/3R tau. This alteration leads to an increased expression of 
4R tau causing agglomeration of tau proteins eventually leading to FTDP-17. 
RNA interference has proven to be an efficient strategy for silencing mutant 
alleles of dominant disease genes as in Alzheimer’s disease, Machado-Joseph 
disease, Spinocerebellar ataxia type 3 and tau mutation (V337M) that causes 
fronto-temporal dementia (Miller V et al., 2003). 
This part of project explores the feasibility of a siRNA-based gene therapy to 
enable post-transcriptional gene silencing of exon10 in FTDP-17. A panel of 
siRNAs targeting tau mRNA containing exon 10 have been designed and 
synthesized. They were tested in two different contexts. 
A minigene reporter system containing N279 mutation, and an endogenous 
system of cells recapitulating FTDP-17. 
The effects of siRNAs on the minigene reporter system were confirmed using an 
image based approach and semi quantitative RT-PCR analysis, whereas the effect 
on endogenous context was monitored using semi quantitative RT-PCR analysis. 
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3.1. Materials and Methods: 
 
3.1.1. Design of panel of siRNAs against Exon 10 
 
A panel of siRNAs targeting exon 10 was designed to mediate target selective 
depletion of the transcript (Table 3.1).  
The oligos were synthesized by the Eurofins / mwg operon company. The 
siRNAs have been designed on the basis of following rules:  
 Avoid stretches of 4 or more bases such as AAAA, CCCC 
 Avoid regions with GC content <30% or > 60% 
 Avoid repeats and low complex sequence 
 Avoid single nucleotide polymorphism (SNP) sites 
 Perform BLAST homology search to avoid off-target effects on other genes 
or sequences 
Name Oligonucleotide sequence (5’-3’) 
siRNA 0 GAUAAUUAAUAAGAAGCUGTT 
CAGCUUCUUAUUAAUUAUCTT 
siRNA 1 AGUCCAAGUGUGGCUCAAATT 
UUUGAGCCACACUUGGACUTT 
siRNA 2 GAUAAUUAAGAAGAAGCUGTT 
CAGCUUCUUCUUAAUUAUCTT 
siRNA 3 GGCUCAAAGGAUAAUAUCATT 
UGAUAUUAUCCUUUGAGCCTT 
siRNA 4 CGUCCCGGGAGGCGGCAGUTT 
ACUGCCGCCUCCCGGGACGTT 
siRNA 5 GCAACGUCCAGUCCAAGUGTT 
CACUUGGACUGGACGUUGCTT 
siRNA control UAAUGUAUUGGAACGCAUATT 
UAUGCGUUCCAAUACAUUATT 
 
Table 3.1. | List of siRNA oligos targeted against exon 10. Both the sense strands and the 
antisense strands are reported on the right side of the panel. 
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3.1.2. Creation of a minigene mutant plasmid bearing N279 mutation 
 
3.1.2. (i) Site-directed mutagenesis 
 
The fluorescent reporter plasmid created by Peter Stoilov and colleagues 
(Stoilov P et al., 2008) PFLARE 5A MAPT exon 10 also referred to as the wild-
type (WT) plasmid (Fig.3.1), was mutated using the Quick change II site XL site-
directed mutagenesis kit following the manufacturer’s instructions. The 
following primers were designed such that they incorporated the nucleotide 
change of T to G.  
Forward primer Reverse primer 
CCA AAG GTG CAG ATA ATT AAG AAG GTT GCT AAG ATC CAG CTT CTT CTT 
 
 
 
 
Fig. 3.1 | Schematic representation of the bichromatic reporter plasmid produced by Peter 
Stoilov et al., 2008. An alternative splicing of Exon 10 leads to production of two different splice 
isoforms. The ribosome scans for the first available AUG codon to initiate translation of specific 
reporter proteins such that Exon 10 results in the production of RFP and Exon 10-results in the 
production of GFP. 
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3.1.2. (ii) Preparation of competent cells and transformation 
 
Refer to section 2.1.1.6 
 
The resulting plasmid PFLARE 5A MAPT MUT exon 10 will be referred to as 
mutant N279 (Mut) plasmid. 
 
3.1.3. SH-SY5Y cell line: 
 
It is a thrice cloned (SK-N-SH -> SH-SY -> SH-SY5 -> SH-SY5Y) subline of the 
neuroblastoma cell line SK-N-SH.with a content of 15% exon 10+ and 85% of 
exon 10- in its transcript. The transfection efficiency (25% to 30%) in this cell 
line is comparitively higher than the other neuroblastoma cell lines. Therefore, 
this cell line was chosen to test the efficacy of siRNAs against endogenous exon 
10 transcripts and for co-transfections of siRNAs with minigene reporter 
plasmids. 
 
3.1.4. Co-transfection of reporter plasmid and siRNAs in SH-SY5Y cells  
 
On the day before the experiment, 5 x 104 cells were seeded on a 24-well plate in 
500 µl of complete medium without antibiotics at 37° C in 5% CO2. The 24-well 
plate format has been chosen to allow the recovery of a sufficient number of cells 
at the end of the assay after the image-based analysis, in order to perform 
downstream molecular analysis, such as RT-PCR and Western Blot. Transfections 
were performed as instructed by the manufacturer with a ratio of DNA (ng): 
Lipofectamine 3000 (µl) being 1:2 in Opti-MEM medium. The plasmids were 
used at a concentration of 0.25µg and 0.5 µg per well in a final volume of 500 µl. 
Two different plasmid reporters were used for transfection namely the wild-type 
(WT) plasmid and the mutant type plasmid (Mut). 
The siRNAs were used at the concentrations from 10nM to 100nM in a final 
volume of 500 µl per well. Following transfection, the cells were incubated at 37° 
C in 5% CO2 for 48 hours.  
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3.1.5. Optimisation of high throughput screening assay to monitor effects of 
siRNAs on minigene 
 
Since the out-put of read-outs are based on fluorescent intensities emitted from 
each of the fluorescent proteins, it was essential to optimize the screening 
strategy and set up threshold intensities and conditions to acquire images for a 
sensitive and robust analysis.  
Therefore, a novel image based approach was developed to perform screening 
and validate the effects of siRNA on the dual fluorescent reporter plasmid. 
The step-by-step approach of which has been schematically represented in 
Figure 3.2. 
 
 
 
Fig.3.2 (i) | Work flow for the screening of effect of siRNAs on reporter plasmids. After 
transfection, the images are acquired from the 24-well plates and analysed using the high content 
imaging system. The samples are then subjected to downstream analyses such as RT-PCR to 
validate results observed through image based analysis. 
Work-flow for screening of plasmid reporters using high content imaging 
sytem 
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3.1.5. (i) Preparation of cells for acquisition 
 
Images of transfected cells were captured with a High content imaging system 
(Operetta, Perkin Elmer). After 48 hours of transfection, the cells were incubated 
for 20 minutes at 37° C in the presence of 1mg/ml of Hoechst 33342 fluorescent 
dye. This allows counter-staining the nuclei which will enable the subsequent 
analyses.  
 
3.1.5. (ii) Image acquisition 
 
Images were taken with a 20X LWD objective, in combination with different filter 
sets: in particular a filter for Hoechst 3342 stain (excitation filter: 360-400 nm, 
emission filter: 410-480 nm) is used to image the stained nuclei at 20ms 
exposure time, whereas a combination of filters is used to measure the reporters’ 
intensities: GFP (excitation filter: 460-490 nm, emission filter :500-550 nm) and 
RFP (excitation filter: 560-630 nm , emission filter: 580-620 nm), both at 200ms 
exposure time. 
 
3.1.5. (iii) Image analysis 
 
a) For the feature extraction protocol, cells were segmented and analyzed using 
the following workflow; 
b) The first step is the identification of Nuclei, the primary objects of interest that 
are segmented by using the most suitable algorithm. 
c) Assuming a homogeneous distribution of both GFP and RFP in the cells, the 
nuclear region was selected to quantify the mean fluorescence intensity in the 
two channels. 
d) The sub-population of transfected cells was identified using a double-
threshold strategy to filter out the cells being either positive for G(GFP) or for 
R(RFP) or for both. 
e) After restricting the analysis to the transfected cells, the ratio between the 
fluorescence properties G and R mean intensity is calculated on a per-cell basis. 
G/R is a parameter that indicates the prevalence of expression of one reporter 
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over the other. Specifically, a low score indicates inclusion of the cassette exon, 
while a high one is connected with an efficient splicing of Exon 10.  
f) If allowed by the analysis software, an overview of the numerical properties of 
the cells can be visualized field by field in a scatter plot. Alternatively, to get a 
more complete representation of all the cells within a well, scatter plots or 
histograms of single cell properties can be created for representative wells of the 
WT and the Mut plasmid conditions. Such graphical representations allow a 
more accurate selection of an upper threshold J and a lower threshold K, 
distinguishing for cells preferentially expressing GFP (G/R>J), RFP (G/R<K) or 
equally expressing both the reporters (K<G/R<J). 
g) The thresholds were then applied in a filter-based module to classify the cells 
in three different subpopulations. 
h) Feature outputs include total cell count, transfected cells count and % 
calculated over the total number of cells, G/R median value of all the cells of the 
well, the % of cells preferentially expressing GFP (G/R>J), RFP (G/R<K) and 
equally expressing both the reporters (K<G/R<J). 
i) Percentage of cell viability was calculated as follows: (total number of cells in 
transfected well/total number of cells in mock) x 100. 
 
3.1.6. Semi-quantitative reverse transcriptase analysis on SH-SY5Y cell line 
 
3.1.6. (i) RNA extractions  
Refer to section 2.1.3. (i) 
 
3.1.6. (ii) cDNA preparation 
Refer to section 2.1.3. (ii) 
 
3.1.6. (iii) Semi quantitative RT-PCR assay to evaluate expression of exon 
10 transcript in minigene reporter  
 
The expression levels of Exon 10 containing transcripts in the minigene were 
analysed with the following primers: 
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Reagent [C]i [C]f 
cDNA - - 
RBC reaction buffer 10X 1X 
dNTPs mix (Euroclone) 10 mM 0.2 mM 
RBC Taq polymerase 5U/ μL 1U /25 μL 
Forward primer (ß actin)  10 μM 0.5 μM 
Reverse primer (ß actin) 10 μM 0.5 μM 
Water - - 
Final volume: 25 μL 
 
Amplified products were allowed to run with 100bp DNA ladder (Fermentas) on 
a 2% Agarose gel electrophoresis (5% Ethidium Bromide) at 100 volts in 1X TBE 
running buffer for 40 minutes. Densitometric analyses are performed with Image 
J software after image acquisition with BioDoc –It imaging. 
 
3.1.7. NSC-34 cell line and Primary cortical neurons 
 
Mouse Motor neuron like hybrid cell line NSC-34 is produced by fusion of 
motor neuron enriched, embryonic mouse spinal cord cells with mouse 
neuroblastoma. The cultures contain two populations of cells: small, 
undifferentiated cells that have the capacity to undergo cell division and larger, 
multi-nucleate cells. These cells express many properties of motor neurons, 
including choline acetyltransferase, acetylcholine synthesis, storage and release 
and neurofilament triplet proteins. These cells can be differentiated using the all 
trans retinoic acid (atRA) thus establishing itself as a suitable model for the in 
vitro study of pathophysiology in motor neurons. 
 
Gene Forward primer (5’-3’) Reverse primer(5’-3’) Product 
dimension 
(bp) 
 
Exon 10 / 
Exon 10- 
 
AAACAGATCTACCATTGGTGCACCTGACTCC 
 
CGTCGCCGTCCAGCTCGACCAG 
 
300 / 207 
 
ß-actin 
 
GAT CAA GAT CAT TGC TCC TCC TG 
 
 
AGG GTG TAA AAC GCA GCT 
 
200 
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Primary neuronal culture on the other hand, is a powerful tool for 
understanding cellular and molecular mechanisms of neuronal development 
(Lesuisse C et al., 2001).Therefore the effects of the siRNAs can be studied on this 
system that is close to functional neurons. 
To this end, primary cortical neurons were provided by Dr. Mauela Basso from 
the Laboratory of Transcriptional Neurobiology. The Primary mouse cortical 
neurons were obtained from C57BL/6 TG2+/− mice mated to generate male and 
female TG2+/+, TG2−/+, or TG2−/− embryos at day 15 (Basso M et al., 2012). 
Neurons were dissociated out of the cortex as described by Ratan et al., 1994 and 
plated in 6 well plates. After 24 hours following plating of neurons, they were 
supplied with neurobasal media and B27 with antioxidant. The media was 
changed every two days until complete maturation (DIV14). The cells at DIV 14 
were subjected to further analysis. 
 
 
Fig. 3.2 (ii) | Representative images of A) NSC-34 cells on day 4 of differentiation with retinoic 
acid acquired with the Zeiss microscope at 20X stained with Hoechst and calcein. Primary 
cortical neurons on DIV 14 (14 Days in vitro) acquired with confocal microscopy at B) 40X and C) 
100X after being stained with DAPI and MAP2 antibody.(Image courtesy: Dr. Lorena Zubovic and 
Dr. Manuela Basso). 
110 
 
3.1.8. Transfection of siRNAs in NSC-34 cells 
On the day before the experiment, 5 x 104 cells were seeded on a 24 well plate in 
500 µl of complete medium without antibiotics at 37° C in 5% CO2. Transfections 
were performed as instructed by the manufacturer with 1 µl Lipofectamine 3000 
for a range of siRNA concentration starting from 10nM to 100nM (in Opti-MEM 
medium) per well in a final volume of 500 µl. 
As controls, cells were treated with Lipofectamine 3000 only (Mock) and 
transfected with non-targeting siRNA (Non-specific controls). Following 
transfection, the cells were incubated at 37° C in 5% CO2 for 48 hours.  
 
3.1.9. Semi-quantitative reverse transcriptase analysis on NSC34 cell line 
 
3.1.9.(i) RNA extractions  
 
Refer to section 2.1.3. (i) 
 
3.1.9.(ii) cDNA preparation 
 
Refer to section 2.1.3. (ii) 
 
3.1.9 (iii) Semi quantitative RT-PCR assay to evaluate expression of MAPT  
mRNA in endogenous condition 
 
The expression levels of Exon 10 containing transcripts were analysed with the 
following primers: 
 
Gene Forward primer (5’-3’) Reverse primer(5’-3’) Product 
dimension 
(bp) 
Exon 10 / 
Exon 10- 
 
CTGAAGCACCACCAGCCGGGAGG 
 
TGGTCTGTCTTGGCTTTGGC 
 
368 / 275 
ß-actin  
GAT CAA GAT CAT TGC TCC TCC TG 
 
 
AGG GTG TAA AAC GCA GCT 
 
200 
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Reagent [C]i [C]f 
cDNA - - 
RBC reaction buffer 10X 1X 
dNTPs mix (Euroclone) 10 mM 0.2 mM 
RBC Taq polymerase 5U/ μL 1U /25 μL 
Forward primer (ß actin)  10 μM 0.5 μM 
Reverse primer (ß actin) 10 μM 0.5 μM 
Water - - 
Final volume: 25 μL 
 
Amplified products were allowed to run with 100bp DNA ladder (Fermentas) on 
a 2% Agarose gel electrophoresis (5% Ethidium Bromide) at 100 volts in 1X TBE 
running buffer for 40 minutes. Densitometric analyses are performed with Image 
J software after image acquisition with BioDoc –It imaging.  
 
3.1.10. Semi-quantitative reverse transcriptase analysis on primary 
cortical neurons 
The semi quantitative RT-PCR analysis was performed on the primary cortical 
neurons at 14 DIV (Days in vitro) as described in section 2.1.3 and with the same 
set of primers. 
 
4.1.1. Western blot analysis 
For Western blot analysis, SH-SY5Y and NSC-34 cells were washed with PBS and 
harvested in radioimmunoprecipitation assay (RIPA) buffer (1% Nonidet P-40, 
0.5% sodium deoxycholate, and 0.1% sodium dodecyl sulfate (SDS) in PBS) plus 
protease inhibitors (Complete, Roche Molecular Biochemicals, Indianapolis, IN, 
USA) and phosphatase inhibitors (New England Biolabs) at 4°C. Cell 
homogenates were centrifuged at 100,000 g for 30 min. Supernatants were 
collected, and the protein content was determined using a commercial kit (Bio-
Rad, Hercules, CA, USA). Samples were separated on 4-12% gradient SDS gels 
and electrotransferred to nitrocellulose membrane (Millipore, Bedford, MA, USA) 
after dephosphorylation (NEB). Membranes were washed, blocked, and 
incubated overnight with rabbit anti-tau (1:10,000; Dako) antibody, followed by 
a second washing step before incubating with secondary antibody an Infra-red 
chromophore Goat anti-Rabbit 800 CW (Li-COR) for 1 h.  
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3.2. Results 
 
3.2.1. Design of a panel of siRNAs targeting Exon 10 
 
Six different siRNAs were designed to target different regions of exon 10 as 
shown in Fig.3.3.  
 
 
Fig 3.3 | Schematic representation of Exon 10 sequence with the mutations and design of siRNAs 
along the stretch of exon 10 region. 
 
3.2.2. Analysis of fluorescent reporter plasmids transfected in SH-SY5Y cell 
line 
 
One of the remarkable contributions of Stoilov and colleagues includes the 
production of two-colour fluorescent reporter assay with a cassette of MAPT 
exon 10 to test for the effect of compounds that might alter splicing (Stoilov P et 
al., 2008). This reporter relies on the emission of fluorescence such that: GFP 
(Green fluorescence protein) is transcribed upon skipping of exon 10 and RFP 
(Red fluorescence protein) is produced when exon 10 is included in the 
transcript. The plasmid was constructed on the basis of: 
 ORFs of destabilized GFP and RFP are expressed from a single promoter 
as a bicistronic transcript. 
 The start codon of GFP is split between two constitutive exons by an 
alternative exon cassette with its flanking introns. 
 Skipping of alternative exon cassette enables the formation of start codon of 
GFP ORF following its expression in the mature transcript and expression of 
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GFP, whereas exon inclusion leads to unavailable GFP start codon and upon 
further scanning, the ribosome will find the first available AUG codon in 
Kozak sequence of RFP ORF thus translating RFP. 
  
3.2.2. (i) Comparison of wild type and N279 mutant reporter plasmids 
 
This dual reporter plasmid containing MAPT exon 10 (Stoilov P et al., 2008) was 
mutagenised by incorporating a point mutation N279 which results in 
asparagine to lysine substitution (T to G). This mutation affects splicing allowing 
exon 10 to be incorporated more frequently in tau transcripts thus causing an 
increase of 4R expression over 3R. 
 
After 48 hours of transfection of the wild type and mutant plasmid in SHYS5Y 
cell lines, the cells were subjected to an image based analysis using the protocol  
On comparing the two conditions, there was an increased production of red 
fluorescent signal in the mutant plasmid as observed in the representative image 
(Fig.3.4) and fits well with the expected results. 
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Fig.3.4 | Images of SHYS5Y cell line transfected with 0.25 µg of Wild type plasmid and 
Mutant plasmid. Representative Images of SH-SY5Y cells expressing the two plasmid reporters 
each with a different inclusion level of Exon 10: Wild type (Top panel) and Mutant N279 plasmid 
reporters (Bottom panel). The cells were analyzed by High-Content screening system (Operetta) 
after 48 h of transfection. The images were acquired using a 20× LWD objective in wide-field 
mode in combination with filters for Hoechst 33342 (excitation filter: 360–400 nm; emission 
filter: 410–480 nm) and Alexa Fluor 488 (excitation filter: 460–490 nm; emission filter: 500–550 
nm). 
 
 
 
Fig.3.5 | Setting up of threshold values based on intensities of RFP and GFP. Scatter plots 
representing G/R values of each cell in a particular well bearing one of the dual reporter 
plasmids (WT and Mut, respectively). The indicated thresholds are arbitrarily selected to classify 
the cell population in three different classes.  
 
Application of threshold values on these images, further allows discrimination of 
varied population of cells (with different intensities) within each well. 
As observed from the graph, cells transfected with Wild type plasmid possesses 
mainly green cells (E10-) and yellow cells (E10+/E10-) with a very few red cells 
(E10+) (Fig.3.5). 
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However, cells transfected with mutant plasmid indicates the shift of threshold 
towards a majority of red cells, and a few yellow and green cells. This confirms 
the production of RFP due to the introduction of N279 point mutation causing an 
increase of exon 10 (characteristic hall mark of FTDP-17) (Fig.3.6). 
 
 
Fig.3.6 | Image based analysis of SH-SY5Y cells transfected with Wild type and Mutant 
reporter plasmids. Histogram represents the selected read-outs of the quantitative analysis of 
the two reporters, such as the relative percentages of the three sub-populations of SH-SY5Y cells 
classified by intensity properties, the transfection efficiency and the cell viability. Values 
represent mean±SD (n=3).  
 
The image based analysis on the SH-SY5Y cells transfected with Wild type and 
Mutant plasmids, shows that the N279 point mutation shifts splicing of exon 10 
thus altering the fluorescent signals from a relatively low level of RFP (2%) to a 
very high level (65%) due to exon 10 inclusion (exon 10+) (Fig.3.6). 
Cells containing both exon 10+ and exon 10-transcripts (yellow cells) have thus 
shifted from 85% to 30% whereas cells containing only exon 10- shows a 
decrease from 15% to 5% (Fig.3.6). 
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In both conditions of transfection, there is no variation of transfection efficiency 
and cell viability thus confirming that they were subjected to the same 
conditions and the fluorescent signals are not biased outputs, but are coherent 
with the N279 mutation. 
 
In order to validate these effects at a molecular level, an RT-PCR was performed 
using a forward and reverse primer designed to bind to the 5’ end of exon 1 and 
3’ end of GFP in the mutant plasmid. 
Since the plasmid encodes exon 10 that undergoes alternative splicing, this 
reaction is expected to produce two different transcript isoforms (i) exon 10+ 
and (ii) exon 10-.(Fig. 3.7). The mutant is expected to show a higher amount of 
transcripts containing exon 10 due to the incorporated N279 mutation. 
 
 
Fig.3.7 | Schematic representation of primers on WT / Mutant plasmid and the alternatively 
spliced transcript isoforms with and without exon 10. 
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Fig.3.8 | RT-PCR analysis of Exon 10 mRNA levels in the wild type and mutant minigene 
plasmid transfected in SH-SY5Y cells. Gels showing the RT-PCR products of transcripts 
containing exon 10+ (300 bp) and exon 10-(207 bp). Histogram represents the densitometric 
units of each treatment condition normalised on ß actin. Values represent mean SD±(n=3).  
 
Results of the semi quantitative PCR analysis on the samples containing cells 
(transfected with the WT and Mut plasmids) were checked on a 2% agarose gel. 
As expected, the samples showed amplification of two bands (corresponding to 
exon 10+ and exon 10- from the reporter plasmids) along with the expression of 
housekeeping gene ß-actin. (Fig. 3.8). 
The content of exon 10 increases from 35% in WT to 85% in mutant reporter 
plasmid, thus the observations in the image based analysis has been confirmed 
through RT-PCR which shows an increased inclusion of exon 10. 
 
3.2.2 (ii) Screening for the effect of siRNAs on mutant N279 plasmid 
reporter 
 
In order to assess the potentiality of suitable siRNAs to mediate transcriptional 
gene silencing, the following two strategies were adopted; 
 
 An image based analysis on transfected samples; 
 A subsequent RT-PCR analysis on those samples for further validation. 
 
The six different siRNAs designed to target exon 10 was tested with varying 
concentrations ranging from 10 nM to 100 nM to test their efficacy in inducing 
transcriptional gene silencing of exon 10 containing transcripts. These effects 
were validated on two different concentrations of the reporter plasmids (i.e: 
0.25µg and 0.5 µg) (Fig.3.9 and 3.10). 
 
The experiments were performed as biological triplicates with technical 
duplicates each. The samples that were subjected to image based analysis were 
further used for downstream analyses (i.e: RT-PCR) to quantify the amounts of 
exon 10 containing transcripts post-treatment with siRNAs. 
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The image based analysis on cells transfected with 0.25µg of mutant plasmid and 
varied concentrations of siRNAs confirms a variation of effects mediated through 
different siRNAs. (Fig.3.9). 
Compared to the non-treated mutant plasmid, plasmid treated with siRNA 0 and 
siRNA 2 shows a slight increase in inclusion of exon 10 containing transcripts 
whereas siRNA 1, siRNA 3 and siRNA 5 shows a decrease in exon 10 containing 
transcripts. siRNA 4 however shows no effect on exon 10 The control siRNA at 
varied concentrations does not impose any effect on exon 10. 
 
The effect of each siRNA at specific concentration is described below (Fig.3.9). 
 
siRNAs 0, 2 and 4 
 
siRNA 0 shows no variation in exon 10 upon treatment with 10nM and 25 nM 
followed by an increase of 10% upon treatment with 50nM concentration and 
no effect upon treatment with a 100nM concentration. 
siRNA 2 shows no difference upon treatment with concentrations 10nM and 25 
nM .However, at 50nM there is an increase of 10% of exon 10 and at 100 nM 
there is no effect observed. siRNA 4 showed no effects regardless of varied 
concentrations. 
 
Interestingly, these data also reflects a concentration dependent effect of 
potential siRNAs 1, 3 and 5 on reducing exon 10. 
 
siRNA 1 
 
Upon treatment with 10 nM there is a slight decrease of exon 10 by 10% .A 
concentration of 25 nM further reduces exon 10 by15% and concentrations of 
50 nM and 100 nM leads to a reduction by 20%. This gradual decrease of 
almost 20% of exon 10 containing cells is accompanied by a 15% increase of 
cells containing both exon 10+ and exon 10- (Fig.3.9 and 3.11). 
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siRNA 3  
 
Upon treatment with 10 nM and 25 nM concentrations there is a decrease of 
exon 10 transcripts by 20 % followed by a further reduction of 30% with 50 
nM and 100 nM concentration. This gradual decrease of almost 30% of E10+ is 
accompanied by a 30% increase of cells containing both exon 10+ and exon 10- 
(Fig.3.9 and 3.11). 
 
siRNA 5 
 
Upon treatment with 10 nM and 25 nM, there is a reduction of 15% of exon 10 
transcripts and treatment with 50 nM and 100 nM led to a further decrease of 
25% of exon 10 transcripts. This gradual decrease is accompanied by a 25% 
increase of cells containing both exon 10+ and exon 10-(Fig.3.9 and 3.11). 
 
siRNA control 
 
The control siRNA at varied concentrations does not impose any effect on exon 
10. 
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The image-based analysis on cells transfected with 0.5µg of mutant plasmid and 
varied concentrations of siRNAs confirms a variation of effects mediated through 
different siRNAs. (Fig 3.10). 
Compared to the non-treated mutant plasmid, plasmid treated with siRNA 0 and 
siRNA 2 shows a slight increase in inclusion of exon 10 containing transcripts 
whereas siRNA 1, siRNA 3 and siRNA 5 shows a decrease in exon 10 containing 
transcripts. siRNA 4 however shows no effect on exon 10 The control siRNA at 
varied concentrations does not impose any effect on exon 10. 
 
The effect of each siRNA at specific concentration is described below. 
 
siRNAs 0, 2 and 4 
 
siRNA 0 shows no variation in exon 10 upon treatment with 10nM ,25 nM and 50 
nM, followed by an increase of 10% upon treatment with 100nM concentration  
siRNA 2 shows no difference upon treatment with concentrations 10nM and 25 
nM .However, at 50nM and 100nM there is an increase of 10%of exon 10. siRNA 
4 showed no effects regardless of varied concentrations. 
 
Interestingly, these data also reflect a concentration dependent effect of 
potential siRNAs 1, 3 and 5 on reducing exon 10. 
 
siRNA 1 
 
Upon treatment with 10 nM and 25nM there is a slight decrease of exon 10 by 
10% and concentrations of 50 nM and 100 nM leads to a further reduction of up 
to 30%. 
This gradual decrease of almost 30% of exon 10+ is accompanied by a 30% 
increase of cells containing both exon 10+ and without exon 10- 
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siRNA 3  
 
All the different concentrations led to a decrease of 40% of exon 10 containing 
transcripts. This gradual decrease of almost 40% of exon 10+ is accompanied 
by a 35% increase of cells containing both exon 10+ and exon 10-. 
 
siRNA 5 
 
Treatment with 10 nm led to a decrease of 25% of exon 10 containing 
transcripts followed by a 35% reduction upon treatment with 25 nM and 50 
nM. A concentration of 100 nM led to a reduction of 30% exon 10 containing 
transcripts. Reduction of cells expressing solely exon 10 was accompanied by an 
increase of cells expressing both isoforms  
 
siRNA control 
 
The control siRNA at varied concentrations does not impose any effect on Exon 
10. 
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Fig. 3.11 | Images of SH-SY5Y cell line transfected with 0.25 µg of Mutant plasmid and a) 
siRNA 1 b) siRNA 3 c) siRNA 5 Representative Images of SH-SY5Y cells expressing the mutant 
plasmid reporter with varied concentrations of siRNA1 from 10nM to 100nM (Top to bottom). 
The cells were analyzed by High-Content screening system (Operetta) after 48 h of transfection. 
The images were acquired using a 20× LWD objective in wide-field mode in combination with 
filters for Hoechst 33342 (excitation filter: 360–400 nm; emission filter: 410–480 nm) and Alexa 
Fluor 488 (excitation filter: 460–490 nm; emission filter: 500–550 nm). 
 
Representative images in Fig.3.11 are acquired from the transfected cells 
containing mutant plasmid and potential siRNAs 1, 3 and 5 at varied 
concentrations. It can be observed that siRNA 3 is the most potent of the three 
siRNAs with a highest effect observed upon treatment with 50 nM and 100 nM 
concentrations. 
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3.2.3. Semi quantitative RT-PCR analysis on MAPT exon 10 of mutant 
minigene upon co-transfection with siRNAs  
 
In order to evaluate and confirm the effects of the three potential siRNAs 1, 3 and 
5 on inducing degradation of exon 10 containing transcripts, an RT-PCR analysis 
was performed as described in section 3.2.2. The non treated mutant plasmid 
was compared to varied treatment conditions of three siRNAs. Their relative 
expressions were normalised against ß-actin gene. 
 
 
 
Fig 3.12 | RT-PCR analysis of SH-SY5Y cells transfected with the mutant plasmid and siRNA 1 at 
varied concentrations A) The upper band corresponds to the Exon 10 transcript with a length of 
300 bp, whereas the lower band corresponds to the Exon 10-transcript with a length of 207 bp. 
B) ß actin is used as a house keeping gene (200 bp) to calculate the relative expression levels of 
these two isoforms. C) Relative expression levels of the two isoforms  
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The RT-PCR analysis further confirms that treatment with siRNA 3 leads to a 10 
% reduction of exon 10 containing transcripts at a concentration of 50 nM as 
observed in Fig 3.12. 
 
 
Fig 3.13 | RT-PCR analysis of SH-SY5Y cells transfected with the mutant plasmid and siRNA 3 at 
varied concentrations A) The upper band corresponds to the Exon 10 transcript with a length of 
300 bp, whereas the lower band corresponds to the Exon 10-transcript with a length of 207 bp. ß 
actin is used as a house keeping gene (200 bp) to calculate the relative expression levels of these 
two isoforms. C) Relative expression levels of the two isoforms  
 
The RT-PCR analysis further confirms that treatment with siRNA 3 leads to a 25 
% reduction of exon 10 containing transcripts at a concentration of 50 nM as 
observed in Fig 3.13. 
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Fig 3.14 | RT-PCR analysis of SH-SY5Y cells transfected with the mutant plasmid and siRNA 5 at 
varied concentrations A) The upper band corresponds to the exon 10+ transcript with a length of 
300 bp, whereas the lower band corresponds to the exon 10-transcript with a length of 207 bp. 
ß-actin is used as a house keeping gene (200 bp) to calculate the relative expression levels of 
these two isoforms. 
 
The RT-PCR analysis further confirms that treatment with siRNA 3 leads to a 20 
% reduction of Exon 10 containing transcripts at a concentration of 50 nM as 
observed in Fig 3.14. 
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3.2.4. Selection of cell line for analyzing the effect of siRNA in an 
endogenous context - NSC 34 cell line 
 
In order to evaluate the effects of siRNA on an endogenous context, an RT-PCR 
analysis was performed on a number of neuroblastoma cells for the presence of 
excessive content of Exon 10. 
This was an essential step to identify a neuroblastoma model that recapitulates 
FTDP-17 so as to monitor the efficacies of the siRNA oligos. 
 
 
 
Fig.3.15 | Semi-quantitative RT-PCR shows MAPT mRNA levels in the endogenous context of Non 
treated NSC 34 cells A) Upper band (368 bp) represents exon 10+ transcript wheras the bottom 
band (275 bp) corresponds to exon 10- transcript B) Relative expression levels of two different 
MAPT isoforms. (Error bars represent the standard deviation of band intensities in two different 
biological replicates). 
 
The primers were designed such that the forward primer detects the 3’ end of 
exon 9 and the reverse primer detects the 5’ end of exon 13. 
Since exon 10 undergoes an alternative splicing, two different transcripts (Exon 
10+ (368 bp) and Exon 10-(275 bp)) are produced.  
Fig.3.15 shows RT-PCR on MAPT mRNA in which 83% content of Exon 10 versus 
17% of transcripts without exon 10 was observed.Therefore, NSC 34 cell line 
was chosen as the optimal model system due to an excessive presence of exon 10 
transcripts. 
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3.2.5. Semi quantitative RT-PCR analysis on MAPT exon 10 in endogenous 
context of NSC 34 cell line upon transfection with siRNAs 
 
 
In order to validate the effects observed in the minigene reporter system, the 
three potential siRNAs 1, 3 and 5 were transfected in NSC 34 cells with a range of 
concentrations from 10 nM to 100 nM. As a control, a non specific siRNA was 
used. These treatment conditions were compared to cells treated with 
lipofectamine reagent as an additional control. 
Semi-quantitative RT-PCR confirmed the effect of siRNAs on exon 10 transcripts 
in endogenous condition such that, siRNAs 1 and 3 induced a reduction from 
75% to 65% and 30% respectively and showed a very slight dose-dependent 
reduction. However, siRNA 5   showed a dose dependent effect starting from a 
50% when treated with a concentration of 10nM and reaching upto 40% upon 
treatment with 25nM, 50nM and 100nM concentrations (Fig.3.16). 
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3.2.6. Semi quantitative RT-PCR analysis on MAPT exon 10 in endogenous 
context of primary cortical neurons 
 
 
 
Fig.3.17 | Semi-quantitative RT-PCR shows MAPT mRNA levels in the endogenous context of 
primary cortical neurons at 14 DIV. A) Upper band (368 bp) represents 4R tau isoforms wheras 
the bottom band (275 bp) corresponds to 3R tau isoforms. GAPDH is used as a house keeping 
control (110 bp) B) Relative expression levels of two different MAPT isoforms. (Error bars 
represent the standard deviation of band intensities in two different biological replicates). 
 
Fig.3.17 shows RT-PCR on MAPT mRNA in which 70% content of Exon 10 versus 
30% of transcripts without Exon 10 was observed. Therefore, primary cortical 
neurons were chosen as an optimal relevant model system due to an excessive 
presence of Exon 10 transcripts and its neuronal nature. 
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3.2.7. Optimisation of Western blot analysis on SH-SY5Y cells and NSC 34 
cells 
 
 
 
 
Fig.3.18 | A) Images of the western blot analysis of protein levels of tau in SH-SY5Y cells and NSC 
34 cells. B) Relative expression levels of tau isoforms (4R and 3R). 
 
 
The western blot confirms the presence of four different isoforms with varied 
sizes as compared to the literature-based evidence (Hogg et al., 2003) and the 
sizes of the different isoforms are reported as follows: 
 42.9 kDa represents 4R1N 
 39.7 kDa represents 3R1N 
 40.0 kDa represents 4R0N 
 36.8 kDa represents 3R0N  
In the SH-SY5Y cells, the relative percentage of isoforms of 4R (4R1N and 4R0N) 
is 25% and the 3R (3R1N and 3R0N) is 75%. On the contrary, in the NSC34 
cells, the relative percentage of isoforms of 4R (4R1N and 4R0N) is 75% and 
the 3R (3R1N and 3R0N) is 25% (Fig.3.18). 
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3.2.8. Preliminary data on the effect of siRNA on the endogenous tau 
protein in NSC34 cells. 
 
 
 
Fig.3.19 | A) Images of the western blot analysis of protein levels of NSC 34 cells and the tau 
isoforms (4R and 3R) after 48 hours of treatment with siRNAs 3,1 and 5. Ponceau was used as a 
loading control. B) Relative expression levels of the four tau isoforms. 
 
The preliminary data on the western blot analysis indicates a reduction of 4R 
isoforms upon treatment with siRNAs 1, 3 and 5 with a concentration of 50nM 
and 100nM. Considering the percentage of 4R1N and 4R0N in NSC34 cells 
treated with the Non specific control and that of lipofectamine as 40% and 40% 
respectively. It can be observed that upon treatment with siRNA 3 there is a 
reduction of both these isoforms to 30% and 20% respectively with 50nM 
concentration and reaching upto 35% and 10% respectively upon treatment 
with 100nM concentration. siRNA 1 leads to a reduction to 20% and 10% of 
4R1N and 4R0N with a 50nM concentration and 10% and 5% with a 100nM 
concentration. siRNA 5 shows a similar effect on both treatment conditions 
leading to a decrease to 20% and 30% respectively of 4R1N and 4R0N.  
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3.3. Discussion 
 
3.3.1. Rationale behind the design of siRNAs targeting exon 10 
 
An efficient design of siRNA oligos is a key factor in determining the efficiency of 
gene specific silencing (Murali R et al., 2015). 
The siRNAs were designed spanning the entire region of exon 10 following 
certain first generation tools such as Amarzguioui method, Tuschl rules, 
Reynolds rules, Stockholm rules, Ui-Tei rules and Hseih rules. 
Additionally certain second generation tools such as Biopredsi, DSIR, i-Score 
scales and My siRNA-designer were referred for possible predictions of suitable 
siRNAs to mediate knockdown of transcripts containing exon 10. 
The following conditions were applied as a priority for the design (Ui-Tei et al., 
2004): 
(i) A/U at the 5’ end of the antisense strand; (ii) G/C at the 5’ end of the sense 
strand (iii)at least five A/U residues in the 5’ terminal of of the antisense strands 
and (iv) absence of any GC stretch of more than 9 nt in length. 
 
3.3.2. Mutant plasmid containing the N279 mutation in exon 10 was 
created 
 
Alternative splicing has emerged as a promising therapeutic target in a number 
of human disorders. However, the discovery of compounds that target splicing 
has been hindered by the lack of suitable high-throughput screening assays. 
This is also applicable for availability of model systems to test transcriptional 
gene silencing. 
Previous work by Stoilov P et al (2008) has shown that the splicing of a two-
color (Green/Red) fluorescent reporter plasmid with microtubule-associated 
protein tau (MAPT) exon 10 can be modulated using bioactive compounds.  
A mutation (N279) has been introduced in this dual reporter plasmid which 
switches alternative splicing thus favoring the inclusion of Exon 10, in order to 
mimic the pathological alteration frequently observed in Fronto temporal 
dementia and Parkinsonism linked to chromosome 17 (FTDP-17). Further to this 
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an image-based analysis has been developed to quantify the fluorescent 
reporters, obtaining single cell-based read-outs using an High Content Screening 
system.  
 
The content of exon 10 increases from 35% in WT to 85% in mutant reporter 
plasmid, these studies were further confirmed using the image based analysis 
snd RT-PCR  
 
3.3.3. siRNAs targeting exon 10 mediates post-transcriptional gene 
silencing in a minigene context 
 
The mutant plasmid thus created was co-transfected in SH-SY5Y cells along with 
potential siRNAs intended to induce transcriptional gene silencing. 
The screening assays were performed with six different siRNAs and a non 
specific control wherein, three potential siRNAs were shown to induce 
degradation of transcripts containing exon 10. 
 
Although there was a dose dependent effect of siRNAs 1, 3 and 5, concentrations 
of 50 nM and 100 nM induced degradation of transcripts containing exon 10. 
 
Experiments with mutant plasmid (containing 60% of exon 10) of 0.25 µg 
concentration, suggests that siRNA 3 posed the maximum effect with a reduction 
of exon 10 containing transcript reaching to 30% followed by siRNA 5 with 
35% and siRNA 1 that induced a reduction reaching to 40%.  
 
Experiments with mutant plasmid of 0.5 µg concentration (containing 60% of 
exon 10)  suggests that siRNA 3 posed the maximum effect on the transcript with 
a reduction to 15% followed by siRNA 5 with 25% and siRNA 1 that led to 
30%.  
These data suggest that there is a difference in equilibrium between the amounts 
of plasmid and siRNA molecules that plays an important role in determining 
level of silencing of gene expression and the amount of transfection reagent used 
as it depends upon the plasmid concentration.  
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However siRNA 3 seems to work the best in both conditions indicating that 
design of siRNAs and specific location on their target sequences do play an 
important role in silencing. 
Cells transfected with 0.25 µg of mutant plasmid along with varied 
concentrations of each siRNA were further subjected to RT-PCR analysis. 
According to the image based analysis, a concentration of 50 nM was adequate to 
trigger gene silencing with all the three siRNAs 1, 3 and 5. 
RT-PCR analysis confirms that siRNA 1 is able to degrade the transcripts 
containing exon 10 by 10% at a concentration of 50 nM, whereas siRNA 3 led to a 
reduction of 25% of exon 10 containing transcripts and siRNA 5 led to a 20% 
reduction when a concentration of 50nM was used. 
 
These data further supports and confirms the effects observed through the 
image based analysis.  
 
3.3.4. siRNAs targeting exon 10 mediates post-transcriptional gene 
silencing in an endogenous context 
 
NSC-34 cells were found to have an 80% inclusion of exon 10 versus its 20% 
counterpart without exon 10. These cells were chosen to test the efficacy of the 
potential siRNAs. According to the image based analysis and RT-PCR analysis, a 
concentration of 50 nM was adequate to trigger gene silencing with all the three 
siRNAs 1, 3 and 5. However, an increasing dose of siRNAs were tested on this cell 
line from a starting concentration of 10nM reaching up to 100 nM.  
The semi-quantitative RT-PCR analysis confirmed the potential effect of the 
three siRNAs on exon 10 transcripts in endogenous condition such that a 
maximum reduction of observed in each case was as follows: siRNA 1 induced a 
reduction of 10%, siRNA 3 induced a reduction of 45% and siRNA 5 led to a 40% 
reduction. 
Thus, suggesting that all three siRNAs have a role in inducing silencing of exon 
10 expression and the trend of their efficiency is similar (ie: siRNA 3>5>1) to the 
observations made in the minigene through both methods; image based analysis 
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and semi qRT-PCR. Further to this, preliminary data on the western blot 
indicates that all the three siRNAs have an efficient potent to downregulate exon 
10 containing isoforms, however these preliminary data will need to be validated 
with the further experiments.    
 
3.3.5. Molecular mechanisms at the basis of siRNA mediated post-
transcriptional gene silencing 
 
This work suggests that a meticulous and optimal designing of siRNA is an 
imperative step to attain best target hits. With such a rationale, we have obtained 
three out of six siRNAs that show efficiency in degradation of transcript 
containing exon 10.  
Out of the three siRNAs (1, 3 and 5), siRNA 3 shows maximum efficiency. These 
results have been validated using a minigene recapitulating splicing mutation 
N279, in the SH-SY5Y (neuroblastoma cell line) system and a similar effect is 
exhibited on the endogenous context of NSC-34 (Hybrid of mouse spinal cord 
motor neurons and neuroblastoma cell line) cells. 
 
Although three potential siRNAs have now been discovered to mediate 
transcriptional gene silencing in the context of exon 10, the following intriguing 
questions have risen: 
 
 Why are only three siRNAs effective and what prevents the action of other 
siRNAs? 
 Why are two other siRNAs 0 and 2 causing an increased inclusion of exon 
10? 
 Is a reduction of 30% of exon 10+ adequate to restore splice defects in 
FTDP-17? 
 
To address the first question, many studies have shown that although possible 
siRNAs can be designed against a particular target, only a fraction of them are 
able to induce degradation. Moreover, all siRNAs do not result in equal 
knockdown effects (Murali R et al., 2015). 
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Though we have referred to different tools to optimize an efficient designing 
strategy, since these tools use different features and weights in their model 
design (Murali R et al., 2015) the best hits are still biased. 
However, additionally another prospect could be rendered to an alteration in the 
secondary structure of these transcripts that may not be available for binding of 
siRNAs 0, 2 and 4, thus preventing degradation of transcripts containing exon 10. 
 
Additionally, proteins involved in post transcriptional regulation could be bound 
to the transcript containing exon 10 and inhibit binding of siRNAs 0, 1 and 2. 
 
To this end, the Splice Aid database was referred to identify known splicing 
factors (proteins) bound to exon 10 (Fig.3.3.5). Although the siRNAs are known 
to pose an effect in the cytoplasm, knowledge of known proteins involved in the 
splicing of exon 10 enables identification of several of these proteins which may 
shuttle between nucleus and cytoplasm. These shuttling proteins still being 
bound to exon 10, could block specific sites targeted by siRNAs 0, 2 and 4. 
 
 
Fig.3.19 | Splice aid database highlighting the binding of splicing factors to the pre-mRNA of exon 
10.(This database is constructed based on experimentally validated results) and the target sites 
for siRNAs 0, 1, 2, 3,4 and 5. 
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In Fig.3.19 it can be observed that in the pre-mRNA of exon 10, these targets are 
bound by various proteins such as HTra 2 (alpha and beta 1), SC35, SRp (20, 30, 
40, 54) ETR-3 and hnRNP (H1, H2 and H3). Although these proteins are mainly 
involved in regulation of splicing, they also have an active role in transport, 
stability, editing and translation of mRNA (Tacke R et al., 1998, Chaudhury et al., 
2010, Twyffels et al., 2011). 
A possible elucidation for the mechanism through which siRNAs 0 and 2 
produced an increase in the levels of exon 10 could be supported by the studies 
of Jackson and colleagues. They have demonstrated that siRNAs could implicate 
silencing of non-targeted genes even if they have a similarity of only eleven 
nucleotides (Jackson AL et al., 2003). However, this is a limitation as BLAST 
searches close to 80% to 100% are considered to eliminate off-target effects in 
this study. 
Thus, the genes (with partial sequence similarity) may have an essential role in 
splicing and could be silencers of exon 10 and be silenced by the siRNAs. 
Therefore, upon down-regulation of these silencers, there is an enhanced exon 
10 expression. This possible hypothesis is further supported by the fact that a 
recent paper by Liu and colleagues have supported the activity of single stranded 
RNAi in nucleus where it has shown to modulate the splicing events of 
dystrophin gene (Liu J et al., 2015). Most of these hnRNPs are known to shuttle 
between the nucleus and cytoplasm. However ongoing studies are aimed at 
deciphering additional information such as their localization and function and 
these shuttling hnRNP proteins are known to define, at least in part, the nuclear 
history of individual mRNAs and thereby influence their cytoplasmic fate. 
Therefore, it could be possible that hnRNP H1 and H2 travel along with the 
mRNA (containing exon 10) from nucleus to the cytoplasm and inhibiting 
binding of siRNAs 0, 2 and 4 all of which target the sites that are bound by these 
two proteins. 
To address the second question, on the efficiency of transcript degradation,  
a simulation of the effect of the siRNA 3 on the diseased state is proposed to 
restore the altered ratios of 4R and 3R to its normal state (Fig.3.20). 
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Fig.3.20 | A simulation model for the effect of siRNA 3 on patient with FTDP-17 
 
Since FTDP-17 is characterized by the altered ratio of the two isoforms, it is 
essential to maintain the balance between the two isoforms by enabling gene 
specific silencing such that the final product is in a ratio of 1:1. A complete 
degradation of transcript containing exon 10 would shift the ratio between the 
two isoforms, (4R and 3R) in such a way to possess higher amounts of 3R, a 
characteristic feature of Pick’s disease state. 
Therefore, a reduction by 30% is adequate to restore the balance between 
isoforms to 1:1. 
Hence the proposed work opens a novel therapeutic strategy aimed to correct 
splice defects in exon 10 of MAPT, especially on those inducing formation of 
excessive 4R isoforms, thus addressing a subtype of FTDP disease. 
 
3.3.6. Two efficient systems to validate the functional effects of siRNAs have 
been established 
 
In order to validate the functional effects of the siRNAs on inducing isoform 
specific target degradation, it is vital to establish an optimized method to 
observe all possible isoforms in the cells. 
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Since literature evidences have shown that the six isoforms of tau being very 
close in size are highly inseparable. This poses a challenge to observe 
modulations in the isoforms after treatment with siRNAs. 
Moreover, human neuroblastoma cells have a higher expression of the 3R 
isoforms compared to its 4R counterpart. This trend has been observed both in 
the RNA levels and protein levels, thus limiting its utility in the context of this 
study. Therefore, considering that NSC-34 cells express higher amount of 4R 
compared to its 3R counterpart, in its RNA forms, this cell line was chosen as the 
best model system to study the effect of siRNAs in the tau proteins. 
To this end, western blot analysis was optimized after repetitive applications of 
different experimental conditions. As a result, a well established protocol has 
been developed and four of the existing isoforms of SHSY5Y and NSC-34 cells can 
be visualized through the western blot. 
The results indicate that four isoforms of tau protein can be clearly visualized in 
the western blot. The four isoforms are namely, 4R1N, 3R1N, 4R0N, and 3R0N. 
The SH-SY5Y cells predominantly expressed the 3R isoforms whereas the NSC-
34 cells predominantly expressed the 4R isoforms. These results indicate the 
suitability of this model system to validate effects of potential siRNAs. 
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Abstract* 
 
The MAPT gene is known to play an important role in the broad class of 
neurodegenerative disorders called the tauopathies, that are characterized by 
the presence of abnormal fibrillar aggregates of tau protein in the affected brain. 
Furthermore, mutations in MAPT cause familiar frontotemporal dementia 
(FTLD), and common polymorphisms in MAPT (in the form of the non-inverted 
H1 haplotype) leads to a significant increased risk of the sporadic tauopathies, 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and 
Parkinson’s disease (PD) (Vandrovcova J, et al., 2010). 
This project is focused role of non-coding RNAs (ncRNAs) that are specific to 
MAPT and their roles in regulation of transcription and splicing. Many protein 
coding genes, including MAPT, have overlapping antisense genes that code for 
non-coding transcripts (natural antisense transcripts, NATs). These transcripts 
are co-expressed with the overlapping protein-coding gene, with either negative 
or positive correlations in their transcriptional levels (Gustincich et al., 2006; 
Katayama et al., 2005). 
In many cases the NATs have been shown to regulate the “host” gene by several 
possible processes including transcription initiation, epigenetic silencing, 
translation or stability (Magistri M et al., 2012). 
The collaborators have identified two ncRNA genes that overlap with the MAPT 
promoter region. These genes are termed NAT1 and NAT2, and they overlap 
with the MAPT core promoter and 5’UTR and extend beyond the neighboring 
IMP5 gene. Preliminary studies have shown that these ncRNAs significantly 
modulate MAPT expression level. 
Further to this, a possible role in regulation of splicing of exon 10 is currently 
being validated using the image-based analysis. 
 
 
 
*This project was done in collaboration with Reta Lila Weston Institute, University College 
London (UCL) as a part of internship period pursued during the PhD. The project was 
supervised by Dr.Rohan De Silva and experiments were performed under the guidance of 
the post doctoral fellow, Dr.Roberto Simone. 
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4.1. Materials and methods 
 
SH-SY5Y cell lines that were stably expressing the NATs both wild-types and 
mutants were designed and produced by Dr.Roberto Simone and available prior 
to the set-up described below. 
 
Sequence of NAT transcripts 
 
Human-NT1  
GCCCCAGUCUGCGGAGAGGGAGGGCGAGGGGCGGCGGCGCAGGGGUGCACAGAGGCGGACGGCGAGGC
AGAUUUCGGAGCCGCGGCGCUUACCUGAUAGUCGACAGAGGCGAGGACGGGAGAGGACAGCGGAGGAG
GAGAAGGUGGCUGUGGUGGCGGCGGCAGAAGGAGUCAGAACAAGGACGGGCCUGUGAUGUGUCUGUC
UAUGACGAGGAGGACAAUGUCCUAAGGAAUGGAGAGGAAGAAAGUGAAGGGAACCAGGUCCCUGGAU
UCCAUGUGGAACAGUAGCCCAGGAUGUGCACUAUGGACUGUUACAAGAGAGAGACAUGAUCUUCCUU
AAGGCAUUGAUUUGUCAUGAGUCUCUUUGUUAUAGCCACUUAACGUUACCUUAAUACACCCACUUCA
UGGAUAAGUAAAACUGAGGCUUGGAGAAGCCCACAUUGACACAGC 
 
 
Human-NT 2  
 
GCGGCCGCCGAGUCCGUCCACAUCGCCAGGCCAGGACCUUGGACAGGGCCCAGCACAGGGGCCCUGGAA
UGUGGACUGUCUCAGUGGAUUCUUGUUUAUAGGAAUUAGAGGAAGGUGGAAGAAGCUCAUUCCAGA
GUGCAAUCAAUAACAGUGGAAAGAAGUCCCUGGAGCCCAGUGCAGUGGCUUGAACUGAGAAUGCACU
CACUGGCUGUUGCAGCCAAGACUCCAGUUCUCGCCUCUCUUUCCCUGACUCCCCUGUGCCCACCUUUC
CCCUGCAGGAGUCAGAACAAGGACGGGCCUGUGAUGUGUCUGUCUAUGACGAGGAGGACAAUGUCCU
AAGGAAUGGAGAGGAAGAAAGUGAAGGGAACCAGGUCCCUGGAUUCCAUGUGGAACAGUAGCCCAGG
AUGUGCACUAUGGACUGUUACAAGAGAGAGACAUGAUCUUCCUUAAGGCAUUGAUUUGUCAUGAGUC
UCUUUGUUAUAGCCACUUAACGUUACCUUAAUACACCCACUUCAUGGAUAAGUAAAACUGA 
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4.1.1. Western blot analysis 
 
For Western blot analysis, SH-SY5Y cells stably expressing the NATs were 
washed with PBS and harvested in radioimmunoprecipitation assay (RIPA) 
buffer (1% Nonidet P-40, 0.5% sodium deoxycholate, and 0.1% sodium dodecyl 
sulfate (SDS) in PBS) plus protease inhibitors (Complete, Roche Molecular 
Biochemicals, Indianapolis, IN, USA) and phosphatase inhibitors (New England 
Biolabs) at 4°C. Cell homogenates were centrifuged at 100,000 g for 30 min. 
Supernatants were collected, and the protein content was determined using a 
commercial kit (Bio-Rad, Hercules, CA, USA). Samples were separated on 4-12% 
gradient SDS gels and electrotransferred to polyvinylidene difluoride (PVDF) 
(Millipore, Bedford, MA, USA). Membranes were washed, blocked, and incubated 
overnight with rabbit anti-tau (1:10,000; Dako) antibody, followed by asecond 
washing step before incubating with secondary antibody (an Infra-red 
chromophore Goat anti-Rabbit 800 CW (Li-COR) for 1 h. For each sample, ß-actin 
was probed as a control using a mouse anti-beta actin antibody (Sigma) as 
primary antibody and a Donkey anti-Mouse 680 CW IRdye secondary antibody 
(Li-COR). The western blot bands were acquired using an Odyssey infrared 
scanner. 
 
4.1.2. Bioinformatics predictions analysis 
 
Multiple sequence alignments (MSA) were performed followed by the use of 
tools such as PET cofold and intaRNA to determine the RNA: RNA interactions 
between the non coding antisense transcripts and splice sites of exon 10. 
 
4.1.2. Image-based analysis of fluorescence reporter plasmid 
 
Refer to section 3.1.5 
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4.2. Results 
 
4.2.1. Non-coding RNAs regulate expression of MAPT 
 
Non-coding RNAs that were antisense to human MAPT gene were identified 
computationally and examined in the Ensembl browser 
(http://www.ensembl.org). They were termed as Non coding antisense 
transcripts (NATs). 
 
The NAT1 and NAT2 were lncRNAs that were antisense to the MAPT promoter 
hence, their role in regulation of MAPT was examined by establishing stable cell 
lines expressing either the full length or isoforms containing deleted portions of 
specific domains of the two NATs. 
 
The SH-SY5Y stable cell lines were established such that it pre-dominantly 
expressed the following versions: 
1. Empty vector carrying the NAT sequences (V5) 
2. Full length NAT transcripts (NT1) and (NT2) 
3. Deletion constructs lacking the 5’ first exon (NT1 Δ3’) and (NT2 Δ3’) 
4. Deletion of the 3’ domain (NT 1 Δ5’) and (NT 2 Δ5’)  
5. An artificial construct containing the non-overlapping region (NT1 Non) 
6. An artificial construct containing the overlapping sequence in NAT (NT 1 
Over) 
7. Constructs with the flipped version of the overlapping sequence in exon 1 
(NT1 flip) 
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Fig. 4.1. Schematic representation of the A) Region of complementarity of MAPT and NAT1 B) 
different versions. of NAT 1 transcript C) Western blot analysis of tau in SH-SY5Y stable cell lines 
expressing varied forms of NAT1 transcripts.(These images were obtained in collaboration with 
Dr.Roberto Simone and Faiza Javad,University college London,UK). 
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Fig. 4.2. A) Schematic representation of the A) Region of complementarity of MAPT and NAT2 B) 
different versions of NAT 2 transcript. C) Western blot analysis of tau in SH-SY5Y stable cell lines 
expressing varied forms of NAT2 transcripts. .(These images were obtained in collaboration with 
Dr.Roberto Simone and Faiza Javad,University college London,UK) 
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In stable cell lines expressing the NAT 1 trancripts, it can be observed that the 
full length NT1 induces reduction of tau protein to 23%. NT1 Δ5’ and NT1 Non 
do not show any effect on tau protein. However, NT 1 Δ3’ and NT1 over 
transcripts show a slight reduction to 77% and 79% respectively. On the 
contrary, NTflip shows an increase of tau protein levels to almost double times 
with 188%. 
 
In stable cell lines expressing the NAT 2 transcripts, it can be observed that the 
full length NT2 induces reduction of tau protein to 13%. NT2 Δ5’ does not show 
any effect on tau protein. However, NT 2 Δ3’ shows a slight reduction to 70%. 
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4.2.2. Predictions reveal possible binding between splice junctions and 
NATs 
 
The genomic tract spanning 147 bp upstream and 111 bp downstream of MAPT 
exon 10 (Exon 10 -147+111) was utilized for its homology with the NATs 
sequence. This region includes the splice junctions and the classical stem-loop. 
Bioinformatics predictions tool such as the PETcofold and inta-RNA were 
integrated to analyse the putative complementary regions. 
Dr. Roberto Simone identified that the NT1 targets both the branch point region 
and the region immediately above an imperfect repeat domain (before the 3’ ss) 
in exon 10. 
Although discordance was observed in the predictions between PETcofold and 
inta RNA for the NAT1 transcripts, it was attributed to the possibility that 
PETcofold considers folding constraints using MSA, in contrast to intaRNA that 
does not rely on the former. 
NT2 was able to target a second stem loop structure laying downstream the 
classical stem-loop structure at the 5’ splice site. 
Most of the complementary regions resided in exon 3 of the NT2 transcript. 
Since the putative targets of the NATs resided on the splice site or branch point, 
it intrigued us to proceed further and analyze if this potential binding had an 
impact on splicing. 
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4.2.2. Effect of Non-coding RNAs in regulation of splice events 
 
 
 
Fig.4.3. An image based screening assay has been performed on the wild type plasmid co-
transfected with different concentrations of NATs (A) Wild type plasmid (0.5µg) and NATs (0.5 
µg) (B) Wild type plasmid (0.5µg) and NATs (0.25 µg). 
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The image based analysis shows that cells treated with V5 expresses 6% of exon 
10+,11% exon 10- and 83% of exon 10+/-.Treatments with the NATs plasmids 
shows the following trend when a ratio of 1:1 (WT:NATs) was used: 
 
NT1= 10% of exon 10+, 13% exon 10- and 77% of exon 10+/- 
NT2= 8% exon 10+, 14% of exon 10-and 78% of exon 10+/- 
NT1Δ3= 11% exon 10+, 13% exon 10- and 76% exon 10+/- 
NT1Δ5= 10% exon 10+, 13% exon 10- and 77% exon 10+/- 
NT2Δ3= 7.5% exon 10+, 12.5% exon 10- and 80% exon 10+/- 
NT2Δ5= 8% exon 10+, 12% exon 10- and 80% exon 10+/- 
WT= 5% exon 10+, 15% exon 10- and 80% exon 10+/- 
 
However, the following trend was observed upon treatment with NATs using a 
ratio of 2:1 (WT: NATs): 
 
NT1= 3.5% of exon 10+, 4.5% exon 10- and 92% of exon 10+/- 
NT2= 4% exon 10+, 4% of exon 10-and 92% of exon 10+/- 
NT1Δ3= 3.5% exon 10+, 7% exon 10- and 89.5% exon 10+/- 
NT1Δ5= 4% exon 10+, 5% exon 10- and 91% exon 10+/- 
NT2Δ3= 6% exon 10+, 5% exon 10- and 89% exon 10+/- 
NT2Δ5= 5% exon 10+, 4.5% exon 10- and 90% exon 10+/- 
WT= 3% exon 10+, 6% exon 10- and 91% exon 10+/- 
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Fig. 4.4. R/G values expressing the ratio between the red cells over the green cells in (A) Wild 
type plasmid (0.5µg) and NATs (0.5 µg) (B) Wild type plasmid (0.5µg) and NATs (0.25 µg). 
 
Relative expression levels of Exon 10+ and Exon 10-were calculated using the 
using the below mentioned formula: 
 
 
 
This calculation enables an easy output to determine the type of transcript (i.e: 
exon 10+ or exon 10-) that undergoes a differential expression pattern upon 
treatment with NATs. 
This ratio indicates the relative amounts of exon 10 containing cells in the total 
population of cells transfected with the wild type plasmid and corresponding 
NATs. 
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Treatment condition 1 (1:1 ratio of WT plasmid and NATs): 
It can be observed that the R/G ratio is 0.6 times upon treatment with the V5 
which serves as a control to monitor effects upon subsequent treatment with 
NATs.  
Upon treatment with NT1, there is an effect on exon 10 inclusion as the ratio 
increases to 0.8 times. 
NT2 poses no effect in this condition. However, NT1Δ3’ and NT1Δ5’ indicate an 
increase of this ratio to upto 0.8 and 0.7 times respectively. 
Similar to the trend observed in NT2, there is no effect upon treatment with 
NT2Δ3 and NT2Δ5. 
However, the cells treated with only WT plasmid shows only 0.3 times exon 10. 
 
Treatment condition 2 (2:1 ratio of WT plasmid and NATs): 
The basal expression level of exon 10 upon treatment with V5 shows a ratio of 
0.8 times. Upon treatment with NT1, this ratio increases to upto 1 time. 
Treatment with NT2 and NT1Δ3 showed a reduction of the ratio reaching up to 
0.5 and 0.55 times respectively. NT1Δ5 showed no change. NT2Δ3 and NT2Δ5 
showed an increase of exon 10 inclusion. 
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4.3. Discussion 
 
“Nature is the source of all true knowledge. She has her own logic, her own laws, she has no effect 
without cause nor invention without necessity”. 
-Leonardo da Vinci 
 
4.3.1. Non-coding RNAs decreases expression of MAPT protein 
 
The Non-coding antisense transcripts (NATs) implicates a regulatory function on 
tau protein by mediating its expression (Fig. 4.1 and 4.2). 
The full length transcript (NT1 FL) is shown to have a strong effect of reduction 
on tau protein levels. Transcripts with deletion of the first exon at the 5’ end 
(NT1 Δ5’) is unable to reduce the levels of tau protein, indicating that this 
domain plays an important in imposing a strong downregulation of tau. 
Transcripts containing only the non overlapping region (NT1 Non) also has no 
effect on tau indicating that this region is not a crucial player in eliciting the 
effect on decrease of tau protein. 
However, transcripts containing deletion of the 5’ domain (NT 1 Δ3’) shows a 
slight reduction of tau protein level indicating that this region (although not 
complementary to the tau region mRNA) is particularly essential for the NT1 to 
regulate its mode of action on tau. 
Transcripts containing only the overlapping region is able to induce reduction of 
tau but not as efficient as the full length. 
On the contrary, the transcript containing the flipped version of the overlapping 
region (NT flip) shows an increased production of tau proteins by almost double 
times reaching upto 188%. 
This data suggests that a domain in the first exon is crucial for the reduction of 
tau levels however, it is not adequate to impose the effect and its regulation is 
dependent on the critical sequences available on the last three exons (Fig. 4.1). 
 
In stable cell lines expressing the NAT 2 trancripts, it can be observed that the 
full length NT2 induces reduction of tau protein to 13%. NT1 Δ5’ do not show 
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any effect on tau protein. However, NT 1 Δ3’ shows a slight reduction to 70% 
(Fig.4.2). 
The full length transcript (NT2 FL) is shown to have a strong effect of reduction 
on tau protein levels. Transcripts with deletion of the first exon at the 5’ end 
(NT2 Δ5’) is unable to reduce the levels of tau protein, indicating that this 
domain plays an important in imposing a strong down-regulation of tau. 
However, transcripts containing deletion of the 5’ domain (NT 2 Δ3’) shows a 
slight reduction of tau protein level indicating that this region (although not 
complementary to the tau region mRNA)is particularly essential for the NT2 to 
regulate its mode of action on tau. 
This data suggests that although the overlapping region confers the specificity of 
these NATs to regulate MAPT and the domain in the first exon is crucial for the 
reduction of tau levels, however, it is not adequate to impose the translational 
repression. Thus, suggesting that a functional element mediating the regulation 
of NATs is governed by other critical sequence elements. 
 
4.3.2. Non coding RNAs may pose an effect on splicing of Exon 10 
 
The non coding natural antisense transcripts (NATs) were expected to influence 
splicing based on their putative binding predictions on exon 10. 
To confirm the bioinformatics prediction, a screening assay was carried out 
using the WT plasmid reported in section 3.1.2 to co-transfect with the NATs 
plasmids (Fig.4.3). 
Based on the preliminary observations on the R/G ratio (Fig.4.4), it can be seen 
that when the plasmid and NATs are present in equal amounts in the cell (1:1 
ratio (or) 0.5µg:0.5µg), NT1, NT 1 Δ3’ and NT 1 Δ5’increases the inclusion of 
exon 10 reaching up-to 0.8 times compared to the basal expression of 0.6 times. 
No effects were observed upon treatment with NT2, NT 2 Δ3’ and NT 2 Δ5’. 
 
Upon increasing the amounts of WT plasmid to a reach a ratio of 2:1,it can be 
observed that the NT1 still seems to increase exon 10 but the NT2, NT 1 Δ3’ and 
NT 1 Δ5’ poses an exon skipping effect by decreasing the exon 10 content. NT 2 
Δ3’ and NT 2 Δ5’ poses effects similar to NT1 and enhance inclusion of exon 10. 
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In both cases, the content of exon 10+ is slightly increased in the cells treated 
with empty vector compared to the cells treated with only WT plasmid indicating 
an artefact or non specific effect exhibited by the plasmid backbone. 
From these results, it is quite evident that NATs exhibit an effect on splicing of 
exon 10. NAT1 has implicated exon 10 inclusion regardless of the treatment 
conditions. NT1Δ3’ and NT1Δ5’ have been shown to impose similar effects when 
the ratio of WT plasmid and NATs is 1:1. However, they lose this tendency and 
begin to induce skipping of exon 10 when used in a ratio of 2:1 (WT: NATs). 
NT2, NT2Δ3’ and NT2Δ5’ poses no effect in a ratio of 1:1.But, in a ratio of 2:1, 
NT2 induces exon skipping and NT2Δ3’ and NT2Δ5’ increase exon 10 inclusion. 
 
Interestingly, the full length transcript, NT1 has always shown an inclusion of 
exon 10 regardless of the different ratios used in the study, indicating a strong 
relevance of this NAT in regulation of splicing. 
 
Although lncRNAs can exhibit its role on transcriptional regulation and could 
work either in cis (when the effect is restricted to chromosome from which they 
are transcribed) or trans (effect is extended to other chromosomes) to negatively 
or positively control gene expression. 
Here we show that the NATs which overlap with the sense strand of promoter 
region of MAPT is able to regulate expression of MAPT at post transcriptional 
level. 
 
Additionally our preliminary data suggests that NT1 could impose an auxiliary 
role in splicing of exon 10 in which it aids exon 10 inclusion and NT2 induces 
exon skipping when there is double the amounts of WT plasmid. These 
observations also imply that a stoichiometric balance between the pre-mRNA 
and NATs could influence their mode of action.  
Evidences in literature support the notion on NATs being involved in modulation 
of alternative splicing patterns of their overlapping genes (Krystal et al., 1990, 
Munroe et al., 1991, Yan et al., 2005). 
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The mechanism through which the effect of NT 1 and NT 2 is observed needs 
further investigation. However, possible processes include binding of NT1 to 
spliceosome machinery wherein it imparts its effect through blocking access of 
spliceosome to the pre-mRNA of exon 10 thus facilitating its inclusion. NT2 on 
the other hand could be directly involved by base-pairing with the exon 10 
region leading to its skipping. 
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Chapter 5. Conclusions and Future perspectives 
 
“If we examine the accomplishments of man in his most advanced endeavors, in theory and in 
practice, we find that the cell has done all this long before him, with greater resourcefulness and 
much greater efficiency". 
— Albert Claude 
Nobel Lecture, The Coming Age of the Cell, 12 Dec 1974 
 
The U1 and U7 scramble constructs were successfully produced and all the 
available versions of the constructs were tested on PC12 cells. The drawback of 
low transfection efficiency was solved by employing a suitable transfection 
method known as electroporation. 
However, these constructs were not able to induce exon 10 skipping in PC12 
cells. To this end, with the utilization of available literature studies it is 
hypothesized that PC12 cell line may not be an appropriate model to validate 
effects of these constructs due to the presence of double stem loop structure 
which can alter the secondary structure of exon 10 (Yamashita et al., 2005) and 
hinder the binding of U1 and U7 snRNA. 
Further work should be focused on employing a suitable cell model that 
recapitulates FTDP-17. Since previous studies on exon skipping have validated 
the use of modified chimeric small nuclear RNAs to treat mice with DMD, NSC-34 
cell line being a mouse cell line can be used as an alternative model to test the 
efficacy of these U1 and U7 constructs targeting exon 10. The underlying reasons 
being; (i) The presence of exon 10 has been validated in this system (as a part of 
the project 2) and recapitulates the diseased state and (ii) this cell line originates 
from mouse cells serving as an optimal choice before beginning the studies in the 
N279 mouse model. 
In addition, analysis by Real time PCR would be an advantage to monitor slight 
variations upon exon 10 skipping. 
 
In order to approach the same question from a different perspective, Post 
transcriptional gene silencing was employed using an siRNA based approach. As 
a result, six different siRNAs were designed, a plasmid reporter recapitulating 
FTDP-17 was created. A novel method was developed to screen the effects 
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observed upon treatment with siRNAs and suitable model systems were 
identified to validate the effects of these siRNAs on an endogenous condition. 
Three out of six siRNAs have been implicated to impose a therapeutic effect. Out 
of which one, siRNA 3 has shown the best effect of reduction of 30% of exon 
10+ transcripts. 
 
Currently, primary cortical neurons are being analysed for the effect of siRNAs 
on the endogenous state. Western blot protocol has been optimised for the NSC-
34 cell line, therefore, effectof siRNAs at protein level will be monitored using 
western blot approaches in this model and the primary cortical neurons. 
 
The N279 mutation under this study has been shown to pose an implication only 
in the RNA level in which the mutation leads to an aberrant splicing thus forming 
excessive exon 10 containing transcripts. However it does not impose an effect 
on the protein level as the microtubule binding assays have revealed no 
alterations in the microtubule binding (Hasegawa et al., 1999). There is no 
evidence that the missense substitution is toxic or poses a dominant effect. 
Although this siRNA was tested in the context of N279 mutation, this approach is 
also applicable to other similar mutations such as the S305N whose primary 
effects are at the RNA level. Future application would be directed towards 
employment of these siRNAs in the N279 mouse model. 
 
The N279 mouse model developed by Dawson and colleagues (Dawson et al., 
2007) has been able to recapitulate several of the FTDP-17 disease hallmarks 
hence will serve as a suitable animal model to begin the clinical trials in vivo. 
 
A recent review by Rettig and colleagues have summarized the possible delivery 
approaches of the siRNA molecules and their success in clinical trials (Rettig et al 
2012).The current development in the field and ongoing studies establishes the 
significance of these synthetic siRNAs, which may serve as potential therapeutics 
upon suitable delivery and administration. 
Direct CNS (Central nervous system) administration is used as a method of 
choice in neurodegenerative diseases due to restricted entry across the blood 
brain barrier. Options of delivery include intrathecal, intraventricular, epidural 
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and direct intratissue injection. Administration methods include long term 
infusions or through the use of mini pumps (Rettig et al., 2012). 
Chronic intraventricular pumps were used for the delivery of siRNAs against 
Amyloid precursor protein gene (App) to study Alzheimers related functions in 
adult mice. Efficient knockdowns were observed through potent siRNAs 
(Senechal, Y et al., 2007). 
By employing naked and unassisted delivery of siRNAs in buffered saline, 
chronic infusion was performed in non-human primates to suppress levels of α 
synucein. This protein is known to be associated with Parkinson’s disease. Mini 
osmotic pumps were used for the direct infusion into the substantial niagra 
leading to a decrease in α-synucein both at mRNA and protein levels 
(McCormack et al., 2010). 
siRNAs with modified PS linkages and 2’F-pyrimidine residues near the ends of 
each strand were used for chronic infusion in to the CNS of SOD1(G93A) mouse 
model of amyotrophic lateral sclerosis (ALS). Significant reduction of sod1 
mRNA was observed in the spinal cord. In the transgenic mouse model, an 
infusion over a 28 day period led to alleviated the progression of disease. The 
siRNAs were stable over the course of this period. 
Cholestrol conjugated siRNAs were used for the direct intrastriatal injection to 
target mutant Huntingtin gene (Htt) in the context of Huntington’s disease. 
 
The above mentioned strategies highlight the different modes of delivery of 
siRNAs and demonstrate efficacy in vivo, suggesting the promising future for the 
siRNAs developed in this work. 
 
As a part of collaborative project, the role of long non coding RNAs in regulation 
of MAPT gene have been deciphered for the first time. An additional implication 
in splicing of exon 10 is currently under investigation. 
 
Transcription is pervasive throughout the eukaryotic genome giving rise to many 
functional ncRNAs with key roles.Although the numerous functions of lncRNAs is 
becoming increasingly evident, only a few of them have been fully characterised. 
The effect of ncRNAs in increasing the stability of BACE1 mRNA involved in AD 
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conditions have been recently studied thus emphasising their inevitable and 
predominant roles in regulation of gene expression. 
Therefore identifying the mechanisms through which the regulation is employed 
will be the most fundamental strategy to understand their roles. Since NT1 and 
NT2 have been shown to regulate MAPT expression at protein levels, they can 
serve as therapeutic molecules for AD pathology with increased tau protein 
levels. 
  
164 
 
BIBLIOGRAPHY 
Abdelgany, A., Wood, M., Beeson, D., 2003. Allele-specific silencing of a 
pathogenic mutant acetylcholine receptor subunit by RNA interference. Hum. 
Mol. Genet. 12, 2637–44. doi:10.1093/hmg/ddg280 
Amaral, P.P., Dinger, M.E., Mercer, T.R., Mattick, J.S., n.d. as an RNA Machine 26–
29. 
Amaral, P.P., Mattick, J.S., 2008. Noncoding RNA in development. Mamm. Genome 
19, 454–92. doi:10.1007/s00335-008-9136-7 
Avila, S., Lucas, J., Pe, M.A.R., Biologı, C. De, Pé, M., 2004. Role of Tau Protein in 
Both Physiological and Pathological Conditions 361–384. 
Baker, M., Kwok, J.B.J., Kucera, S., Crook, R., Farrer, M., Houlden, H., Isaacs, A., 
Lincoln, S., Onstead, L., Hardy, J., Wittenber, L., Dodd, P., Webb, S., Hayward, N., 
Tannenberg, T., Schofield, P., Dark, F., 1997. Localization of Frontotemporal 
Dementia with Parkinsonism in an Australian Kindred to Chromosome 17q2 1-
22 794–798. 
Barabino, SM, Blencowe, BJ, Ryder, U, Sproat, BS, Lamond, AI., 1990. Targeted 
snRNP depletion reveals an additional role for mammalian U1 snRNP in 
spliceosome assembly. Cell 63(2):293-302. 
Baralle, D., Baralle, M., 2005a. Splicing in action: assessing disease causing 
sequence changes. J. Med. Genet. 42, 737–48. doi:10.1136/jmg.2004.029538 
Baralle M, Baralle FE. 2008 Genetics and molecular biology: variations in 
alternative spliced pre-mRNA-protein isoforms and their role in disease. Curr 
Opin Lipidol. 19(4): 429-30. doi: 10.1097/MOL.0b013e328306f0b8. 
 
Barash, Y., Calarco, J.A., Gao, W., Pan, Q., Wang, X., Shai, O., Blencowe, B.J., Frey, 
B.J., 2010. Deciphering the splicing code. Nature 465, 53–59. 
doi:10.1038/nature09000 
Barbara, S., 1994. Identification of a Novel Microtubule Binding and Assembly 
Domain in the Developmentally Regulated Inter-repeat Region of Tau 124, 769–
782. 
Beaudoing, E., Freier, S., Wyatt, J.R., Claverie, J., Gautheret, D., 2000. Patterns of 
Variant Polyadenylation Signal Usage in Human Genes 1001–1010. 
Beelman, C.A., Parker, R., 1995. Degradation of mRNA in Eukaryotes Review 
179–183. 
165 
 
Bertram, L., Tanzi, R.E., 2005. Review series The genetic epidemiology of 
neurodegenerative disease 115, 1449–1457. doi:10.1172/JCI24761.The 
Beyer, AL, Christensen, ME, Walker, BW, LeStourgeon, WM., 1977. Identification 
and characterization of the packaging proteins of core 40S hnRNP particles. Cell. 
11(1):127-38. 
Bird, TD, Wijsman, EM, Nochlin, D, Leehey, M, Sumi, SM, Payami, H, Poorkaj, P, 
Nemens, E, Rafkind, M, Schellenberg, GD.1997. Chromosome 17 and hereditary 
dementia: linkage studies in three non-Alzheimer families and kindreds with 
late-onset FAD. Neurology. 48(4):949-54. 
Black, DL, Steitz, JA., 1986 Pre-mRNA splicing in vitro requires intact U4/U6 
small nuclear ribonucleoprotein. Cell. 1986 Aug 29;46(5):697-704. 
 
Bond, A.M., Vangompel, M.J.W., Sametsky, E. a, Clark, M.F., Savage, J.C., Disterhoft, 
J.F., Kohtz, J.D., 2009. Balanced gene regulation by an embryonic brain ncRNA is 
critical for adult hippocampal GABA circuitry. Nat. Neurosci. 12, 1020–7. 
doi:10.1038/nn.2371 
Bradley, T., Cook, M.E., Blanchette, M., 2014. SR proteins control a complex 
network of RNA-processing events 75–92. doi:10.1261/rna.043893.113. 
Brun, C, Suter, D, Pauli, C, Dunant, P, Lochmüller, H, Burgunder, JM, Schümperli, 
D, Weis, J., 2003. U7 snRNAs induce correction of mutated dystrophin pre-mRNA 
by exon skipping. Cell Mol Life Sci. 60(3):557-66. 
Buratti, E., Baralle, D., 2014. Novel roles of U1 snRNP in alternative splicing 
regulation. RNA Biol. 7, 412–419. doi:10.4161/rna.7.4.12153 
Burright, E.N., Clark, H.B., Servadio, A., Matilla, I.I.T., Duvick, L.A., Zoghbi, H.Y., 
1995. SCA1 Transgenic Mice: A Model for Neurodegeneration Caused by an 
Expanded CAG Trinucleotide Repeat 82, 937–948. 
Cartegni, L., Chew, S.L., Krainer, A.R., 2002. Listening to silence and 
understanding nonsense: exonic mutations that affect splicing. Nat. Rev. Genet. 3, 
285–98. doi:10.1038/nrg775 
Carter, J.E., Schuchman, E.H., Gene, C., Apy, T., n.d. Gene therapy for 
neurodegenerative diseases : fact or fiction ? 392–395. 
Chapman, E.J., Carrington, J.C., 2007. Specialization and evolution of endogenous 
small RNA pathways. Nat. Rev. Genet. 8, 884–96. doi:10.1038/nrg2179 
Chaudhury, A., Chander, P., Howe, P.H., 2010. Heterogeneous nuclear 
ribonucleoproteins ( hnRNPs ) in cellular processes : Focus on hnRNP E1 ’ s 
multifunctional regulatory roles 1449–1462. doi:10.1261/rna.2254110.groups 
166 
 
Chemicals, R., 1998. letters to nature 391, 806–811. 
Clancy, B.S., Education, P.D.N., 2008. RNA Splicing : Introns , Exons and 
Spliceosome 1. 
Contribution, O., 2005. Frontotemporal Lobar Degeneration 62. 
Cooper, T. a, Wan, L., Dreyfuss, G., 2009. RNA and disease. Cell 136, 777–93. 
doi:10.1016/j.cell.2009.02.011 
Courtney, E., Kornfeld, S., Janitz, K., Janitz, M., 2010. Transcriptome profiling in 
neurodegenerative disease. J. Neurosci. Methods 193, 189–202. 
doi:10.1016/j.jneumeth.2010.08.018 
Covello G, Siva K, Adami V, Denti MA. 2014 An electroporation protocol for 
efficient DNA transfection in PC12 cells. Cytotechnology. 66(4):543-53. doi: 
10.1007/s10616-013-9608-9. 
 
D’Souza, I., Poorkaj, P., Hong, M., Nochlin, D., Lee, V.M., Bird, T.D., Schellenberg, 
G.D., 1999. Missense and silent tau gene mutations cause frontotemporal 
dementia with parkinsonism-chromosome 17 type, by affecting multiple 
alternative RNA splicing regulatory elements. Proc. Natl. Acad. Sci. U. S. A. 96, 
5598–603. 
D’Souza, I., Schellenberg, G.D., 2000. Determinants of 4-repeat tau expression. 
Coordination between enhancing and inhibitory splicing sequences for exon 10 
inclusion. J. Biol. Chem. 275, 17700–9. doi:10.1074/jbc.M909470199 
D’Souza, I., Schellenberg, G.D., 2005. Regulation of tau isoform expression and 
dementia. Biochim. Biophys. Acta 1739, 104–15. 
doi:10.1016/j.bbadis.2004.08.009 
Dal Mas, A., Rogalska, M.E., Bussani, E., Pagani, F., 2014. Improvement of SMN2 
Pre-mRNA Processing Mediated by Exon-Specific U1 Small Nuclear RNA. Am. J. 
Hum. Genet. 96, 93–103. doi:10.1016/j.ajhg.2014.12.009 
De Conti, L., Skoko, N., Buratti, E., Baralle, M., 2012. Complexities of 5’splice site 
definition: implications in clinical analyses. RNA Biol. 9, 911–23. 
doi:10.4161/rna.20386 
De Souza, J.E.S., Ramalho, R.F., Galante, P. a F., Meyer, D., de Souza, S.J., 2011. 
Alternative splicing and genetic diversity: silencers are more frequently modified 
by SNVs associated with alternative exon/intron borders. Nucleic Acids Res. 39, 
4942–8. doi:10.1093/nar/gkr081 
167 
 
Denisont, R.A., Weiner, A.M., 1982. Human Ul RNA Pseudogenes May Be 
Generated by Both DNA- and RNA-Mediated Mechanisms 2, 815–828. 
Denti MA, Rosa A, Sthandier O, De Angelis FG, Bozzoni I. 2004 A new vector, 
based on the PolII promoter of the U1 snRNA gene, for the expression of siRNAs 
in mammalian cells. Mol Ther.10(1):191-9. 
Denti, M.A., Rosa, A., Antona, G.D., Sthandier, O., Angelis, F.G. De, Auricchio, A., 
Nicoletti, C., Allocca, M., Pansarasa, O., Parente, V., Musaro, A., Bottinelli, R., 
Bozzoni, I., 2006. Body-wide gene therapy of Duchenne muscular dystrophy in 
the mdx mouse model 103. 
Denti MA, Incitti T, Sthandier O, Nicoletti C, De Angelis FG, Rizzuto E, Auricchio A, 
Musarò A, Bozzoni I. 2008 Long-term benefit of adeno-associated 
virus/antisense-mediated exon skipping in dystrophic mice. Hum Gene Ther.19 
(6):601-8. doi: 10.1089/hum.2008.012. 
 
Ding, H., Schwarz, D.S., Keene, A., Affar, E.B., Fenton, L., Xia, X., Shi, Y., Zamore, 
P.D., Xu, Z., 2003. Selective silencing by RNAi of a dominant allele that causes 
amyotrophic lateral sclerosis 209–217. 
Doolittle, R. F., 1995. The multiplicity of domains in proteins. Annu. Rev. 
Biochem. 64, 287–314. 
Drechsel, D.N., Hyman, A.A., Cobb, M.H., Kirschner, M.W., 1992. Modulation of the 
Dynamic Instability of Tubulin Assembly by the Microtubule-Associated Protein 
Tau 3, 1141–1154. 
Dreyfuss, G., Kim, V.N., Kataoka, N., 2002. Messenger-RNA-binding proteins and 
the messages they carry. Nat. Rev. Mol. Cell Biol. 3, 195–205. 
doi:10.1038/nrm760 
Drubin, D.G., Nelson, W.J., 1996. Origins of Cell Polarity Review 84, 335–344. 
Du, H., Rosbash, M., 2002. The U1 snRNP protein U1C recognizes the 5’ splice site 
in the absence of base pairing 419, 1–5. doi:10.1038/nature00999.1. 
Dufour BD, Smith CA, Clark RL, Walker TR, McBride JL. 2014 Intrajugular vein 
delivery of AAV9-RNAi prevents neuropathological changes and weight loss in 
Huntington's disease mice. Mol Ther. 22(4):797-810. doi: 10.1038/mt.2013.289 
Dykxhoorn, D.M., Novina, C.D., Sharp, P. a, 2003. Killing the messenger: short 
RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4, 457–67. 
doi:10.1038/nrm1129 
168 
 
Egloff, S., O’Reilly, D., Murphy, S., 2008. Expression of human snRNA genes from 
beginning to end. Biochem. Soc. Trans. 36, 590–4. doi:10.1042/BST0360590 
Elbashir, S.M., Lendeckel, W., Tuschl, T., 2001. RNA interference is mediated by 
21- and 22-nucleotide RNAs 188–200. doi:10.1101/gad.862301.vents 
Faghihi, M.A., Modarresi, F., Khalil, A.M., Wood, D.E., Sahagan, B.G., Morgan, T.E., 
Finch, C.E., St, G., Iii, L., Kenny, P.J., Wahlestedt, C., 2008. Expression of a 
noncoding RNA is elevated in Alzheimer ’ s disease and drives rapid feed-
forward regulation of b -secretase 14, 723–730. doi:10.038/nm1784 
Fairbrother, W.G., Chasin, L.A., 2000. Human Genomic Sequences That Inhibit 
Splicing 20, 6816–6825. 
Fernandez Alanis E, Pinotti M, Dal Mas A, Balestra D, Cavallari N, Rogalska ME, 
Bernardi F, Pagani F.2012 An exon-specific U1 small nuclear RNA (snRNA) 
strategy to correct splicing defects. Hum Mol Genet. 21(11):2389-98. doi: 
10.1093/hmg/dds045. 
 
Fontana F, Siva K, Denti MA. 2015 A network of RNA and protein interactions in 
Fronto Temporal Dementia. Front Mol Neurosci. 2015 Mar 19;8:9. doi: 
10.3389/fnmol.2015.00009. eCollection 2015. 
 
Foster, NL, Wilhelmsen, K, Sima, AA, Jones, MZ, D'Amato, CJ, Gilman, S., 1997 
Frontotemporal dementia and parkinsonism linked to chromosome 17: a 
consensus conference. Conference Participants. Ann Neurol. 41(6):706-15. 
Francisco, S., 1998. Pathogenic implications of mutations in the tau gene in 
pallido-ponto-nigral degeneration and related neurodegenerative disorders 
linked to chromosome 17 95, 13103–13107. 
Froelich, S., Basun, H., Forsell, C., Lilius, L., Axelman, K., Andreadis, A., Lannfelt, L., 
1997. Mapping of a Disease Locus for Familial Rapidly Progressive 
Frontotemporal Dementia to Chromosome 17q12-21 385, 380–385. 
Fu, Y., Masuda, A., Ito, M., Shinmi, J., Ohno, K., 2011. AG-dependent 3’-splice sites 
are predisposed to aberrant splicing due to a mutation at the first nucleotide of 
an exon. Nucleic Acids Res. 39, 4396–404. doi:10.1093/nar/gkr026 
Fukumura, K., Inoue, K., 2014. Role and mechanism of U1-independent pre-
mRNA splicing in the regulation of alternative splicing. RNA Biol. 6, 395–398. 
doi:10.4161/rna.6.4.9318 
Gabellini, N., 2001. A polymorphic GT repeat from the human cardiac Na 1 Ca 2 1 
exchanger intron 2 activates splicing 1083, 1076–1083. 
169 
 
Gamblin, T.C., 2005. Potential structure/function relationships of predicted 
secondary structural elements of tau. Biochim. Biophys. Acta 1739, 140–9. 
doi:10.1016/j.bbadis.2004.08.013 
Gao, F., 2010. Context-dependent functions of specific microRNAs in neuronal 
development 1–9. 
Garcia-blanco, M.A., Baraniak, A.P., Lasda, E.L., 2004. Alternative splicing in 
disease and therapy 22, 535–546. 
Ge, X., Chen, Y., Lv, N., 2013. Advances with RNA interference in Alzheimer ’ s 
disease research 117–125. 
Genc, S., Koroglu, T.F., Genc, K., 2004. RNA interference in neuroscience. Brain 
Res. Mol. Brain Res. 132, 260–70. doi:10.1016/j.molbrainres.2004.02.004 
Gilbert,W., 1978. Why genes in pieces? Nature 9;271(5645):501. 
doi:10.1038/271501a0 4  
Glaus, E., Schmid, F., Da Costa, R., Berger, W., Neidhardt, J., 2011. Gene 
therapeutic approach using mutation-adapted U1 snRNA to correct a RPGR 
splice defect in patient-derived cells. Mol. Ther. 19, 936–41. 
doi:10.1038/mt.2011.7 
Goedert, M., 2004. Tau protein and neurodegeneration. Semin. Cell Dev. Biol. 15, 
45–9. doi:10.1016/j.semcdb.2003.12.015 
Goedert, M., Ghetti, B., Spillantini, M.G., 2015. Frontotemporal Dementia : 
Implications for Understanding Alzheimer Disease 1–22. 
Goedert, M., Jakes, R., 2005. Mutations causing neurodegenerative tauopathies. 
Biochim. Biophys. Acta 1739, 240–50. doi:10.1016/j.bbadis.2004.08.007 
Goedert, M., Spillantini, M.G., 2000. Tau mutations in frontotemporal dementia 
FTDP-17 and their relevance for Alzheimer ’ s disease 1502, 110–121. 
Gomase, VS, Tagore, S., 2008. RNAi--a tool for target finding in new drug 
development.Curr Drug Metab. 9(3):241-4. 
 
Goodson, H. V, n.d. Motors and membrane traffic and Thomas 18–28. 
Gordon, F.E., Nutt, C.L., Cheunsuchon, P., Nakayama, Y., Provencher, K. a, Rice, K. 
a, Zhou, Y., Zhang, X., Klibanski, A., 2010. Increased expression of angiogenic 
genes in the brains of mouse meg3-null embryos. Endocrinology 151, 2443–52. 
doi:10.1210/en.2009-1151 
170 
 
Gorman, L., Mercatante, D.R., Kole, R., 2000. Restoration of correct splicing of 
thalassemic beta-globin pre-mRNA by modified U1 snRNAs. J. Biol. Chem. 275, 
35914–9. doi:10.1074/jbc.M006259200 
Goyenvalle, A., Wright, J., Babbs, A., Wilkins, V., Garcia, L., Davies, K.E., 2012. 
Engineering multiple U7snRNA constructs to induce single and multiexon-
skipping for Duchenne muscular dystrophy. Mol. Ther. 20, 1212–21. 
doi:10.1038/mt.2012.26 
Gozani, O.R., Potashkin, J., Reed, R., 1998. A Potential Role for U2AF-SAP 155 
Interactions in Recruiting U2 snRNP to the Branch Site 18, 4752–4760. 
Grover, A., Deture, M., Yen, S., Hutton, M., 2002. Effects on splicing and protein 
function of three mutations in codon N296 of tau in vitro 323, 33–36. 
Gross, JD, Moerke, NJ, von der Haar T, Lugovskoy, AA, Sachs, AB, McCarthy, JE, 
Wagner, G., 2003. Ribosome loading onto the mRNA cap is driven by 
conformational coupling between eIF4G and eIF4E. Cell. 12;115 (6):739-50. 
Gueneau de Novoa, P., Williams, K.P., 2004. The tmRNA website: reductive 
evolution of tmRNA in plastids and other endosymbionts. Nucleic Acids Res. 32, 
D104–8. doi:10.1093/nar/gkh102 
Guttman, M., Amit, I., Garber, M., French, C., Lin, M.F., Feldser, D., Huarte, M., Zuk, 
O., Carey, B.W., Cassady, J.P., Cabili, M.N., Jaenisch, R., Mikkelsen, T.S., Jacks, T., 
Hacohen, N., Bernstein, B.E., Kellis, M., Regev, A., Rinn, J.L., Lander, E.S., 2009. 
Chromatin signature reveals over a thousand highly conserved large non-coding 
RNAs in mammals. Nature 458, 223–7. doi:10.1038/nature07672 
Hamilton, A.J., Baulcombe, D.C., 1999. A Species of Small Antisense RNA in 
Posttranscriptional Gene Silencing in Plants 213, 1997–2000. 
Hammond, S.M., Bernstein, E., Beach, D., Hannon, G.J., 2000. An RNA-directed 
nuclease mediates post-transcriptional gene silencing in Drosophila cells 527, 
524–527. 
Hammond, S.M., Wood, M.J. a, 2011. Genetic therapies for RNA mis-splicing 
diseases. Trends Genet. 27, 196–205. doi:10.1016/j.tig.2011.02.004 
Hasegawa, M., Smith, M.J., Iijima, M., Tabira, T., Y, M.G., 1999. FTDP-17 mutations 
N279K and S305N in tau produce increased splicing of exon 10 443, 93–96. 
Hastings, M.L., Krainer, A.R., 2001. Pre-mRNA splicing in the new millennium 
302–309. 
171 
 
Hernandez, N., 2001. Small nuclear RNA genes: a model system to study 
fundamental mechanisms of transcription. J. Biol. Chem. 276, 26733–6. 
doi:10.1074/jbc.R100032200 
Heutink, P., Stevens, S.M., Rizzu, P., Bakker, E., Kros, S.J.M., 1997. Hereditary 
Frontotemporal Dementia Is Linked to Chromosome 17q21-q22 : A Genetic and 
Clinicopathological Study of Three Dutch F d e s. 
Himmelstein, D.S., Ward, S.M., Lancia, J.K., Patterson, K.R., Binder, L.I., 2012. Tau 
as a therapeutic target in neurodegenerative disease. Pharmacol. Ther. 136, 8–
22. doi:10.1016/j.pharmthera.2012.07.001 
Hollenbeck, PJ, Swanson, JA., 1990 Radial extension of macrophage tubular 
lysosomes supported by kinesin. Nature. 30;346(6287):864-6. 
Huang, Q., Jacobson, M.R., Pederson, T., 1997. 3 Ј Processing of Human Pre-U2 
Small Nuclear RNA : a Base-Pairing Interaction between the 3 Ј Extension of the 
Precursor and an Internal Region 17, 7178–7185. 
Incitti, T., De Angelis, F.G., Cazzella, V., Sthandier, O., Pinnarò, C., Legnini, I., 
Bozzoni, I., 2010. Exon skipping and duchenne muscular dystrophy therapy: 
selection of the most active U1 snRNA antisense able to induce dystrophin exon 
51 skipping. Mol. Ther. 18, 1675–82. doi:10.1038/mt.2010.123 
Ingram, E.M., Spillantini, M.G., 2002. Tau gene mutations : dissecting the 
pathogenesis of FTDP-17 8, 555–562. 
Jacobson, M.R., Huang, Q., Pederson, T., 2002. JBC Papers in Press. Published on 
April 15, 2002 as Manuscript M202258200. 
Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G, 
Linsley PS.2003 Expression profiling reveals off-target gene regulation by RNAi. 
Nat Biotechnol. 21(6):635-7. 
Jana, S., Chakraborty, C., Nandi, S., Deb, J.K., 2004. RNA interference: potential 
therapeutic targets. Appl. Microbiol. Biotechnol. 65, 649–57. 
doi:10.1007/s00253-004-1732-1 
Jeganathan S, von Bergen, M, Mandelkow, EM, Mandelkow, E., 2008. The natively 
unfolded character of tau and its aggregation to Alzheimer-like paired helical 
filaments. Biochemistry. 7;47(40):10526-39. doi: 10.1021/bi800783d. 
Keren, H., Lev-Maor, G., Ast, G., 2010. Alternative splicing and evolution: 
diversification, exon definition and function. Nat. Rev. Genet. 11, 345–55. 
doi:10.1038/nrg2776 
Kieffer, T., Sands, J., Cannon, B., n.d. PHYSIOLOGICAL Editor : Dennis Brown 
European Editorial Committee. 
172 
 
Kiss, T., 2004. Biogenesis of small nuclear RNPs. J. Cell Sci. 117, 5949–51. 
doi:10.1242/jcs.01487 
Kolarova, M., García-Sierra, F., Bartos, A., Ricny, J., Ripova, D., 2012. Structure and 
pathology of tau protein in Alzheimer disease. Int. J. Alzheimers. Dis. 2012, 
731526. doi:10.1155/2012/731526 
Kolkman, J. A. & Stemmer, W. P. 2001. Directed evolution of proteins by exon 
shuffling. Nature Biotech. 19, 423–428. 
Kornienko, A.E., Guenzl, P.M., Barlow, D.P., Pauler, F.M., 2013. Gene regulation by 
the act of long non-coding RNA transcription. BMC Biol. 11, 59. 
doi:10.1186/1741-7007-11-59 
Koutsilieri, E, Rethwilm, A, Scheller, C. J., 2007. The therapeutic potential of 
siRNA in gene therapy of neurodegenerative disorders.Neural Transm 
Suppl.7;(72):43-9. 
Krecic, A.M., Swanson, M.S., n.d. hnRNP complexes : and function Annette M 
Krecic * and Maurice S Swanson ? 
Kuhlman, T.C., Cho, H., Reinberg, D., 1999. The General Transcription Factors IIA , 
IIB , IIF , and IIE Are Required for RNA Polymerase II Transcription from the 
Human U1 Small Nuclear RNA Promoter 19, 2130–2141. 
Kyriakopoulou, C., Larsson, P., Liu, L.E.I., Schuster, J., Kirsebom, L.A., Virtanen, A., 
2006. U1-like snRNAs lacking complementarity to canonical 5 9 splice sites 
1603–1611. doi:10.1261/rna.26506.4 
Lee, G., Leugers, C.J., 2013. NIH Public Access 319–335. doi:10.1016/B978-0-12-
385883-2.00004-7.Tau 
Lendon, CL, Lynch, T, Norton, J, McKeel, DW Jr, Busfield, F, Craddock, N, 
Chakraverty S, Gopalakrishnan, G, Shears, SD, Grimmett, W, Wilhelmsen, KC, 
Hansen, L, Morris, JC, Goate, AM., 1998. Hereditary dysphasic disinhibition 
dementia: a frontotemporal dementia linked to 17q21-22. Neurology 
50(6):1546-55. 
Lev-maor, G., Sorek, R., Shomron, N., Ast, G., 2003. The Birth of an Alternatively 
Spliced Exon : 3  Splice-Site Selection in Alu Exons 300, 1288–1292. 
Lewandowska, M.A., 2013. The missing puzzle piece : splicing mutations 6, 
2675–2682. 
Lewejohann, L., Skryabin, B. V, Sachser, N., Prehn, C., Heiduschka, P., Thanos, S., 
Jordan, U., Dell’Omo, G., Vyssotski, a L., Pleskacheva, M.G., Lipp, H.-P., Tiedge, H., 
Brosius, J., Prior, H., 2004. Role of a neuronal small non-messenger RNA: 
173 
 
behavioural alterations in BC1 RNA-deleted mice. Behav. Brain Res. 154, 273–89. 
doi:10.1016/j.bbr.2004.02.015 
Liebert, M.A., Denti, M.A., Rosa, A., Antona, G.D., Sthandier, O., Angelis, F.G.D.E., 
Nicoletti, C., Allocca, M., Pansarasa, O., Parente, V., Musarò, A., Auricchio, A., 
Bottinelli, R., Bozzoni, I., 2006. Nuclear RNA Effectively Rescues Dystrophin 
Synthesis and Muscle Function by Local Treatment of mdx Mice 574, 565–574. 
Lijima, M, Tabira, T, Poorkaj, P, Schellenberg, GD, Trojanowski, JQ, Lee, VM, 
Schmidt, ML, Takahashi, K, Nabika, T, Matsumoto, T, Yamashita, Y, Yoshioka, S, 
Ishino, H., 1999. A distinct familial presenile dementia with a novel missense 
mutation in the tau gene. Neuroreport. 25;10(3):497-501. 
Liu, F., Gong, C.-X., 2008. Tau exon 10 alternative splicing and tauopathies. Mol. 
Neurodegener. 3, 8. doi:10.1186/1750-1326-3-8 
Liu, S., Asparuhova, M., Brondani, V., Ziekau, I., Klimkait, T., Schümperli, D., 2004. 
Inhibition of HIV-1 multiplication by antisense U7 snRNAs and siRNAs targeting 
cyclophilin A. Nucleic Acids Res. 32, 3752–9. doi:10.1093/nar/gkh715 
Liu J, Hu J, Hicks JA, Prakash TP, Corey DR. 2015. Modulation of Splicing by 
Single-Stranded Silencing RNAs. Nucleic Acid Ther. doi: 10.1089/nat.2014.0527 
 
Mackay, J.P., Sunde, M., Lowry, J. a., Crossley, M., Matthews, J.M., 2008. Response 
to Chatr-aryamontri et al.: Protein interactions: to believe or not to believe? 
Trends Biochem. Sci. 33, 242–243. doi:10.1016/j.tibs.2008.04.003 
Madhani, HD, Guthrie, C., 1994. Dynamic RNA-RNA interactions in the 
spliceosome. Annu Rev Genet. 1994;28:1-26. 
Makarova, O. V, Makarov, E.M., Urlaub, H., Will, C.L., Gentzel, M., Wilm, M., 
Lührmann, R., 2004. A subset of human 35S U5 proteins, including Prp19, 
function prior to catalytic step 1 of splicing. EMBO J. 23, 2381–91. 
doi:10.1038/sj.emboj.7600241 
Malca, H., Shomron, N., Ast, G., 2003. The U1 snRNP Base Pairs with the 5 Ј Splice 
Site within a Penta-snRNP Complex 23, 3442–3455. 
doi:10.1128/MCB.23.10.3442 
Manuscript, A., 2010. NIH Public Access 12, 214–222. 
Manuscript, A., 2013. NIH Public Access 3, 34–42. 
doi:10.1016/j.biomed.2013.01.001.Long 
Marquis, J., Meyer, K., Angehrn, L., Kämpfer, S.S., Rothen-Rutishauser, B., 
Schümperli, D., 2007. Spinal muscular atrophy: SMN2 pre-mRNA splicing 
174 
 
corrected by a U7 snRNA derivative carrying a splicing enhancer sequence. Mol. 
Ther. 15, 1479–86. doi:10.1038/sj.mt.6300200 
Martins, H., Mao, Q., Harper, S.Q., Staber, P.D., He, X., Eliason, S.L., Yang, L., Kotin, 
R.M., Paulson, H.L., Davidson, B.L., 2005. RNA interference improves motor and 
neuropathological abnormalities in a Huntington’s 102. 
Masato Hasegawaa, Michael J Smitha, Masaaki Iijimab, Takeshi Tabirac, Michel 
Goederta, 1999. FTDP-17 mutations N279K and S305N in tau produce increased 
splicing of exon 10.FEBS lett.443,(2), 93–96 doi:10.1016/S0014-
5793(98)01696-2. 
 
Massone, S., Vassallo, I., Fiorino, G., Castelnuovo, M., Barbieri, F., Borghi, R., 
Tabaton, M., Robello, M., Gatta, E., Russo, C., Florio, T., Dieci, G., Cancedda, R., 
Pagano, A., 2011. 17A, a novel non-coding RNA, regulates GABA B alternative 
splicing and signaling in response to inflammatory stimuli and in Alzheimer 
disease. Neurobiol. Dis. 41, 308–17. doi:10.1016/j.nbd.2010.09.019 
Matlin, A.J., Clark, F., Smith, C.W.J., 2005. Understanding alternative splicing: 
towards a cellular code. Nat. Rev. Mol. Cell Biol. 6, 386–98. 
doi:10.1038/nrm1645 
McManus, C.J., Graveley, B.R., 2011. RNA structure and the mechanisms of 
alternative splicing. Curr. Opin. Genet. Dev. 21, 373–9. 
doi:10.1016/j.gde.2011.04.001 
Meister, G., Tuschl, T., 2004. Mechanisms of gene silencing by double-stranded 
RNA 431, 343–349. 
Mercer, T.R., Dinger, M.E., Mariani, J., Kosik, K.S., Mehler, M.F., Mattick, J.S., 2008. 
Noncoding RNAs in Long-Term Memory Formation. Neuroscientist 14, 434–45. 
doi:10.1177/1073858408319187 
Mercer, T.R., Qureshi, I.A., Gokhan, S., Dinger, M.E., Li, G., Mattick, J.S., Mehler, 
M.F., 2010. Long noncoding RNAs in neuronal-glial fate specification and 
oligodendrocyte lineage maturation 1–15. 
Meyer, K., Marquis, J., Trüb, J., Nlend Nlend, R., Verp, S., Ruepp, M.-D., Imboden, H., 
Barde, I., Trono, D., Schümperli, D., 2009. Rescue of a severe mouse model for 
spinal muscular atrophy by U7 snRNA-mediated splicing modulation. Hum. Mol. 
Genet. 18, 546–55. doi:10.1093/hmg/ddn382 
Miller, V.M., Gouvion, C.M., Davidson, B.L., Paulson, H.L., 2004. Targeting 
Alzheimer’s disease genes with RNA interference: an efficient strategy for 
silencing mutant alleles. Nucleic Acids Res. 32, 661–8. doi:10.1093/nar/gkh208 
175 
 
Miller, V.M., Paulson, H.L., Gonzalez-Alegre, P., 2005. RNA interference in 
neuroscience: progress and challenges. Cell. Mol. Neurobiol. 25, 1195–207. 
doi:10.1007/s10571-005-8447-4 
Miller, V.M., Xia, H., Marrs, G.L., Gouvion, C.M., Lee, G., Davidson, B.L., Paulson, 
H.L., 2007. Allele-specific silencing of dominant disease genes 100, 7195–7200. 
Mills, J.D., Janitz, M., 2012. Alternative splicing of mRNA in the molecular 
pathology of neurodegenerative diseases. Neurobiol. Aging 33, 1012.e11–24. 
doi:10.1016/j.neurobiolaging.2011.10.030 
Morris, R.L., Hollenbeck, P.J., 1993. The regulation of bidirectional mitochondrial 
transport is coordinated with axonal outgrowth 927, 917–927. 
Mount, S.M., 2000. Genomic Sequence , Splicing , and Gene Annotation 6, 788–
792. 
Mount, SM, Pettersson, I, Hinterberger, M, Karmas, A, Steitz, JA. The U1 small 
nuclear RNA-protein complex selectively binds a 5' splice site in vitro 1983 Cell. 
33(2):509-18. 
Muller, B., 1997. The U7 snRNP and the hairpin binding protein : Key players in 
histone mRNA metabolism 8. 
Murrell, J.R., Koller, D., Goedert, M., Spillantini, M.G., Edenberg, H.J., Farlow, M.R., 
Ghetti, B., 1997. Familial Multiple-System Tauopathy with Presenile Dementia Is 
Localized to Chromosome 17 1131–1138. 
Mus, E., Hof, P.R., Tiedge, H., 2007. Dendritic BC200 RNA in aging and in 
Alzheimer ’ s disease. 
Nally, M.T.M.C., 1999. U1 Small Nuclear Ribonucleoprotein and Splicing 
Inhibition by the Rous Sarcoma Virus Negative Regulator of Splicing Element 73, 
2385–2393. 
Naro, C., Sette, C., 2013. Phosphorylation-Mediated Regulation of Alternative 
Splicing in Cancer 2013. 
Neuenkirchen, N., Chari, A., Fischer, U., 2008. Deciphering the assembly pathway 
of Sm-class U snRNPs. FEBS Lett. 582, 1997–2003. 
doi:10.1016/j.febslet.2008.03.009 
Niblock, M., Gallo, J.-M., 2012. Tau alternative splicing in familial and sporadic 
tauopathies. Biochem. Soc. Trans. 40, 677–80. doi:10.1042/BST20120091 
Nilsen, T.W., 2003. The spliceosome: the most complex macromolecular machine 
in the cell? Bioessays 25, 1147–9. doi:10.1002/bies.10394 
176 
 
Nurtdinov, R.N., 2003. Low conservation of alternative splicing patterns in the 
human and mouse genomes. Hum. Mol. Genet. 12, 1313–1320. 
doi:10.1093/hmg/ddg137 
Ole, R.Y.K., 1998. Stable alteration of pre-mRNA splicing patterns by modified U7 
small nuclear RNAs 95, 4929–4934. 
Patton, J.R., Patterson, R.J., Pederson, T., 1987. Reconstitution of the Ul Small 
Nuclear Ribonucleoprotein Particle 7, 4030–4037. 
Peng, T., Li, Y., 2009. Tandem exon duplication tends to propagate rather than to 
create de novo alternative splicing. Biochem. Biophys. Res. Commun. 383, 163–6. 
doi:10.1016/j.bbrc.2009.03.162 
Peng KA, Masliah E. 2010 Lentivirus-expressed siRNA vectors against Alzheimer 
disease. Methods Mol Biol. 614:215-24. doi: 10.1007/978-1-60761-533-0_15. 
Petersen, RB, Tabaton, M, Chen, SG, Monari, L, Richardson, SL, Lynch, T, Manetto, 
V, Lanska, DJ, Markesbery, WR, Lynch, T et al., 1995. Familial progressive 
subcortical gliosis: presence of prions and linkage to chromosome 17. Neurology. 
45(6):1062-7. 
Pomeranz Krummel, D. a, Oubridge, C., Leung, A.K.W., Li, J., Nagai, K., 2009. 
Crystal structure of human spliceosomal U1 snRNP at 5.5 A resolution. Nature 
458, 475–80. doi:10.1038/nature07851 
Poorkaj, P, Bird, TD, Wijsman, E, Nemens, E, Garruto, RM, Anderson, L, Andreadis, 
A, Wiederholt, WC, Raskind, M, Schellenberg, GD., 1998. Tau is a candidate gene 
for chromosome 17 frontotemporal dementia Ann Neurol. 43(6):815-25. 
Pozzoli, U., Sironi, M., 2005. Silencers regulate both constitutive and alternative 
splicing events in mammals. Cell. Mol. Life Sci. 62, 1579–604. 
doi:10.1007/s00018-005-5030-6 
Qian, W., Liu, F., 2014. Regulation of alternative splicing of tau exon 10. Neurosci. 
Bull. 30, 367–77. doi:10.1007/s12264-013-1411-2 
Qureshi, I. a, Mehler, M.F., 2011. Non-coding RNA networks underlying cognitive 
disorders across the lifespan. Trends Mol. Med. 17, 337–46. 
doi:10.1016/j.molmed.2011.02.002 
Rabbitts, T.H, Forster,A., 1978. Evidence for noncontiguous variable and constant 
region genes in both germ line and myeloma DNA. Cell 13(2):319-27. 
Ralph, G.S., Radcliffe, P. a, Day, D.M., Carthy, J.M., Leroux, M. a, Lee, D.C.P., Wong, 
L.-F., Bilsland, L.G., Greensmith, L., Kingsman, S.M., Mitrophanous, K. a, Mazarakis, 
N.D., Azzouz, M., 2005. Silencing mutant SOD1 using RNAi protects against 
177 
 
neurodegeneration and extends survival in an ALS model. Nat. Med. 11, 429–33. 
doi:10.1038/nm1205 
Raponi M, Baralle D.2008, Can donor splice site recognition occur without the 
involvement of U1 snRNP? Biochem Soc Trans. 3 548-50. doi: 
10.1042/BST0360548. 
Raoul, C., Abbas-Terki, T., Bensadoun, J.-C., Guillot, S., Haase, G., Szulc, J., 
Henderson, C.E., Aebischer, P., 2005. Lentiviral-mediated silencing of SOD1 
through RNA interference retards disease onset and progression in a mouse 
model of ALS. Nat. Med. 11, 423–8. doi:10.1038/nm1207 
Reed, R., 2000. Mechanisms of fidelity in pre-mRNA splicing 1–6. 
Riedl, L., Mackenzie, I.R., Förstl, H., Kurz, A., Diehl-schmid, J., 2014. 
Frontotemporal lobar degeneration : current perspectives 297–310. 
Rnas, L., Mercer, T.R., Dinger, M.E., Mattick, J.S., n.d. insights into functions. 
Road, H., Kingdom, U., Adrian, E.D., Way, R., 1999. Structure of tau exon 10 
splicing regulatory element RNA and destabilization by mutations of 
frontotemporal dementia and parkinsonism linked to chromosome 17 96, 8229–
8234. 
Roca, X., Krainer, A.R., Eperon, I.C., 2013. Pick one , but be quick : 5 9 splice sites 
and the problems of too many choices 129–144. 
doi:10.1101/gad.209759.112.that 
Rosso, S.M., Donker Kaat, L., Baks, T., Joosse, M., de Koning, I., Pijnenburg, Y., de 
Jong, D., Dooijes, D., Kamphorst, W., Ravid, R., Niermeijer, M.F., Verheij, F., 
Kremer, H.P., Scheltens, P., van Duijn, C.M., Heutink, P., van Swieten, J.C., 2003. 
Frontotemporal dementia in The Netherlands: patient characteristics and 
prevalence estimates from a population-based study. Brain 126, 2016–22. 
doi:10.1093/brain/awg204 
Ruskin, B, Zamore, PD, Green, MR., 1988. A factor, U2AF, is required for U2 
snRNP binding and splicing complex assembly. Cell. 1988 Jan 29;52(2):207-19. 
Samuels, D.C., Schon, E. a, Chinnery, P.F., 2004. Two direct repeats cause most 
human mtDNA deletions. Trends Genet. 20, 393–8. doi:10.1016/j.tig.2004.07.003 
Sapru, M.K., Yates, J.W., Hogan, S., Jiang, L., Halter, J., Bohn, M.C., 2006. Silencing of 
human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. 
Exp. Neurol. 198, 382–90. doi:10.1016/j.expneurol.2005.12.024 
Scholefield, J., Greenberg, L.J., Weinberg, M.S., Arbuthnot, P.B., Abdelgany, A., 
Wood, M.J. a, 2009. Design of RNAi hairpins for mutation-specific silencing of 
178 
 
ataxin-7 and correction of a SCA7 phenotype. PLoS One 4, e7232. 
doi:10.1371/journal.pone.0007232 
Schonrock, N., Götz, J., 2012. Decoding the non-coding RNAs in Alzheimer’s 
disease. Cell. Mol. Life Sci. 69, 3543–59. doi:10.1007/s00018-012-1125-z 
Schwarz, D.S., Ding, H., Kennington, L., Moore, J.T., Schelter, J., Burchard, J., 2006. 
Designing siRNA That Distinguish between Genes That Differ by a Single 
Nucleotide 2. doi:10.137/journal.pgen.0020140 
Sciences, B., Words, K., May, R., 1992. U1 snRNP targets an essential splicing 
factor , U2AF65 . to the 3 ’ splice site by a network interactions spanning the 
exon 2554–2568. 
Seelaar, H., Rohrer, J.D., Pijnenburg, Y. a L., Fox, N.C., van Swieten, J.C., 2011. 
Clinical, genetic and pathological heterogeneity of frontotemporal dementia: a 
review. J. Neurol. Neurosurg. Psychiatry 82, 476–86. 
doi:10.1136/jnnp.2010.212225 
Séraphin, B, Kandels-Lewis, S.,1993. 3' splice site recognition in S. cerevisiae 
does not require base pairing with U1 snRNA. Cell. 21;73(4):803-12. 
Sergeant, N., Delacourte, A., Buée, L., 2005. Tau protein as a differential 
biomarker of tauopathies. Biochim. Biophys. Acta 1739, 179–97. 
doi:10.1016/j.bbadis.2004.06.020 
Seyhan, A.A., 2011. RNAi : a potential new class of therapeutic for human genetic 
disease 583–605. doi:10.1007/s00439-011-0995-8 
Sharp, P.A., 1997. A Minimal Spliceosomal Complex A Recognizes the Branch Site 
and Polypyrimidine Tract 17, 2944–2953. 
Shuey, D.J., Mccallus, D.E., Giordano, T., 2002. RNAi : gene-silencing in therapeutic 
intervention 7, 1040–1046. 
Siuda, J., Fujioka, S., Wszolek, Z.K., 2014. Parkinsonian syndrome in familial 
frontotemporal dementia. Parkinsonism Relat. Disord. 20, 957–64. 
doi:10.1016/j.parkreldis.2014.06.004 
Siva K, Covello G, Denti MA. 2014 Exon-skipping antisense oligonucleotides to 
correct missplicing in neurogenetic diseases. Nucleic Acid Ther. 24(1):69-86. doi: 
10.1089/nat.2013.0461 
 
Snowden, JS, Helen L, Griffiths and Neary, D., 1996. Semantic-Episodic Memory 
Interactions in Semantic Dementia: Implications for Retrograde Memory 
Function. Cognitive Neuropsychology Vol. 13, Iss. 8. 
179 
 
Sontheimer, EJ, Steitz, JA., 1993. The U5 and U6 small nuclear RNAs as active site 
components of the spliceosome Science. 24;262(5142):1989-96. 
Sperling, J., Azubel, M., Sperling, R., 2008. Structure and function of the Pre-
mRNA splicing machine. Structure 16, 1605–15. doi:10.1016/j.str.2008.08.011 
Spillantini, M.G., Goedert, M., 1998. Tau protein pathology in neurodegenerative 
diseases 2236, 428–433. 
Spillantini, MG, Yoshida, H, Rizzini, C, Lantos, PL, Khan, N, Rossor, MN, Goedert, 
M, Brown, J., 2000. A novel tau mutation (N296N) in familial dementia with 
swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol. 
48(6):939-43. 
Spillantini, M.G., Goedert, M., 2013. Tau pathology and neurodegeneration. 
Lancet Neurol. 12, 609–22. doi:10.1016/S1474-4422(13)70090-5 
Staknis, D., Reed, R., 1994. SR Proteins Promote the First Specific Recognition of 
Pre-mRNA and Are Present Together with the Ul Small Nuclear 
Ribonucleoprotein Particle in a General Splicing Enhancer Complex 14, 7670–
7682. 
Stanford, P.M., Halliday, G.M., Brooks, W.S., Kwok, J.B.J., Storey, C.E., Creasey, H., 
Morris, J.G.L., Fulham, M.J., Schofield, P.R., 2010. Progressive supranuclear palsy 
pathology caused by a novel silent mutation in exon 10 of the tau gene Expansion 
of the disease phenotype caused by tau gene mutations 880–893. 
Taft, R.J., Pang, K.C., Mercer, T.R., Dinger, M., Mattick, J.S., 2010. Non-coding RNAs 
: regulators of disease 126–139. doi:10.1002/path 
Tan, L., Yu, J.-T., Hu, N., Tan, L., 2013. Non-coding RNAs in Alzheimer’s disease. 
Mol. Neurobiol. 47, 382–93. doi:10.1007/s12035-012-8359-5 
Tanaka, Y., Kanai, Y., Okada, Y., Nonaka, S., Takeda, S., Harada, A., Hirokawa, N., 
1998. Targeted Disruption of Mouse Conventional Kinesin Heavy Chain , kif5B , 
Results in Abnormal Perinuclear Clustering of Mitochondria 93, 1147–1158. 
Tauopathies, O.F., Sontag, E., Nunbhakdi-craig, V., Lee, G., Brandt, R., 
Kamibayashi, C., Kuret, J., Iii, C.L.W., Mumby, M.C., Bloom, G.S., 1999. Molecular 
Interactions among Protein Phosphatase 2A , Tau , and Microtubules 
IMPLICATIONS FOR THE REGULATION OF TAU PHOSPHORYLATION AND THE 
DEVELOPMENT 274, 25490–25498. 
Tazi, J., Bakkour, N., Stamm, S., 2009. Alternative splicing and disease. Biochim. 
Biophys. Acta 1792, 14–26. doi:10.1016/j.bbadis.2008.09.017 
180 
 
Uchikawa, H., Fujii, K., Kohno, Y., Katsumata, N., Nagao, K., Yamada, M., Miyashita, 
T., 2007. U7 snRNA-mediated correction of aberrant splicing caused by 
activation of cryptic splice sites. J. Hum. Genet. 52, 891–7. doi:10.1007/s10038-
007-0192-8 
Vazquez, F, Vaucheret, H, Rajagopalan, R, Lepers, C, Gasciolli, V, Mallory, AC, 
Hilbert, JL, Bartel, DP, Crété, P., 2004 Endogenous trans-acting siRNAs regulate 
the accumulation of Arabidopsis mRNAs Mol Cell. 16(1):69-79. 
Vitro, F.I.N., Brandt, R., Lee, G., 1993. Functional Organization of Microtubule-
associated Protein Tau 268, 3414–3419. 
Von Bergen, M., Barghorn, S., Biernat, J., Mandelkow, E.-M., Mandelkow, E., 2005. 
Tau aggregation is driven by a transition from random coil to beta sheet 
structure. Biochim. Biophys. Acta 1739, 158–66. 
doi:10.1016/j.bbadis.2004.09.010 
Vučićević, D., Schrewe, H., Orom, U. a, 2014. Molecular mechanisms of long 
ncRNAs in neurological disorders. Front. Genet. 5, 48. 
doi:10.3389/fgene.2014.00048 
Wahl, M.C., Will, C.L., Lu, R., 2009. Review The Spliceosome : Design Principles of 
a Dynamic RNP Machine 701–718. doi:10.1016/j.cell.2009.02.009 
Wang, J., Zhang, J., Zheng, H., Li, J., Liu, D., Li, H., Samudrala, R., Yu, J., Wong, G.K.-S., 
2004. Mouse transcriptome: Neutral evolution of “non-coding” complementary 
DNAs. Nature 431, 26–27. doi:10.1038/nature03016 
Ward, A.J., Cooper, T.A., 2010. The pathobiology of splicing 152–163. 
doi:10.1002/path 
Ward, A.J., Cooper, T.A., 2011. NIH Public Access 220, 152–163. 
doi:10.1002/path.2649.The 
West, S., Gromak, N., Proudfoot, N.J., 2004. Human 5’ --> 3' exonuclease Xrn2 
promotes transcription termination at co-transcriptional cleavage sites. Nature 
432, 522–5. doi:10.1038/nature03035 
Wiemer, E.A.C., Wenzel, T., Deerinck, T.J., Ellisman, M.H., Subramani, S., 1997. 
Visualization of the Peroxisomal Compartment in Living Mammalian Cells: 
Dynamic Behavior and Association with Microtubules 136, 71–80. 
Wilhelmsenss, K.C., 1997. Rapidly Progressive Autosomal Dominant 
Parkinsonism and Dementia with Pallido-Ponto-Nigral Degeneration ( PPND ) 
and Disinhibition-Dementia-Parkinsonism- Amyotrophy Complex ( DDPAC ) are 
Clinically Distinct Conditions that are Both Linked to 17q21-22 . 3, 67–76. 
181 
 
Will, C.L., Lührmann, R., 2001. Spliceosomal UsnRNP biogenesis , structure and 
function 290–301. 
Will, CL, Lührmann, R. 2005 Splicing of a rare class of introns by the U12-
dependent spliceosome. Biol Chem. 386(8):713-24. 
Wood, M.J. a, Gait, M.J., Yin, H., 2010. RNA-targeted splice-correction therapy for 
neuromuscular disease. Brain 133, 957–72. doi:10.1093/brain/awq002 
Wszolek, Z.K., Tsuboi, Y., Ghetti, B., Pickering-Brown, S., Baba, Y., Cheshire, W.P., 
2006. Frontotemporal dementia and parkinsonism linked to chromosome 17 
(FTDP-17). Orphanet J. Rare Dis. 1, 30. doi:10.1186/1750-1172-1-30 
Wu, S., Romfo, C.M., Nilsen, T.W., Green, M.R., Page, S.D.S., 1999. Functional 
recognition of the 3 9 splice site AG by the splicing factor U2AF 35 402. 
Xu, H, Rösler, TW, Carlsson, T, Andrade, AD, Fiala, O, Hollerhage, M, Oertel, WH, 
Goedert, M, Aigner A, Höglinger, GU., 2014. Tau Silencing by siRNA in the P301S 
Mouse Model of Tauopathy. Curr Gene Ther. 14(5):343-51. 
Zamore, P.D., Haley, B., 2005. Ribo-gnome : The Big World of Small RNAs 1519–
1525. 
Zamore, P.D., Tuschl, T., Sharp, P.A., Bartel, D.P., 2000. RNAi : Double-Stranded 
RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide 
Intervals 101, 25–33. 
Zhou, J., Yu, Q., Zou, T., 2008. Alternative splicing of exon 10 in the tau gene as a 
target for treatment of tauopathies. BMC Neurosci. 9 Suppl 2, S10. 
doi:10.1186/1471-2202-9-S2-S10 
Zhu, H., Gup, W., Zhang, L., Davis, J.J., Wu, S., Teraishi, F., Cao, X., Smythe, W.R., 
Fang, B., 2014. Enhancing TRAIL-induced apoptosis by Bcl-XL siRNA. Cancer Biol. 
Ther. 4, 399–403. doi:10.4161/cbt.4.4.1616 
  
182 
 
LIST OF CONTRIBUTIONS  
 
 
A. Projects  
 
 
1) Screening for modified U1 snRNAs to modulate splicing of Exon 10 in 
MAPT pre-mRNA (Year 2011-2012). 
 Produced the U1 and U7 scramble chimeric constructs that were essential 
to validate the specificity of exon skipping effects. 
 Optimized the transfection protocol for successful delivery of DNA in 
PC12 cells and contributed to the results obtained via lipid-based 
transfection methods. 
 Optimized the RT-PCR protocol for the analysis of U1 and U7 snRNA in 
PC12 cells. 
 Validated the effect of U1 and U7 constructs on exon 10 skipping in PC12 
cells. 
 Proposed the utilization of another cell line NSC34 to validate effects of 
U1 and U7 constructs. 
 Optimized the western blot protocol for validation of the effects of U1 and 
U7 snRNAs in neuroblastoma cells (SH-SY5Y and NSC-34). 
  
183 
 
2) Screening for siRNA molecules to mediate isoform specific target 
degradation of exon 10 containing MAPT pre-mRNA (Year 2013-2015). 
 Postulated a novel hypothesis on the prospect of employing siRNAs in the 
context of FTDP-17 after being inspired by the work of Miller V et al., 
2005. 
 Designed a set of six siRNAs to target exon 10 of MAPT gene under the 
supervision of Prof. Michela Alessandra Denti. 
 Designed experimental strategies to screen the effect of siRNAs on a dual 
fluorescent reporter plasmid provided by Stoilov P et al 2003. 
 Modified the reporter plasmid via mutagenesis and developed a screening 
assay along with Dr. Valentina Adami to provide a high throughput read 
out of the observations. 
 Executed screening analysis of all the siRNAs in the minigene reporter 
system. 
 Identified a suitable model system, NSC-34 to validate the effects of these 
siRNAs in an endogenous context. 
 Identified another model system, primary cortical neurons to validate the 
effects of these siRNAs on a functional neuronal model 
 Optimized the western blot protocol for validation of the effects of siRNAs 
in neuroblastoma cells. 
 Filed a patent application for the above proposed project based on the 
results that I obtained during my research period. 
 
3) Role of long non-coding RNAs in regulation of MAPT (Year 2013-2015) 
 Reproduced western blot assays on pre-validated stable cell lines to 
provide adequate replicates. 
 Applied the novel method of screening to validate the effects of NATs on 
splicing of exon 10. 
  
184 
 
B. Manuscripts 
An electroporation protocol for efficient DNA transfection in PC12 cells. 
Cytotechnology (2013).  
Experiments on Lipid-based transfection methods were performed thus 
contributing to Figures 1 and 2 of the manuscript. 
Antisense oligonucleotides for Exon Skipping in Neurogenetic Diseases. 
Nucleic acid therapeutics (2014). 
All the contents in the text were written following a thorough literature search 
under the guidance of Prof. Michela Alessandra Denti. 
A global network in Fronto Temporal Dementia: -an RNA perspective”. 
Frontiers in Molecular Neuroscience (2015). 
The following contents were contributed: 
 Material of text pertaining to TDP43, MAPT and VCP  
 Figures of TDP43, MAPT and VCP 
 Table of contents for TDP43, MAPT and VCP 
 
C. Patent 
 
“RNA interference mediated therapy for neurodegenerative diseases”. EU Patent 
application number TO2015A000185 valid from March 2015). 
 
The complete content of patent application was written and all the results were 
produced and reported as figures through independent research work. 
 
 
 
185 
 
LIST OF PUBLICATIONS 
 
1. Covello Giuseppina, Siva Kavitha, Michela A.Denti. “An electroporation 
protocol for efficient DNA transfection in PC12 cells”. Cytotechnology. (2013). 
66(4): 543–553. doi:  10.1007/s10616-013-9608-9. 
 
2. Siva Kavitha*, Covello Giuseppina*, Michela A. Denti. “Antisense 
oligonucleotides for Exon Skipping in Neurogenetic Diseases”. Nucleic acid 
therapeutics (2014)(*Co-authorship). 24(1): 69–86.doi:  10.1089/nat.2013.0461. 
 
3. Francesca Fontana*, Siva Kavitha*, Michela A. Denti .“A global network in 
Fronto Temporal Dementia: -an RNA perspective”. Frontiers in Molecular 
Neuroscience. (2015)(*Co-authorship). 8: 9. doi:  10.3389/fnmol.2015.00009. 
 
4. Siva Kavitha, Covello Giuseppina, Michela A. Denti, “RNA interference 
mediated therapy for neurodegenerative diseases” (EU Patent application 
number TO2015A000185 valid from March 2015). 
  
5. Siva Kavitha , Adami Valentina, Zubovic L, Covello Giuseppina, Macchi P, 
Basso M, Michela A. Denti. “An siRNA mediated regulation of Exon 10 in FTDP-
17”. (Submission in progress) (2015).  
 
6. Covello Giuseppina, Siva Kavitha, Michela A.Denti . Antisense RNA-induced 
exon-skipping for the gene therapy of Frontotemporal Dementia and 
Parkinsonism associated with chromosome 17 (FTDP-17) (In preparation) 
(2015). 
 
7. Roberto Simone, Faiza Javad, Warren Emmett, Kavitha Siva, Victoria Kay, 
Geshanti Hondhamuni, Vincent Pagnol, Michela Denti, Daniah Trabzuni, Mina 
Ryten, Selina Wray, Elizaveth Preza, Andrew Lees, John Hardy, Thomas T 
Warner, Jernej Ule and Rohan de Silva. Long non-coding antisense RNA represses 
MAPT IRES-mediated translation through an embedded MIR repeat. (In 
preparation) (2015). 
186 
 
LIST OF ABBREVIATIONS 
 
3R:                   Tau with 3 nucleotide binding domains 
4R:                   Tau with 4 nucleotide binding domains 
Aa:                   Amino acid 
AAV:                  Adeno associated virus 
ACE:                   A/C rich enhancer 
AD:                   Alzheimer’s disease 
ALS:                  Amyotrophic lateral sclerosis 
AS:                  Alternative splicing 
ASOs:                  Antisense oligonucleotides 
bp:                   base pairs 
BPS:                 Branch point sequence 
CBD:                  Cortico basal degeneration 
cDNA:                 Complementary DNA 
CHMP-2B:    Chromatin modifying protein 2B 
CNS:                Central nervous system 
DDPAC:  Disinhibition-Dementia-Parkinsonism-Amyotrophy Complex 
DMEM:   Dulbecco’s modified eagles medium 
DNA:                De-oxy ribonucleic acid 
DSE:                Distal sequence element 
dsRNA: double stranded RNA  
E10-:                MAPT isoform without exon 10 
E10+:                MAPT isoform containing exon 10 
EDTA:  Ethylene diamine tetra acetic acid 
ESE:                Exon splicing enhancer 
ESS:                Exonic splicing silencer 
EtBr:                Ethidium bromide 
FBS:                Fetal bovine serum 
FCS:                Fetal calf serum 
FTD:                Fronto temporal dementia 
FTDP-17:  Fronto temporal dementia and pakinsonism linked to chromosome   
                           17 
187 
 
FTLD:                 Frontotemporal lobar degeneration 
FTLD-U:             FTLD with ubiquitin-positive inclusions 
GFP:                 Green fluorescent protein 
HD:                 Huntington's disease 
hnRNP:     heterogenous nuclear ribonucleoprotein 
HS:                   Horse serum 
ISE:                  Intronic splicing enhancer 
ISM:                   Intronic splicing modulator 
ISS:                   Intronic splicing silencer 
ITRs:                   Inverted terminal repeats 
Kb:                   Kilobase 
kDa:                   Kilodalton 
lncRNA:      Long non-coding RNA 
lncRNAs:      Long non-coding RNAs 
MAPs:      Microtubule associated proteins 
MAPT:      Microtubule associated protein tau 
miRNA:     micro-RNA 
MND:                    Motor neuron disease 
mRNA:       messenger RNA 
MTOC:      Microtubule organising centre 
NATs:                    Natural antisense transcripts 
NFTs:                     Neurofibrillary tangles 
nfvPPA:      Non fluent variant progressive non fluent aphasia 
NSC-34:       Mouse motor neuron-like hybrid cell line 34 
nt:                     nucleotides 
PBS:                     Phosphate buffer saline 
PC12:                     Rat pheochromocytoma cells 
PCR:                     Polymerase chain reaction 
PD:                    Parkinson’s disease 
PGRN:        Progranulin 
PNFA:                     Primary non –fluent aphasia 
PPA:                     Progressive non fluent aphasia 
PPE:                 Polypurine enhancer 
188 
 
PSP:                   Progressive supranuclear palsy 
PTB:                Polypyrimidine tract binding protein 
RFP:               Red fluorescent protein 
RISC:               RNA induced silencing complex  
RNA Pol :  RNA polymerase I 
RNA Pol II:  RNA polymerase II 
RNA Pol III:  RNA polymerase III 
RNA:                Ribonucleic acid 
RNAi:               RNA interference 
RRM:                RNA recognition motif 
rRNA:               Ribosomal RNA 
RS:                Arginine-serine rich motif 
RT:               Reverse transcriptase 
RT:                Room temperature 
RT-PCR:  Reverse transcription PCR 
SCA-3:              Spinocerebellar ataxia type 3 
SCCMS: Slow channel congenital myasthenic syndrome disease 
SD:                Semantic dementia 
sds:                splicing donor site 
SDS:                Sodium dodecyl sulphate 
SELEX:  Systematic evolution of ligands by exponential enrichment 
shRNA: short-hairpin RNA 
SH-SY5Y:  A thrice cloned (SK-N-SH -> SH-SY -> SH-SY5 -> SH-SY5Y) subline  
                            of the neuroblastoma cell line SK-N-SH 
siRNA:  small interferring RNA 
SNAPc: snRNA  activator protein complex 
snRNA:  small non-coding RNA 
snRNP:  small non coding ribonucleoprotein 
SR:               Serine-Rich 
SRE:                Splicing regulatory element 
ss:                Splice site 
svPPA:  Semantic variant PPA 
TBE:                  Tris-borate-EDTA buffer 
189 
 
TDP-43:           Transactive response DNA binding protein 43 kDa 
TE:                Transposable elements 
TF:                Transcription factor 
TG:                Thyroglobulin 
tRNA:                  Transfer RNA 
U2AF:                 U2 snRNP auxiliary factor 
UTR:                  Untranslated region 
VCP:                  Valosin containing protein 
Wt:                   Wild type 
  
 
 
 
 
 
 
 
MANUSCRIPTS 
 
 
 
“Success is not a function of the size of your title but the richness of your contribution” 
-Robin Sharma 
TECHNICAL NOTE
An electroporation protocol for efficient DNA transfection
in PC12 cells
Giuseppina Covello • Kavitha Siva •
Valentina Adami • Michela A. Denti
Received: 6 April 2013 / Accepted: 14 June 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract A wide variety of mammalian cell types is
used in gene transfection studies. Establishing trans-
fection methods that enable highly efficient DNA
uptake has become increasingly important. PC12 is an
established rat pheochromocytoma cell line, which
responds to exposure to NGF with cessation of growth,
expression of cytoplasmic processes, and differentia-
tion into cells resembling sympathetic neurons.
Although PC12 cells represent an important model
system to study a variety of neuronal functions, they
proved relatively difficult to transfect. We have
compared the efficiency of three different chemical
transfection reagents (Lipofectamine 2000, Lipofect-
amine LTX and TransIT-LT1) and of two electropor-
ation systems (Neon and Gene Pulser Xcell) in
transiently transfecting undifferentiated PC12 cells.
By comparing efficiencies from replicate experiments
we proved electroporation (in particular Neon) to be
the method of choice. By optimizing different
parameters (voltage, pulse width and number of
pulses) we reached high efficiency of transfection
(90 %) and viability (99 %). We also demonstrated
that, upon electroporation, cells are not altered by the
transfection and maintain their ability to differentiate.
Keywords PC12 cells  Cell culture  DNA
transfection  DNA electroporation  NGF  Neural
differentiation
Introduction
PC12 cells are a cell line originating from pheochro-
mocytoma in the rat adrenal medulla (Schaefer et al.
1987) and grow in culture as undifferentiated neuro-
blasts. Since its characterization in 1976 (Greene and
Tischler 1976) PC12 cells have become a commonly
employed model system for studies of neuronal
development and function (Grau and Greene 2012).
One of the important features of PC12 cells is that they
are small cells with a limited amount of cytoplasm and
long doubling time. They possess remarkable ability to
respond to nerve growth factor (NGF), a neurotrophic
polypeptide, inducing morphological and biochemical
changes resulting in differentiation of PC12 cells into
a sympathetic neuron-like phenotype (Greene and
Tischler 1976; Grau and Greene 2012; Nagase et al.
2005; Dhar et al. 2007; Park et al. 2007). For this
reason PC12 cells have been regarded as a research
model to study neuronal development, sympathetic
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neurotransmission and neurodegenerative diseases
(Wang et al. 2002; Seth et al. 2002). In general, when
challenged with physiological levels of NGF, these
cells cease division, become electrically excitable,
extend long branching neurites, and gradually acquire
many characteristics of mature sympathetic neurons.
Under serum-free conditions, NGF promotes not only
neuronal differentiation of PC12 cells, but also their
survival (Greene 1978; Fujita et al. 1989; Rukenstein
et al. 1991). Several of their attributes have led to their
widespread popularity in neurobiological research.
These include their relatively high degree of differen-
tiation before and after NGF treatment, homogeneous
response to stimuli, availability in large numbers for
biochemical studies, and suitability for genetic manip-
ulations. However, finding transfection techniques
that enable efficient DNA uptake into PC12 cells is
relatively difficult. Moreover, it is important to have a
good method to transfect these cells with high
efficiency devoid of cellular alteration, and maintain-
ing their ability to differentiate. An important limita-
tion of working with PC12 cells is that they tend to be
very sensitive to physical stress, alterations in tem-
perature, pH shifts, or changes in osmolarity. There-
fore, handling and manipulation during transfection is
a crucial step.
Various transfection methods have been attempted
to transfect this cell line. In general, cells can be gene-
modified in vitro and in vivo using chemical or physical
methods (Azzam and Domb 2004; Marples and Dachs
2002). Chemical methods of transfection are widely
used, as they are relatively simple, cheap, and safe
(Douglas 2008). They include calcium phosphate,
liposomes, cationic lipids (e.g., dioleoyl trimethylam-
monium propane (DOTAP)), cationic polymers (e.g.,
polyethylenimine (PEI), dendrimers) and cationic
polysaccharides (Eliyahu et al. 2005; Godbey et al.
1999a, b). In general, these reagents act via packaging
mechanism to condense and deliver DNA to the
cytoplasm of cells, usually by endocytosis (Vijayana-
than et al. 2002). These reagents are used rapidly in
high-throughput assays and can transfer DNA of
various sizes (Ewert et al. 2008). However, they can
be susceptible to nuclease degradation, are potentially
harmful (Colombo et al. 2001) and are usually, but not
always, cell cycle-dependent (Brunner et al. 2002).
In the particular case of PC12 cells, cationic lipids
formulations have been employed to increase
transfection efficiency. Using Lipofectamine 2000
(Invitrogen) the transfection efficiency was about
14 % and was similar to the efficiency obtained with
polyethyleneimine (PEI) (15 %) (Lee et al. 2008).
A higher efficiency (30 %) was reported with Meta-
fectene Pro (Biontex) (Cogli et al. 2010). An increase
in the transfection efficiency (40–50 %) was observed
by simultaneous treatment with Lipofectamine and
0.1 lM GALA, a pH-sensitive fusogenic peptide
which accelerates the endosomal escape of the plas-
mid/liposome complexes to the cytosol (Futaki et al.
2005). However, this method has not encountered
wide popularity thereafter.
Physical methods, including electroporation, bio-
listics and injection, are used with varying success and
are cell cycle-independent but may be more toxic for
some cell types and usually require cell suspensions
in vitro and specialized equipment (Villemejane and
Mir 2009). However, the electroporation methods
enable efficient transfer of exogenous DNA to a large
number of cells and serve ideal in terms of material
and time consumption. As with chemical methods of
transfection, high-efficiency electroporation protocols
for PC12 cells are not available. The literature reports
efficiencies between 10 and 20 % (Darchen et al.
1995; Akamatsu et al. 1999) and 35 % (Lombardi
et al. 2001), which increases to 50 % when parameters
are carefully optimized (Espinet et al. 2000).
The aim of this work was to find a protocol ensuring
high transfection efficiency in PC12 cells, while
retaining viability and ability to differentiate. We
compared two electroporation systems (Neon trans-
fection and Gene Pulser Xcell) and three chemical
transfection methods (Lipofectamine 2000, Lipofect-
amine LTX, TransIT-LT1).
Materials and methods
Plasmid
DNA plasmid used for transfection or electroporation
was pEGFP-C1 (BD Biosciences Clontech, Palo Alto,
CA, USA) driving the expression of an enhanced green
fluorescent protein (EGFP) under the control of the
CMV promoter. Plasmid was amplified in Escherichia
coli DH5a; it was isolated and purified using Endo-
Maxi Free Kit from QIAGEN. DNA purity and
integrity were determined spectroscopically (OD260nm/
OD280nm = 1.90–2.00), (OD260nm/OD230nm [ 2.00).
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Culture of PC12 cells
Rat PC12 cells (ATCC entry CRL-1721) were grown
at 37 C (5 % CO2) in supplemented DMEM: Dul-
becco’s modified Eagle’s medium with 4.5 % glucose
(Lonza, Visp, Switzerland) supplemented with 10 %
fetal bovine serum (Gibco, Grand Island, NY, USA),
5 % horse serum (Gibco), 1 mM glutamine (Gibco),
1 mM Penicillin/Streptomycin (Gibco). Cells were
seeded onto T-75 cm2 flasks (Corning, NY, USA)
coated with 50 ng/ml poly-D-lysine hydrobromide
(Sigma, St. Louis, MO, USA), to achieve 70 %
confluence. Cells from passages 8–10 were used.
Cells were split every other day at a ratio of about 2:3.
A Pasteur pipette was used to de-aggregate cell
clusters.
Viable cells counts
A Trypan Blue Stain exclusion test (Invitrogen,
Carlsbad, CA, USA) was used to distinguish viable
from nonviable cells. The suspended cells (9 ll) were
mixed with 1 ll of 0.4 % Trypan Blue Stain and
analyzed in the CountessTM Automated Cell Counter
(Invitrogen) chamber slide. The percentage of viable
cells was calculated as follows: (number of viable
cells/total number of cells) 9 100.
Lipid-mediated DNA transfection
The transfection reagents used in this study were:
TransIT-LT1 Transfection Reagent (Mirus, Madison,
WI, USA), Lipofectamine 2000 and Lipofectamine
LTX (Invitrogen).
4 9 104 cells/well were seeded on poly-D-lysine-
coated 24-well plates (Corning) one day before trans-
fection and grown in supplemented DMEM at 37 C
and 5 % CO2. PC12 cells grown to 70 % confluence
were transfected with the mammalian expression
vector pEGFP-C1. Transfection procedures were
performed as indicated by manufacturer. The ratio
DNA (lg) : transfection reagent (ll) was always 1:3.
Transfection by electroporation
DNA electroporation was performed with the Neon
Transfection System MPK5000 (Invitrogen) or the
Gene Pulser Xcell System (BIORAD, Hercules, CA,
USA).
For the electroporation with the Neon System, PC12
cells were grown to 70 % confluence in a poly-D-
lysine-coated T-25 flask and washed twice with
10 ml Phosphate-Buffered Saline without Ca2? and
Mg2?(PBS) (Lonza). This was followed by addition of
1 ml 19 trypsin (Lonza) and incubation for 2 min at
37 C. After adding 9 ml of supplemented DMEM, the
cells were resuspended, transferred in a 15 ml polypro-
pylene tube (Sarstedt, Verona, Italy) and centrifuged at
2.2009g for 10 min. The pellet was resuspended in
10 ml of PBS and cells were counted in a Bu¨rker
chamber (PAUL MARIENFELD GmbH). Cells were
pelleted again and re-suspended in Resuspension Buffer
R (Neon 10 ll kit Invitrogen) to a final concentration
of 1 9 107 cells ml-1. 0.6 9 105 and 1 9 105 cells
were transferred to a sterile 1.5 ml microcentrifuge tube
(Sarstedt), brought to 10 ll final volume of cell
suspension with Buffer R, and mixed with 500 ng of
pEGFP-C1 vector. To optimize the best condition of
transfection, electroporation was then carried out with
different voltage, pulse and time parameters, according
to manufacturer’s instructions, as reported in Results
and Discussion. Cells were seeded in a 24- well poly-D-
lysine-coated cell plate with 0.5 ml of pre-warmed
supplemented DMEM without antibiotics.
For the electroporation with the Gene Pulser Xcell
System, PC12 cells were grown to 70 % confluence in a
poly-D-lysine-coated T-75 flask and washed and tryp-
sinized as described above. After adding supplemented
DMEM, the cells were resuspended, transferred in a
polypropylene tube and centrifuged at 4009g for
5 min. The pellet was resuspended and counted as
above, and re-suspended in an appropriate amount of
PBS. 0.4 ml of cell suspension containing 6 9 105 or
1 9 106 cells and 8 lg of DNA (pEGFP-C1 vector),
were incubated on ice for 10 min, and transferred into a
4-mm electroporation cuvette (BTX). The Gene Pulser
Xcell System (BIORAD) was used for single-cuvette
electroporation. Electroporations were carried out with
different voltage and capacitance parameters, accord-
ing to manufacturer’s instructions, as reported in
Results and Discussion. Cells were seeded in a 12-
well poly-D-lysine-coated cell plate with 1 ml of pre-
warmed supplemented DMEM without antibiotics.
High-content image acquisition and analysis
Upon chemical transfection or electroporation of pEG-
FP-C1 vector, EGFP expression and cell nuclei were
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visualized using Operetta High Content Imaging Sys-
tem (PERKIN ELMER, Monza, Italy). To count total
cell numbers, nuclei were counterstained with Hoechst
33342 (Invitrogen). Forty-eight hours after transfection,
cells were washed once with PBS and incubated in
0.5 ml of supplemented DMEM containing 1 mg/ml of
Hoechst 33342, for 20 min at 37 C and 5 % CO2. Cells
were washed once with PBS and replaced with supple-
mented DMEM without phenol red (Gibco) for imaging.
Images were acquired on an Operetta System using a
209 LWD objective in wide-field mode in combination
with filters for Hoechst 33342 (excitation filter:
360–400 nm; emission filter: 410–480 nm) and Alexa
Fluor 488 (excitation filter: 460–490 nm; emission
filter: 500–550 nm). The laser autofocus was applied
and 10 image fields were acquired per well. For
quantitative analyses, individual cells were segmented
based on the Hoechst 33342 nuclear stain using the Find
Nuclei building block in the Harmony High Content
Imaging and Analysis Software (PERKIN ELMER) and
GFP intensity was quantified within the Hoechst-
defined boundaries for each cell. The Select Population
module of Harmony allowed to set a fluorescence
intensity threshold in order to identify the sub-popula-
tion of transfected cells and to determine the transfection
efficiency. The average and standard error mean (SEM)
were calculated from biological experimental triplicates
and technical duplicates.
Cell differentiation
Electroporated PC12 cells were plated at a density of
1 9 105 cells/well on poly-D-Lysine-coated 12-well
plates and grown in supplemented DMEM without
antibiotics at 37 C in 5 % CO2. After 24 h the medium
was replaced with differentiation medium (Dulbecco’s
modified Eagle’s medium with 4.5 % glucose supple-
mented with 0.3 % fetal bovine serum, 0.7 % horse
serum, 1 mM glutamine) containing 75 ng/ml of NGF
2.5S (Invitrogen). The cells were maintained at 37 C
and 5 % CO2 and the differentiation medium was
replenished every 2nd day for 7 days.
Neurite analysis
Neuronal differentiation was estimated every day, for
7 days, after exposure to NGF 2.5S, by measurement of
morphological parameters. Images were acquired using
a fluorescence microscope (DFC420C, Leica, Milan,
Italy) and a 20X objective (magnification). Filter A
(Exciter BP340–380 nm; Dichromatic Mirror 400 nm)
and I3 (Exciter BP450–490 nm; Dichromatic Mirror
510 nm) were used and the images were analysed with
ImageJ software (http://imagej.nih.gov/ij/) to determine
the neurite length (ImageJ plugin NeuronJ) and to
quantify the percentage of differentiated cells. A neurite
was defined as a process of length equal to or greater
than one time the diameter of the cell body. Triplicate
wells were used routinely for each experimental con-
dition. Images of three different fields were taken per
well. The experiment was repeated two times.
Statistical analysis
All statistical analyses were performed using Graph-
pad Prism software package (GraphPad Software, San
Diego, CA, USA). Student’s t test and One-way
analysis of variance (ANOVA) with Bonferroni’s
multiple comparison were adopted. A single level of
0.05 (*p \ 0.05) was used, unless otherwise stated.
Data are shown with the standard error of the mean
(mean ± SEM, n = 3).
Results and discussion
Comparison of transfection chemical methods
in PC12 cells
We compared transfection efficiencies obtained in
PC12 cells with the lipopolyplex transfection reagent
TransIT-LT1 (Mirus) and the cationic lipids Lipofect-
amine 2000 and LTX (Invitrogen). Cells were grown
in conditions promoting proliferation including use of
an enriched medium, but the transfections were carried
out in a serum- and antibiotic- free environment. We
performed these experiments with different amounts
of pEGFP-C1 DNA (Clontech), a plasmid driving the
expression of an enhanced green fluorescent protein
(EGFP) under the control of the CMV promoter. The
ratio DNA (lg): transfection reagent (ll) was 1:3 and
we transfected increasing amounts of plasmid (0.25,
0.5, 0.75 and 1 lg).
Forty-eight hours after transfection, nuclei were
stained with the viable Hoechst 33342 fluorescent dye
and images were acquired on an Operetta System,
which combines fluorescence microscopy in a multi-
well format with automated image acquisition and
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quantitative analysis (Fig. 1). Data analysis for trans-
fection efficiency was performed by using the Har-
monyHigh-Content Imaging Software (Perkin Elmer),
comparing the number of EGFP-positive cells (detected
with an Alexa Fluor 488 filter) to the total number of cells
(detected with an Hoechst 33342 filter). Mock transfec-
tion controls using the transfection reagent without DNA
had an auto-fluorescence background in both the Hoe-
chst 33342 or Alexa Fluor 488 channels comparable to
un-transfected PC12 cells (data not shown).
As shown in Fig. 2a, the TransIT-LT1 Transfection
Reagent (Mirus) was not effective in facilitating
transfection of DNA in PC12 cells, even when a higher
concentration of DNA was used. However, in parallel
experiments performed on the HEY4 ovarian cancer
cell line, TransIT-LT1 had a transfection efficiency of
approximately 35 %, thereby indicating that efficiency
depends on the cell type (data not shown).
On the contrary, when we performed the transfec-
tion experiments by using Lipofectamine LTX and
Lipofectamine 2000 we managed to transfect DNA
into PC12 cells, with efficiencies that ranged from 7
and 15 % respectively, with 0.25 lg DNA, to 35 and
46 % respectively, when 1 lg of DNA was used.
As expected, transfection efficiency for both
reagents correlates with the amounts of DNA used.
However, in comparing the transfection efficiency of
the two cationic lipids, Lipofectamine LTX seems to
perform better than Lipofectamine 2000 at low DNA
amounts, while Lipofectamine 2000 outperforms
Lipofectamine LTX at higher DNA amounts.
In particular, comparing our results with those by
Lee and colleagues (2008), with Lipofectamine 2000
we reached 21 % transfection efficiency (with 0.5 lg
of DNA in a 24-well plate) while Lee and collabora-
tors reported 14 % efficiency in similar conditions
(1 lg of DNA in a 12-well plate).
Cell viability was measured by Trypan Blue
Staining 48 h after transfection (Fig. 2b). Mock-
transfected cells had a viability comparable to the
non-transfected cells with either of the three transfec-
tion reagents (approx. 95 %). For all methods, viabil-
ity decreased as the DNA amounts increased.
However, as clearly indicated in Fig. 2b, there is a
variation of trend for different reagents. TransIT-LT1
had a milder impact on cell viability, reaching 92 %
when 1 lg of DNA was used. On the contrary,
Lipofectamine 2000 and Lipofectamine LTX reached
87–88 % viability in those conditions.
DNA electroporation in PC12 cells
As the transfection efficiency obtained with Lipofect-
amine 2000 was not sufficient for our purposes, we
investigated if we could obtain a higher percentage of
transfected PC12 cells with an electroporation method
(Neon Transfection System, Invitrogen).
To optimize conditions, 0.5 lg of plasmid DNA
and two different cell densities (6 9 104 or 1 9 105
cells/well) were used. Moreover, a range of voltage,
pulse width and pulse number combinations were
tested (Table 1).
Fig. 1 Transfection of rat PC12 cells. PC12 cells were
transfected by liposoluble agents (TransIT-LT1 Transfection
Reagent [Mirus], Lipofectamine LTX [L_LTX] and Lipofect-
amine 2000 [L_2000]) and different concentrations of a plasmid
encoding EGFP. Fluorescence images of transfected PC12 cells
were analyzed by High-Content screening system (Operetta) 48
h after transfection. The panel shows photographs taken with a
green filter (left) and a blue filter (center), and the merged
images (right). Original magnification 920 (Scale
bars = 200 lm). (Color figure online)
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Forty-eight hours after transfection, nuclei were
stained with Hoechst 33342 and images were acquired
on an Operetta System (Fig. 3). Data analysis of
transfection efficiency was carried out as detailed
above and revealed that the density of the cells in the
suspension is one of the most important variables
affecting transfection efficiency in our electroporation
protocols (Fig. 4a). In fact, with higher cell density,
any electroporation condition tested yields high
transfection efficiency, ranging between 80 and
98 %. On the contrary, when a lower cell density
was used, conditions can be separated into two classes,
based on the effect they have on transfection effi-
ciency: a high-efficiency class (84–91 %) and a low-
efficiency class (20–66 %).
It has to be pointed out, however, that all condi-
tions, except one (6 9 104 cells, 1,500 V, 20 ms, 1
pulse), yielded a transfection efficiency higher than
that one obtained by the use of Lipofectamine 2000
(dashed line in Fig. 4a).
The method shows high reproducibility, as deter-
mined by comparing efficiencies from several repli-
cate experiments.
Cell viability was measured by Trypan Blue Stain-
ing 48 h after transfection (Table 1). Mock-electropo-
rated cells were manipulated as the electroporated cells
but did not receive DNA nor an electrical pulse, and
had a viability comparable to the non-electroporated
cells (approx. 90 %). In the case of cell viability, there
was no clear correlation with cell density, although in
general cells at higher density performed better
(Fig. 4b). Furthermore, different electroporation con-
ditions worked better for the different cell densities,
and a general trend could not be inferred from the graph
in Fig. 4b. In general, the electroporation protocol
appeared to be more pernicious to PC12 cells than the
Fig. 2 Transfection efficiency and viability of rat PC12 cells.
a The percent of transfected cells was calculated by dividing the
number of EGFP positive cells by the total population. The best
result was obtained by using 1 lg of plasmid and Lipofectamine
2000 (efficiency of transfection 45.9 %). b The percentage of
viable cells after transfection was measured by a Trypan Blue
assay. The best cell viability (93.6 %) was obtained with 0.5 lg
of plasmid and Lipofectamine 2000. Data represent mean ±
SEM obtained from triplicates
Table 1 Parameters for DNA electroporation by Neon transfection System, transfection efficiency and cell viability
Pulse voltage (V) Pulse width (ms) Pulse no. Transfection Efficiency (%) Cell viability (%)
0.6 9 105
cells/well
1 9 105
cells/well
0.6 9 105
cells/well
1 9 105
cells/well
Control without electroporation – – 90.00 90.00
1,500 20 1 20.33 93.94 63.30 86.70
1,400 30 1 64.37 80.97 38.40 67.70
1,500 10 3 66.20 90.37 54.70 99.00
1,400 10 3 84.63 87.07 64.20 79.70
1,300 30 1 84.37 97.83 86.70 62.87
1,000 40 1 91.32 94.03 24.90 51.70
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lipofection protocols, as only few conditions provided
a cell viability comparable or higher than that one
obtained by Lipofectamine LTX and 1 lg of DNA
(dashed line in Fig. 4b).
In order to establish if electroporation in general is a
better method than lipofection, or if the Neon System in
particular has a high performance in transfecting PC12
cells, we performed electroporation with a different
system, namely Gene Pulser Xcell (Bio-Rad). 8 lg of
plasmid DNA and two different cell densities (6 9 105
or 1 9 106 cells/well) were used. The increase in DNA
and cell amounts, compared to Neon System, is due to
the fact that, while the Neon system is miniaturized to
use electroporation tips and 10 ll transfection volumes,
the Gene Pulser XCell requires specific 400 ll cuvettes.
For each cell density we tested three different voltage
and capacitance combinations (Table 2), in triplicate
experiments. Namely, we tried 240 V/1,000 lF (Mur-
phy et al. 2008), 250 V/960 lF (Yaron et al. 2001) and
300 V/500 lF (Lombardi et al. 2001). Analysis of the
transfection efficiency and cell viability was carried out
as described above. As visible in Fig. 4c and in Table 2,
in our hands the Gene Pulser Xcell system outper-
formed lipofection methods, reaching efficiencies
higher than the ones reported in the literature. However,
when comparing Gene Pulser Xcell with Neon System,
the latter remained the method of choice for the
transfection of PC12 cells (Fig. 4a, c). As far as
viability is concerned, though, Gene Pulser Xcell
compared to lipofection (Fig. 4d) and was better than
Neon System in the majority of conditions.
For our purposes, the best electroporation condi-
tions were obtained with Neon transfection System,
1 9 105 cells/well and 3 pulses of 1,500 V and 10 ms
each. These conditions, in fact, yielded 90 % trans-
fection efficiency and 99 % viability. We have chosen
these conditions for the subsequent experiments.
Cell differentiation and neurite analysis
With the aim of investigating whether the electropo-
rated PC12 cells retain the ability to differentiate into
neuron-like cells, we transfected the cells using the
conditions reported above, and treated them with NGF
2.5S (75 ng/ml) starting 24 h after transfection (day 0)
and for the subsequent 7 days (Fig. 5a).
Images were taken at 8 h and every 24 h after
transfection, in bright field and with a green fluores-
cence filter (Fig. 5b). NGF-treated PC12 cells showed
increase in neurite length and generation during time
(Fig. 5b). The total number of cells and the number of
cells presenting neurites was counted in the bright-
field images. Differentiated PC12 cells progressively
increased reaching 23 % of total cells 4 days after
induction. At later times the percentage of differen-
tiated cells remained stable (Fig. 5c).
Fig. 3 Representative
images of PC12 cells 48 h
after electroporation.
Electroporation was carried
out using different
conditions of voltage (1000,
1300, 1400 or 1500 Volts),
pulse width (10, 20, 30 or 40
ms) and pulse number (1 or 3
pulses), as indicated on the
left side of the panels.
Pictures were taken with the
high-content operetta
system with a blue filter
(Hoechst) and a green filter
(EGFP), and merged
(MERGE). Original
magnification: 920 (Scale
bars = 50 lm). (Color
figure online)
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Fig. 4 Optimization of PC12 cells transfection by electropor-
ation. Electroporation was carried out in different conditions
which are indicated on the panels’ x-axes in the format ‘‘voltage
(V)/pulse width (ms)/pulse number’’ for panels A and B, and in
the format ‘‘pulse voltage (V)/capacitance (lF)’’ for panels C
and D. a Histograms of percentages of transfected PC12 cells
show an increase of efficiencies comparing Neon electropora-
tion with lipofecting agents. Dashed line represents the best
transfection efficiency obtained in lipofection experiments as
shown in Fig. 2. The best condition (99 %) was obtained by
0.5 lg of plasmid, 1 9 105 cells/well, and 1 pulse of 1,300 Volt
and 30 ms. b The percentage of viable cells after Neon
electroporation was measured by Trypan Blue Staining. The
best cell viability (97.8 %) was obtained with 0.5 lg of plasmid,
1 9 105 cells/well, and 3 pulses of 1,500 Volt and 10 ms each.
Dashed line represents worst viability percentage obtained in
lipofection experiments as shown in Fig. 2. c Transfection
efficiency of electroporation experiments performed using Gene
Pulser Xcell. Dashed line represents the best transfection
efficiency obtained in lipofection experiments as shown in
Fig. 2. d Viability of cells electroporated with Gene Pulser
Xcell. Dashed line represents worst viability percentage
obtained in lipofection experiments as shown in Fig. 2. Data
represent mean ± SEM obtained from triplicates
Table 2 Electroporation
parameters applied for
DNA transfection by Gene
Pulser Xcell, transfection
efficiency and cell viability
Pulse voltage (V) Capacitance (lF) Transfection efficiency (%) Cell viability (%)
0.6 9 106
cells/well
1 9 106
cells/well
0.6 9 106
cells/well
1 9 106
cells/well
Control without electroporation – – 98.22 97.94
240 1,000 46.54 54.01 97.08 95.98
250 960 49.56 73.58 94.88 96.56
300 500 63.44 62.98 90.42 91.91
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EGFP expression was observed both in differenti-
ated and non-differentiated cells. The intensity of
EGFP signal increased over time. At the initial time
point, the intracellular expression of EGFP in NGF-
differentiated PC12 cells was located in the nucleus.
At later time points, it was around cytoplasm and
Fig. 5 Differentiation of electroporated PC12 cells. a Time
course of PC12 differentiation. At each indicated time point,
pictures were taken in bright field and in green fluorescence, and
cells were counted. b Representative images of PC12 cells
treated with NGF for the indicated time. Original magnification:
920 (Scale bars = 50 lm). c Histogram of cell numbers after
transfection and differentiation. Cells were grouped in four
categories: green, differentiated cells; green, non-differentiated
cells; non-green, differentiated cells; non-green, non-differen-
tiated cells. Data represent images of three different fields taken
per each well. The experiment was repeated two times. (Color
figure online)
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inside the nucleus. On the 7th day post-transfection,
EGFP was seen throughout the entire cell, spreading
out to the tips of the neurite extensions (not shown).
The number of transfected cells was counted in
pictures taken with the GFP filter. Already 8 h after
electroporation 20 % of cells showed EGFP signal.
When NGF was added, 24 h after electroporation,
69 % of cells were EGFP-positive. The maximum
transfection efficiency was reached 48 h after electro-
poration (86 %), and rapidly decreased to reach 33 %
at days 6 and 7.
The discrepancy between the maximum transfec-
tion efficiency in these experiments and the results
described in the previous paragraph (where 90 % of
transfection efficiency was obtained) might reflect the
change in serum percentages in the growth medium
and the addition of NGF, 24 h after transfection.
Electroporation posed no impairment on differen-
tiation ability of PC12 cells, since about half of the
differentiated cells were green. On the contrary, our
observations suggest that electroporation might even
induce PC-12 cells to differentiate. It is remarkable in
fact, that approximately 30 % of green cells were
presenting neurite outgrowth, from day 4 onwards,
while the percentage of differentiated cells in non-
green PC-12 cells was about 20 %.
This stimulus to differentiate might explain why at
days 0, 1 and 2, green differentiated cells were already
present (6, 10 and 12 % of the total cells) while non-
green differentiated cells reached comparable per-
centages (12 %) only at day 3.
Moreover, looking at the actual cell numbers, it
appears that at day 2 non-green, non-differentiated cells
started outnumbering green, non-differentiated cells,
possibly indicating a higher proliferation rate of non-
transfected cells, compared to non-transfected cells.
Acknowledgments This work was supported by ‘‘Fondazione
Telethon’’ (Grant GGP08244), by Italian Ministry of Health,
Young Investigators 2008 (Grant GR-2008-1136933) and by
Italian Ministry of Education, University and Research, ‘‘Futuro
in Ricerca’’ (Grant RBFR-0895DCB). We thank Dr. Margherita
Grasso (CIBIO, University of Trento) for sharing with us her
results with TransIT-LT1 transfection on HEY 4 cell line.
Conflict of interests The authors declare no competing
interests.
Open Access This article is distributed under the terms of the
Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the
original author(s) and the source are credited.
References
Akamatsu W, Okano HJ, Osumi N, Inoue T, Nakamura S,
Sakakibara S-I, Miura M, Matsuo N, Darnell RB, Okano H
(1999) Mammalian ELAV-like neuronal RNA-binding
proteins HuB and HuC promote neuronal development in
both the central and the peripheral nervous systems. Proc
Natl Acad Sci USA 96:9885–9890
Azzam T, Domb AJ (2004) Current developments in gene
transfection agents. Curr Drug Deliv 1:165–193
Brunner S, Furtbauer E, Sauer T, Kursa M, Wagner E (2002)
Overcoming the nuclear barrier: cell cycle independent
nonviral gene transfer with linear polyethylenimine or
electroporation. Mol Ther 5:80–86
Cogli L, Progida C, Lecci R, Bramato R, Kruuttgen A, Bucci C
(2010) CMT2B-associated Rab7 mutants inhibit neurite
outgrowth. Acta Neuropathol 120:491–501
Colombo MG, Citti L, Basta G, De Caterina R, Biagini A, Ra-
inaldi G (2001) Differential ability of human endothelial
cells to internalize and express exogenous DNA. Cardio-
vasc Drugs Ther 15:25–29
Darchen F, Senyshyn J, Brondyk WH, Taatjes DJ, Holz RW,
Henry J-P, Denizot J-P, Macara IG (1995) The GTPase
Rba3a is associated with large dense core vesicles in
bovine chromaffin cells and rat PC12 cells. J Cell Sci
108:1639–1649
Dhar S, McConnell MP, Gharibjanian NA, Young CM, Rogers
JM, Nguyen TD, Evans GR (2007) Herpes simplex virus-
thymidine kinase-based suicide gene therapy as a molec-
ular switch off for nerve growth factor production in vitro.
Tissue Eng 13:2357–2365
Douglas KL (2008) Toward development of artificial viruses for
gene therapy: a comparative evaluation of viral and non-
viral transfection. Biotechnol Prog 24:871–883
Eliyahu H, Barenholz Y, Domb AJ (2005) Polymers for DNA
delivery. Molecules 10:34–64
Espinet C, Go´mez-Arbone´s X, Egea J, Comella JX (2000)
Combined use of the green and yellow fluorescent proteins
and fluorescence-activated cell sorting to select popula-
tions of transiently transfected PC12 cells. J Neurosci
Methods 100:63–69
Ewert KK, Ahmad A, Bouxsein NF, Evans HM, Safinya CR
(2008) Non-viral gene delivery with cationic liposome-
DNA complexes. Methods Mol Biol 433:159–175
Fujita K, Lazarovici P, Guroff G (1989) Regulation of the dif-
ferentiation of PC12 pheochromocytoma cells. Environ
Health Perspect 80:127–142
Futaki S, Masui Y, Nakase I, Sugiura Y, Nakamura T, Kogure
K, Harashima H (2005) Unique features of a pH-sensitive
fusogenic peptide that improves the transfection efficiency
of cationic liposomes. J Gene Med 7(11):1450–1458
Godbey WT, Wu KK, Mikos AG (1999a) Poly (ethylenimine)
and its role in gene delivery. J Control Release 60:149–160
Godbey WT, Wu KK, Mikos AG (1999b) Tracking the intra-
cellular path of poly (ethylenimine)/DNA complexes for
gene delivery. Proc Natl Acad Sci USA 96:5177–5181
Grau CM, Greene LA (2012) Use of PC12 cells and rat superior
cervical ganglion sympathetic neurons as models for neu-
roprotective assays relevant to Parkinson’s disease. Meth-
ods Mol Biol 846:201–211
Cytotechnology
123
Greene LA (1978) Nerve growth factor prevents the death and
stimulates the neuronal differentiation of clonal PC12
pheochromocytoma cells in serum-free medium. J Cell
Biol 78:747–755
Greene LA, Tischler AS (1976) Establishment of a noradren-
ergic clonal line of rat adrenal pheochromocytoma cells
which respond to nerve growth factor. Proc Natl Acid Sci
USA 73:2424–2428
Lee JH, Ahn HH, Kim KS, Lee JY, Kim MS, Lee B, Khang G,
Lee HB (2008) Polyethyleneimine-mediated gene delivery
into rat pheochromocytoma PC-12 cells. J Tissue Eng
Regen Med 2:288–296
Lombardi D, Palescandolo E, Giordano A, Paggi MG (2001)
Interplay between the antimetastatic nm23 and the Reti-
noblastoma-related Rb2/130 genes in promoting neuronal
differentiation of PC12 cells. Cell Death Diff 8:470–476
Marples B, Dachs GU (2002) Cancer gene therapy: ‘‘delivery,
delivery, delivery’’. Front Biosci 7:d1516–d1524
Murphy KL, Zhang X, Gainetdinov RR, Beaulieu J-M, Caron
MG (2008) A regulatory domain in the N-terminus of
tryptophan hydroxylase 2 controls enzyme expression.
J Biol Chem 283:13216–13224
Nagase H, Yamakuni T, Matsuzaki K, Kasahara J, Hinohara Y,
Kondo S, Mimaki Y, Sashida Y (2005) Mechanism of
neurotrophic action of nobiletin in PC12D cells. Bio-
chemistry 25:13683–13691
Park IK, Lasiene J, Chou SH, Horner PJ, Pun SH (2007) Neuron-
specific delivery of nucleic acids mediated by Tet1-modi-
fied poly(ethylenimine). J Gene Med 9:691–702
Rukenstein A, Rydel R, Greene L (1991) Multiple agents rescue
PC12 cells from serum-free cell death by translation- and
transcription independent mechanisms. J Neurosci
11:2552–2563
Schaefer T, Karli UO, Scweizer FE, Burger MM (1987)
Docking of chromaffin granules-a necessary step in exo-
cytosis? Biosci Rep 7:269–279
Seth K, Agrawal AK, Aziz MH, Ahmad A, Shukla Y, Mathur N,
Seth PK (2002) Induced expression of early response
genes/oxidative injury in rat Pheochromocytoma (PC12)
cell line by 6-hydroxydopamine: implication for Parkin-
son’s disease. Neurosci Lett 330:89–93
Vijayanathan V, Thomas T, Thomas TJ (2002) DNA nonapar-
ticles and development of DNA delivery vehicles for gene
therapy. Biochemistry 41:14085–14094
Villemejane J, Mir LM (2009) Physical methods of nucleic acid
transfer: general concepts and applications. Br J Pharmacol
157:207–219
Wang R, Zhou J, Tang XC (2002) Tacrine attenuates hydrog-
enperoxide-induced apoptosis by regulating expression of
apoptosis-related genes in rat PC12 cells. Brain Res Mol
Brain Res 107:1–8
Yaron Y, McAdara JK, Lynch M, Hughes E, Gasson JC (2001)
Identification of novel functional regions important for
the activity of HOXB7 in mammalian cells. J Immunol
166:5058–5067
Cytotechnology
123
Exon-Skipping Antisense Oligonucleotides to Correct
Missplicing in Neurogenetic Diseases
Kavitha Siva,1,* Giuseppina Covello,1,* Michela A. Denti1,2
Alternative splicing is an important regulator of the transcriptome. However, mutations may cause alteration of
splicing patterns, which in turn leads to disease. During the past 10 years, exon skipping has been looked upon
as a powerful tool for correction of missplicing in disease and progress has been made towards clinical trials. In
this review, we discuss the use of antisense oligonucleotides to correct splicing defects through exon skipping,
with a special focus on diseases affecting the nervous system, and the latest stage achieved in its progress.
Introduction
Alternative splicing is the process by which exons ofprimary transcripts can be spliced into alternative ar-
rangements to produce structurally and functionally different
messenger RNA (mRNA) and protein variants. The splicing
process can be regulated by different cis- and trans-acting
factors that influence splice site selection ( Johnson et al.,
2009). Point mutations in a gene may weaken or strengthen
splice sites; enhancer or silencer elements or lead to their
destruction. This in turn causes alteration of splicing events
and consequent disease.
Additionally, most eukaryotic genes contain several
pseudoexons, sequences resembling perfect exons, which are
nonetheless ignored by the splicing machinery (Dhir and
Buratti, 2010). Aberrant pseudoexon inclusion due to deep
intronic mutations has been uncovered in recent years as a
frequent cause of human diseases. When a pseudoexon in-
clusion leads to premature insertion of a termination codon in
the mRNA, the term ‘‘nonsense exon’’ is used, also indicat-
ing that the mRNA undergoes rapid degradation by nonsense-
mediated decay (NMD) pathways (Dhir and Buratti, 2010).
It has been observed that 50% of human genetic diseases
arise due to mutation that affect the splicing process,
including numerous that are associated with neurogenetic
diseases (Matlin et al., 2005; Mills et al., 2012). The brain, in
fact, being the most complex organ, expresses a relatively
higher number of alternatively spliced genes, some of which
were found to be linked to neurological and neurodegenera-
tive diseases. Because these diseases cannot presently be
cured and are degenerative, they place a great burden on
caregivers and represent some of the most costly diseases
for society.
Antisense Oligonucleotide-Mediated
Splicing Modulation
The most widely studied gene therapy approach for the
correction of aberrant splicing is the use of antisense oligo-
nucleotides (AONs) that target the pre-mRNA. AONs are
short synthetic modified nucleic acids that bind RNA through
base pairing and enable modulation of its expression
(Southwell et al., 2012). (For a thorough overview on the
applications of antisense-mediated exon skipping, see van
Roon-Mom and Aartsma-Rus, 2012).
Design of AONs that can bind to splice sites or to exonic or
intronic enhancing cis-regulatory sequences in the pre-
mRNA [exonic splice enhancers (ESEs) or intronic splice
enhancers (ISEs)] leads to masking of these regions and the
inability of trans-splicing regulatory factors to bind effec-
tively, thus inducing switching between alternative splice
isoforms via exon skipping (Fig. 1). In the same way, by
masking of cryptic splice sites, AONs have been used for the
correction of cryptic splicing.
As point mutation or deletions can disrupt the open reading
frame in a transcript, AONs have also been used to induce the
skipping of one or more additional exons, to restore the
transcript reading frame, allowing the production of an in-
ternally deleted, but sometimes (partially) functional protein
(Turczynski et al., 2012). This strategy has its most advanced
examples in the exon skipping approaches to the treatment of
Duchenne muscular dystrophy (DMD, Aartsma-Rus, 2012).
Further, AONs-mediated exon skipping can also be used to
induce reading frame disruption and protein knockdown
(Disterer and Khoo, 2012). However, to achieve a robust
therapeutic effect, it is essential that sufficient amounts of
AONs are taken up specifically by the tissue affected by the
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disease, which is often not the case. Moreover, other tech-
niques such as RNA interference have shown higher efficacy
and feasibility. On the other hand, protein knockdown via
exon skipping may exhibit advantages over other techniques
that simply knock down gene expression: the alternative
isoforms may have dominant negative behavior towards the
normal isoform, present additional therapeutic properties, or
may avoid side effects that are associated with near total
downregulation of the normal isoform.
In principle, AONs appropriately targeted to block exonic
or intronic splicing silencers (ESSs or ISSs) can also restore
exon inclusion in the context of disease-associated exon
skipping. The exon-inclusion strategy has proven effective
in vitro and in vivo as a possible therapy for spinal muscular
atrophy (SMA), as extensively described in recent reviews
(Hua and Krainer, 2012; Douglas and Wood, 2013).
Notably, most advanced AON-mediated exon skipping
approaches are clinical phase 3 trials for DMD (Arechavala-
Gomeza et al., 2012) and earlier clinical trials are in prepa-
ration for SMA (Porensky and Burges, 2013).
Different Oligonucleotide Chemistries are Available
for the Correction of Splicing
The currently used AONs are rarely regular RNA or DNA
oligonucleotide, as alternative AON chemistries have been
developed to improve affinity, boost stability in the circula-
tion and in target cells, and enhance cell penetration and
nuclear accumulation. This issue will be here only briefly
outlined and the reader is referred to (Saleh et al., 2012) for a
more complete discussion of AON chemistry.
The non-bridging oxygen in the phosphate backbone has
been replaced with a sulfur atom, generating phosphor-
othioate (PS) AONs (De Clercq et al., 1969). This modifi-
cation enhances cellular uptake and improves resistance to
nucleases but reduces the affinity of the AON to the target
RNA. Moreover, the PS modification does not abrogate the
ability, proper of DNA oligos, to induce RNase H cleavage of
the target RNA.
Addition of a methyl or a methoxyethyl group to the 2¢-O
atom of the ribose sugar (2¢OMe and 2¢OMOE, respectively)
renders the AON–target RNA hybrid RNase H-resistant
and increases the affinity of the AON for the target RNA
(Sproat et al., 1989; Manoharan et al., 1999). Most AONs
currently under study for splicing corrections have both the
2¢O and the phosphorothioate (PS) modification (2¢OMe-PS
and 2¢OMOE-PS), probably because they have a good safety
profile and their synthesis is relatively inexpensive.
2¢OMe-PS were the first AONs to be used for exon skip-
ping (Sierakowska et al., 1996; Khang et al., 1998) and the
first to be used for dystrophin exon skipping in cultured pri-
mary muscle cells from mdx dystrophic mice (Dunckley
et al., 1998). Some years later, exon skipping and dystrophin
protein recovery was demonstrated upon delivery of 2¢OMe-
PS into mdx mice, aided by the nonionic block copolymer
pluronic F127, and injected either locally in skeletal muscles
(Lu et al., 2003) or systemically via tail vein (Lu et al., 2005).
2¢OMe-PS AONs targeting dystrophin exon 51 (GSK-
2402968/PRO051/drisapersen) have proven successful in
intramuscular clinical trials in DMD patients (van Deutekom
et al., 2007) and have demonstrated significant dystrophin
restoration, good safety and tolerance in systemic clinical
trials (Goemans et al., 2011).
2¢OMOE-PS AONs have been used in cell lines to redirect
splicing of murine interleukin-5 receptor alpha chain (il5ra,
Karras et al., 2000) and of myD88 (Vickers et al., 2006) and
to correct aberrantly spliced reporter enhanced green fluo-
rescent protein (EGFP; Sazani et al., 2001). Importantly,
FIG. 1. Methods of anti-
sense oligonucleotide-mediated
modification of splicing: (A)
Alternative exon: antisense oli-
gonucleotides (AONs) directed
toward splice sites or exonic
enhancers induce exon skip-
ping. (B) Pseudoexon: AONs
directed toward cryptic splice
sites restore the normal tran-
script. (C) Nonsense exon:
AONs targeting cryptic splice
sites of nonsense exons restore
normal transcripts. (D) Exonic
cryptic splice site: AONs, tar-
geting the exonic cryptic splice
site, restore normal splicing.
70 SIVA, COVELLO, AND DENTI
2¢OMOE-PS have been recently used successfully for exon
inclusion of the SMN2 gene as a potential approach for the
treatment of SMA in cultured cells (Hua et al., 2007) and
in vivo by intracerebroventricular (ICV) infusion or injection
in a mouse model of SMA (Hua et al., 2010). In this latter
work, a side-by-side comparison was also made between an
18-mer 2¢OMOE-PS and an overlapping 20-mer 2¢OMe-PS
AON. The 2¢OMOE-PS was found to be more effective after
ICV infusion into adult mice central nervous system (CNS)
and to elicit less unwanted proinflammatory effects (Hua
et al., 2010).
In a different available oligonucleotide chemistry, a
methylene bridge connects the 2¢-O and the 4¢-C of the ribose,
forcing the nucleotide in the ‘‘endo’’ conformation, in what
has been dubbed ‘‘locked nucleic acid’’ (LNA; Obika et al.,
1998). This modification leads to a very high affinity for the
target nucleic acid.
Aartsma-Rus and colleagues (2004) reported that an AON
completely made of LNA was very effective for exon skip-
ping in cells derived from an exon 45-deleted DMD patient.
However, this AON also showed reduced specificity, prob-
ably due to the very high affinity of the 14-mer LNA with the
target (Aartsma-Rus et al., 2004). In the applications that use
oligonucleotides as steric inhibitors, the specificity issues
associated with LNA have been solved by using a mixmer of
LNA and DNA backbone sequence (Elayadi et al., 2002) or
LNA and 2¢OMe backbone (Arzumanov et al., 2001; Fabani
and Gait, 2008). Roberts and colleagues (2006) have shown
that upon intraperitoneal (IP) injection in the EGFP splice-
switching mouse model, a 16-mer LNA/DNA mixmer con-
taining 8 LNA units alternating with the DNA units, and with
an all-PS backbone, showedmuch higher potency in the liver,
colon, and small intestine than an overlapping 2¢OMe 18-mer
AON (Roberts et al., 2006).
In addition to the described negatively charged oligonu-
cleotides (2¢OMe-PS, 2¢OMOE-PS, and LNA), two more
oligonucleotide chemistries have been used in attempts to
modulate splicing: peptide nucleic acids (PNAs) and phos-
phorodiamidate morpholino oligomers (PMOs). Both these
types of charge-neutral oligonucleotides are resistant to exo-
and endonucleases and RNase H cleavage.
PNAs have a 2-aminoethyl glycine backbone linked to
nucleobases (Larsen et al., 1999) and show high affinity to
both RNA and DNA targets and good sequence specificity
(Egholm et al., 1993). It is common to incorporate additional
cationic lysine residues in the PNA oligonucleotide, to get
good water solubility, and to improve cell entry by facili-
tating the binding to the negatively charged surface of cells.
Karras and colleagues have shown that a 15-mer PNA con-
taining a single C-terminal Lys residue had similar efficiency
as a 2¢OMOE-PS AON in modulating the splicing of the
IL5R-a pre-mRNA when electroporated into BCL1 lym-
phoma cells (Karras et al., 2001). In the absence of a trans-
fection agent, an 18-mer PNA containing four Lys residues
(PNA-4Lys) was shown to be taken up by HeLa cells better
than a PNA of identical sequence with one Lys residue only
and to modulate reporter EGFP splicing (Sazani et al., 2001).
In the same conditions, 2¢OMe-PS and 2¢OMOE-PS AONs of
identical sequence were not able to induce splicing correction
(Sazani et al., 2001). The same PNA-4Lys 18-mer, when IP-
injected in the splice-switching EGFP mouse, was very ef-
fective in inducing EGFP production in a number of organs,
such as kidney, liver, heart, and lung, whereas the PNA with
only a single Lys residue was inactive (Sazani et al., 2002).
However, a PNA-4Lys 14-mer was not effective in in-
ducing dystrophin exon skipping in exon-45-deleted DMD
patient myoblasts (Aartsma-Rus et al., 2004), probably due to
its short length.
A 20-mer PNA without Lys addition was shown to be
moderately effective in dystrophin exon skipping in the mdx
mouse model upon local muscle injection (Yin et al., 2008a).
The same authors showed recently that, upon tail vein in-
jection into mdx mice, a 25-mer PNA without Lys is more
effective than the 20-mer PNA in dystrophin exon skipping
and doses up to 100mg/kg were well tolerated (Yin et al.,
2010).
PMOs consist of morpholine rings that are connected
through phosphorodiamidate groups (Summerton and Weller,
1997). Generally, PMOs used are longer than 2O¢Me-PS
AONs due to their slightly lower affinity. Schmajuk and col-
leagues (1999) have shown that a PMO 18-mer was 20-fold
more effective than a corresponding 2¢OMe-PS 18-mer in
modulating splicing in free uptake in cell culture (Schmajuk
et al., 1999).
As PMOs are charge neutral, they are difficult to transfect.
Gebski and colleagues (2003) successfully transfected PMOs
in mdxmouse muscle cells in combination with a sense oligo
(leash) and Lipofectin, to allow formation of a cationic li-
poplex. In these cells they showed efficient dystrophin exon
skipping with a 25-mer PMO, and exon skipping and dys-
trophin production was also observed by intramuscular in-
jection of the cationic lipoplex in the mdx mouse (Gebski
et al., 2003). The same PMO 25-mer was also effective in
generating dystrophin in a number of muscle types when
injected intravenously and uncomplexed in mdx mice (Alter
et al., 2006). Direct comparisons in the mdx mouse of the
PMO 25-mer to a 2¢OMe-PS of identical sequence and
length, suggested that PMO generates higher exon skipping
and dystrophin production upon both local and systemic
delivery than 2¢OMe-PS (Fletcher et al., 2006). However,
leash transfection of a 22-mer PMO into exon 45-deleted
DMD patient’s muscle cells did not result in as good exon
skipping as for a 20-mer 2¢OMe-PS ON (Aartsma-Rus et al.,
2004). The reason for these discrepancies might be different
effectiveness of 2¢OMe-PS and PMO AONs depending on
the target exon sequence as well as on AON length, as also
suggested by exon skipping studies in a range of human exons
in humanized DMD mice (Heemskerk et al., 2009).
A PMO 30-mer targeting dystrophin exon 51 (AVI-4658/
eteplirsen) has proven successful in intramuscular clinical
trials (Kinali et al., 2009). In recent systemic studies, ete-
plirsen has demonstrated significant dystrophin restoration,
good safety, and tolerance (Cirak et al., 2011).
To facilitate delivery into cells ex vivo and in vivo, dif-
ferent cell-penetrating peptides (CPPs) have been conjugated
to PMOs, yielding pPMOs (peptide-conjugated PMOs).
While toxicity has been associated with moderate doses of
the peptide conjugates (Abes et al., 2006; Burrer et al., 2007),
pPMOs have been used in vivo for effective oligo delivery at
doses below those causing observed toxicity (Amantana
et al., 2007). The systemic injection of a pPMO conjugated to
different Arg-rich peptides and targeting exon 23 led to
dramatic enhancement of dystrophin production and exon
skipping in the skeletal muscles and heart of mdx mouse
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( Jearawiriyapaisarn et al., 2008; Wu et al., 2008; Yin et al.,
2008b, 2009, 2011; Wu et al., 2012).
In a different approach, a non-peptidic cell-penetrating
moiety, consisting in an octaguanidinium dendrimer, has
been attached to the 3¢ end of a PMO (Li and Morcos, 2008).
Such delivery-enhabled PMOs, called ‘‘vivo-morpholinos,’’
are efficiently uptaken in cells (Li and Morcos, 2008) and
have been successfully injected systemically in mdx mice
showing good activity in exon skipping and dystrophin pro-
duction and no signs of toxicity at the injected doses (Wu
et al., 2009).
Success in the preclinical studies involving exon-skipping
treatment of DMD has prompted studies aimed at extending
the range of application of these antisense oligonucleotides
from neuromuscular to many other genetic diseases. In the
following pages, we will review AON-mediated exon skip-
ping treatments that have been studied in relation to the
central nervous system (CNS) and for neurogenetic diseases.
Exon Skipping as a Therapeutic Approach
for Neurogenetic Diseases
Ataxia telangiectasia
Ataxia telangiectasia (AT) is a progressive autosomal re-
cessive neurodegenerative disorder resulting from mutations
in the ataxia telangiectasia mutated (ATM) gene (Perlman
et al., 2003). To date, close to 600 ATMmutations have been
identified (www.hgmd.cf.ac.uk/ac/gene.php?gene =ATM).
The phenotypic changes include progressive cerebellar
ataxia, increased cancer incidence, and chromosome insta-
bility (Teraoka et al., 1999). Worldwide incidence for this
disease is estimated at 1 in 40,000 to 1 in 100,000 individuals.
Disease onset is in early childhood, usually before age 5.
The ATM gene (located on chromosome 11q22.3) includes
66 exons and encodes a 13-kb mature transcript with an open
reading frame of 9,168 nt. The first two exons, 1a and 1b, are
spliced differentially in alternative transcripts. The ATM
protein is a serine/threonine kinase with 30 phosphorylation
targets (Bakkenist et al., 2003) constitutively expressed in all
tissues, primarily in the nucleus. It has a role in the control of
cell cycle checkpoints, repair of double-stranded DNA
breaks, responses to oxidative stress and apoptosis, and is a
potent tumor suppressor.
Approximately half of the mutations in AT have been re-
ported as splicing mutations (Teraoka et al., 1999; Nakamura
et al., 2012; Cavalieri et al., 2013) that either create new
cryptic splice sites or interfere with splice regulatory ele-
ments. Some of these mutations elicit the activation of 5¢ or 3¢
cryptic splice sites within exonic regions, leading to the de-
letion of a part of the exon. Du and colleagues designed a
customized mutation-based approach for AT by transfecting
antisense PMOs in immortalized lymphoblastoid cell lines
from three different AT patients (Du et al., 2007). Cell line
TAT[C] is homozygous for the mutation 7865C >T
(A2622V) that creates a new 5¢ splice site in exon 55. This, in
turn, results in the deletion of 64 nt in the spliced mRNA,
frameshifting, and the appearance of a premature stop codon.
The ATM protein produced is therefore shorter and possibly
the mutated mRNA would undergo NMD. Cell line IRAT9 is
homozygous for the mutation 513C >T (Y171Y), which ac-
tivates a stronger 3¢ cryptic splice site within exon 8, resulting
in a deletion of the first 22 nt of exon 8, frameshifting and the
appearance of a premature stop codon. This in turn causes the
ATM protein to be truncated. Cell line AT203LA carries in
heterozygosis the mutation IVS28-159A >G, that results in
the insertion of a 112-nt segment of intron 28 in the mRNA,
frameshifting, and premature translation termination (Fig. 2).
For TAT[C] and IRAT9 cells, PMOs were designed to
mask the aberrantly activated cryptic splice sites (Fig. 2A, B),
and correction was observed at transcriptional level with a
40% of pre-mRNA being spliced in the normal manner.
PMOs could redirect aberrant splicing as early as 8 hours
after treatment and this effect lasted at least 84 hours. The
maximum effect, however, occurred at 48 hours. At the
protein level, less than 10% ATM protein was induced at 24
hours of treatment, as compared with the ATM protein level
in controls and as measured by western blots on nuclear
extracts. However, the ATM protein level continued to in-
crease until 84 hours, and the restored ATM protein was
functional for kinase activity, as evaluated by ATM autop-
hosphorylation and downstream transactivation of ATM
substrates p53 and SMC1.
For the AT203LA cell line, two different PMOs were de-
signed, one targeting the 3¢splice site and one targeting the 5¢
splice site of the pseudoexon (Fig. 2C). Only the latter PMO
showed effective blocking of pseudoexon inclusion and al-
most completely restored normal splicing, as evaluated both
at the mRNA and protein levels.
The most debilitating feature of AT is the progressive loss
of Purkinje cells in the cerebellum and the accompanying
progressive ataxia. Therefore, for any compound to be
effective in treating AT patients, it will have to cross the
blood–brain barrier (BBB) and target brain cells, particularly
Purkinje cells. Following their study in cells, Du and col-
leagues further extended the exon skipping strategy into
preclinical studies, by investigating whether the coupling of
an arginine-rich CPP to PMOs could enable their delivery to
brain and cerebellum (Du et al., 2011). They showed that
the targeting efficiency of these pPMOs is greatly improved
in ex-vivo experiments, compared with PMOs of identical
sequence: when the pPMO were tested on previously estab-
lished cell lines (TAT[C], AT203LA) a complete abolish-
ment of mutant transcripts along with 80% correction of
ATM protein level was observed. This work was extended
to the in vivo systemic administration of fluorescent pPMOs
in wild type mice, via tail vein injection, which showed
efficient uptake in the brain, and in Purkinje cells in particular
(Du et al., 2011). However, no report is presently available on
the in vivo exon-skipping efficacy of these pPMOs.
Nakamura and colleagues studied ATM mutations in eight
families of Japanese AT patients ( JPAT) where 16 different
mutations were found. Six of these mutations were involved
in splicing, four of which were novel (Nakamura et al., 2012).
Their exon-skipping analysis was performed on lympho-
blastoid cell lines of patients JPAT 11/12 bearing a splicing
mutation (c.2639-384A >G) in heterozygosity with a large
deletion (c.6807 + 272_7516-275del5350). Mutation c.2639-
384A >G creates a cryptic 5¢ splice site resulting in the in-
clusion of a 58-nt pseudoexon (Fig. 2D). This leads to a
frameshift and a predicted secondary premature stop codon.
They used a PMO (AMO-J11) to target the cryptic 5¢ splice
site, and delivered it to patient’s lymphoblastoid cell line via
the Endo-Porter system (Summerton, 2005). A complete
ablation of mutant transcript was observed by reverse
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transcription–polymerase chain reaction (RT-PCR), in a
PMO dose-dependent manner, and the full-length ATM
protein was recovered. They also used a vivo-morpholino of
identical sequence, which was able to induce a significant
amount of functional protein at lower concentrations than the
PMO, as validated by the western blot (Nakamura et al.,
2012). However, authors report possible cytotoxic effects of
the vivo-morpholino at the used concentration, on the lym-
phoblastoid cell line.
In a recent work, Cavalieri and colleagues identified a new
ATM mutation c.1236-405C >T located in intron 11, which
affects splicing by creating a novel cryptic 5¢ splice site, thus
including a pseudoexon (Cavalieri et al., 2013). Patients bear
the mutation in heterozygosis with the known missense
mutation c.6326G >A. Cavalieri and colleagues (2013) used
a PMO to mask the 5¢ cryptic splice site created by the mu-
tation (Fig. 2E) in patient’s lymphoblasts and reported a 26%
increase of the correctly spliced mRNA as observed by RT-
PCR, when cells were treated with 50mM PMO. Moreover,
they used a vivo-morpholino of identical sequence and
showed in patient’s lymphoblasts an exon skipping efficiency
of 50% to 95%, depending on AON concentrations used
(1mM or 2 mM). At these concentrations, the authors also
report a cytotoxic effect of vivo-morpholinos, after 84 hours
of treatment. The functional protein activity determined
through kinase activity was 50% of wild-type levels. Since
AT patients with 5% to 20% of functional ATM have a mild
AT phenotype, and ATM heterozygotes having 40% to 50%
of normal ATM protein levels do not show any sign of dis-
ease, Cavalieri and colleagues have hypothesized that even a
minimal rescue of functional ATM protein levels could
provide therapeutic benefit to these patients.
Congenital disorder of glycosylation
Congenital disorder of glycosylation (CDG) is an autoso-
mal recessive disorder that affects glycan synthesis. The most
prevalent form of CDG, type 1a, has an incidence of 1 in
50,000 to 1 in 100,000 individuals, and is caused by muta-
tions in PMM2 gene, which is located on chromosome 16p13
and gene encodes phosphomannomutase 2 (PMM2), a key
enzyme that controls the synthesis of GDP-mannose and is
essential for the generation of N-glycans. Mutations in the
PMM2 gene lead to the hypoglycosylation of different pro-
teins in different tissues (Dupre´ et al., 2000). CDG involves
multi organ failure, but also leads to neurologic deficits in-
cluding cognitive impairment, ataxia, pigmentary retinal
degeneration, and neuropathy (Pearl et al., 2001). Clinical
FIG. 2. Schematic representation of five splicing mutations identified in the ataxia telangiectasia mutated (ATM) gene,
and locations of blocking antisense oligonucleotides that restore normal splicing (Du et al., 2007, 2011; Nakamura et al.,
2012; Cavalieri et al., 2013).
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presentation and course are highly variable, ranging from
infants who die in the first year of life to mildly involved
adults. N-glycosylation defect of cerebrospinal fluid b-trace
protein, (a glycoprotein synthesized by glia-rich fractions of
the brain) were observed in CDG type 1a patients (Pohl et al.,
1997; Gru¨newald et al., 1999).
Since the total lack of the PMM2 gene product is lethal, no
patient with two copies of any inactivating mutation has ever
been recorded. Patients are usually compound heterozygous.
Though 95% of the mutations are missense in nature, there
are yet a fewmutations that cause pre-termination codons and
splicing mutations (Vuillaumier-Barrot et al., 2006; Schollen
et al., 2007; Vega et al., 2009). One such mutation has been
targeted by Vega and colleagues, who reported the use of
PMOs to revert a deep intronic mutation (c.640-15479C >T)
that leads to the activation of a cryptic 5¢ splice site in intron 7
(Vega et al., 2009).
Two different 25-nt-long PMOs were designed, comple-
mentary to the 5¢ or 3¢ cryptic splice sites of the pseudoexon
in intron 7 (Fig. 3) and both these PMOs were transfected at
the same time into patient’s fibroblasts carrying the c.640-
15479C >T mutation in heterozygosity with missense mu-
tation c.691G >A, via the Endo-Porter reagent (Summerton,
2005). There was a 100% restoration of the correctly spliced
mRNA. The levels of PMM2 protein after transfection in-
creased from 9% to 23% of the quantity detected for the
control cell line. PMM2 enzymatic activity was rescued al-
most to 50% that of the control fibroblasts.
Fronto-temporal dementia and Parkinsonism linked
to chromosome 17
Fronto-Temporal Dementia and Parkinsonism linked to
chromosome 17 (FTDP-17) is an autosomal dominant neu-
rodegenerative disorder showing cognitive impairment, be-
havioral and personality changes and motor symptoms. The
incidence of FTDP-17 is unknown; however, it is an ex-
tremely rare condition. It is caused by mutations in theMAPT
gene on chromosome 17q21, which encodes microtubule-
associated protein tau. Over 100 families with 44 different
mutations in theMAPT gene have been identified worldwide.
The symptoms and onset age of FTDP-17 vary not only be-
tween families carrying different mutations but also between
and within families carrying the same mutations. Pathologi-
cal hallmarks of the disease are aggregation of tau into
neurofibrillary tangles (NFT) in neurons and/or glial cells.
The pathogenetic mechanisms underlying the disorder are
related to the altered proportion of tau isoforms or to the
ability of tau to bind microtubules and to promote microtu-
bule assembly. There is currently no cure for FTDP-17 and
treatment is only symptomatic and supportive. The prognosis
and rate of the diseases progression vary considerably among
individual patients, ranging from life expectancies of several
months to several years, and, in exceptional cases, as long as
two decades after diagnosis (Tsuboi et al., 2009).
Tau is constitutively and abundantly expressed in both the
central (CNS) and the peripheral nervous system (PNS). In
the CNS, tau is enriched in the axons of mature and growing
neurons, though low levels of tau are also present in oligo-
dendrocytes and astrocytes.
Tau functions in microtubule (MT) assembly, influences
MT stability, and is important for neurogenesis, axonal
maintenance, and axonal transport. The human MAPT gene
consists of 16 exons and its expression is regulated by com-
plex alternative splicing (Andreadis, 2012). Exons 9–12 each
encode a 31- to 32-amino-acid imperfect repeat that com-
prises the MT-binding domain of tau. In adult human brain,
exons 2, 3, and 10 are alternatively spliced to produce six
different tau isoforms. Exon 10 (E10) inclusion generates
isoforms with four microtubule repeats called 4R tau. When
E10 is skipped, the result is 3R tau isoforms. In fetal brain,
only the shortest 3R tau isoform is expressed because of
constitutive exclusion of exons 2, 3, and 10.
While several missense mutations in MAPT are known,
approximately one-half of the mutations observed in FTDP-
17 alter the relative levels of 4R versus 3R tau by affecting
alternative splicing of E10 (Andreadis, 2012). These
mutations include missense (N279K, N296H, G303V, and
S305N), silent (L284L, N296N), and deletion mutations
(Delta280K, Delta296N) in E10, and intronic mutations
(E10–10, E10 + 3, E10 + 11, E10 + 12, E10 + 13, E10 + 14,
E10 + 16, and E10 + 19) in introns 9 and 10. Most of these
mutations increase E10 inclusion. The result is that the 4R/3R
ratio, which is normally 1, is increased to 2–3. These muta-
tions demonstrate that the 4R/3R ratio is crucial to the cor-
rect functioning of tau, although the mechanism by which
this alteration leads to neurodegeneration and FTDP-17 is
presently unclear.
Kalbfuss and his colleagues have shown that AONs di-
rected against MAPT exon 10 splice sites could suppress
FIG. 3. Congenital disorder of glycosylation type 1A. Diagram of splicing mutations and antisense oligonucleotides
locations that rescue the aberrant transcript in congenital disorder of glycosylation type 1a causal gene PMM2 (for
phosphomannomutase 2) (Vega et al., 2009).
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inclusion of E10 (Kalbfuss et al., 2001). The experiment was
performed on COS-1 green monkey kidney cells by co-
transfecting reporter minigenes (with a single point mutations
either at position - 1, + 3, or + 14 relative to E10) with 17- to
21-nt-long 2¢OMe PS AONs targeting either the 5¢ or the 3¢
splice site of E10 (Fig. 4). Both these AONs were successful
in skipping E10 in the three minigenes, as assessed by RT-
PCR. They further proved these results in rat pheochromo-
cytoma PC12 cells, in which both AONs effectively excluded
exon 10 from the endogenous wild type MAPT mRNA, as
observed through RT-PCR. Western blots confirmed the re-
duction of tau 4R isoform. Furthermore, they observed that
exon skipping-inducing AONs had a significant and specific
physiological effect by destabilizing the microtubule cyto-
skeleton and altering cell morphology, when transfected in
rat AR42J pancreatic acinar cells.
Donahue and colleagues have validated the use of the 5¢
splice site-targeting 2¢OMe-PS AON described by Kalbfuss,
in HeLa cells cotransfected with luciferase reporter mini-
genes, in the wild-type and mutant E10 + 14 versions (Do-
nahue et al., 2006). Transfection of the AONs resulted in a
decrease in luciferase expression of about 50%, relative to
cells transfected with a control oligoribonucleotide. Real-
time RT-PCR confirmed an increase of approximately 15
time of the 3R/4R mRNA ratio, relative to control treatment.
The work of Kalbfuss and colleagues (Kalbfuss et al.,
2001) has been further extended by Peacey and colleagues by
targeting E10 5¢ splice site with a bipartite 2¢OMe-PS AON
and comparing its efficiency in inducing E10 skipping to that
of Kalbfuss’ ‘‘continuous’’ 5¢ splice site-targeting 2¢OMe-PS
oligonucleotide (Peacey et al., 2012). The bipartite 2¢OMe-
PS AON was designed to interact with the 5¢ and 3¢ regions
immediately flanking an hairpin located at the junction be-
tween exon 10 and intron 10, and consists of 10 bases com-
plementary to the 3¢ flank, a linker of one adenosine, and 9
bases complementary to the 5¢ flank.
Cotransfection of the bipartite 2¢OMe-PS or the ‘‘contin-
uous’’ 2¢OMe-PS along with wild-type minigene in SK-N-
SH neuroblastoma cells induced exon skipping with a
reduction in 4R of 68% and 66%, respectively. In addition,
bipartite 2¢OMe-PS and ‘‘continuous’’ 2¢OMe-PS signifi-
cantly increased expression of 3R tau by 37 and 65%, re-
spectively. When tested on a E10 + 14 mutant form of the
minigene, the bipartite 2¢OMe-PS and the ‘‘continuous’’
2¢OMe-PS significantly reduced expression of 4R tau by 57
and 61%, respectively with concomitant increase in 3R tau
expression. The effect of bipartite 2¢OMe-PS AON on en-
dogenous tau mRNA was verified in HEK 293 cells that
showed 42% reduction of E10 inclusion.
Niemann-Pick disease type C
Niemann-Pick disease Type C (NPC) is an autosomal re-
cessive disorder due to mutations in genes NPC1 or NPC2,
with an incidence of 1 in 150,000 individuals. NPC is in-
volved in a significant reduction of life expectancy (Miao
et al., 2012) and is mainly associated with progressive neu-
rodegeneration and neurological, psychiatric, and hepatic
manifestations. Approximately 50% of cases present before
10 years of age, but manifestations may first be recognized as
late as the sixth decade. Neurological symptoms vary with
age accompanied by hypotonia, delay in developmental
motor milestones, learning difficulties, ataxia with cognitive
deficits, and psychosis (Kheder et al., 2013).
In the NPC neurons, there is a gross alteration in the overall
amounts of cholesterol and an accumulation of unesterified
cholesterol and glycosphingolipids in the lysosome-like
storage organelles in the cell bodies (Mukherjee et al., 2004).
Though most of the mutations in NPC1 are missense, some
splicing mutations have been found (Rodrı´guez-Pascau et al.,
2009; Macı´as-Vidal et al., 2011). Work by Rodrı´guez-Pascau
and colleagues focused on mutation c.1554-1009G>A, lo-
cated in intron 9 of NPC1 gene, leading to the insertion of a
194-nt pseudoexon, both in HeLa cells transfected with a
mutant minigene and in patient fibroblasts, which carry the
mutation in heterozygosis with in-frame deletion-insertion
p.N961_F966delinsS (Rodrı´guez-Pascau et al., 2009). A PMO
complementary to the cryptic 5¢ splice site was used to block
the access of the splicing machinery to the pre-mRNA thus
avoiding the formation of the aberrantly spliced transcript (Fig.
5). The PMO was able to prevent the inclusion of the pseu-
doexon and restored normal splicing upon delivery to patients’
fibroblasts via the Endo-Porter system (Summerton, 2005).
RT-PCR analysis shows the complete disappearance of the
amplicon corresponding to the aberrant splicing, upon 48 hours
of treatment with 10mMPMO (Rodrı´guez-Pascau et al., 2009).
Neurofibromatosis type 1
Neurofibromatosis type 1 (NFT 1) is an autosomal domi-
nant disorder characterized by cafe´-au-lait spots, cutaneous
FIG. 4. Frontotemporal dementia and Parkinson’s disease. Schematic representation of Exon 10 splicing mutations in
MAPT gene, which encodes microtubule-associated protein tau, and of the locations of antisense oligonucleotides that
induce skipping of exon 10 (Kalbfuss et al., 2001; Peacey et al., 2012).
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neurofibromas, Lisch nodules, inguinal and axillary freck-
ling, and a high predisposition to develop certain types of
tumors. It affects 1 in 3,000 individuals, especially targeting
young children (Friedman et al., 1999). Affected individuals
develop glial neoplasms (optic gliomas, malignant astrocy-
tomas) and neuronal dysfunction leading to learning dis-
abilities and attention deficits (Gutmann et al., 2012).
NFT1 is caused by mutations in the NF1 gene, which is
located on chromosome 17q11.2, contains 57 constitutive
exons and encodes for an 11- to 13-kb mRNA transcript. The
gene product neurofibromin negatively regulates Ras and acts
as a tumor suppressor. Neurofibromin also plays important
roles in cell growth, neuronal activity and bone metabolism
(Hseuh et al., 2012).
About 44% of the mutations found in NF1 are splicing
mutations (Pros et al., 2008). A small subset of these muta-
tions (20%) are deep intronic single nucleotide changes that,
creating either a novel 5¢ or 3¢ site, increase pseudoexon in-
clusion into mature mRNA.
Work by Pros and colleagues aimed at restoring normal
splicing using PMOs in primary fibroblast and lymphocyte
cell lines derived from six NFT1 patients bearing three
different deep intronic mutations (c.288+ 2025T >G,
c.5749 + 332A >G and c.7908-321C >G) (Pros et al., 2009).
PMOs were designed against the mutant cryptic 5¢ splice
sites, and delivered via Endo-porter reagent (Summerton,
2005) (Fig. 6). PMO treatment effectively restored normal
NF1 splicing at the mRNA level for the three mutations
FIG. 5. Niemann Pick disease type C (NPC1). Scheme of splicing mutations and location of antisense oligonucleotides
that restore the aberrant transcript in NPC1 (Rodriguez-Pascau et al., 2009).
FIG. 6. Neurofibromatosis type 1 (NF1). Schematic representation of four NF1 deep intronic mutations and of the location
of specific phosphorodiamidate morpholino oligomers (PMOs) used to restore the correct splicing (Pros et al., 2009;
Ferna´ndez-Rodrı´guez et al., 2011).
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studied in the different cell lines analyzed. The efficiency of
NF1 splicing correction in fibroblasts after 24 hours of
treatment ranged from 87 to 100% in the different mutations.
These authors also found that PMOs had a rapid effect in
fibroblasts that lasted for several days, acting in a sequence-
specific manner and interfering with the splicing mechanism.
A lower degree of aberrant splicing correction (30%–70%)
was observed in lymphocyte cell lines, and a higher con-
centration of PMO, together with a longer time of exposure,
was needed to produce similar effects to those seen in fi-
broblasts. These differences are probably due to the greater
difficulty of lymphocyte transfection. To test whether the
correction of aberrant NF1 splicing also restored neurofi-
bromin function to wild-type levels, the authors measured the
amount of Ras-GTP after PMO treatment in primary fibro-
blasts, as an indirect indication of the GTPase activity of
neurofibromin. The results clearly show a PMO-dependent
decrease in Ras-GTP levels, which is consistent with the
restoration of neurofibromin function.
Ferna´ndez-Rodrı´guez and colleagues analysed the genetic
basis of a benign phenotype observed in a NFT1 patient
carrying themutation c.3198-314G>A in intron 19a of theNF1
gene (Ferna´ndez-Rodrı´guez et al., 2011). This deep intronic
mutation creates a new cryptic 3¢ splice site that uses two dif-
ferent 5¢ splice sites present in the wild type sequence, gener-
ating two aberrantly spliced transcripts leading to the inclusion
of two different pseudoexons, both of which would generate the
same putative truncated protein. A minigene construct con-
taining mutation c.3198-314G>A indicated the production of
both mutated and wild type transcripts, with a low proportion of
the mutated form due to leaking in the splicing mechanism,
contributing to the benign nature of NF1 mutation and conse-
quent mild phenotypic effect observed in the patient.
As a personalized therapeutic approach for NF1 mutations,
PMOs were delivered in patient’s fibroblasts. Three different
PMOs were designed, which the authors named antisense mor-
pholino oligomers (AMOs): AMO-A, blocking the 3¢ splice site;
AMO-D1, blocking the first 5¢ (donor 1) splice site; and AMO-
D2, blocking the second 5¢ (donor 2) splice site (Fig. 6). Re-
duction of the mutant transcripts was validated by RT-PCR.
However, a complete correction was observed only when a
combination of the three PMOs was used. In order to provide
insights into the functional validation, and in agreement with the
results obtained by Pros and colleagues (Pros et al., 2009), a
significant reduction of Ras-GTP was observed in fibroblasts
treated with specific PMOs.
Neurofibromatosis type 2
Neurofibromatosis type 2 (NFT 2) is an autosomal domi-
nant disorder that affects about 1 in 33,000 newborns, char-
acterized by tumors of the nervous system and ocular
abnormalities. The presence of bilateral vestibular nerve
schwannomas is the most distinctive feature of NFT 2, but
patients can develop other clinical manifestations such as
schwannomas in other cranial, spinal and peripheral nerves,
and also other types of tumors, like meningiomas (both in-
tracranial and intraspinal) and ependymomas (low-grade
CNS malignancies). This cancer syndrome is caused by
mutations in the tumor suppressorNF2 gene that is located on
chromosome 22q12 and that codes for the tumor suppressor
protein merlin.
Human merlin mainly located in adherens junctions and is
predominantly found in nervous tissue, but also in several
other fetal tissues. Merlin links receptors at the plasma
membrane to their cytoplasmic kinases to promote contact-
mediated growth inhibition. It is also involved in interaction
with other cytoplasmic and nuclear proteins that affect cell
cycle progression (Beltrami et al., 2013). Around 85% of the
germline NF2 mutations are point mutations, among which
approximately 25% seem to affect splicing. In the recent
work by Castellanos and colleagues, a patient with a deep
intronic mutation (g.74409T >A, NG_009057.1) was iden-
tified (Castellanos et al., 2013). This mutation leads to the
inclusion of a nonsense pseudoexon of 167 nt in the mature
mRNA, between exon 13 and exon 14, thus resulting in a
truncated Merlin protein. Castellanos and colleagues have
been successful in devising a therapeutic strategy for the first
time for an NFT 2 case, using a PMO targeting the deep
intronic mutation (Fig. 7).
Patient-derived fibroblasts were treated with three differ-
ent PMO concentrations (5, 10, and 20mM) for 24 hours, and
a complete inhibition of pseudoexon inclusion was already
observed at the lowest concentration tested. PMOs were de-
livered via the Endo-porter system (Summerton, 2005).
Merlin protein levels, although starting to recover at 24
hours, were not significantly increased until 48 hours after
PMO delivery. Merlin transcript levels were not affected by
control PMO treatment in patient-derived fibroblasts or in
fibroblast derived from a non-NF2 individual treated with
PMO, further supporting the sequence-specific effect of
PMO treatment. Based on the role that Merlin has in contact-
dependent inhibition of proliferation, the functionality of
FIG. 7. Neurofibromatosis type 2. Schematic representation of the identified NF2 deep intronic mutation and PMO
location (Castellanos et al., 2013).
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recovered Merlin protein was tested by BrdU incorporation
assay. Cell proliferation was reduced by 41% at 24 hours and
by 67% at 48 hours when compared with control PMO-treated
cells. Functional restoration of Merlin was also proven, by
showing that F-acting polymerization abnormalities were
eliminated in PMO-treated cells (Castellanos et al., 2013).
Megalencephalic leukoencephalopathy
with subcortical cysts type 1
Megalencephalic leukoencephalopathy with subcortical
cysts type 1 (MLC1) is a rare type of leukodystrophy (inci-
dence*1 in 500,000 individuals) associatedwithmutations in
MLC1 gene. The essential features of this disease include
macrocephaly (large head) with onset in infancy, motor delay
followed by motor disability in the form of progressive spas-
ticity and ataxia, seizures and cognitive decline. MLC1 is an
oligomeric plasma membrane (PM) protein, mainly expressed
in glial cells and neurons. Most disease-causing missense
mutations dramatically reduce the total and PM MLC1 ex-
pression levels in mammalian cells (Duarri et al., 2008).
In a recent work, Mancini and colleagues have described a
homozygousMLC1 deep intronic mutation (c.895-226T>G),
which leads to the reduction of transcripts due to the inclusion
of a 264 nt nonsense exon between exons 10 and 11 (Mancini
et al., 2012). Studies performed with the mutated minigene
transfected in HeLa cells showed only a partial inclusion of
the pseudoexon, suggesting a ‘‘leaky’’ mechanism of the
mutation. A PMOwas used tomask the crytpic 5¢ splice splice
site activated by this mutation in a patient’s lymphoblastoid
cell line (Fig. 8). This led to complete abrogation of the 264-nt
pseudoexon, as analyzed by RT-PCR.
Pelizaeus-Merzbacher disease
Pelizaeus-Merzbacher disease (PMD) is a recessive X-
linked dysmyelinating disorder of the CNS. PMD affects 1 in
400,000 individuals and its onset is usually in early infancy.
The most characteristic early signs are nystagmus (rapid,
involuntary, rhythmic motion of the eyes) and hypotonia (low
muscle tone). Motor abilities are delayed or never acquired,
mostly depending upon the severity of the mutation.
Causes of PMD include PLP1 deletions, duplications, and
point mutations. While deletions are reported only rarely,
duplications account for 60%–70% of cases, and point mu-
tations have been identified in 20% of cases. Mutations in the
PLP1 gene can also give rise to spastic paraplegia type 2
(SPG2), which is an allelic form of the disease. A spectrum of
CNS disorders from mild SPG2 to severe connatal PMD is
associated with the mutations in this gene.
Various types of PLP1 mutations result in missplicing:
Bonnet-Dupeyron et al. (2008) reported that of the 33 mu-
tation they detected, 7 were splicing mutations, including one
considered as a missense in exon 2 and a nucleotide substi-
tution in intron 3 outside the classical donor and acceptor
splicing sites; Hobson et al. (2002) reportered a 19-bp dele-
tion in intron 3 causing missplicing of PLP1; Hu¨bner et al.
(2005) described a nucleotide exchange (c.762G >T) at the 3¢
border of exon 6 that resulted in partial skipping of exon 6 in
the PLP1 mRNA; Lassuthova´ et al. (2013), finally, recently
described three new PLP1 splicing mutations.
PLP1 encodes proteolipid protein (PLP), a major four-pass
transmembrane protein in CNS myelin, and is abundantly
expressed in oligodendrocytes (Woodward et al., 2008).
The PLP 1 gene undergoes alternative splicing and pro-
duces the PLP protein and a shorter protein isoform DM20,
which lacks 35 amino acids from the intracellular domain.
Two competing 5¢splice sites residing within the 3¢ portion of
exon 3 are responsible for the alternative splicing of the gene
transcript (Nave et al., 1987; Gabern et al., 2007).
Recent work by Regis and colleagues has focused on an
exonic missense mutation c.436C >G in the PLP1 gene of a
patient affected by Pelizaeus-Merzbacher disease (Regis
et al., 2013). This mutation led to introduction of regulatory
motifs that perturb splicing, leading to a loss of the major PLP
transcript. An antisense-based approach was used for in vitro
correction and restoration of PLP transcript in the murine ol-
igodendrocyte precursor cell line Oli-neu transfected with
mutated reporter minigenes (Regis et al., 2013) (Fig. 9). A
PMO was designed to target the mutated region in a co-
transfection experiment of the mutant minigene along with the
PMO in Oli-neu cells. Using real-time PCR the authors esti-
mated the increase of the PLP/(DM20+PLP) mRNA ratio as
58% of the wild-type ratio. It remains to be estimated the PMO
effect at the protein level, and whether the recovered PLP
protein, which bears a mutated amino acid, is functional.
Concluding Remarks
As AONs-induced exon skipping is proving a powerful
tool for the correction of DMD and progress has been made
towards clinical trials, the scientific community is learning
the principles of successful oligonucleotide design and
FIG. 8. Megalencephalic leukoencephalopathy with subcortical cysts type 1 (MLC1). Schematic representation of the
identified MLC1 deep intronic mutation and specific PMO location (Mancini et al., 2012).
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delivery to skeletal and cardiac muscles. Parallel to the de-
velopment of exon skipping strategies for DMD, the ability to
investigate and identify the genetic causes of other genetic
diseases has been improving, thanks to new sequencing
methodologies. The number of identified splicing mutations
and deep intronic mutations inducing inclusion of pseu-
doexons is accordingly increasing.
The time appears therefore ripe for extending exon-
skipping strategies to many other diseases. In this review, we
cover, to the best of our knowledge, the use of antisense
oligonucleotides to correct splicing defects through exon
skipping, with a special focus on diseases affecting the ner-
vous system. The papers presented here for nine different
neurogenetic diseases provide proofs of principle that exon
skipping can become a therapy for many neurogenetic dis-
eases. However, all the reviewed papers show efficacy either
on reporter minigenes in transfected cells or in patient-
derived cells in culture (Table 1). To move this therapeutic
approach towards clinical application, in vivo preclinical
studies will be needed, which will be made possible by the
availability of animal models of these diseases, bearing
splicing mutations. For FTDP-17, for example, two such
mouse models are available: the T279 mouse (Dawson et al.,
2007) that expresses human N279Kmutated tau protein from
a minigene, which allows alternative splicing of exon 10 and
is under the regulation of the human TAU promoter; and the
E10 + 16C >T mouse, which bears a transgenic human tau
minigene with the intronic mutation E10+ 16C >T (Umeda
et al., 2013). Both models show progressive neurodegen-
eration and tau accumulation.
Since the treatment of neurogenetic disorders with AONs
may require life-long repeated dosing, it would be preferable
to be able to administer such agents systemically. AONs,
indeed, have a relatively long half-life and do not elicit im-
munogenic responses.
The principal obstacle that hampers the systemic delivery
of therapeutic AONs to the CNS is the blood-brain barrier
(BBB) (Chen et al., 2012; Wong et al., 2012). Molecules can
only enter the brain interstitial fluid by transport through the
brain capillary endothelial cells. However, modified AONs
are taken up extremely fast in neurons and glial cells with a
long residence, once inside the blood brain barrier (BBB).
It has been demonstrated that AONs with a PS backbone
have a saturable BBB transport system, which allows them to
easily access the CNS when systemically administered
in vivo. A PS 42-mer injected in the tail vein of mice over-
expressing amyloid precursor protein entered the cerebro-
spinal fluid (CSF) and the parenchymal space of the brain;
transport was especially high in the hippocampus (Banks
et al., 2001; Erickson et al., 2012). However, as many studies
indicated lately that BBB is altered in a wide spectrum of
brain diseases, care should be taken when extending studies
on wild-type animals or specific disease models, to other
disease models.
In mdx mice, nanoparticles have been used to deliver
2¢OMe-PS AONs to muscles by intraperitoneal injections
(Rimessi et al., 2009; Ferlini et al., 2010). Notably, the AON
doses needed for exon skipping and dystrophin restoration
were much lower than with 2¢OMe-PS alone. Several studies
have been recently focused at the development of nano-
particles for brain drug delivery (reviewed in Masserini,
2013) in general and for the delivery of nucleic acids in
particular (reviewed in Pe´rez-Martı´nez et al., 2011). It is
likely, therefore, that future attempts to systemic delivery of
exon-skipping AONs to the brain will take advantage of the
knowledge on nanoparticles that is currently accumulating.
Extracellular vesicles in the form of exosomes, the focus of
much ongoing research, might also prove capable of deliv-
ering AONs across the BBB (Lee et al., 2012). Research in
drug delivery to the brain is also attempting transient BBB
opening, via bacterial proteins, ultrasounds, or small mole-
cules (such as mannitol or bradykinin).
Delivering AONs via the nasal passages could provide a
noninvasive way to bypass the BBB and avoid toxicity due to
systemic administration (Dhuria et al., 2010). Small inter-
fering RNAs, for example, have been delivered intranasally
to the olfactory bulbs of mice via the olfactory nerve path-
way, either naked (Renner et al., 2012) or in cell-penetrating
peptide-modified nanomicelles (Kanazawa et al., 2013).
Partially destroying the BBB.
Even if systemic delivery would represent a less invasive
therapeutic protocol, it still has several disadvantages: the
majority ofAONs end up in the liver and kidney for each of the
different AON chemistries (Sazani et al., 2002; Fluiter et al.,
2003; Swayze et al., 2007; Aartsma-Rus and van Ommen,
2009). Moreover, although some AONs have been shown to
cross the BBB, approximately 100-fold higher doses must be
delivered systemically to achieve AONs concentrations simi-
lar to those achieved by intra-CNS delivery (Banks et al.,
2001; Erickson et al., 2012) increasing the risk of toxicity.
Many animal studies have therefore employed alternative
routes of administration (intraparenchimal injections in
specific brain areas, intracerebroventricular injections, in-
trathecal injections), sometimes administering the AONs
FIG. 9. Pelizaeus-Merzbacher disease. Schematic representation of the identified PLP1 gene mutation and specific PMO
location (Regis et al., 2013).
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through the use of micro-osmotic pumps (Smith et al., 2006;
Hua et al., 2010).
In recent years, oligonucleotides have being successfully
employed in preclinical studies on neurodegenerative diseases
and for some diseases are being tested in clinical trials. For the
therapy of Huntington’s disease (HD), AONs that catalyze
RNase H-mediated degradation of huntingtin mRNA were
proven effective by intraparenchymal bolus delivery directly to
the striatum of mice (Carroll et al., 2011) and by transient
infusion into the CSF of symptomatic HD mouse models and
nonhuman primates (Kordasiewicz et al., 2012). For Alzhei-
mer’s disease, AONs directed against the Ab region of amyloid
precursor protein (APP) were injected intracerebroventricular
(Kumar et al., 2000; Banks et al., 2001; Chauhan et al., 2002;
Chauhan et al., 2007; Fiorini et al., 2013), or systemically in the
tail vein (Banks et al., 2001). In amyotrophic lateral sclerosis
(ALS)AONs continuously infused intraventricularly have been
demonstrated to distribute widely throughout the CNS of ro-
dents and primates (Smith et al., 2006; Winer et al., 2013).
Results of a phase 1 clinical trial with an AON against super-
oxide dismutase 1 (SOD1), delivered intrathecally in patients
with SOD1 familial ALS have been recently reported (Miller
et al., 2013). For SMA, AONs have been ICV infused in the
mouse model by means of a micro-osmotic pump and have
been observed to be uptaken from CSF bymotoneurons of both
upper and lower spinal regions (Hua et al., 2011; Passini et al.,
2011). A single ICV injection was sufficient to rescue SMA in
embryonic or neonate mice (Porensky et al., 2012). On these
premises, a phase 1 clinical trial for SMA has been started,
which consists in a single AON intratechal injection (Clin-
icalTrials.gov identifier NCT01494701).
In proceeding toward oligonucleotide-based exon-skip-
ping therapies for neurogenetic diseases, several issues must
be considered. Not only effective AON chemistry and design
should be found, but the chemistry should be such that the
AON can be synthesized easily and cost effectively on at least
gram scale or higher and under good manufacturing practice.
Moreover, the best delivery route should be found for the
specific disease, aiming at the affected part of the CNS or
PNS and keeping in mind that the disease itself could alter the
normal physiology, including the BBB.
Finally, as we are dealing often with rare diseases and with
patient-specific mutations, we are confronted with issues af-
fecting the development and implementation of personalized
medicine and placing new demands upon the regulatory
frameworks that control the licensing ofmedicinal products. For
example, at present, each AON for each specific mutation need
its own approval procedure from the European Medicines
Agency or from the U.S. Food and Drug Administration.
The lessons learned in the delivery of oligonucleotides to
the brain for the cure of the above-mentioned neuromuscular
and neurodegenerative disorders, together with the experi-
ence gained in the successful design of exon-skipping AONs
for the cure of DMD will hopefully make personalized exon-
skipping therapies for several neurogenetic disorders a reality
in the next few years.
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Frontotemporal dementia (FTD) is a neurodegenerative disorder characterized by
degeneration of the fronto temporal lobes and abnormal protein inclusions. It exhibits
a broad clinicopathological spectrum and has been linked to mutations in seven different
genes. We will provide a picture, which connects the products of these genes, albeit
diverse in nature and function, in a network. Despite the paucity of information available
for some of these genes, we believe that RNA processing and post-transcriptional
regulation of gene expression might constitute a common theme in the network. Recent
studies have unraveled the role of mutations affecting the functions of RNA binding
proteins and regulation of microRNAs. This review will combine all the recent findings on
genes involved in the pathogenesis of FTD, highlighting the importance of a common
network of interactions in order to study and decipher the heterogeneous clinical
manifestations associated with FTD. This approach could be helpful for the research
of potential therapeutic strategies.
Keywords: FTD, TDP-43, FUS, progranulin, tau, CHMP2B. C9ORF72
Frontotemporal Dementia
Despite 90% of the human genome being transcribed to RNA, only 1.2% of genomic sequence is
protein-coding, indicating that a huge proportion of non-coding RNAs (ncRNAs) are likely to par-
ticipate in a number of physiological processes in cell types, including neurons (Lander et al., 2001;
Birney et al., 2007; Wilhelm et al., 2008; Clark et al., 2011). The transcribed precursors of messen-
ger RNAs (pre-mRNA) undergo splicing, such that the non-coding introns are removed and exons
are combined variably to produce an RNA that would code for protein (Pandit et al., 2008). The
pre-mRNAs undergoes alternative splicing producing mature messenger RNAs (mRNAs) which
are then expressed in specific tissues and cell types in different stages of development. These
mRNAs then associate with the ribosomal machinery to be translated into proteins in the cyto-
plasm. Non-coding RNAs (among which microRNAs and long non-coding RNAs), might regulate
the translation of specific mRNAs, thereby representing a post-transcriptional mechanism exerting
a fine-tuned control in the production of specific proteins.
microRNAs (miRNAs) are a group of small non-coding RNAs of 21–22 nt with important reg-
ulatory roles on the post-transcriptional expression of target mRNAs (Bartel, 2009; Ghildiyal and
Zamore, 2009). MiRNAs are generating from longer transcripts of different lengths called primary
transcripts (pri-miRNAs), usually transcribed by RNA polymerase II, from intragenic or intergenic
DNA regions (Lee et al., 2004; Garzon et al., 2010). The pri-miRNAs are processed in the nucleus by
the micro-processor complex, formed by an RNase III enzyme, Drosha, and its cofactor DiGeorge
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syndrome critical region in gene eight termed (DGCR8) (Lee
et al., 2003). The process lead to the production of small hairpin
structure of 70–100 nt called precursor miRNAs (pre-miRNAs).
Pre-miRNAs are exported to the cytoplasm through Exportin 5
(Kim, 2004), where they are further processed by an RNase III
nuclease, Dicer to produce RNA duplex (Bernstein et al., 2001;
Grishok et al., 2001; Hutvagner et al., 2001). One strand is loaded
on the RNA-Induced Silencing Complex (RISC) and associated
with Argonaute-2 (Ago2) to interact with the target mRNA. The
miRNA-RISC complex induces mRNA downregulation through
two different ways: mRNA cleavage in case of perfect com-
plementarity between miRNA and target mRNA or translation
inhibition if there is an imperfect binding (Wahid et al., 2010)
(Figure 1). In case of perfect complementarity, Ago2 is the pro-
tein involved in the cleavage of the target mRNA in humans
(Liu et al., 2004). However, in animals, translational repression
is the most frequent way of action for miRNAs (Huntzinger and
Izaurralde, 2011; Pasquinelli, 2012), although the exact process is
still unknown since is not clear if the repression occur at the ini-
tiation step or during the translation process (Wahid et al., 2010).
Even the mechanisms for target regulation played by miRNAs
are still unclear, the target mRNA could be repressed by the pro-
motion of deadenylation, sequestration of miRNAs and target by
stress granules and P-Bodies (Valencia-Sanchez et al., 2006), dis-
ruption of translation initiation or protein degradation caused by
RISC after translation (Tang et al., 2008).
FIGURE 1 | Representation of miRNA biogenesis.
The enormous content of non-coding RNA (ncRNA) in the
cell intrigues its role and function in the cells. LncRNAs are
defined as transcripts longer than 200 nucleotides and lacking
an appreciable open reading frame (usually less than 100 amino
acids). They may be transcribed by RNA polymerase II (RNA Pol
II) or RNAPol III, andmay undergo splicing or comprise of a sin-
gle exon. In contrast to small ncRNAs, lncRNAs tend to be poorly
conserved evolutionarily and regulate gene expression by diverse
mechanisms that are not entirely understood. As a functionally
diverse macromolecule, the biological roles of lncRNAs cannot
be determined solely from their nucleotide sequence, secondary
structures, or genomic locations (Ng et al., 2013).
Recent work has begun to elucidate the roles of some lncR-
NAs, such as architectural function in nuclear paraspeckles
(Sunwoo et al., 2009; Souquere et al., 2010), transcriptional
co-regulators (Feng et al., 2006; Bond et al., 2009), and as
endogenous competing RNAs (ceRNAs) (Cesana et al., 2011;
Tay et al., 2011). LncRNA expression is abundant in cells
of the CNS (Mehler and Mattick, 2007; Mercer et al., 2008)
and recent studies have suggested that lncRNAs play crucial
roles in spatial-temporal control of gene expression in brain
development (Mercer et al., 2008). They have also known to
be involved in brain development, neural differentiation and
maintenance, synaptic plasticity, cognitive function and mem-
ory, and in aging and neurodegenerative disorders (Wu et al.,
2013b).
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Though different mechanisms may play a role in causing
neurodegenerative disorders, recent studies show increasing evi-
dence of abnormalties in RNA processes, highlighting the pos-
sible putative role of RNA in neurodegeneration. An mRNA
gain-of-toxic-function has been proposed for some neurode-
generative diseases (Osborne and Thornton, 2006; O’Rourke
and Swanson, 2009; Todd and Paulson, 2010) whereas other
neurodegenerative disorders are driven through altered or lost
non-coding RNA, RNA splicing and RNA binding activities
(Gallo et al., 2005; Cooper et al., 2009; Lagier-Tourenne et al.,
2010).
Fronto temporal lobar degeneration (FTLD) is the most com-
mon cause of dementia after Alzheimer’s disease. The clinico-
pathological spectrum of FTLD includes frontal and temporal
variants of frontotemporal dementia (FTD), primary progressive
aphasia, semantic dementia, Cortico-basal degeneration (CBD),
progressive supranuclear palsy (PSP), progressive subcortical
gliosis (PSG) and FTD with motor neuron disease (FTD–MND)
(Bugiani, 2007). Moreover, despite Amyotrophic Lateral Sclero-
sis (ALS) and FTD being two different neurodegenerative dis-
orders, they often share genetic, neuropathological and clinical
characteristics; therefore they are considered part of the same
spectrum of diseases (Ling et al., 2013). Frontotemporal demen-
tia symptoms can also be present along with disabling muscle
weakness and osteolytic bone lesions, in IBMPFD1 (Inclusion
body myopathy with early-onset Paget disease with or without
Frontotemporal dementia 1).
It is estimated that one in seven people in the US might
develop a neurodegenerative disorder in their lifetime, with
dementia being one of the leading causes of death in US (Thies
and Bleiler, 2011). Though this broad spectrum of disorders has
been studied based on protein aggregation and research has been
focusing on protein functions and alterations, emerging avenues
in research unravels the role of RNA and RNA processing in
contributing to neurodegeneration (Belzil et al., 2013).
To date, FTD has been linked to mutations in seven different
genes (TARDBP, FUS,MAPT, GRN, VCP, CHMP2B, C9ORF72).
Findings that showed the presence of ubiquitinated protein
TDP-43 in sporadic cases of ALS with FTD further linked these
two diseases (Arai et al., 2006; Neumann et al., 2006). Following
these findings, mutations in the gene coding for the RNA bind-
ing protein TDP-43 were discovered in ALS cases (Kabashi et al.,
2008; Sreedharan et al., 2008; Van Deerlin et al., 2008) and FTD
cases (Borroni et al., 2009; Kovacs et al., 2009).
With the broadening knowledge on the impact of impaired
RNA binding proteins in mediating the disease process, muta-
tions in the fused in sarcoma/translocated in liposarcoma
(FUS/TLS) gene were found to account for an additional 5% of
familial ALS and few rare cases of FTD (Kwiatkowski et al., 2009;
Vance et al., 2009).
TDP-43 and FUS share similar structural and functional prop-
erties with a likely role in multiple steps of RNA processing
and they are both linked to RNA metabolism. The patholog-
ical accumulation of these proteins is observed in over 90%
ALS and 50% FTD patients. These studies also highlight that
errors in RNA processing might be enough to initiate the disease
process.
MAPT mutations were observed in several FTD families with
abnormally phosphorylated tau proteins being isolated from
neuroectoderm cells of patients. Mutations present in the C
terminal repeat domains lead to the inhability of abnormal
tau protein to bind microtubules, thus leading to its instability
and accumulation and causing neuronal degeneration (Bugiani,
2007). FTD with tau inclusions was characterized as a tauopathy
and dubbed FTLD-tau.
However, a different class of patients were found to have had
accumulated ubiquitin and ubiquitin-associated proteins (FTLD-
U). Co-localization of abnormal proteins with ubiquitin in the
nucleus and perikaryon of neuronal cells, indicated the involve-
ment of proteasome dysfunction in the pathology. Analysis of
significant genes on chromosome 17, close to the MAPT locus,
led to the discovery ofmutations inGRN (Baker et al., 2006; Cruts
et al., 2006). GRN is known to be involved in the cell cycle control
and motility.
Studies on an ALS/FTD-affected Scandinavian family (Morita
et al., 2006) and on IBMPFD1 families suggested the possible role
of mutations in chromosome 9 in FTD. The disorder was associ-
ated to mutations in VCP, encoding the valosin-containing pro-
tein essential for ubiquitin-mediated protein degradation (Watts
et al., 2004; Johnson et al., 2010).
Other FTLD mutations are located on chromosome 3 (FTD-
3), in the CHMP2B gene, which encodes for a protein involved
in degradation of surface receptor proteins and formation of
endocytic multivesicular bodies (Skibinski et al., 2005).
Another link between ALS and FTD are the large intronic hex-
anucleotide repeat expansions in the C9ORF72 gene located on
chromosome 9 found in ALS, FTD, or ALS/FTD cases (DeJesus-
Hernandez et al., 2011; Renton et al., 2011; Gijselinck et al.,
2012).
This review will focus on the single genes known to have
implications in FTD and their altered functions in the diseased
state. The ultimate aim is to explorepossible functional connec-
tions between these seven diverse genes and describe a network in
which a possible common thread might be represented through
RNA mediated processes.
TARDBP (TDP 43)
Human TDP-43 was discovered in 1995 in a screen for tran-
scriptional repressors of the trans-active response (TAR) DNA
binding element of the HIV-1 virus, and thus the gene is named
TARDNA Binding Protein (TARDBP) (Ou et al., 1995). TARDBP
is composed of six exons and maps on chromosome 1p36.22.
The protein TARDBP produces is being labeled as TDP-43
due to its molecular weight of 43KDa (Neumann et al., 2006).
TARDBP is ubiquitously expressed in various human tissues
(Table 1) including brain and spinal cord (Wang et al., 2008a). To
date, 34 different TDP-43 mutations have been discovered in 131
different FTD and ALS families (Cruts et al., 2012). Pathogenic
mutations observed in TDP-43 are highlighted in Table 2.
Structure
TDP-43 is a 414 amino acids protein (Figure 2A) containing two
RNA recognition motifs (RRMs), a glycine-rich low sequence
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TABLE 1 | Protein localisation of different genes associated to FTD.
Gene Genomic
location
Protein Tissue localization in the
brain
Cell type Subcellular localization
TARDBP Chromosome 1
p36.22
TDP-43 Cerebral cortex, hippocampus,
lateral ventricle, cerebellum
and spinal cord
Endothelial, neuronal, glial cells,
neuropil and cell in granular and
molecular layer, Purkinje cells
Nucleus and cytoplasm
FUS Chromosome 16
p11.2
FUS Cerebral cortex, hippocampus,
lateral ventricle and cerebellum
Endothelial, neuronal, glial cells,
neuropil and cell in granular and
molecular layer, Purkinje cells
Nucleus and cytoplasm
MAPT Chromosome 17
q21.3
Tau Cerebral cortex, hippocampus,
lateral ventricle and cerebellum
Neuronal, glial cells, neuropil and cell
in granular and molecular layer,
Purkinje cells
Cytoskeleton, cytoplasm, nucleus
and plasma membrane
GRN Chromosome 17
q21.31
Progranulin Cerebral cortex, hippocampus,
lateral ventricle and cerebellum
Neuronal, glial, endothelial cells and
cell in granular layer
Vesicles, endoplasmic reticulum,
golgi, extracellular space
VCP Chromosome 9
p13.3
VCP Cerebral cortex, hippocampus,
lateral ventricle and cerebellum
Endothelial, neuronal, neuropil, glial
cells and cell in granular and
molecular layer, Purkinje cells
Endoplasmic reticulum, nucleus,
cytoplasm
CHMP2B Chromosome 3
p11.2
CHMP2B Lateral ventricle Neuronal cells Cytosol, endosome, nucleus,
mitochondria
C9ORF72 Chromosome 9
p21.2
C9ORF72 Cerebral cortex, hippocampus
and lateral ventricle
Endothelial, neuropil, glial cells Cytoplasm, nucleus, cytoskeleton
The information provided are derived through integration of two different databases (http://www.genecards.org/ and http://www.proteinatlas.org/) and literature reported in the text.
TABLE 2 | List of mutations in TARDBP and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
FTD g.6142C>T p.N12 Pathogenic Luquin et al., 2009
FTD g.9253C>T A90V Pathogenic Sreedharan et al., 2008
FTD/PSP g.14575A>G K263E Pathogenic Kovacs et al., 2009
ALS/FTD g.14588A>G N267S Pathogenic Corrado et al., 2009
FTD g.14671G>A G295S Pathogenic Benajiba et al., 2009
FTD g.14932G>A A382T Pathogenic Chiò et al., 2010
FTD, Frontotemporal Dementia; PSP, Progressive supranuclear palsy.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
complexity prion-like domain (Wang et al., 2013). A nuclear
localization signal motif (NLS) and a nuclear export signal motif
(NES) allow TDP-43 to shuttle between the nucleus and the
cytosol (Buratti and Baralle, 2001).
Localization and Function
Though TDP-43 expression is seen in the nucleus with low
cytosolic localization (Ayala et al., 2005), there is a significant
cytosolic TDP-43 expression especially in large motor neurons
where TDP-43 has an additional role in mRNA transport as a
neuronal activity responsive factor in dendrites thus promoting
dendritic branching (Wang et al., 2008a; Barmada et al., 2010;
Kabashi et al., 2010).
TDP-43 was found to be accumulated in cytoplasmic stress
granules due to oxidative stress (Colombrita et al., 2009).
Stress granules are aggregations, formed after cell insults such
as oxidative stress or heat shock that temporarily store non-
translating mRNAs, small ribosome subunits, RNA-binding pro-
teins and translation initiation factors (Buchan and Parker, 2009).
Formation of stress granules protects the cells, allowing a trans-
lational block and initiation of repair processes (Anderson and
Kedersha, 2008).
Upregulation of nuclear TDP-43 has also been shown to pro-
vide protection to primary neurons against glutamate induced
excitotoxicity (Zheng et al., 2012). These findings also sug-
gest that TDP-43 regulates synaptic plasticity by governing
the transport and splicing of synaptic mRNAs. In a recent
review, Belzil and co-authors postulate that altered TDP-43
could lead to impaired hippocampal plasticity and render
neurons more vulnerable to cellular stressors (Belzil et al.,
2013).
TDP-43 is highly conserved from human to C. elegans,
both in the RNA binding motifs and in the carboxy-terminal
portion (Ayala et al., 2005). In situ hybridization studies
showed that TDP-43 is expressed very early in the brain
and spinal cord of zebrafish (Shankaran et al., 2008) sug-
gesting that it plays an important role in nervous system
development.
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FIGURE 2 | (A) TAR DNA-binding protein 43 (TDP-43) contains two
RNA-recognition motifs (RRM1 and RRM2), a carboxy-terminal glycine-rich
domain, a bipartite nuclear localization signal (NLS), and a nuclear export
signal (NES). Mutations are mainly located in the glycine-rich domain. (B) The
network of interactions of TDP-43 with proteins and RNAs. Green arrows
indicate binding interactions or processes that result in activation or increased
expression. Red arrows indicate binding interactions or processes that result
in inhibition of activity or reduced expression. Black arrows indicate binding
interactions or processes whose result can be either positive or negative.
Dashed arrows indicated indirect processes. Symbols as in Legend.
lncRNAs, long non-coding RNAs; IGF-1, insulin-like growth factor 1; HDAC4,
histone deacetylase 4; NRXN1, neurexin 1; TDP-43, TAR DNA binding
protein; FUS, fused in sarcoma; GRN, progranulin; NEAT1, nuclear-enriched
autosomal transcript 1; NEAT2, nuclear-enriched autosomal transcript 1.
Implications of RNA in Pathogenesis
Many studies have linked TDP-43 to neurodegenerative dis-
orders, including ALS and FTLD (Neumann et al., 2006;
Lagier-Tourenne et al., 2010; Lee et al., 2012). Janssens and
Van Broeckhoven (2013) have highlighted the increasing evi-
dence of role of impaired RNA metabolism in TDP-43-driven
neurodegeneration.
TARDBP primary transcript undergoes alternative splicing to
produce eleven different mRNAs including the one encoding
TDP-43. Seven of these are shorter transcripts which are gener-
ated through the seven different splicing reactions within exon
6 of TARDBP pre-mRNA using a combination of four different
5′ donor sites and four different 3′ acceptor sites (Wang et al.,
2004a).
In few ALS cases a smaller TDP-43 isoform (∼28KDa) was
observed additionally to the 43 kDa isoform, lacking exon 3 and
a significant portion of exon 6-encoded amino acids (Strong et al.,
2007). This smaller isoform lacks the carboxy-terminal portion of
the protein and is thought to be associated with disease pathology
(Neumann et al., 2006).
Converging lines of evidence in research suggest that TDP-
43 regulates RNA in various ways (Figure 2B; Lee et al., 2012).
The RRM1 domain of TDP-43 is critical for its binding to single-
stranded RNA (Ou et al., 1995; Buratti and Baralle, 2001; Wang
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et al., 2004a; Ayala et al., 2005). TDP-43 preferentially binds
UG repeats, but is also found to be associated with non-UG
repeat sequences (Buratti and Baralle, 2001; Ayala et al., 2005;
Polymenidou et al., 2011; Tollervey et al., 2011).
Pathological TDP-43 aggregates are ubiquitinated and phos-
phorylated. Under normal conditions, these forms are not readily
detectable in brain tissues, thus making them disease-specific.
Over-expression of full-length TDP-43 in a variety of transgenic
animal models lead to the presence of phosphorylated TDP-43
aggregates similar to ALS and FTD cases (Wegorzewska et al.,
2009; Shan et al., 2010; Stallings et al., 2010; Wils et al., 2010; Xu
et al., 2010a). The phosphorylated form has a longer half-life than
the non-phosphorylated form thus leading to accumulation of
phosphorylated proteins. Despite the progress toward describing
the full spectrum of TDP-43 pathology in human neurodegen-
erative diseases, the fundamental question of whether TDP-43
dysfunction mediates neuro-degeneration through gain of toxic
function or a loss of normal function remains unanswered (Lee
et al., 2012).
Upon depletion of TDP-43 from adult mouse brain with anti-
sense oligonucleotides, levels of 601 mRNAs, including FUS,
GRN and other transcripts involved in neurodegeneration, were
altered, along with 965 varied splicing events. RNAs depleted by
the reduction of TDP-43 were coded by genes with long introns
(Polymenidou et al., 2011).
In-vivo searches for TDP-43 RNA targets in mouse
(Polymenidou et al., 2011), human brain (Tollervey et al.,
2011), rat cortical neurons (Sephton et al., 2011), a mouse
NSC-34 cell line (Colombrita et al., 2012), and a human neu-
roblastoma cell line (Xiao et al., 2011) revealed that there are
more than 6000 RNA targets which constitutes to about 30% of
total transcriptome. TDP-43 was found to preferentially bind to
introns (including deep intronic sites), 3′ untranslated regions
(UTRs), and non-coding RNAs (Polymenidou et al., 2011;
Tollervey et al., 2011), indicating a multifaceted role in RNA
maturation. TDP-43 can influence splice site selection by binding
to exon-intron junctions and intronic regions, mRNA stability
and transport by binding on 3′UTRs. A substantial amount of
mRNAs regulated by TDP-43 at splicing levels were involved
in neuronal development or in neurological diseases (Tollervey
et al., 2011). Additional data show that when TDP-43 is reduced
the levels of several other mRNAs increase. As the affected
mRNAs include more than 300 mRNAs without TDP-43 binding
sites, these observation point toward an indirect mechanism
(Polymenidou et al., 2011) of modulation.
i-CLIP experiments have also shown that TDP-43 binds to
long ncRNAs (lncRNAs), including nuclear-enriched autosomal
transcript 1 (NEAT1) and metastasis-associated lung adenocar-
cinoma transcript 1 (MALAT1, also called NEAT 2) (Tollervey
et al., 2011). Expression of both lncRNAs is elevated in FTD
patients with TDP-43 inclusions, thus correlating with their
increased association with TDP-43 (Tollervey et al., 2011).
The binding of TDP-43 to small (<200 base) ncRNAs and
miRNAs remains largely unexplored. However, the association of
TDP-43 with Droshamicroprocessor (Ling et al., 2010) and Dicer
complexes (Freibaum et al., 2011; Kawahara and Mieda-Sato,
2012) provides a suggestive role of TDP-43 involvement in
miRNA biogenesis. Indeed, let-7b miRNA is downregulated,
whereas miR-663 is upregulated upon reduction of TDP-43
(Buratti et al., 2010). Di Carlo and collegues demonstrated that
TDP-43 directly interacts with Drosha and controls its stability at
different levels. Moreover, TDP-43 is also involved in the Drosha
substrate recognition as in the regulation mediated by Drosha of
Neurogenin 2, an important andmaster gene in neurogenesis (Di
Carlo et al., 2013).
Fan et al. (2014) have performed CLIP-seq analysis to exam-
ine the small RNAs (pri-miRNAs, miRNAs, and piRNAs) bound
to TDP-43 and found that a novel miRNA (miR-NID1), which
is processed from the intron five of human neurexin 1 gene
(NRXN1), interacts with TDP-43 and represses expression of
NRXN1. Neurexins are cellular proteins that function as cell
adhesion molecules and receptors in the vertebrate nervous sys-
tem, involved in synaptic development including calcium sig-
naling, heterogeneous cell-to-cell adhesion and synaptogenesis
(Craig et al., 2006; Bottos et al., 2011) Disruptions or mutations
of NRXN1 have been reported to associate with autistic spectrum
disorder (ASD), mental retardation, and schizophrenia (Reichelt
et al., 2012).
Recent studies by King and colleagues identified a physical
interaction between TDP-43 and miR-1 family which is known
to be involved in smooth muscle gene repression in heart and
an opposing myogenic differentiation (King et al., 2014). TDP-
43 overexpression in skeletal muscle led to decrease of miR-1
and increased protein levels of the miR-1 family targets, IGF-1
and HDAC4. These results demonstrate that TDP-43 could influ-
ence miRNA regulation through a physical interaction by limit-
ing their bioavailability for RISC loading and offer a mechanism
by which mature miRNAs can be differentially regulated.
The expression of TDP-43 is tightly autoregulated through
a complex interplay between transcription, splicing, and 3′
end processing (Avendaño-Vázquez et al., 2012): TDP-43 over-
expression in humans and mice leads to activation of a 3′ UTR
intron which results in excision of proximal polyA site (PAS)
which in turn activates a cryptic PAS and prevents TDP-43
expression through a nuclear retention mechanism.
The above mentioned studies have highlighted that TDP-43 is
linked to various mRNAs and non-coding RNAs, in a neuronal
context wherein it mediates effects through splicing or interac-
tion with Drosha and Dicer complexes. It is also involved in its
autoregulation mediated at the RNA level.
Additionally, TDP 43 is known to interact with MATR3, a
DNA RNA binding protein. Their interaction was confirmed to
be RNA based. Mutations in this gene have been linked to cases
of ALS. The authors further report that the phenotype observed
in patients with MATR3 was a combination of those observed in
cases of ALS and myopathy. Clinical symptoms were similar to
patients with VCP mutations (Johnson et al., 2014).
FUS
FUS, (fused in sarcoma, also called TLS: translocated in liposar-
coma) belongs to the TET family of RNA binding proteins
involved in many different cellular processes (Bertolotti et al.,
1996; Law et al., 2006; Tan and Manley, 2009). FUS, located
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on chromosome 16 at locus p11.2, encodes a multifunctional
protein able to bind and interact with single stranded RNA and
double stranded DNA, participating in different aspects of RNA
metabolism (Shelkovnikova et al., 2014).
Structure
FUS is characterized by different domains (Figure 3A): a
N-terminal domain with transcriptional activating properties
mainly composed of glutamine, glycine, serine, and tyrosine
residues (Law et al., 2006), a glycine rich region, a RNA binding
domain, and a highly conserved C-terminus capable of binding
DNA, RNA and splicing factors (Law et al., 2006).
Localization and Function
FUS is mainly localized in the nucleus (Colombrita et al., 2009;
Van Blitterswijk and Landers, 2010; Kawahara and Mieda-Sato,
2012) but it is also actively implicated in other cellular processes
that occur in the cytoplasm such as mRNA transport, mRNA sta-
bility and translation (Buratti and Baralle, 2010; Colombrita et al.,
2011). Indeed FUS was reported to shuttle between the nucleus
and the cytoplasm, exporting to the cytoplasm spliced mRNAs in
ribonucleoprotein complexes (Zinszner et al., 1997). Particularly,
upon stimulation in hippocampal neurons FUS was reported
to accumulate in the spines of mature dendrites, where local
translation occurred (Fujii and Takumi, 2005). FUS immunore-
activity was also observed in dendritic spines in mature primary
cultures and in adult hippocampus in situ (Belly et al., 2005;
Table 1).
The C-terminal part of FUS encodes for a non-classic nuclear
localization signal (Figure 3A; Iko et al., 2004) that is necessary
for nuclear import, as it was demonstrated through the genera-
tion of deletion mutant lacking 13 amino acids in the C-terminal
part of FUS(Dormann et al., 2010).
Several papers reported that mutations and aberrations of FUS
are linked to the pathogenesis of frontotemporal degeneration
(FTD) as well as familial and sporadic ALS (Kwiatkowski et al.,
2009; Vance et al., 2009), as reported in Table 3. Moreover, FUS
accumulates in inclusions in the cytoplasm of autopsied spinal
cords and brains of sporadic and familial ALS and FTD. FUS
inclusions are not only observed in presence of FUS mutations,
as they were found in patients with different or unknown genetic
defects such as sporadic ALS, ALS/dementia or FTLD (with or
without progranulin mutations), FUS or TDP43mutation-linked
familial ALS, SOD1-negative familial ALS. These inclusions were
also positive for TDP43/ubiquitin and p62 (Deng et al., 2010).
ALS/FTD patients show mutations mainly in the Glycine
rich region and C-terminal part (Lagier-Tourenne et al., 2010).
The mechanism underlying the pathogenesis of FUS mutations
was related to FUS nucleus/cytoplasmic imbalance since ALS
mutations increase its localization in the cytoplasm, observed
through immunostaining of FUS in postmortem ALS brain sam-
ples (Kwiatkowski et al., 2009), or through the analysis in neu-
roblastoma cell lines of the subcellular localization of recombi-
nant mutant FUS fused either to green fluorescent protein (GFP)
(Kwiatkowski et al., 2009; Morlando et al., 2012), an N-terminal
hemagglutinin (HA) tag (Vance et al., 2009), a C-terminal V5-His
tag, or an N-terminal myc tag in HeLa (Ito et al., 2011).
Both the loss of FUS nuclear function and the potential gain of
toxic effect by FUS in the cytoplasm could explain pathogenesis
(Shelkovnikova et al., 2014).
Very few studies so far reported FTD cases associated with
FUSmutations. The first analysis of FUS in FTD patients showed
a novel missense mutation in the glycine-rich region of FUS, pre-
dicted to be pathogenic by in silico analysis (Van Langenhove
et al., 2010). Subsequently another study found novel missense
mutations in patients with familial ALS with features of fron-
totemporal dementia (FALS/FTD) and one with familial ALS
with parkinsonism and dementia (FALS/PD/DE) (Yan et al.,
2010). Recently, another study found two novel heterozygous
missense mutations in FUS in patients with behavioral variant
FTD (bvFTD), however the pathogenicity of these mutations
needs to be further investigated in other screening (Huey et al.,
2012).
FUS has been reported to co-localize with TDP-43 in nuclear
complexes (Kim et al., 2010b; Ling et al., 2010) and in larger
cytoplasmic complexes (Kim et al., 2010b). Purified FUS has
also been reported to interact with purified His-tagged TDP-
43 in vitro in an RNA-independent manner, associated to the
C-terminal region of TDP-43 (Kim et al., 2010b). These ubiq-
uitously expressed binding proteins seem to have similar and
complementary functions.
Only the mutant form of FUS was found in stress granules
in reponse to translational arrest (Bosco et al., 2010). FUS and
TDP-43 were observed to co-localize in cytoplasmic aggregations
of ALS/FTLD-affected neurons (Da Cruz and Cleveland, 2011).
Dormann and colleagues found stress granule markers such as
PABP-1 and eIF4G co-deposited with FUS inclusions in sections
of post-mortem brain and spinal cord tissue from familial ALS-
FUS and sporadic FTDLD-U. On the contrary, TDP inclusions
did not show any co-localization with stress granules proteins in
HeLa transiently transfected with the mutated form of FUS, after
heat shock for 1 h (Dormann et al., 2010). Another study reported
that ubiquitin-positive inclusions in frozen post-mortem tissue
from FTLD-TDP patients were not stained with anti-FUS anti-
bodies (Neumann et al., 2009b), therefore FUS and TDP-43 are
not always found in the same inclusions or aggregates.
The relation between FUS and TDP-43 is reported as a deli-
cate equilibrium, where small alteration on their relative quantity
and presence in nucleus/cytoplasm could very likely cause seri-
ous problem over a long period (Colombrita et al., 2012), which
might be an accumulation of events due to an alteration of their
targetome.
Implications of RNA in Pathogenesis
FUS is involved in pre-mRNA splicing (Figure 3B), by inter-
acting with splicing factors such as SRm160, PTB, and ser-
ine/arginine rich proteins (SR proteins) (Yang et al., 1998; Meiss-
ner et al., 2003). In addition the recent sequencing approaches
applied to clarify the function and identify the targets of FUS
reinforced its fundamental role in splicing (Colombrita et al.,
2012) by revealing its binding to intronic sequences or to splice
site acceptors.
Similarly to many other splicing factors, FUS can bind
the C-terminal domain of RNA polymerase II and prevent
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FIGURE 3 | (A) Schematic representation of the functional domains in
FUS/TLS. FUS contains a N-terminal part enriched in glutamine, glycine,
serine and tyrosine residues (QGSY region), a glycine-rich region, a
nuclear export signal (NES), an RNA recognition motif (RRM), repeats of
arginine, glycine, glycine (RGG), a zinc finger motif (ZNF), and a
C-terminal nuclear localization signal (NLS). Most of the mutation are
localized in the glycine rich region and in the last 17 amino acids of the
NLS part. (B) The network of interactions of FUS with proteins and
RNAs. Green arrows indicate binding interactions or processes that result
in activation or increased expression. Red arrows indicate binding
interactions or processes that result in inhibition of activity or reduced
expression. Black arrows indicate binding interactions or processes
whose result can be either positive or negative. Dashed arrows indicated
indirect processes. Symbols as in Legend. lncRNAs, long non-coding
RNAs; IGF-1, insulin-like growth factor 1; HDAC4, histone deacetylase 4;
NRXN1, neurexin 1; TDP-43, TAR DNA binding protein; FUS, fused in
sarcoma; MAPT, microtubule-associated protein tau; NEAT1,
nuclear-enriched autosomal transcript 1; CCND1, G1/S-specific cyclin-D1;
CBP, CREB-binding protein; p300, Histone acetyltransferase p300; PolII
CTD, Carboxy-terminal Domain of the RNA polymerase II.
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TABLE 3 | List of mutations in FUS and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
FTD g.4961A>G M254V Unclear Van Langenhove et al., 2010
bvFTD g.31183985C>T P106L Unclear Huey et al., 2012
ALS/FTD g.31185031G>A G206S Unclear Yan et al., 2010
FALS/PD/DE g.31191418C>T R521C Unclear Yan et al., 2010
ALS/FTD g.31191419G>A R521H Pathogenic Broustal et al., 2010
ALS, Amyotrophic lateral sclerosis; FTD, Frontotemporal Dementia; bv FTD, behavioral variant Frontotemporal Dementia; FALS, Familial Amyotrophic lateral sclerosis; PD, Parkinson’s
disease; DE, Dementia.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
the premature hyperphosphorylation of Ser2 in the C-terminal
domain of RNA polymerase II. Moreover the lack of FUS leads to
an accumulation of RNA polymerase II at the transcription start
site with a shift toward abundance of mRNA isoforms with early
polyadenylation (Schwartz et al., 2012).
FUS can bind to the promoter antisense strand transcript of
some genes such as Ptprn2, Xrn1, Gak, or Glt1d1 and this interac-
tion downregulates the transcription of the coding sense strand,
but this effect seems to be specific for some genes enriched with
GO terms connected to the reproductive process(Ishigaki et al.,
2012).
As FUS was shown to regulate RNA polymerase II at many
more gene promoters than the genes reported for splicing defects,
its role on transcription could be a separated function in addi-
tion to the regulation on splicing (Schwartz et al., 2012). How-
ever, a small proportion of FUS target regions is localized in
exonic sequences and in the 3′UTRs (Hoell et al., 2011), suggest-
ing another potential role, such as the transport of mRNAs or
the control of mRNA stability and translation (Fujii et al., 2005;
Fujii and Takumi, 2005). A model was suggested, in which FUS
is released from actin filaments, when cytoskeletal organization
collapses, becoming free to be linked to the mRNA that is trans-
ported to the local translational machinery in the spines (Fujii
and Takumi, 2005).
Recent techniques, like HITS-CLIP or RIP-CHIP were also
used to identify FUS binding motif, but all the studies lead to the
common assumption that FUS binds to specific secondary struc-
tures on its RNA targets and a primary sequences analysis is not
sufficient (Colombrita et al., 2012; Ishigaki et al., 2012).
Interestingly, silencing of FUS was reported to alter splicing
events in genes, such as MAPT, that have an important neu-
ronal function (Ishigaki et al., 2012). This finding leads an unex-
pected connection between these two genes, both involved in the
pathogenesis of FTD. In particular, FUS was shown to help the
skipping of MAPT exon 10 in primary cortical neurons (Ishi-
gaki et al., 2012). The alternative splicing of MAPT exon 10 is
known to have a causative role in FTD as discussed later (MAPT
paragraph).
FUS is also involved inmicroRNA biogenesis (Morlando et al.,
2012), specifically interacting with pri-miRNAs and Drosha, and
helping the recruitment of Drosha for the correct miRNA pro-
cessing in neuronal cells. Several miRNAs like miR-9, miR-
132, and miR-125b whose biogenesis is controlled by FUSare
important for neuronal functions, neuronal differentiation, and
synaptogenesis (Morlando et al., 2012). Additionally miR-9 and
miR-132 have also been shown to control neurite extension and
branching through downregulation of Foxp2 (Forkhead box pro-
tein P2) (Clovis et al., 2012) Moreover this role of FUS seems
to be prominent in neuronal cells compared to non-neuronal
cells, such as HeLa cells, in which the proportion of miRNAs
affected by FUS knockdown was lower. Indeed the mutations
known to induce a cytoplasmic delocalization of FUS would
impede its nuclear role as pri-miRNA processor. Though the
balance of nuclear and cytoplasmic FUS seems necessary, the
sole role of nuclear FUS should not be neglected and further
investigations would be needed to clarify its biological func-
tion within this cell compartment. Recently, the same labora-
tory demonstrated the presence of a regulatory loop in which
FUS can enhance the expression of miR-141 and miR-200a,
which in turn regulate FUS, through a binding on its 3′UTR.
This pathway seems to be affected in the presence of one
mutation found in two ALS patients (Dini Modigliani et al.,
2014).
FUS is also reported to bind lncRNAs. The binding to
lncRNA CCND1 induces an allosteric change in FUS, thus in
turn permits its interaction with CBP/p300. As FUS represses
CBP/p300-mediated transcription by inhibiting their histone
acetyltransferase (HAT) functions (Wang et al., 2008a), in the
presence of ncRNA CCDN1, CBP/p300-mediated transcription
is repressed.
The nuclear-enriched abundant transcript 1 (NEAT1) pro-
duces two types of lncRNAs from the same promoter NEAT1_1
and NEAT1_2 (Nishimoto et al., 2013). FUS was shown to
bind NEAT1_2, known to assemble and organize the core pro-
teins of paraspeckles (Wang et al., 2008a; Hoell et al., 2011;
Lagier-Tourenne et al., 2012), which represent a storage for
the rapid release of RNAs during stress condition or a nuclear
retention of long hyperedited transcripts (Prasanth et al., 2005;
Chen and Carmichael, 2009). According to observations and data
obtained from cultured cells, transgenic mice and human post-
mortem tissue, paraspeckles represents an important protective
cell mechanism during stress conditions (Nakagawa et al., 2011;
Nakagawa and Hirose, 2012; Shelkovnikova et al., 2014).
Paraspeckels are present in almost all the cultured cells (Fox
and Lamond, 2010), but in normal tissues are found only in cells
that contain high levels of NEAT1_2 RNA and coherently, in
neurons where NEAT1 is express at low levels, paraspeckles are
not observed (Nakagawa et al., 2011).
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The presence of FUS in paraspeckles was confirmed in differ-
ent cell lines by three studies (Naganuma et al., 2012; Nishimoto
et al., 2013; Shelkovnikova et al., 2014) Moreover, NEAT1 was
shown through PAR-CLIP to be a target of both WT and mutant
FUS (Hoell et al., 2011).
Paraspeckles are found in spinal motoneurons of patients at
early stage of ALS. The possibility that aging induces an increase
in the level of NEAT1_2 was ruled out due to the fact that
human control cases were older that ALS cases of an average of
10 years. However, the process that induces an up-regulation
of NEAT1_2 lncRNA during the early phases of ALS is still
unknown (Nishimoto et al., 2013). Overall FUS seems to play a
key role on the regulation of RNA at different levels, acting on
transcription, splicing, transport, and stability of mRNA with a
particular function in microRNA biogenesis and interaction with
non-coding RNAs.
MAPT (Tau)
MAPT (microtubule associated protein) encodes for protein Tau
and is located on chromosome 17q21.3. The gene, which is
150 kb-long, contains 16 exons, out of which 11 are expressed in
CNS (Wolfe, 2012).
Structure
The protein consists of a projection domain, including an acidic
and a proline-rich region, which interacts with cytoskeletal ele-
ments (Figure 4A). The N-terminal part is involved in sig-
nal transduction pathways by interacting with proteins such as
PLC-γ and Src-kinases. The C-terminal part, referred to as the
microtubule binding domain, regulates the rate of microtubules
polymerization and is involved in binding with functional pro-
teins such as protein phosphatase 2A (PP2A) or presenilin 1
(PS1) (Luna-Muñoz et al., 2013).
Localization and Function
Tau is a microtubule-associated protein which is found in abun-
dance in the axons of Central nervous system (CNS) and Periph-
eral nervous system (PNS) (Binder et al., 1985; Couchie et al.,
1992; Table 1). It is also observed in astrocytes and oligoden-
drocytes in the CNS. The tau pre-mRNA undergoes alternative
splicing at exons 2, 3, and 10 to give six different possible iso-
forms. Inclusion of exon 10 generates 4-repeat or 4R tau, while
exclusion forms 3-repeat or 3R tau. In neurons this ratio is con-
trolled throughout development, emphasizing the importance of
this balance for neuronal functions.
Implications of RNA in Pathogenesis
In FTD populations, MAPT mutation frequency ranges from 8
to 50%. To date, 44 different MAPT mutations, either mis-sense
or splice mutations or both, have been discovered in 138 dif-
ferent families (Cruts et al., 2012). The list of pathogenic muta-
tions observed inMAPT are reported in Table 4). Most missense
mutations alter ability of tau to bind to microtubules, thus lead-
ing to the formation of inclusion in neurons and glia, called
neurofibrillary tangles (NFT) (Lee et al., 2005).
About half of the mutations inMAPT, however, are associated
with alteration of splicing of exon 10 and increase the ratio of 4R
to 3R. The mutations near exon 10 5′splice site enhance inclusion
of exon 10 either by altering the linear cis-splicing elements or by
FIGURE 4 | (A) Schematic representation of the functional domains of the
largest tau isoform (441 amino acids 2N4R isoform). The N-terminal
projection domain, including an acidic and a proline-rich region, interacts
with cytoskeletal elements. The N-terminal part is also involved in signal
transduction pathways by interacting with proteins such as PLC-γ and
Src-kinases. The C-terminal part, also known as the microtubule-binding
domain, regulates the rate of microtubules polymerization and is involved in
binding with proteins such as protein phosphatase 2A (PP2A) or presenilin
1(PS1). (B) Schematic representation of the progranulin structure encoded
by the major human transcript containing all the 13 exons. The lettered
boxes on the progranulin scheme represent the individual granulin domains
containing cystein-rich motifs.
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TABLE 4 | List of mutations in MAPT and their characteristic phenotypes.
Subtypes of dementia Mutation Change in amino acid Type References
FTD g.75756G>A R5H Pathogenic Hayashi et al., 2002
FTD g.110018A>C K592T Pathogenic Rizzini et al., 2000
FTD g.110026A>G I595V Pathogenic Grover et al., 2003
FTD g.110044C>G L601V Pathogenic Kobayashi et al., 2003
FTD g.110063G>T G607V Pathogenic Schenk, 1959
FTD g.110065G>A G608R Pathogenic Van der Zee et al., 2006
FTD g.123725T>G N614K Pathogenic Wszolek et al., 1992
FTD g.123729_123731delAAG DeltaK616 (alias 1K280;1K281) Unclear Rizzu et al., 1999
FTD g.123740T>C L619 Pathogenic D’Souza et al., 1999
FTD g.123774A>C N631H Pathogenic Iseki et al., 2001
FTD g.123776T>C N631 Pathogenic Brown et al., 1996
FTD g.123789C>A P636T Pathogenic Lladó et al., 2007
FTD g.123789C>T P636S Pathogenic Bugiani et al., 1999
FTD g.123790C>T P636L Pathogenic Hutton et al., 1998
FTD g.123802G>A S640N Pathogenic Iijima et al., 1999
FTD g.123802G>T S640I Pathogenic Kovacs et al., 2008
FTD g.123803T>C S640 Pathogenic Spillantini and Goedert, 2000
FTD/PSP g.123806G>A Intronic Pathogenic Spillantini et al., 1997
FTD g.123814T>C Intronic Pathogenic Miyamoto et al., 2001
FTD g.123815C>T Intronic Pathogenic Takamatsu et al., 1998
FTD g.123816A>G Intronic Pathogenic Hutton et al., 1998
FTD g.123817C>T Intronic Pathogenic Lynch et al., 1994
FTD g.123819C>T Intronic Pathogenic Lanska et al., 1994
FTD g.123822C>G Intronic Pathogenic Stanford et al., 2003
FTD g.127672T>G L650R Pathogenic Rosso et al., 2003
FTD g.127673G>A L315 Pathogenic (Bird, 2005, Personal
Communication)
FTD g.127678A>T K652M Pathogenic Zarranz et al., 2005
FTD/PD/MND g.127687C>T S655F Pathogenic Rosso et al., 2002
FTD g.132033G>A G670S Pathogenic Spina et al., 2007
FTD g.132034G>T G670V Pathogenic Neumann et al., 2005
FTD g.137420G>A G389R Pathogenic Pickering-Brown et al., 2000
FTD g.137420G>C G389R Pathogenic Murrell et al., 1999
FTD g.137471C>T R741W Pathogenic Dickson, 1997
FTD g.137525C>A Q424K Pathogenic (Brice, 2005, Personal
Communication)
FTD g.137535C>T T762M Pathogenic Giaccone et al., 2004
bvFTD c.163G>A G55R Pathogenic Iyer et al., 2013
FTD c.363T>C V363A Pathogenic Rossi et al., 2014
FTD c.363C>A V363I Pathogenic Rossi et al., 2014
FTD c.454G>A A152T Pathogenic Kara et al., 2012
FTD c.530A>T D177V Unclear Kim et al., 2014
FTD c.853A > C S285R Pathogenic Ogaki et al., 2013
FTD c.892 A>G K298E Pathogenic Iovino et al., 2014
FTD c.1090C>T P364S Pathogenic Rossi et al., 2012
FTD c.1096G>A G366R Pathogenic Rossi et al., 2012
FTD c.1228A>C N410H Pathogenic Kouri et al., 2014
FTD c.1381-74G > A Intronic Pathogenic Kim et al., 2010a
FTD c.1908G > A P636P Pathogenic Kim et al., 2010a
FTD c.1815G > A P605P Pathogenic Kim et al., 2010a
FTD c.1828-47C > A Intronic Pathogenic Kim et al., 2010a
FTD c.2002+90G > A Intronic Pathogenic Kim et al., 2010a
(Continued)
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TABLE 4 | Continued
Subtypes of dementia Mutation Change in amino acid Type References
FTD c.2092G>A V363I Pathogenic Bessi et al., 2010
FTD IVS10+4A>C Intronic Pathogenic Anfossi et al., 2011
FTD IVS9-15T>C Intronic Pathogenic Anfossi et al., 2011
FTD g.132037A>G Q336R Pathogenic Pickering-Brown et al., 2004
FTD, Frontotemporal Dementia; bv FTD, behavioral variant frontotemporal Dementia.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
destabilizing a stem-loop structure at the exon-intron junction
(D’Souza et al., 1999; Grover et al., 1999; Spillantini and Goedert,
2013). This stem-loop arises as a result of the self complementar-
ity among bases in this region and has a putative role in masking
the 5′ splice site Mutations that disrupt the stem-loop structure
make the 5′ splice site accesible to splicing factors, leading to
inclusion of exon 10 (Wolfe, 2012).
Though mutations lead to alteration of splicing at the mRNA
level, their primary effect becomes pathogenic through changes
in the protein level in about half of the cases (Goedert and Jakes,
2005).
The human MAPT 3′UTR, as well as that of rodents, con-
tains two Polyadenylation Signals (PAS) in tandem and can
undergo alternative polyadenylation (APA) to produce tran-
scripts of approximately 2 or 6 kb, namely the short and long
transcript variants (Poorkaj et al., 2001). Dickson and colleagues
investigated the role of human MAPT 3′-UTR in regulating tau
expression (Dickson et al., 2013). They observed that the two
MAPT 3′UTR variants are differentially regulated and influence
both mRNA stability and protein expression levels. The same
authors have reported that miR-34a can bind the human MAPT
3′-UTR long form and reduce tau levels, whereas inhibition of
endogenous miR-34 family members leads to increased tau lev-
els, leading to a hypothesis that up-regulation of miR-34 observed
during neuronal differentiation could be a compensatory mech-
anism to decrease the expression of tau aggregates. Recent work
(Wu et al., 2013a) also confirms the finding that MAPT is reg-
ulated by miRNA 34c-5p and miRNA 34c-3p, which bind to its
3′UTR.
Additionally, work by Zovoilis and colleagues have suggested
that miR-34c could be a marker for the onset of cognitive distur-
bances linked to Alzheimers disease and they also indicate that
targeting miR-34c could thus be a suitable therapy (Zovoilis et al.,
2011).
Studies also reported that miR-34 regulates apoptosis by
blocking the SIRT1 gene (Hermeking, 2010) and astrocytic apop-
tosis has been observed as an early event in FTLD conditions
(Broe et al., 2004). These findings suggest that miRNAs might be
involved in FTD through apoptotic mechanisms.
Tau is known to spread through synaptic and non-synaptic
mechanisms (Medina and Avila, 2014) and its accumulation is
thought to be mediated through spreading of the protein from
cell to cell. Tau has been reported to be secreted unconvention-
ally in naked form (Chai et al., 2012) or associated to exosomes
(Saman et al., 2012) and/or other membrane vesicles (Simón
et al., 2012). Thismethod of elimination of tau has been suggested
as a response mechanism to inhibit tau secretion and toxicity.
Recent reports have suggested that tau is released into culture
medium from neuroblastoma cells, tau-expressing non-neuronal
cells, induced pluripotent stem cell-derived human neurons, and
mouse primary neurons (Kim et al., 2010a; Shi et al., 2012).
This has also been observed in the brain interstitial fluid of both
wild-type and P301S tau-expressing mice in micro-dialysis stud-
ies (Yamada et al., 2011). Clinico-pathological studies underline
the tau pathology progression from entorhinal cortex through
the hippocampus and into limbic system (Arriagada et al., 1992).
Recent in vivo studies in tauopathy transgenic mouse models
have also highlighted the spreading of tau pathology through a
trans-synaptic mechanism in anatomically connected neuronal
networks (De Calignon et al., 2012; Liu et al., 2012). Apart from
these, intracerebral inoculation of synthetic tau fibrils induced
NFT (Neuro fibrillary tangles) like inclusions that propagated
from injected sites to other connected regions of brain (Iba et al.,
2013).
Current hypotheses also include that pathological progression
of improperly folded of tau could be transferred between neu-
ronal cells via a prion-like seeding mechanism which might lead
to neurodegeneration.
Themajor implication observed uponmutations which lead to
splice defects highlights the relevance of regulation at RNA level
which decides the fate of onset of neurodegeneration. The regu-
lation of MAPT mediated through miRNAs further indicates the
role of non-coding RNAs in determining tau protein levels.
GRN (Progranulin)
GRN is located on the long arm of chromosome 17 at the locus
q21.31 which is present at a distance of 1.7 Mb from MAPT
(Baker et al., 2006; Cruts et al., 2006). GRN encodes for a 593 aa
precursor protein of 68.5 kDa called progranulin.
Structure
Progranulin can be N-glycosylated at five potential sites and
secreted as a mature protein of 88 kDa (Chen-Plotkin et al., 2010;
Songsrirote et al., 2010). The protein is formed by 7.5 cysteine-
rich granulin domains, separated through linker sequences that
contain disulfide bridges (He and Bateman, 2003), as represented
in Figure 4B. This characteristic structure can be cleaved at the
intra-linker spacer sequences to produce seven non-identical
granulins that contain cysteine-rich motifs. Different proteases
can cleave progranulin, such as matrix metalloproteinase-14
(Butler et al., 2008), elastase (Zhu et al., 2002), proteinase 3, and
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neutrophil elastase (NE) at the pericellular microenvironment of
the neutrophil cell surface (Kessenbrock et al., 2008). The full-
length progranulin, once secreted, is protected from cleavage by
the high-density lipoprotein (HDL)/Apolipoprotein A-I complex
(Okura et al., 2010) and the secretory leukocyte protease inhibitor
(SLPI) (Zhu et al., 2002).
Localization and Function
Progranulin is present in many tissues, is highly expressed in
immune system cells (Daniel et al., 2000) and in a medium level
in the brain (Bhandari et al., 1996; Ahmed et al., 2007), where
it is highly expressed in specific populations of neuronal cells,
such as cortical neurons, and granule cells of the hippocampus
(Daniel et al., 2000; Table 1). The subcellular location of pro-
granulin seems to be the endoplasmic reticulum (ER) and Golgi,
where it is particular abundant in mouse cortical neurons and
mouse microglia (Almeida et al., 2011). Progranulin is implicated
in a wide range of biological processes such as embryogenesis
(Díaz-Cueto et al., 2000; Daniel et al., 2003; Bateman and Ben-
nett, 2009), cell survival and cell growth (Plowman et al., 1992; He
and Bateman, 1999), inflammation and wound repair (Zhu et al.,
2002; He et al., 2003; Kessenbrock et al., 2008; Yin et al., 2010),
transcriptional repression (Hoque et al., 2003, 2010) and several
reports suggest its role in neuronal development (Van Damme
et al., 2008). Interestingly, progranulin and the proteolytically
cleaved granulins can have coherent functions, such as in the reg-
ulation of neurite outgrowth (Van Damme et al., 2008), or they
can have contrasting roles, such as in inflammation processes (He
and Bateman, 2003).
To date, 69 different GRN mutations have been discovered
in 231 families (Cruts et al., 2012). A list of detailed pathogenic
mutations are reported inTable 5. TheGRNmutations frequency
range from 1 to 11.7% in FTD patients, but the frequency rises
to 12–25% in familial FTD (Cruts et al., 2006; Gass et al., 2006;
Huey et al., 2006; Bronner et al., 2007; Borroni et al., 2008). There
are different types of GRN mutations, the majority are classified
as non-sense, frameshift, and splice site mutations that cause a
premature stop codons (Baker et al., 2006; Cruts et al., 2006).
However, the pathogenic variants include also missense muta-
tions with a partial decrease of progranulin and a loss of its
function (Mukherjee et al., 2006, 2008; Shankaran et al., 2008;
Wang et al., 2010). Silent and intronic mutation with unknown
pathology can also occur. Generally the pathogenic GRN muta-
tions lead to a decreased GRN expression due to a non-sense-
mediated mRNA decay, resulting in a GRN haploinsufficiency
inherited in an autosomal dominant manner (Baker et al., 2006;
Cruts et al., 2006; Gass et al., 2006; Cruts and Van Broeckhoven,
2008).
Indeed progranulin levels, measured in either the serum
or cerebrospinal fluid (CSF) of patients with GRN mutations
are ∼30–50% of normal (Van Damme et al., 2008). More-
over, a decreased progranulin level can be also detected in
plasma of GRN mutations patients (Finch et al., 2009) and a
reduced GRN mRNA level can be observed in patient whole
blood samples through microarray experiments (Coppola et al.,
2008). In contrast an increased level of GRN mRNA was
observed in the frontal cortex from post-mortem brain samples
of FTD patients with GRN mutations, as compared to FTD
patients without GRN mutations (Chen-Plotkin et al., 2010).
The higher level of GRN transcripts could be due to the robust
microglia infiltrations, observed in the brain tissues of GRN
mutation patients. Indeed microglia shows high level of GRN
expression.
Implications of RNA in Pathogenesis
Most of the patients with FTLD-U show GRN mutations with
presence of TDP-43 ubiquitin positive inclusions, hence bear-
ing the term FTLD-TDP (Mackenzie et al., 2006, 2010; Sam-
pathu et al., 2006). The relation between TDP-43 and pro-
granulin is not fully understood, however several recent stud-
ies indicate that TDP-43 controls the expression of progranulin
by binding to GRN mRNA. On a study in which TDP-43 tar-
gets were identified through a RIP-chip analysis, it is shown
that TDP-43 has a post-transcriptional regulation on GRN and
VEGFA (Vascular endothelial growth factor A) (Colombrita et al.,
2012).
As previously mentioned, TDP-43 was shown to specifically
bind GRN 3′UTR controlling GRN mRNA stability and the
final quantity of progranulin protein (Polymenidou et al., 2011;
Colombrita et al., 2012). Moreover a knock-down of TDP-43 in
mice showed an increase in the amount of GRN mRNA level
(Polymenidou et al., 2011; Colombrita et al., 2012). Depletion
of TDP-43 also led to altered splicing of sortilin, the putative
progranulin receptor (Polymenidou et al., 2011). The relation
between GRN and TDP-43 was also demonstrated in vitro: cells
that were treated with siRNA against GRN for 72 h, showed a
caspase-dependent cleavage of TDP-43 into fragments (Zhang
et al., 2007); whereas primary neuronal cultures upon knowck-
down of GRN showed a re-localization of TDP-43 in the cyto-
plasm (Guo et al., 2010).
Through genetic association analysis, a common genetic vari-
ation localized on the 3′UTR of GRN (rs5848) was shown to
represent a genetic risk factor for FTD (Rademakers et al., 2008).
Progranulin levels in brain extracts from rs5848 TT homozy-
gous FTD patients were lower than in CC carriers, as observed
through western blot analyses, ELISA, and immunohistochem-
istry. A stronger binding of miR-659 in the 3′UTR of GRN was
shown in the presence of the rs5848 T variant, and might explain
the reduced progranulin levels.
It is reported that miR-107 is downregulated in presence of
Alzheimer’s disease at early stage (Wang et al., 2008b). Another
study demonstrated through a RIP-Chip analysis performed in
human H4 neuroglioma cells that the open reading frame of
GRN mRNA contains many recognizing sequences elements
for miR-107 (Wang et al., 2010), showing implications of miR-
107 deregulation in neurodegenerative diseases. In particular
miR-107 regulation of GRN seems to be relevant to glucose
metabolism in cultured H4 neuroglioma cells. Previous analy-
sis identified miR-107 as one of the microRNAs that increase
their expression with glucose supplementation in cell culture
medium (Tang et al., 2009). Wang and colleagues reported that
glucose metabolic pathway may recruit miR-107 to regulate
GRN expression. Another microRNAs that was found signifi-
cantly down-regulated in brains of Alzheimer’s disease patients
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TABLE 5 | List of mutations in GRN and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
FTD delGRN[DR184] Complete gene deletion Pathogenic Gijselinck et al., 2008
FTD c.-7-20C>T INTRON Suggesting Pathogenic Kim et al., 2010a
FTD c.349+ 34C > T INTRON Suggesting Pathogenic Kim et al., 2010a
FTD IVS6+5_8delGTGA N/A Unclear Marcon et al., 2011; Skoglund et al., 2011
FTD c.1138C>G Q380E Unclear Kim et al., 2014
FTD g.2988_2989delCA P439_R440fsX6 Pathogenic Gabryelewicz et al., 2010
FTD g.5215A>T Complete protein degradation Pathogenic Le Ber et al., 2007
FTD g.5217G>C Complete protein degradation Pathogenic Cruts et al., 2006
FTD g.5913A>G INTRON Pathogenic Mukherjee et al., 2008
FTD/PD g.8948_12532del Complete protein deletion Pathogenic Rovelet-Lecrux et al., 2008
FTD g.9044T>C Predicted failed translation Pathogenic Baker et al., 2006
FTD g.9045G>A Predicted failed translation Pathogenic Cruts et al., 2006
FTD/MND g.9055G>C V5L Unclear Lopez de Munain et al., 2008
FTD g.9061T>C W7R Unclear Le Ber et al., 2007
FTD/PPA g.9068C>A A9D Pathogenic Mukherjee et al., 2006
FTD g.9132_9133insCTGC C31LfsX35 Pathogenic Baker et al., 2006
FTD/PPA g.9144delC G35EfsX19 Pathogenic Gass et al., 2006
FTD g.9181G>A Failed translation initiation Pathogenic Gass et al., 2006
FTD/AD g.9319delA T52HfsX2 Pathogenic Gass et al., 2006
FTD g.9399_9400delAG G79DfsX39 Pathogenic Gass et al., 2006
FTD g.9408delC S82VfsX174 Pathogenic Bronner et al., 2007
FTD g.9429G>A E88 Unclear Gass et al., 2006
FTD g.9593T>C C105R Unclear Gass et al., 2006
FTD g.10129C>T Q125X Pathogenic Baker et al., 2006
FTD g.10134 C>G C126W Unclear Bernardi et al., 2012
FTD g.10136_10137delCT P127RfsX2 Pathogenic Cruts et al., 2006
FTD g.10144_10147delCAGT Q130SfsX125 Pathogenic Baker et al., 2006
FTD g.10319G>A A155WfsX56 Pathogenic Gass et al., 2006
FTD/PPA g.10645_10646delCA S226WfsX28 Pathogenic Gass et al., 2006
FTD g.10668C>A P233Q Unclear Bronner et al., 2007
FTD g.10678C>T N236 Unclear Gass et al., 2006
FTD g.10679G>C V200GfsX18 Pathogenic Gass et al., 2006
FTD g.10965_10966delTG C253X Pathogenic Gass et al., 2006
FTD g.11002 G>C A266P Unclear Bernardi et al., 2012
FTD g.11041_11042insCTGA A237WfsX4 Pathogenic Cruts et al., 2006
FTD/CBS g.11240G>C V279GfsX5 Pathogenic Gass et al., 2006
FTD g.11266G>C E287D Unclear Gass et al., 2006
FTD g.11315_11316insTG W304LfsX58 Pathogenic Gass et al., 2006
FTD g.11316G>A W304X Pathogenic Gass et al., 2006
FTD g.11339G>A V279GfsX5 Pathogenic Baker et al., 2006
FTD/CBS g.11639delC T382SfsX30 Pathogenic Baker et al., 2006
FTD g.11651G>A W386X Pathogenic Baker et al., 2006
FTD g.11944_11945delGT V411SfsX2 Pathogenic Bronner et al., 2007
FTD g.11965C>T R418X Pathogenic Baker et al., 2006
FTD g.12054C>T H447 Unclear Bronner et al., 2007
FTD g.12108_12109insC C466LfsX46 Pathogenic Gass et al., 2006
FTD g.12115C>T Q468X Pathogenic Baker et al., 2006
FTD g.12227C>T C474 Unclear Gass et al., 2006
FTD g.12282C>T R493X Pathogenic Huey et al., 2006
FTD g.12428G>C W541C Unclear Bronner et al., 2007
AD, Alzheimers disease; CBS, Corticobasal syndrome; FTD, Frontotemporal Dementia; PPA, Primary progressive aphasia; MND, Motor neuron disease; PD, Parkinsons disease.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
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is miR-29b, that beloged to the miR-29a/b-1 cluster (Hébert et al.,
2008). Interestingly progranulin can also be regulated bymiR-29b
through a binding in the 3′UTR of GRNmRNA (Jiao et al., 2010).
It would be useful to know if these microRNAs deregulation
can contribute to the pathogenesis of dementia. So far different
microRNAs seem to be important for the control of progranulin
along with the role played by TDP-43 on the stability of GRN
mRNA and its expression.
VCP
The VCP (Valosin-containging protein) gene is located on chro-
mosome 9p13.3. It also called p97 or CDC48, consists of 17
coding exons.
Structure
The VCP protein is composed of four domains vital for its proper
functioning, namely the N, D1 D2 and C-terminal domains
(Figure 5B; DeLaBarre et al., 2006; Pye et al., 2007). The VCP
N domain is encoded by exons 1, 2, 3, 4 and 5, while the D1
and D2 domains are encoded by exons 6, 7, 8, 9, 10 and 12, 13,
14, respectively. There are two linker domains in the protein: the
N-D1 linker and the flexible D1-D2 linker.
VCP is a member of theAAA-ATPase gene superfamily
(ATPase Associated with diverse cellular Activities) (Woodman,
2003; Wang et al., 2004b), and is one of the most abundant
cytosolic proteins (Table 1) conserved throughout in mammals.
The complete protein contains 806 amino acids. The N domain
of VCP is responsible for the cofactor and ubiquitin binding
FIGURE 5 | (A) Schematic representation of the CHMP2B which contains an
acidic negatively charged C-terminal domain and a basic positively charged
N-terminal domain, a predicted coiled-coil structure (14-51 aa) and a
conserved Snf7 domain (16-178 aa). The autoinhibitory structure formed in
the cytosol due to the C- and N- terminal part interactions is reverted through
the binding of VSP4 on the VPS4 binding domain (VPS4 BD), localized on
the C-terminal part. (B) Schematic representation of the six functional
domains of the VCP protein: the N-terminal domain, the weak ATPase
domain (D1), the major ATPase domain (D2), the N-D1 linker domain, the
flexible D1–D2 linker domain and the C-terminal domain. (C) Overview of the
genomic structure of the C9ORF72 gene, with white boxes representing the
coding exons and gray boxes representing the non-coding exons. The
position of the hexanucleotide repeat (GGGGCC), the start codon (ATG), and
the stop codon (TAA) are indicated in the scheme.
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FIGURE 6 | A possible network of interactions between proteins and
RNAs, at the basis of FrontoTemporal Dementia. Green arrows indicate
binding interactions or processes that result in activation or increased
expression. Red arrows indicate binding interactions or processes that result
in inhibition of activity or reduced expression. Black arrows indicate binding
interactions or processes whose result can be either positive or negative.
Purple arrows indicate binding interactions or processes which are
hypotetical. Symbols as in Legend. lncRNAs, long non-coding RNA; TDP-43,
TAR DNA binding protein; FUS, Fused in Sarcoma; GRN, progranulin; MAPT,
Microtubule-Associated Protein Tau; VCP, Valosin Containing Protein;
C9ORF72. CHMP2B, Charged multivesicular body protein 2b; Rab7,
Ras-related protein 7.
function (Wang et al., 2004b). While the D1 domain mediates
oligomerization-independent nucleotide binding, the D2 domain
confers most of the ATPase activity (Wang et al., 2004b).
Localization and Function
This protein functions as a molecular chaperone in various dis-
tinct cellular processes including ubiquitin-dependent protein
degradation, stress responses, programmed cell death, nuclear
envelope reconstruction, and Golgi and endoplasmic reticulum
(ER) assembly (Guinto et al., 2007).
VCP is known to be involved in protein aggregation/quality
control of mitochondria and cell proliferation (Hayashi, 2013)
and is vital for retro-translocation of misfolded proteins from
Endoplasmic reticulum to cytoplasm (Kimonis et al., 2008).
Mutation and depletion studies of VCP have provided evidence
of accumulation of poly-ubiquitinated proteins (Dai and Li,
2001). Mutations in this gene may suggest the disruption of nor-
mal protein degradation pathway in the disease. This could be
facilitated through the disruption of binding between the VCP
and protein adaptors.
The expression of mutant VCP in myoblastic cell lines is
associated with increased ubiquitin conjugated proteins (Weihl
et al., 2006). Studies on overexpression of mutant VCP protein
in transgenic mice implicated an age-dependent muscle weak-
ness and Ubiquitin-positive inclusions and accumulation of high
molecular weight protein aggregates (Weihl et al., 2007).
VCP functions as a homohexamer (Zhang et al., 2000; Rouiller
et al., 2002) by binding to multiple proteins associated with
Ubiquitin proteasome system (UPS). The VCP complex binds
to polyubiquitin chains and unbounds ubiquitinated proteins
from their binding partners thereby facilitating transport to
the UPS.
Implications of RNA in Pathogenesis
To date, 18 different VCP mutations have been discovered in
48 different families, which include FTLD that is associated
with ALS, inclusion body myopathy, and Paget disease (Cruts
et al., 2012). Table 6 high-lights the list of pathogenic mutations
observed so far. The association of inclusion body myopathy and
FTD was established by Kovach et al. (2001).
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TABLE 6 | List of mutations in VCP and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
IBMPFD g.284G>A R92H Unclear Kaleem et al., 2007
IBMPFD g.410C>T P137L Pathogenic Stojkovic et al., 2009
IBMPFD g.4438C>T R93C Pathogenic Guyant-Maréchal et al., 2006
IBMPFD g.4444C>G R95G Pathogenic Watts et al., 2004
IBMPFD g.4444C>T R95C Pathogenic Kimonis et al., 2008
IBMPFD g.6990C>T R155C Pathogenic Watts et al., 2004
IBMPFD g.6991G>A R155H Pathogenic Watts et al., 2004
IBMPFD g.6991G>T R155L Unclear Kumar et al., 2010
IBMPFD g.6991G>C R155P Pathogenic Watts et al., 2004
IBMPFD g.6990C>A R155S Pathogenic Stojkovic et al., 2009; Vesa et al., 2009
IBMPFD g.6996G>C G157R Pathogenic Stojkovic et al., 2009; Djamshidian et al., 2009
IBMPFD g.7002C>T R159C Pathogenic Bersano et al., 2009
IBMPFD g.7003G>A R159H Pathogenic Haubenberger et al., 2005
IBMPFD g.7099G>A R191Q Pathogenic Watts et al., 2004
IBMPFD g.8085T>G L198W Pathogenic Watts et al., 2007
IBMPFD g.8187C>A A232E Pathogenic Watts et al., 2004
IBMPFD g.9349A>G T262A Pathogenic Spina et al., 2008
IBMPFD g.10742A>C N387H Pathogenic Watts et al., 2007
IBMPFD g.11295G>C A439P Pathogenic Shi et al., 2012
IBMPFD g.11295G>T A439S Pathogenic Stojkovic et al., 2009
IBMPFD, Inclusion body myopathy with Paget’s disease of the bone and frontotemporal dementia.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
A recent work by Jacquin et al. (2013) has showed R155H (464
G>A) mutation of the VCP gene in a French family, led to the
Inclusion body myopathy with Paget’s disease of the bone and
frontotemporal dementia (IBMPFD), with a psychiatric onset of
FTD.
The expression of IMBPFD-associated VCP mutations in
skeletal muscle cells reduced UNC-45 (a molecular chaperone
involved in myosin assembly) degradation that is linked to severe
myofibril disorganization in myotubules. This study suggests a
possible mechanism for the selective vulnerability of skeletal
muscle in IBMPFD; however, the implication for the pathogen-
esis of FTD still remains unknown. Studies on a VCP-mutant
transgenic mouse have shown TDP-43 and ubiquitin positive
accumulations (Custer et al., 2010) suggesting a possible interplay
between these proteins. IBMPFD is known to have TDP-43 aggre-
gation with VCP mutations (Nalbandian et al., 2011). Ju et al.
(2009) have established a link between VCP and autophagosomes
wherein the loss of VCP leads to accumulation of autophago-
somes, thus establishing a possible cause of aggregation of pro-
teins such as TDP-43.
VCP has been detected in a few inclusions of neurodegenera-
tive diseases such as senile plaques in Alzheimer’s disease, Lewy
bodies in Parkinson’s disease, neuronal intranuclear inclusions in
CAG/polyglutamine diseases and ubiquitin-positive inclusions in
ALS (Hirabayashi et al., 2001; Mizuno et al., 2003; Ishigaki et al.,
2004).
Bartolome and colleagues have performed analyses in fibrob-
lasts derived from patients with three different pathogenic VCP
mutations, VCP-deficient cells, mouse cortical primary neurons
and astrocytes, to conclude that reduction of VCP led to
uncoupling of mitochondria and increased oxygen consumption
and a subsequent decrease in ATP of cells leading to cellular
toxicity and neuronal death (Bartolome et al., 2013).
VCP has been recently involved in clearance of mRNP gran-
ules (Buchan et al., 2013), thereby unraveling a new mechanism
in clearance of RNPs from the cell. This might indicate why VCP
mutations lead to accumulation of stress granule constituents or
cytoplasmic inclusions. mRNP granules assemble to form stress
granules as a consequence of their aggregation (Erickson and
Lykke-Andersen, 2011). Wang et al. (2015) have shown a direct
interaction between VCP and FUS. VCP being a key regulator of
protein degradation, DNA interaction, and mitochondrial activ-
ity, its direct interaction with FUS is intriguing. Although there
is no evidence which shows a direct interaction or implication
of VCP mutations on RNA, its association with TDP-43 and
FUS, both of which are RNA binding proteins may suggest their
unraveled interactions in RNA metabolism.
CHMP2B
CHMP2B (Charged multivesicular body protein) is encoded by a
gene located on chromosome 3 and is a component of the endo-
somal sorting complex required for transport-III (ESCRT-III
complex).
Structure
CHMP2B is a protein of 213 amino acids, with an acid C-
terminal domain and basic N-terminal domain (Figure 5A), and
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a predicted coiled-coil structure (Skibinski et al., 2005). The
negatively charged C-terminal domain interacts with the pos-
itively charged N-terminal part, creating a closed and autoin-
hibitory structure in the cytosol (Whitley et al., 2003; Shim et al.,
2007). CHMP2B requires therefore an activation process per-
formed by VPS4, which binds to its C-terminal domain. Indeed
the C-terminal part of CHMP2B contains a binding domain
for VPS4. VPS4 is a member of theAAA-ATPase family and
it has a role in catalyzing the dissociation of ESCRT com-
plexes from endosomes (Katzmann et al., 2002). The ATPase
activity of VPS4 is important for endosomal sorting (Katz-
mann et al., 2002; Obita et al., 2007). Mutations localized in the
VSP4-binding region impair the function of CHMP2B, prevent-
ing the formation of protrusions from the cell (Bodon et al.,
2011).
Localization and Function
Northern-Blot analysis demonstrated that CHMP2B is expressed
in all the major parts of the brain, including the temporal and
frontal lobes (Table 1). Moreover through in situ hybridization
of mouse brain, an enhanced expression of CHMP2B in the
hippocampus, frontal and temporal lobes, and cerebellum was
shown (Skibinski et al., 2005). The endosomal-sorting complex
required for transport (ESCRT) is a protein complex involved
in the endocytosed protein trafficking from endosome to lyso-
somes, playing an important role for sorting of proteins and
for their efficient lysosomal degradation (Urwin et al., 2010).
Moreover ESCRT complexes have a relevant role at the plasma
membrane, during cytokinesis (Carlton and Martin-Serrano,
2007; Elia and Sougrat, 2011), budding of some enveloped
viruses (Usami et al., 2009; Martin-Serrano and Neil, 2011),
autophagy and transcriptional regulation (Roxrud et al., 2010;
Schmidt and Teis, 2012). Endosomal trafficking is a key pro-
cess for the internalization and transport of neuronal growth
factors, secreted growth factors, signaling molecules (Bronf-
man et al., 2007). A dysfunction in this process could lead to
an altered cell-signaling and aberrant communication between
cells.
Implications of RNA in Pathogenesis
In particular ESCRT dysfunction is associated with neurode-
generation, indeed mutation in CHMP2B have been reported
in frontotemporal dementia linked to chromosome 3 (FTD-3)
(Urwin et al., 2010). FTD-3 has an onset of 48–67 years and is an
autosomal dominant dementia with TDP-43 negative FTLD-U,
ubiquitin positive inclusions (Urwin et al., 2010).
As reported in Table 7, several missense mutations are con-
nected with FTD-3 (Skibinski et al., 2005), with familial or spo-
radic cases of ALS (Parkinson et al., 2006; Urwin et al., 2010),
familial frontotemporal lobar degeneration (FTLD) (Ghanim
et al., 2010) or CBD (Van der Zee et al., 2008), however only few
studies analyzed their pathogenic features in cultured neurons.
A point mutation has been identified in the 5′ acceptor site
of exon 6, causing the production of two abnormal transcripts:
CHMP2Bintron5 with retention of intron 5 and CHMP2B110 that
has a 10 bp deletion and a sequence frameshift due to the use
of a criptic splice site in exon 6 (Skibinski et al., 2005). Both
proteins lack 36 amino acids in the C-terminal part with the sub-
sequent absence of VPS4-binding domain and an accumulation
of CHMP2B on the endosomal membrane (Skibinski et al., 2005;
Urwin et al., 2010). This accumulation suggests that the binding
of mutated proteins to the endosomes prevents the recruitment
of the correct proteins necessary for the fusion with lysosomes
(Metcalf and Isaacs, 2010; Urwin et al., 2010). Indeed large and
abnormal endosomal structures are observed in post-mortem
brain tissues, in patient fibroblast cultures and in case of over-
expression of CHMP2B mutant in PC12 and human neuroblas-
toma cell lines (Skibinski et al., 2005; Van der Zee et al., 2008;
Urwin et al., 2010). Moreover CHMP2B seems to act through a
gain of function mechanism in the presence of mutations, since
only the transgenic mice expressing CHMP2Bintron5 show simi-
lar neuropathology features observed in FTD-3 patients, whereas
the knockoutmice with the inactivation of CHMP2B do not show
any pathological characteristics (Ghazi-Noori et al., 2012).
Another non-sense mutation replaces a glutamine residue
with a stop codon, creating a more severe C-terminal truncation
(Van der Zee et al., 2008).
TABLE 7 | List of mutations in CHMP2B and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
FTD g.13227A>G I29V Unclear Cannon et al., 2006
FTD g.18376C>A T104N Unclear Cox et al., 2010
FTD g.25885A>G N143S Unclear Van der Zee et al., 2007
FTD g.25899G>T D148Y Pathogenic Skibinski et al., 2005
FTD g.25950C>T Q165X Pathogenic Van der Zee et al., 2007
FTD g.26189G>C p.M178VfsX2/p.M178LfsX30 Pathogenic Skibinski et al., 2005
FTD g.26214C>T R186X Unclear Momeni et al., 2006
FTD g.26218G>A S187N Unclear Ferrari et al., 2010
FTD g.26276A>C Q206H Pathogenic Parkinson et al., 2006
FTD c.581C>T S194L Unclear Ghanim et al., 2010
FTD, Frontotemporal Dementia.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
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Since CHMP2B is involved in the endosomal trafficking of sig-
nal molecules, it could be interesting and possibly relevant for the
pathology to check if an altered endosomal process can affect the
function of other proteins involved in FTLD, such as progranulin,
as is it also suggested by Urwin et al. (2010).
C9ORF72
Structure
Large expansions of the non-coding GGGGCC repeat in
C9ORF72 (Chromosome 9 open reading frame 72) were recently
demonstrated to cause ALS and FTD (DeJesus-Hernandez et al.,
2011; Renton et al., 2011). Indeed 20–80% of familial and
5–15% of sporadic ALS and FTD in North American and
European patients show this hexanucleotide expansion with
a range of 700–1600 repeats, whereas the normal population
carries less than 30 repeats (DeJesus-Hernandez et al., 2011;
Renton et al., 2011; Smith et al., 2012). Pathogenic mutations
reported in C9ORF72 are listed in Table 8. C9ORF72 is local-
ized on chromosome 9 and is composed of 12 exons, with two
alternate non-coding first exons (Figure 5C, exon 1a and 1b)
(DeJesus-Hernandez et al., 2011). Specifically, the polymorphic
hexanucleotides repeat was identified between the two alterna-
tively spliced non-coding exons, through a sequencing approach
(DeJesus-Hernandez et al., 2011).
Depending on alternative transcription initiation, the
GGGGCC repeat can be located on the promoter of transcrip-
tional variant 1 or in the intron 1 of transcriptional variants 2
and 3. Variant 2 results from splicing of exons 1a and exons 2–5
whereas variant 3 is composed of exon 1a and exons 2–11.
Localization and Function
Expression array data showed wild type C9ORF72 RNA present
in different CNS tissues, including spinal cord and higher expres-
sion in the cerebellum (Renton et al., 2011; Table 1).
The protein encoded by C9ORF72 is still uncharacterized and
with unknown function even if it is well-conserved across species
(DeJesus-Hernandez et al., 2011).
Recently, Farg et al. (2014) demonstrated for the first time
that the endogenous C9ORF72 protein has a function in the
regulation of intracellular trafficking processes in the endoso-
mal and autophagy-lysosomal compartments in neuronal cell
lines. Therefore, they reported the normal cellular function of
C9ORF72 that is essential to understand its role in FTD/ALS.
In particular, they found co-localization in neuronal cell
lines and primary cortical neurons of C9ORF72 with four Rab
proteins, which are involved in endosomal trafficking. In motor
neurons, they found 70% of colocalization with Rab7, which is a
fundamental protein implicated in the biogenesis of lysosomes,
the transport of endosomes and the maturation of autophago-
somes (Gutierrez et al., 2004). A similar mechanism of interac-
tion and recruitment of Rab7 was also described for CHMP2B by
Urwin and collaborators. In CHMP2B mutant cells, an impaired
recruitment of Rab7 onto endosomes was observed with a
decreased fusion with lysosomes and a delayed degradation
(Urwin et al., 2010).
C9ORF72 protein was also found to colocalize with lysosomes,
ubiquilin-2 and autophagosomes, involved in autophagy (Farg
et al., 2014). Interestingly, the ability of C9ORF72 to interact
with hnRNPs and induce not yet characterized nuclear aggregates
and stress granules, could link the C9ORF72 protein with RNA
metabolism processes (Farg et al., 2014).
Implications of RNA in Pathogenesis
Immunocytochemistry analysis on human fibloblasts and mouse
motor neuron NSC-34 cell line revealed a predominant nuclear
localization of C9ORF72 protein (Renton et al., 2011). Immuno-
histochemical analysis showed C9ORF72 expression in neurons
and in FTD- and ALS-affected regions with a predominant cyto-
plasmic staining and a synaptic localization, but the quantitative
mRNA analysis demonstrated that the repeat expansion reduces
C9ORF72 transcript variant 1 expression in lymphoblast cell
lines of expanded repeats carriers and in frontal cortex samples
from unrelated FTLD-TDP patients carrying expanded repeats
(DeJesus-Hernandez et al., 2011). The hexanucleotide repeti-
tions present in the C9ORF72 transcript can form G-tetrad units,
called G-quartets, where G bases are rearranged in a cyclic pat-
tern with eight hydrogen bonds (Fratta et al., 2012). The pres-
ence of RNA G-quadruplexes has been found in different organ-
isms and has been observed in vitro and in vivo (Kikin et al.,
2008; Xu et al., 2010b). Transcripts are enriched in RNA G-
quadruplexes structures in the 5′UTR, 3′UTR and in the first
exon (Eddy and Maizels, 2008; Huppert et al., 2008). Recently
a molecular mechanism was described by which the DNA and
RNA G-quadruplexes in C9ORF72 create structures that pro-
mote the formation of RNA/DNA hybrids (R-loops) (Haeusler
et al., 2014). The pathological mechanism involvingC9ORF72
gene or its function are not clear, even if several studies showed
a decrease in the mRNA levels of some C9ORF72 variants in
ALS, which suggests a loss-of-function mechanism (DeJesus-
Hernandez et al., 2011; Renton et al., 2011; Gijselinck et al., 2012;
Mori et al., 2013b). Moreover, the aberrant transcripts containing
TABLE 8 | List of mutations in C9ORF72 and their characteristic phenotypes.
Subtypes of Dementia Mutation Change in amino acid Type References
FTD/ALS g.5321GGGGCC(?) G4C2 hexanucleotide repeat expansion Pathogenic DeJesus-Hernandez et al., 2011
FTD g.11942A>T T66S Pathogenic Van der Zee et al., 2013
TD, Frontotemporal Dementia; ALS, Amyotrophic lateral sclerosis.
All the information reported in the table is derived from a cumulative study of the literature and the database: http://www.molgen.ua.ac.be/ADMutations/default.cfm?MT=0&ML=2&
Page=FTD.
Frontiers in Molecular Neuroscience | www.frontiersin.org 19 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
the hexanucleotide repeats can accumulate and form structures
in the nucleus called RNA foci, which may produce neurodegen-
eration through a toxic effect (DeJesus-Hernandez et al., 2011).
These transcripts can be aberrantly expressed through repeat-
associated non-ATG (RAN) translation (Mori et al., 2013b).
Several groups reported that the RAN translation of the hex-
anucleotide repeats produces poly(GP), poly(GA) and poly(GR)
proteins, since this type of translation, without an initiation
codon, can have all the possible reading frames (Ash et al., 2013;
Mori et al., 2013b) and RNA can be also bidirectionally tran-
scribed (Gendron et al., 2013). These RAN proteins can form
inclusions in neurons and are considered a hallmark of the dis-
ease (Ash et al., 2013; Mori et al., 2013b). The neuronal inclu-
sions can be detected through antibodies that recognize putative
GGGGCC repeat RAN-translated peptides, therefore this type of
immunoreactivity can be use as a potential biomarker for the
disease (Ash et al., 2013).
It is also reported that RNA focimay sequester important RNA
binding proteins, causing an alteration inside the cell and a sub-
sequent dysfunction of RNA targets, in a process similar to the
formation of RNA foci in myotonic dystrophy type 1 (DM1) (Lee
et al., 2013; Mori et al., 2013a; Reddy et al., 2013; Xu et al., 2013).
Specifically, one study demonstrated that hnRNP-H is seques-
trated by RNA foci, reducing its available amount and its splicing
efficiency on different target transcripts (Lee et al., 2013). A recent
paper by Gendron et al. (2013) contains detailed descriptions of
the proteins found to be sequestered on RNA foci in in vitro
studies.
The presence of both sense and antisense RNA foci in fron-
totemporal dementia with the presence of C9ORF72 repeats
(C9FTLD), was demonstrated in patients, specifically in the
frontal cortex, motor cortex, hippocampus, cerebellum, and
spinal cord (Gendron et al., 2013; Lagier-Tourenne et al., 2013;
Mizielinska et al., 2013; Zu et al., 2013). RNA foci were identified
in neurons and with lower frequency in astrocytes, microglia, and
oligodendrocytes; the highest concentration of foci was found in
the frontal cortex region, compared to cerebellum and hippocam-
pus (Mizielinska et al., 2013). However, another work reported
that foci are localized with higher frequency in the cerebellum
(Lee et al., 2013). Despite this inconsistency, the major part of
RNA foci is localized at the very edge of the nucleus, but the
explanation for this localization is still unknown (Mizielinska
et al., 2013). The cellular toxicity associated with the longer hex-
anucleotide repeats and the presence of RNA foci was demon-
strated using neuroblastoma cells and zebrafish embryos (Lee
et al., 2013). One patient, who was homozygous for the C9ORF72
hexanucleotide repeats, showed a higher proportion of sense and
antisence foci with an early onset of FTD and severe pathological
characteristics, compared to the heterozygous case (Mizielinska
et al., 2013). A recent study found a mechanism for the disease in
which the DNA and RNA–DNA structures formed in the repeat
regions, alter the RNA transcription, with a result of transcrip-
tional pausing and abortion. The accumulation of abortive tran-
scripts with hexanucleotides repeats, creates G-quadruplexes,
and hairpins structures with a binding of essential proteins,
leading to nuclear stress, and further defects (Haeusler et al.,
2014).
TDP-43 and FUS, two FTD related proteins previously
decribed, are structurally related to the hnRNPs that are found
to bind C9ORF72 RNA foci (Lee et al., 2013; Mori et al., 2013b),
however FUS and TDP-43 do not colocalize with C9ORF72
RNA foci in cells, patient motor neuron cultures or in spinal
motor neurons from patients (Lagier-Tourenne et al., 2013; Lee
et al., 2013; Sareen et al., 2013). Since TDP-43 is capable to bind
through its C-terminal region the hnRNP proteins (Buratti et al.,
2005), the accumulation of these ribonucleoprotein on the RNA
foci could indirectly influence TDP-43 function, creating a pos-
sible link of interaction between these two factors involved in
FTD and ALS (Gendron et al., 2013). Indeed most of the cases
with C9ORF72 expansion show TDP-43 inclusions (FTLD-TDP)
(DeJesus-Hernandez et al., 2011; Lagier-Tourenne et al., 2013;
Mackenzie et al., 2014) with some exception, such as a case in
UK with C9ORF72 repeats with FTLD-tau pathology (Snowden
et al., 2012). It was reported that the plasma and CSF level of
phosphorylated TDP-43 is significantly higher in patients with
FTD carrying C9ORF72 expansion or GRN mutations compared
to other FTD patients or healthy controls (Suárez-Calvet et al.,
2014). This finding creates another possible link of interaction
or regulation between TDP-43 and C9ORF72 that needs further
analysis.
Discussion
In this review we describe the different genes involved in FTD,
focusing on their possible interactions, in order to identify a com-
mon network of their combined regulations. We created this
network focusing on the RNA aspect, an emerging and crucial
molecule that plays critical and fundamental functions in the
cells. Recently, research has increased its focus onthe role of RNA
in neurodegeneration (Renoux and Todd, 2012). We believe that
the RNA mediated regulation plays a key role in the unique
integration of all the known genes involved in FTD.
In this picture (Figure 6) FUS and TDP-43 RNA binding pro-
teins are at the core of the network, since they often are associated
factors that share similar features, with sometimes different but
complementary roles (Colombrita et al., 2012). They interact with
RNA in three main roles: as RNA binding proteins participating
on the different aspects of mRNA processing (Bosco et al., 2010;
Colombrita et al., 2011), as regulators of microRNAs processing,
and as regulators of lncRNAs. FUS and TDP-43 were both found
in aggregates in ALS/FTLD affected neurons (Da Cruz and Cleve-
land, 2011), nuclear complexes and in cytoplasmic RNPs (Kim
et al., 2010b). TDP-43 appears to be the main regulator of this
network, being able to interact with FUS pre-mRNA and regu-
late its splicing, and auto-regulate its own pre-mRNA, causing a
reduction of its own expression (Polymenidou et al., 2011).
TDP-43 can also bind GRN pre-mRNA, negatively controlling
its splicing and, accordingly, knock-down of TDP-43 was shown
to increase the amount of GRN mRNA level (Polymenidou et al.,
2011; Colombrita et al., 2012). In the presence ofGRN mutations,
TDP-43 regulation can be altered, causing the formation of inclu-
sions containing TDP-43 (Mackenzie et al., 2006, 2010; Sampathu
et al., 2006). Though TDP-43 aggregation is a typical hallmark
of many other neurodegenerative disorders, such as Alzheimer’s
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disease, Guam Parkinsonism dementia complex, and Lewy body
disease (Dickson, 2008), its impact on FTD in influencing the
regulation of the network should not be underestimated.
On the other side, FUS acts as a splicing regulator of MAPT
mRNA, indeed it was demonstrated that silencing of FUS alters
the splicing of MAPT. In particular, FUS helps the skipping of
exon 10 in primary cortical neurons (Ishigaki et al., 2012). The
presence and the absence of exon 10 inMAPT gene has a funda-
mental role in the regulation of a delicate balance in the ratio of 4
or 3 repeats that can lead to FTD.
For the recently identified C9ORF72 gene, large expansions
of the non-coding GGGGCC repeat correlate with pathogene-
sis, making an RNA gain-of functionmechanism possible. Indeed
the aberrant C9ORF72 transcripts accumulate in nuclear RNA
foci and sequester several RNA-binding proteins, including some
splicing factors. However, other possible pathogenetic mecha-
nisms are under scrutiny for C9ORF72, including impaired tran-
scription of the expanded gene or repeat-associated non-ATG
(RAN) translation of expanded transcripts.
In this scenario, two FTD genes code for proteins that fit in the
picture not for their relation to RNA, but for their role in protein
degradation.
VCP, taking part in the ubiquitin-proteasome pathway and
protein turnover (Zhang et al., 2000; Rouiller et al., 2002),
could be involved in the degradation of protein inclusions
present in different forms of FTD. TDP-43 inclusions were
found in the presence of a VCP mutation (Neumann et al.,
2009a). A direct interaction between VCP and FUS has been
observed suggesting a possible convergence in their functions
(Wang et al., 2015).
CHMP2B regulates protein trafficking between endosomes
and lysosomes and is involved in the protein degradation path-
way through lysosomes (Urwin et al., 2010). Therefore, CHMP2B
could be relevant for the internalization and transport of neu-
ronal growth factors or signaling molecules such as progranulin.
Recently, a function for the C9ORF72 protein was uncov-
ered, in the regulation of intracellular trafficking processes in
the endosomal and autophagy-lysosomal compartments (Farg
et al., 2014), providing an additional link to VCP and CHMP2B
proteins.
During the preparation of this review a recent study per-
formed by Van der Zee and colleagues have demonstrated ananal-
ysis on a European cohort of 1808 FTLD patients revealing muta-
tionsin SQSTM1 (Sequestosome 1) or p62. The p62 protein is
a stress-responsiveubiquitin-binding protein, which is shown to
have a role in degradation ofpolyubiquitinated proteins via the
proteasome pathway or autophagicprocesses (Van der Zee et al.,
2014). This gene was known to be associated with ALS and found
as a rare mutation with a frequency of 1–3% in both ALS and
FTLD cases. This further intrigued its possible role in pathogenic-
ity with a common patho-mechanism. p62 is present in neuronal
and glial ubiquitin-positive inclusions in different tauopathies
and synucleinopathies (Van der Zee et al., 2014). The meta-
analysis performed by Van der Zee and colleagues revealed that
rare mutations clustering in the UBA domain of SQSTM1 may
influence disease susceptibility by doubling the risk for FTLD.
Further, histopathology analysis of autopsied brain of SQSTM1
mutation carriers demonstrated a widespread of neuronal and
glial phospho-TDP-43 pathology. Therefore, this study opens up
another target gene SQSTM1, which is known to have impli-
cations in FTLD/ALS and additionally associated with TDP-43.
Despite further work being needed, to unravel and confirm the
details of the proposed network, we foresee that the construc-
tion of a picture of the interactions between proteins and RNAs
at the basis of the FTD pathology will be of invaluable impor-
tance, not only to comprehend the pathogenetic mechanisms but
also to develop new and more effective therapeutical approaches.
Through the network analysis proposed in this review, it can be
foreseen that more genes can be linked to FTD and their roles
will possibly fall in to two main categories: regulation of gene
expression through RNA or protein degradation. Additionally it
could be predicted that novel genes related to FTD in future will
be possibly a part of the proposed network.
Acknowledgments
This work was supported by a Futuro in Ricerca-Italian Min-
istry of Education, University and Research Grant RBFR-0895DC
“Mechanisms of post-transcriptional regulation of gene expres-
sion in dementias.”
References
Ahmed, Z., Mackenzie, I. R., Hutton, M. L., and Dickson, D. W. (2007). Progran-
ulin in frontotemporal lobar degeneration and neuroinflammation. J. Neuroin-
flammation 4:7. doi: 10.1186/1742-2094-4-7
Almeida, S., Zhou, L., and Gao, F.-B. (2011). Progranulin, a glycoprotein defi-
cient in frontotemporal dementia, is a novel substrate of several protein
disulfide isomerase family proteins. PLoS ONE 6:e26454. doi: 10.1371/jour-
nal.pone.0026454
Anderson, P., and Kedersha, N. (2008). Stress granules: the Tao of RNA triage.
Trends Biochem. Sci. 33, 141–150. doi: 10.1016/j.tibs.2007.12.003
Anfossi, M., Vuono, R., Maletta, R., Virdee, K., Mirabelli, M., Colao, R.,
et al. (2011). Compound heterozygosity of 2 novel MAPT mutations
in frontotemporal dementia. Neurobiol. Aging 32, 757.e1-757.e11. doi:
10.1016/j.neurobiolaging.2010.12.013
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H., et al.
(2006). TDP-43 is a component of ubiquitin-positive tau-negative inclusions in
frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem.
Biophys. Res. Commun. 351, 602–611. doi: 10.1016/j.bbrc.2006.10.093
Arriagada, P. V., Marzloff, K., and Hyman, B. T. (1992). Distribution of
Alzheimer-type pathologic changes in nondemented elderly individuals
matches the pattern in Alzheimer’s disease. Neurology 42, 1681–1688. doi:
10.1212/WNL.42.9.1681
Ash, P. E., Bieniek, K. F., Gendron, T. F., Caulfield, T., Lin, W.-L.,
Dejesus-Hernandez, M., et al. (2013). Unconventional translation of
C9ORF72 GGGGCC expansion generates insoluble polypeptides spe-
cific to c9FTD/ALS. Neuron 77, 639–646. doi: 10.1016/j.neuron.2013.
02.004
Avendaño-Vázquez, S. E., Dhir, A., Bembich, S., Buratti, E., Proudfoot, N., and
Baralle, F. (2012). Autoregulation of TDP-43 mRNA levels involves interplay
between transcription, splicing, and alternative polyA site selection. Genes Dev.
26, 1679–1684. doi: 10.1101/gad.194829.112
Ayala, Y. M., Pantano, S., D’Ambrogio, A., Buratti, E., Brindisi, A., Marchetti, C.,
et al. (2005). Human, Drosophila, and C.elegans TDP43: nucleic acid binding
Frontiers in Molecular Neuroscience | www.frontiersin.org 21 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
properties and splicing regulatory function. J. Mol. Biol. 348, 575–588. doi:
10.1016/j.jmb.2005.02.038
Baker, M., Mackenzie, I. R., Pickering-Brown, S. M., Gass, J., Rademakers, R.,
Lindholm, C., et al. (2006). Mutations in progranulin cause tau-negative fron-
totemporal dementia linked to chromosome 17. Nature 442, 916–919. doi:
10.1038/nature05016
Barmada, S. J., Skibinski, G., Korb, E., Rao, E. J., and Wu, J. Y. (2010). Cyto-
plasmic mislocalization of TDP-43 is toxic to neurons and enhanced by
a mutation associated with familial ALS 30. J. Neurosci. 30, 639–649. doi:
10.1523/JNEUROSCI.4988-09.2010
Bartel, D. P. (2009). MicroRNAs: target recognition and regulatory functions. Cell
136, 215–233. doi: 10.1016/j.cell.2009.01.002
Bartolome, F., Wu, H.-C., Burchell, V. S., Preza, E., Wray, S., Mahoney, C.
J., et al. (2013). Pathogenic VCP mutations induce mitochondrial uncou-
pling and reduced ATP levels. Neuron 78, 57–64. doi: 10.1016/j.neuron.2013.
02.028
Bateman, A., and Bennett, H. P. (2009). The granulin gene family: from cancer to
dementia. Bioessays 31, 1245–1254. doi: 10.1002/bies.200900086
Belly, A., Moreau-Gachelin, F., Sadoul, R., and Goldberg, Y. (2005). Delocalization
of the multifunctional RNA splicing factor TLS/FUS in hippocampal neurones:
exclusion from the nucleus and accumulation in dendritic granules and spine
heads. Neurosci. Lett. 379, 152–157. doi: 10.1016/j.neulet.2004.12.071
Belzil, V. V., Gendron, T. F., and Petrucelli, L. (2013). RNA-mediated tox-
icity in neurodegenerative disease. Mol. Cell. Neurosci. 56, 406–419. doi:
10.1016/j.mcn.2012.12.006
Benajiba, L., Le Ber, I., Camuzat, A., Lacoste, M., Thomas-Anterion, C., Couratier,
P., et al. (2009). TARDBP mutations in motoneuron disease with frontotempo-
ral lobar degeneration. Ann. Neurol. 65, 470–473. doi: 10.1002/ana.21612
Bernardi, L., Frangipane, F., Smirne, N., Colao, R., Puccio, G., Curcio, S. M.,
et al. (2012). Epidemiology and genetics of frontotemporal dementia: a door-
to-door survey in southern Italy. Neurobiol. Aging 33, 2948.e1-2948.e10. doi:
10.1016/j.neurobiolaging.2012.06.017
Bernstein, E., Caudy, A. A., Hammond, S. M., and Hannon, G. J. (2001). Role for
a bidentate ribonuclease in the initiation step of RNA interference. Nature 409,
363–366. doi: 10.1038/35053110
Bersano, A., Del Bo, R., Lamperti, C., Ghezzi, S., Fagiolari, G., Fortunato,
F., et al. (2009). Inclusion body myopathy and frontotemporal demen-
tia caused by a novel VCP mutation. Neurobiol. Aging 30, 752–758. doi:
10.1016/j.neurobiolaging.2007.08.009
Bertolotti, A., Lutz, Y., and Heard, D. (1996). hTAF (II) 68, a novel RNA/ssDNA-
binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is
associated with both TFIID and RNA polymerase II. EMBO J. 15, 5022–5031.
Bessi, V., Bagnoli, S., Nacmias, B., Tedde, A., Sorbi, S., and Bracco, L. (2010).
Semantic dementia associated with mutation V363I in the tau gene. J. Neurol.
Sci. 296, 112–114. doi: 10.1016/j.jns.2010.06.007
Bhandari, V., Daniel, R., Lim, P. S., and Bateman, A. (1996). Structural and func-
tional analysis of a promoter of the human granulin/epithelin gene. Biochem. J.
319(Pt 2), 441–447.
Binder, L. I., Frankfurter, A., and Rebhun, L. I. (1985). The distribution of tau
in the mammalian central nervous system. J. Cell Biol. 101, 1371–1378. doi:
10.1083/jcb.101.4.1371
Birney, E., Stamatoyannopoulos, J. A., Dutta, A., Guigó, R., Gingeras, T. R., and
Margulies, E. H. (2007). Identification and analysis of functional elements in
1% of the human genome by the ENCODE pilot project. Nature 447, 799–816.
doi: 10.1038/nature05874
Bodon, G., Chassefeyre, R., Pernet-Gallay, K., Martinelli, N., Effantin, G., Hulsik,
D. L., et al. (2011). Charged multivesicular body protein 2B (CHMP2B) of the
endosomal sorting complex required for transport-III (ESCRT-III) polymer-
izes into helical structures deforming the plasma membrane. J. Biol. Chem. 286,
40276–40286. doi: 10.1074/jbc.M111.283671
Bond, A. M., Vangompel, M. J., Sametsky, E. A., Clark, M. F., Savage, J. C., Dister-
hoft J. F., et al. (2009). Balanced gene regulation by an embryonic brain ncRNA
is critical for adult hippocampal GABA circuitry. Nat. Neurosci. 12, 1020–1027.
doi: 10.1038/nn.2371
Borroni, B., Archetti, S., Alberici, A., Agosti, C., Gennarelli, M., Bigni, B., et al.
(2008). Progranulin genetic variations in frontotemporal lobar degeneration:
evidence for low mutation frequency in an Italian clinical series. Neurogenetics
9, 197–205. doi: 10.1007/s10048-008-0127-3
Borroni, B., Bonvicini, C., Alberici, A., Buratti, E., Agosti, C., Archetti, S., et al.
(2009). Mutation within TARDBP leads to frontotemporal dementia without
motor neuron disease. Hum. Mutat. 30, E974–E983. doi: 10.1002/humu.21100
Bosco, D. A., Lemay, N., Ko, H. K., Zhou, H., Burke, C., Kwiatkowski, T. J.,
et al. (2010). Mutant FUS proteins that cause amyotrophic lateral sclero-
sis incorporate into stress granules. Hum. Mol. Genet. 19, 4160–4175. doi:
10.1093/hmg/ddq335
Bottos, A., Rissone, A., Bussolino, F., and Arese, M. (2011). Neurexins and neuroli-
gins: synapses look out of the nervous system. Cell. Mol. Life Sci. 68, 2655–2666.
doi: 10.1007/s00018-011-0664-z
Broe, M., Kril, J., and Halliday, G. M. (2004). Astrocytic degeneration relates to
the severity of disease in frontotemporal dementia. Brain 127, 2214–2220. doi:
10.1093/brain/awh250
Bronfman, F. C., Escudero, C. A., and Weis, J. K. A. (2007). Endosomal trans-
port of neurotrophins: roles in signaling and neurodegenerative diseases. Dev.
Neurobiol. 67, 1183–1203. doi: 10.1002/dneu.20513
Bronner, I. F., Rizzu, P., Seelaar, H., van Mil, S. E., Anar, B., Azmani, A., et al.
(2007). Progranulin mutations in Dutch familial frontotemporal lobar degen-
eration. Eur. J. Hum. Genet. 15, 369–374. doi: 10.1038/sj.ejhg.5201772
Broustal, O., Camuzat, A., Guillot-Noël, L., Guy, N., Millecamps, S., Deffond,
D., et al. (2010). FUS mutations in frontotemporal lobar degeneration with
amyotrophic lateral sclerosis. J. Alzheimers Dis. 22, 765–769.
Brown, J., Lantos, P. L., Roques, P., Fidani, L., and Rossor, M. N. (1996). Familial
dementia with swollen achromatic neurons and corticobasal inclusion bodies:
a clinical and pathological study. J. Neurol. Sci. 135, 21–30. doi: 10.1016/0022-
510X(95)00236-U
Buchan, J. R., Kolaitis, R.-M., Taylor, J. P., and Parker, R. (2013). Eukaryotic
stress granules are cleared by autophagy and Cdc48/VCP function. Cell 153,
1461–1474. doi: 10.1016/j.cell.2013.05.037
Buchan, J. R., and Parker, R. (2009). Eukaryotic stress granules: the ins and outs of
translation.Mol. Cell. 36, 932–941. doi: 10.1016/j.molcel.2009.11.020
Bugiani, O. (2007). The many ways to frontotemporal degeneration and beyond.
Neurol. Sci. 28, 241–244. doi: 10.1007/s10072-007-0829-6
Bugiani, O., Murrell, J. R., Giaccone, G., Hasegawa, M., Ghigo, G., Tabaton, M.,
et al. (1999). Frontotemporal dementia and corticobasal degeneration in a fam-
ily with a P301S mutation in tau. J. Neuropathol. Exp. Neurol. 58, 667–677. doi:
10.1097/00005072-199906000-00011
Buratti, E., and Baralle, F. E. (2001). Characterization and functional impli-
cations of the RNA binding properties of nuclear factor TDP-43, a novel
splicing regulator of CFTR exon 9. J. Biol. Chem. 276, 36337–36343. doi:
10.1074/jbc.M104236200
Buratti, E., and Baralle, F. E. (2010). The multiple roles of TDP-43 in pre-
mRNA processing and gene expression regulation. RNA Biol. 7, 420–429. doi:
10.4161/rna.7.4.12205
Buratti, E., Brindisi, A., Giombi, M., Tisminetzky, S., Ayala, Y. M., and Baralle, F.
E. (2005). TDP-43 binds heterogeneous nuclear ribonucleoprotein A/B through
its C-terminal tail: an important region for the inhibition of cystic fibrosis
transmembrane conductance regulator exon 9 splicing. J. Biol. Chem. 280,
37572–37584. doi: 10.1074/jbc.M505557200
Buratti, E., De Conti, L., Stuani, C., Romano, M., Baralle, M., and Baralle, F.
(2010). Nuclear factor TDP-43 can affect selectedmicroRNA levels. FEBS J. 277,
2268–2281. doi: 10.1111/j.1742-4658.2010.07643.x
Butler, G. S., Dean, R. A., Tam, E. M., and Overall, C. M. (2008). Pharma-
coproteomics of a metalloproteinase hydroxamate inhibitor in breast cancer
cells: dynamics of membrane type 1 matrix metalloproteinase-mediated mem-
brane protein shedding. Mol. Cell. Biol. 28, 4896–4914. doi: 10.1128/MCB.
01775-07
Cannon, A., Baker, M., Boeve, B., Josephs, K., Knopman, D., Petersen, R.,
et al. (2006). CHMP2B mutations are not a common cause of frontotempo-
ral lobar degeneration. Neurosci. Lett. 398, 83–84. doi: 10.1016/j.neulet.2005.
12.056
Carlton, J. G., and Martin-Serrano, J. (2007). Parallels between cytokinesis and
retroviral budding: a role for the ESCRT machinery. Science 316, 1908–1912.
doi: 10.1126/science.1143422
Cesana, M., Cacchiarelli, D., Legnini, I., Santini, T., Sthandier, O., Chinappi,
M., et al. (2011). A long noncoding RNA controls muscle differentiation
by functioning as a competing endogenous RNA. Cell 147, 358–369. doi:
10.1016/j.cell.2011.09.028
Frontiers in Molecular Neuroscience | www.frontiersin.org 22 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
Chai, X., Dage, J. L., and Citron, M. (2012). Constitutive secretion of tau pro-
tein by an unconventional mechanism. Neurobiol. Dis. 48, 356–366. doi:
10.1016/j.nbd.2012.05.021
Chen, L., and Carmichael, G. (2009). Altered nuclear retention of mRNAs con-
taining inverted repeats in human embryonic stem cells: functional role of a
nuclear noncoding RNA. Mol. Cell 35, 467–478. doi: 10.1016/j.molcel.2009.
06.027
Chen-Plotkin, A. S., Xiao, J., Geser, F., Martinez-Lage, M., Grossman, M., Unger,
T., et al. (2010). Brain progranulin expression in GRN-associated frontotempo-
ral lobar degeneration. Acta Neuropathol. 119, 111–122. doi: 10.1007/s00401-
009-0576-2
Chiò, A., Calvo, A., Moglia, C., Restagno, G., Ossola, I., Brunetti, M., et al.
(2010). Amyotrophic lateral sclerosis-frontotemporal lobar dementia in 3 fam-
ilies with p.Ala382Thr TARDBP mutations. Arch. Neurol. 67, 1002–1009. doi:
10.1001/archneurol.2010.173
Clark, M. B., Amaral, P. P., Schlesinger, F. J., Dinger, M. E., Taft, R. J., Rinn, J.
L., et al. (2011). The reality of pervasive transcription. PLoS Biol. 9:e1000625;
discussion e1001102. doi: 10.1371/journal.pbio.1000625
Clovis, Y. M., Enard, W., Marinaro, F., Huttner, W. B., and De Pietri Tonelli,
D. (2012). Convergent repression of Foxp2 3′UTR by miR-9 and miR-132
in embryonic mouse neocortex: implications for radial migration of neurons.
Development 139, 3332–3342. doi: 10.1242/dev.078063
Colombrita, C., Onesto, E., Megiorni, F., Pizzuti, A., Baralle, F. E., Buratti,
E., et al. (2012). TDP-43 and FUS RNA-binding proteins bind distinct
sets of cytoplasmic messenger RNAs and differently regulate their post-
transcriptional fate in motoneuron-like cells. J. Biol. Chem. 287, 15635–15647.
doi: 10.1074/jbc.M111.333450
Colombrita, C., Onesto, E., Tiloca, C., Ticozzi, N., Silani, V., and Ratti, A. (2011).
RNA-binding proteins and RNA metabolism: a new scenario in the patho-
genesis of Amyotrophic lateral sclerosis. Arch. Ital. Biol. 149, 83–99. doi:
10.4449/aib.v149i1.1261
Colombrita, C., Zennaro, E., Fallini, C., Weber, M., Sommacal, A., Buratti, E., et al.
(2009). TDP-43 is recruited to stress granules in conditions of oxidative insult.
J. Neurochem. 111, 1051–1061. doi: 10.1111/j.1471-4159.2009.06383.x
Cooper, T. A., Wan, L., and Dreyfuss, G. (2009). RNA and disease. Cell 136,
777–793. doi: 10.1016/j.cell.2009.02.011
Coppola, G., Karydas, A., Rademakers, R., Wang, Q., Baker, M., Hutton, M.,
et al. (2008). Gene expression study on peripheral blood identifies progranulin
mutations. Ann. Neurol. 64, 92–96. doi: 10.1002/ana.21397
Corrado, L., Ratti, A., Gellera, C., Buratti, E., Castellotti, B., Carlomagno,
Y., et al. (2009).High frequency of TARDBP gene mutations in Italian
patients with amyotrophic lateral sclerosis. Hum. Mutat. 30, 688–694. doi:
10.1002/humu.20950
Couchie, D., Mavilia, C., Georgieff, I. S., Liem, R. K., Shelanski, M. L., and
Nunez, J. (1992). Primary structure of high molecular weight tau present in
the peripheral nervous system. Proc. Natl. Acad. Sci. U.S.A. 89, 4378–4381. doi:
10.1073/pnas.89.10.4378
Cox, L. E., Ferraiuolo, L., Goodall, E. F., Heath, P. R., Higginbottom, A., Mortiboys,
H., et al. (2010). Mutations in CHMP2B in lower motor neuron predomi-
nant amyotrophic lateral sclerosis (ALS). PLoS ONE 5:e9872. doi: 10.1371/jour-
nal.pone.0009872
Craig, A., Graf, E., and Linhoff, M. (2006). How to build a central synapse: clues
from cell culture. Trends Neurosci. 29, 8–20. doi: 10.1016/j.tins.2005.11.002
Cruts, M., Gijselinck, I., Van der Zee, J., Engelborghs, S., Wils, H., Pirici, D.,
et al. (2006). Null mutations in progranulin cause ubiquitin-positive fron-
totemporal dementia linked to chromosome 17q21. Nature 442, 920–924. doi:
10.1038/nature05017
Cruts, M., Theuns, J., and Van Broeckhoven, C. (2012). Locus-specific mutation
databases for neurodegenerative brain diseases. Hum. Mutat. 33, 1340–1344.
doi: 10.1002/humu.22117
Cruts, M., and Van Broeckhoven, C. (2008). Loss of progranulin function
in frontotemporal lobar degeneration. Trends Genet. 24, 186–194. doi:
10.1016/j.tig.2008.01.004
Custer, S. K., Neumann, M., Lu, H., Wright, A. C., and Taylor, J. P. (2010). Trans-
genic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of
IBMPFD including degeneration in muscle, brain and bone. Hum. Mol. Genet.
19, 1741–1755. doi: 10.1093/hmg/ddq050
D’Souza, I., Poorkaj, P., Hong, M., Nochlin, D., Lee, V. M., Bird, T. D., et al.
(1999). Missense and silent tau gene mutations cause frontotemporal dementia
with parkinsonism-chromosome 17 type, by affecting multiple alternative RNA
splicing regulatory elements. Proc. Natl. Acad. Sci. U.S.A. 96, 5598–5603. doi:
10.1073/pnas.96.10.5598
Da Cruz, S., and Cleveland, D. W. (2011). Understanding the role of TDP-43
and FUS/TLS in ALS and beyond. Curr. Opin. Neurobiol. 21, 904–919. doi:
10.1016/j.conb.2011.05.029
Dai, R. M., and Li, C. C. (2001). Valosin-containing protein is a multi-ubiquitin
chain-targeting factor required in ubiquitin-proteasome degradation. Nat. Cell
Biol. 3, 740–744. doi: 10.1038/35087056
Daniel, R., Daniels, E., He, Z., and Bateman, A. (2003). Progranulin
(acrogranin/PC cell-derived growth factor/granulin-epithelin precursor) is
expressed in the placenta, epidermis, microvasculature, and brain dur-
ing murine development. Dev. Dyn. 227, 593–599. doi: 10.1002/dvdy.
10341
Daniel, R., He, Z., Carmichael, K. P., Halper, J., and Bateman, A. (2000). Cellu-
lar localization of gene expression for progranulin. J. Histochem. Cytochem. 48,
999–1009. doi: 10.1177/002215540004800713
De Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H.,
Kopeikina, K. J., et al. (2012). Propagation of tau pathology in a model of early
Alzheimer’s disease. Neuron 73, 685–697. doi: 10.1016/j.neuron.2011.11.033
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M.,
Rutherford, N. J., et al. (2011). Expanded GGGGCC hexanucleotide repeat in
noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS.
Neuron 72, 245–256. doi: 10.1016/j.neuron.2011.09.011
DeLaBarre, B., Christianson, J. C., Kopito, R. R., and Brunger, A. T. (2006). Cen-
tral pore residues mediate the p97/VCP activity required for ERAD. Mol. Cell
22, 451–462. doi: 10.1016/j.molcel.2006.03.036
Deng, H.-X., Zhai, H., Bigio, E. H., Yan, J., Fecto, F., Ajroud, K., et al. (2010).
FUS-immunoreactive inclusions are a common feature in sporadic and non-
SOD1 familial amyotrophic lateral sclerosis. Ann. Neurol. 67, 739–748. doi:
10.1002/ana.22051
Díaz-Cueto, L., Stein, P., Jacobs, A., Schultz, R. M., and Gerton, G. L. (2000). Mod-
ulation of mouse preimplantation embryo development by acrogranin (epithe-
lin/granulin precursor). Dev. Biol. 217, 406–418. doi: 10.1006/dbio.1999.9564
Di Carlo, V., Grossi, E., Laneve, P., Morlando, M., Dini Modigliani, S., Ballar-
ino, M., et al. (2013). TDP-43 regulates the microprocessor complex activ-
ity during in vitro neuronal differentiation. Mol. Neurobiol. 48, 952–963. doi:
10.1007/s12035-013-8564-x
Dickson, D. W. (1997). Neurodegenerative diseases with cytoskeletal
pathology: a biochemical classification. Ann. Neurol. 42, 541–544. doi:
10.1002/ana.410420403
Dickson, D. W. (2008). TDP-43 immunoreactivity in neurodegenerative disor-
ders: disease versus mechanism specificity. Acta Neuropathol. 115, 147–149.
doi: 10.1007/s00401-007-0323-5
Dickson, J. R., Kruse, C., Montagna, D. R., Finsen, B., and Wolfe, M. S. (2013).
Alternative polyadenylation and miR-34 family members regulate tau expres-
sion. J. Neurochem. 127, 739–749. doi: 10.1111/jnc.12437
Dini Modigliani, S., Morlando, M., Errichelli, L., Sabatelli, M., and Bozzoni, I.
(2014). An ALS-associated mutation in the FUS 3′-UTR disrupts a microRNA-
FUS regulatory circuitry. Nat. Commun. 5:4335. doi: 10.1038/ncomms5335
Djamshidian, A., Schaefer, J., Haubenberger, D., Stogmann, E., Zimprich, F., Auff,
E., et al. (2009). A novel mutation in the VCP gene (G157R) in a German family
with inclusion-body myopathy with Paget disease of bone and frontotemporal
dementia.Muscle Nerve 39, 389–391. doi: 10.1002/mus.21225
Dormann, D., Rodde, R., Edbauer, D., Bentmann, E., Fischer, I., Hruscha, A., et al.
(2010). ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-
mediated nuclear import. EMBO J. 29, 2841–2857. doi: 10.1038/emboj.2010.143
Eddy, J., and Maizels, N. (2008). Conserved elements with potential to form poly-
morphic G-quadruplex structures in the first intron of human genes. Nucleic
Acids Res. 36, 1321–1333. doi: 10.1093/nar/gkm1138
Elia, N., and Sougrat, R. (2011). Dynamics of endosomal sorting complex required
for transport (ESCRT) machinery during cytokinesis and its role in abscission.
Proc Natl Acad Sci U.S.A. 108, 4846–4851. doi: 10.1073/pnas.1102714108
Erickson, S. L., and Lykke-Andersen, J. (2011). Cytoplasmic mRNP granules at a
glance. J. Cell Sci. 1, 293–297. doi: 10.1242/jcs.072140
Fan, Z., Chen, X., and Chen, R. (2014). Transcriptome-wide analysis of
TDP-43 binding small RNAs identifies miR-NID1 (miR-8485), a novel
miRNA that represses NRXN1 expression. Genomics 103, 76–82. doi:
10.1016/j.ygeno.2013.06.006
Frontiers in Molecular Neuroscience | www.frontiersin.org 23 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
Farg, M. A., Sundaramoorthy, V., Sultana, M. J., Yang, S., Atkinson, R. A. K., Lev-
ina, V., et al. (2014). C9ORF72, implicated in amytrophic lateral sclerosis and
frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet.
23, 3579–3595. doi: 10.1093/hmg/ddu068
Feng, J., Bi, C., Clark, B. S., Mady, R., Shah, P., and Kohtz, J. D. (2006). The Evf-
2 noncoding RNA is transcribed from the Dlx-5/6 ultraconserved region and
functions as a Dlx-2 transcriptional coactivator. Genes Dev. 20, 1470–1484. doi:
10.1101/gad.1416106
Ferrari, R., Kapogiannis, D., Huey, E. D., Grafman, J., Hardy, J., and Momeni, P.
(2010). Novel missense mutation in charged multivesicular body protein 2B
in a patient with frontotemporal dementia. Alzheimer Dis. Assoc. Disord. 24,
397–401. doi: 10.1097/WAD.0b013e3181df20c7
Finch, N., Baker, M., Crook, R., Swanson, K., Kuntz, K., Surtees, R., et al. (2009).
Plasma progranulin levels predict progranulin mutation status in frontotempo-
ral dementia patients and asymptomatic family members. Brain 132, 583–591.
doi: 10.1093/brain/awn352
Fox, A. H., and Lamond, A. I. (2010). Paraspeckles. Cold Spring Harb. Perspect.
Biol. 2:a000687. doi: 10.1101/cshperspect.a000687
Fratta, P., Mizielinska, S., Nicoll, A. J., Zloh, M., Fisher, E. M. C., Parkinson, G.,
et al. (2012). C9orf72 hexanucleotide repeat associated with amyotrophic lat-
eral sclerosis and frontotemporal dementia forms RNA G-quadruplexes. Sci.
Rep. 2:1016. doi: 10.1038/srep01016
Freibaum, B. D., Chitta, R., High, A. A., and Taylor, J. P. (2011). Global analy-
sis of TDP-43 interacting proteins reveals strong association with RNA splic-
ing and translation machinery. J. Proteome Res. 9, 1104–1120. doi: 10.1021/
pr901076y
Fujii, R., Okabe, S., Urushido, T., Inoue, K., Yoshimura, A., Tachibana, T., et al.
(2005). The RNA binding protein TLS is translocated to dendritic spines by
mGluR5 activation and regulates spine morphology. Curr. Biol. 15, 587–593.
doi: 10.1016/j.cub.2005.01.058
Fujii, R., and Takumi, T. (2005). TLS facilitates transport of mRNA encoding an
actin-stabilizing protein to dendritic spines. J. Cell Sci. 118, 5755–5765. doi:
10.1242/jcs.02692
Gabryelewicz, T., Masellis, M., Berdynski, M., Bilbao, J. M., Rogaeva, E., St George-
Hyslop, P., et al. (2010). Intra-familial clinical heterogeneity due to FTLD-U
with TDP-43 proteinopathy caused by a novel deletion in progranulin gene
(PGRN). J. Alzheimer Dis. 22, 1123–1133. doi: 10.3233/JAD-2010-101413
Gallo, J.-M., Jin, P., Thornton, C. A., Lin, H., Robertson, J., D’Souza, I., et al. (2005).
The role of RNA and RNA processing in neurodegeneration. J. Neurosci. 25,
10372–10375. doi: 10.1523/JNEUROSCI.3453-05.2005
Garzon, R., Marcucci, G., and Croce, C. (2010). Targeting microRNAs in cancer:
rationale, strategies and challenges. Nat. Rev. Drug Discov. 9, 775–789. doi:
10.1038/nrd3179
Gass, J., Cannon, A., Mackenzie, I. R., Boeve, B., Baker, M., Adamson, J., et al.
(2006). Mutations in progranulin are a major cause of ubiquitin-positive
frontotemporal lobar degeneration. Hum. Mol. Genet. 15, 2988–3001. doi:
10.1093/hmg/ddl241
Gendron, T. F., Bieniek, K. F., Zhang, Y.-J., Jansen-West, K., Ash, P. E.,
Caulfield, T., et al. (2013). Antisense transcripts of the expanded C9ORF72
hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated
non-ATG translation in c9FTD/ALS. Acta Neuropathol. 126, 829–844. doi:
10.1007/s00401-013-1192-8
Ghanim, M., Guillot-Noel, L., Pasquier, F., Jornea, L., Deramecourt, V., Dubois, B.,
et al. (2010). CHMP2B mutations are rare in French families with frontotem-
poral lobar degeneration. J. Neurol. 257, 2032–2036. doi: 10.1007/s00415-010-
5655-8
Ghazi-Noori, S., Froud, K. E., Mizielinska, S., Powell, C., Smidak, M., Fernandez de
Marco, M., et al. (2012). Progressive neuronal inclusion formation and axonal
degeneration in CHMP2B mutant transgenic mice. Brain 135, 819–832 doi:
10.1093/brain/aws006
Ghildiyal, M., and Zamore, P. D. (2009). Small silencing RNAs: an expanding
universe. Nat. Rev. Genet. 10, 94–108. doi: 10.1038/nrg2504
Giaccone, G., Rossi, G., Di Fede, G., Marcon, G., Farina, L., Sacco, L., et al. (2004).
Familial frontotemporal dementia is associated with the novel tau mutation
T427M. Neurobiol. Aging 25, 449–450. doi: 10.1016/S0197-4580(04)81481-7
Gijselinck, I., Van der Zee, J., Engelborghs, S., Goossens, D., Peeters, K., Matthei-
jssens, M., et al. (2008). Progranulin locus deletion in frontotemporal dementia.
Hum. Mutat. 29, 53–58 doi: 10.1002/humu.20651
Gijselinck, I., Van Langenhove, T., van der Zee, J., Sleegers, K., Philtjens, S., Klein-
berger, G., et al. (2012). A C9orf72 promoter repeat expansion in a Flanders-
Belgian cohort with disorders of the frontotemporal lobar degeneration-
amyotrophic lateral sclerosis spectrum: a gene identification study. Lancet
Neurol. 11, 54–65. doi: 10.1016/S1474-4422(11)70261-7
Goedert, M., and Jakes, R. (2005). Mutations causing neurodegenerative
tauopathies. Biochim. Biophys. Acta. 1739, 240–250. doi: 10.1016/j.bbadis.2004.
08.007
Grishok, A., Pasquinelli, A. E., Conte, D., Li, N., Parrish, S., Ha, I., et al. (2001).
Genes and mechanisms related to RNA interference regulate expression of the
small temporal RNAs that control C. elegans developmental timing. Cell 106,
23–34 doi: 10.1016/S0092-8674(01)00431-7
Grover, A., England, E., Baker, M., Sahara, N., Adamson, J., Granger, B., et al.
(2003). A novel tau mutation in exon 9 (1260V) causes a four-repeat tauopathy.
Exp. Neurol. 184, 131–140. doi: 10.1016/S0014-4886(03)00393-5
Grover, A., Houlden, H., Baker, M., Adamson, J., Lewis, J., Prihar, G., et al. (1999).
J. Biol. Chem. 274, 15134–15143. doi: 10.1074/jbc.274.21.15134
Guinto, J. B., Ritson, G. P., Taylor, J. P., and Forman, M. S. (2007). Valosin-
containing protein and the pathogenesis of frontotemporal dementia asso-
ciated with inclusion body myopathy. Acta Neuropathol. 114, 55–61. doi:
10.1007/s00401-007-0224-7
Guo, A., Tapia, L., Bamji, S. X., Cynader,M. S., and Jia,W. (2010). Progranulin defi-
ciency leads to enhanced cell vulnerability and TDP-43 translocation in primary
neuronal cultures. Brain Res. 1366, 1–8. doi: 10.1016/j.brainres.2010.09.099
Gutierrez, M. G., Munafo, D. B., Beron, W., and Colombo, M. I. (2004). Rab7 is
requie for the normal progression of the autophagic pathway in mammalian
cells. J. Cell Sci. 117(Pt 13), 2687–2697. doi: 10.1242/jcs.01114
Guyant-Maréchal, L., Laquerrière, A., Duyckaerts, C., Dumanchin, C., Bou,
J., Dugny, F., et al. (2006). Valosin-containing protein gene muta-
tions: clinical and neuropathologic features. Neurology 67, 644–651. doi:
10.1212/01.wnl.0000225184.14578.d3
Haeusler, A. R., Donnelly, C. J., Periz, G., Simko, E. A. J., Shaw, P. G., Kim, M.-S.
et al. (2014). C9orf72 nucleotide repeat structures initiate molecular cascades
of disease. Nature 507, 195–200. doi: 10.1038/nature13124
Haubenberger, D., Bittner, R. E., Rauch-Shorny, S., Zimprich, F., Mannhalter,
C., Wagner, L., et al. (2005). Inclusion body myopathy and Paget disease is
linked to a novel mutation in the VCP gene. Neurology 65, 1304–1305 doi:
10.1212/01.wnl.0000180407.15369.92
Hayashi, S., Toyoshima, Y., Hasegawa, M., Umeda, Y., Wakabayashi, K.,
Tokiguchi, S., et al. (2002). Late-onset frontotemporal dementia with a
novel exon 1 (Arg5His) tau gene mutation. Ann. Neurol. 51, 525–530. doi:
10.1002/ana.10163
Hayashi, Y. K. (2013). Inclusion body myopathy with Paget’s disease of bone and
frontotemporal dementia. Rinsho Shinkeigaku 53, 947–950. doi: 10.5692/clini-
calneurol.53.947
He, Z., and Bateman, A. (1999). Progranulin gene expression regulates epithelial
cell growth and promotes tumor growth in vivo. Cancer Res. 3222–3229.
He, Z., and Bateman, A. (2003). Progranulin (granulin-epithelin precursor, PC-
cell-derived growth factor, acrogranin) mediates tissue repair and tumorigene-
sis. J. Mol. Med. (Berl). 81, 600–612. doi: 10.1007/s00109-003-0474-3
He, Z., Ong, C. H. P., Halper, J., and Bateman, A. (2003). Progranulin is a mediator
of the wound response. Nat. Med. 9, 225–229. doi: 10.1038/nm816
Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W.,
Silahtaroglu A. N., et al. (2008). Loss of microRNA cluster miR-29a/b-1
in sporadic Alzheimer’s disease correlates with increased BACE1/beta-
secretase expression. Proc. Natl. Acad. Sci. U.S.A. 105, 6415–1520. doi:
10.1073/pnas.0710263105
Hermeking, H. (2010). The miR-34 family in cancer and apoptosis. Cell Death
Differ. 2, 193–199. doi: 10.1038/cdd.2009.56
Hirabayashi, M., Inoue, K., Tanaka, K., Nakadate, K., Ohsawa, Y., Kamei, Y., et al.
(2001). VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell
death, phenotypes relevant to neurodegeneration. Cell Death Differ. 8, 977–984.
doi: 10.1038/sj.cdd.4400907
Hoell, J. I., Larsson, E., Runge, S., Nusbaum, J. D., Duggimpudi, S., Farazi, T., et al.
(2011). RNA targets of wild-type and mutant FET family proteins. Nat. Struct.
Mol. Biol. 18, 1428–1431. doi: 10.1038/nsmb.2163
Hoque, M., Mathews, M. B., and Pe’ery, T. (2010). Progranulin (granulin/epithelin
precursor) and its constituent granulin repeats repress transcription
Frontiers in Molecular Neuroscience | www.frontiersin.org 24 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
from cellular promoters. J. Cell. Physiol. 223, 224–233. doi: 10.1002/jcp.
22031
Hoque, M., Young, T., and Lee, C. (2003). The growth factor granulin interacts
with cyclin T1 and modulates P-TEFb-dependent transcription. Cell. Biol. 23,
1688–1702.
Huey, E. D., Ferrari, R., Moreno, J. H., Jensen, C., Morris, C. M., Potocnik, F., et al.
(2012). FUS and TDP43 genetic variability in FTD and CBS. Neurobiol. Aging
33, 1016.e9–1016.e17. doi: 10.1016/j.neurobiolaging.2011.08.004
Huey, E. D., Grafman, J., Wassermann, E. M., Pietrini, P., Tierney, M. C.,
Ghetti, B., et al. (2006). Characteristics of frontotemporal dementia patients
with a progranulin mutation. Ann. Neurol. 60, 374–380. doi: 10.1002/ana.
20969
Huntzinger, E., and Izaurralde, E. (2011). Gene silencing by microRNAs: contribu-
tions of translational repression and mRNA decay. Nat. Rev. Genet. 12, 99–110.
doi: 10.1038/nrg2936
Huppert, J. L., Bugaut, A., Kumari, S., and Balasubramanian, S. (2008). G-
quadruplexes: the beginning and end of UTRs. Nucleic Acids Res. 36,
6260–6268. doi: 10.1093/nar/gkn511
Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., et al.
(1998).Association of missense and 5′-splice-site mutations in tau with the
inherited dementia FTDP-17. Nature 393, 702–705. doi: 10.1038/31508
Hutvagner, G., McLachlan, J., Pasquinelli, A. E., Balint, E., Tuschl, T., and Zamore,
P. D. (2001). A cellular function for the RNA-interference enzyme Dicer in
the maturation of the let-7 small temporal RNA. Science 293, 834–838. doi:
10.1126/science.1062961
Iba, M., Guo, J. L., Mcbride, J. D., Zhang, B., Trojanowski, J. Q., and Lee, V.
M. (2013). Synthetic tau fibrils mediate transmission of neurofibrillary tan-
gles in a transgenic mouse model of Alzheimer’s-like Tauopathy J. Neurosci.
33, 1024–1037. doi: 10.1523/JNEUROSCI.2642-12.2013
Iijima, M., Tabira, T., Poorkaj, P., Schellenberg, G. D., Trojanowski, J. Q., Lee, V.
M., et al. (1999). A distinct familial presenile dementia with a novel missense
mutation in the tau gene. Neuroreport 10, 497–501. doi: 10.1097/00001756-
199902250-00010
Iko, Y., Kodama, T. S., Kasai, N., Oyama, T., Morita, E. H., Muto, T., et al. (2004).
Domain architectures and characterization of an RNA-binding protein, TLS.
J. Biol. Chem. 279, 44834–44840. doi: 10.1074/jbc.M408552200
Iovino, M., Pfisterer, U., Holton, J. L., Lashley, T., Swingler, R. J., Calo, L., et al.
(2014). The novel MAPT mutation K,98E: mechanisms of mutant tau toxicity,
brain pathology and tau expression in induced fibroblast-derived neurons.Acta
Neuropathol. 127, 283–295. doi: 10.1007/s00401-013-1219-1
Iseki, E., Matsumura, T., Marui, W., Hino, H., Odawara, T., Sugiyama, N., et al.
(2001). Familial frontotemporal dementia and parkinsonism with a novel
N296Hmutation in exon 10 of the tau gene and a widespread tau accumulation
in the glial cells. Acta Neuropathol. 102, 285–292.
Ishigaki, S., Hishikawa, N., Niwa, J., Iemura, S., Natsume, T., Hori, S., et al.
(2004). Physical and functional interaction between Dorfin and Valosin-
containing protein that are colocalized in ubiquitylated inclusions in neurode-
generative disorders. J. Biol. Chem. 279, 51376–51385. doi: 10.1074/jbc.M40
6683200
Ishigaki, S., Masuda, A., Fujioka, Y., Iguchi, Y., Katsuno, M., Shibata, A., et al.
(2012). Position-dependent FUS-RNA interactions regulate alternative splicing
events and transcriptions. Sci. Rep. 2, 529. doi: 10.1038/srep00529
Ito, D., Seki, M., Tsunoda, Y., Uchiyama, H., and Suzuki, N. (2011). Nuclear trans-
port impairment of amyotrophic lateral sclerosis-linkedmutations in FUS/TLS.
Ann. Neurol. 69, 152–162. doi: 10.1002/ana.22246
Iyer, A., Lapointe, N. E., Zielke, K., Berdynski, M., Guzman, E., Barczak, A.,
et al. (2013). A novel MAPT mutation, G55R, in a frontotemporal dementia
patient leads to altered Tau function. PLoS ONE 8:e76409. doi: 10.1371/jour-
nal.pone.0076409
Jacquin, A., Rouaud, O., Soichot, P., Bejot, Y., Dygai-Cochet, I., Sarazin, M., et al.
(2013). Psychiatric presentation of frontotemporal dementia associated with
inclusion bodymyopathy due to the VCPmutation (R155H) in a French family.
Case Rep. Neurol. 5, 187–194. doi: 10.1159/000356481
Janssens, J., and Van Broeckhoven, C. (2013). Pathological mechanisms underly-
ing TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.Hum.
Mol. Genet. 22, R77–R87. doi: 10.1093/hmg/ddt349
Jiao, J., Herl, L. D., Farese, R. V., and Gao, F.-B. (2010). MicroRNA-29b reg-
ulates the expression level of human progranulin, a secreted glycoprotein
implicated in frontotemporal dementia. PLoS ONE 5:e10551. doi: 10.1371/jour-
nal.pone.0010551
Johnson, J. O., Mandrioli, J., Benatar, M., Van Deerlin, V. M., Trojanowski, J.
Q., Mora, G., et al. (2010). Exome sequencing reveals VCP mutations as
a cause of familial ALS. Neuron 68, 857–864. doi: 10.1016/j.neuron.2010.
11.036
Johnson, J. O., Pioro, E. P., Boehringer, A., Chia, R., Feit, H., Renton, A. E.,
et al. (2014). Mutations in the Matrin 3 gene cause familial amyotrophic lateral
sclerosis. Nat. Neurosci. 17, 664–666. doi: 10.1038/nn.3688
Ju, J.-S., Fuentealba, R. A., Miller, S. E., Jackson, E., Piwnica-Worms, D.,
Baloh, R. H., et al. (2009). Valosin-containing protein (VCP) is required for
autophagy and is disrupted in VCP disease. J. Cell Biol. 187, 875–888. doi:
10.1083/jcb.200908115
Kabashi, E., Lin, L., Tradewell, M. L., Dion, P. A., Bercier, V., Bourgouin, P.,
et al. (2010). Gain and loss of function of ALS-related mutations of TARDBP
(TDP-43) cause motor deficits in vivo. Hum. Mol. Genet. 19, 671–683. doi:
10.1093/hmg/ddp534
Kabashi, E., Valdmanis, P. N., Dion, P., Spiegelman, D., McConkey, B. J.,
Vande Velde, C., et al. (2008). TARDBP mutations in individuals with spo-
radic and familial amyotrophic lateral sclerosis. Nat. Genet. 40, 572–574. doi:
10.1038/ng.132
Kaleem, M., Zhao, A., Hamshere, M., and Myers, A. J. (2007). Identification of
a novel valosin-containing protein polymorphism in late-onset Alzheimer’s
disease. Neurodegener Dis. 4, 376–381. doi: 10.1159/000105158
Kara, E., Ling, H., Pittman, A. M., Shaw, K., de Silva, R., Simone, R., et al.
(2012). The MAPT p.A152T variant is a risk factor associated with tauopathies
with atypical clinical and neuropathological features. Neurobiol. Aging. 33,
2231.e7-2231.e14. doi: 10.1016/j.neurobiolaging.2012.04.006
Katzmann, D. J., Odorizzi, G., and Emr, S. D. (2002). Receptor downregulation
and multivesicular-body sorting. Nat. Rev. Mol. Cell Biol. 3, 893–905. doi:
10.1038/nrm973
Kawahara, Y., and Mieda-Sato, A. (2012). TDP-43 promotes microRNA biogene-
sis as a component of the Drosha and Dicer complexes. Proc. Natl. Acad. Sci.
U.S.A. 109, 3347–3352. doi: 10.1073/pnas.1112427109
Kessenbrock, K., Fröhlich, L., Sixt, M., Lämmermann, T., Pfister, H., Bateman, A.,
et al. (2008). Proteinase 3 and neutrophil elastase enhance inflammation inmice
by inactivating antiinflammatory progranulin. J. Clin. Invest. 118, 2438–2447.
doi: 10.1172/JCI34694
Kikin, O., Zappala, Z., D’Antonio, L., and Bagga, P. S. (2008). GRSDB2 and
GRS_UTRdb: databases of quadruplex forming G-rich sequences in pre-
mRNAs and mRNAs. Nucleic Acids Res. 36, D141-D8.(Database issue):D141-8.
doi: 10.1093/nar/gkm982
Kim, E.-J., Kwon, J. C., Park, K. H., Park, K.-W., Lee, J.-H., Choi, S. H.,
et al. (2014). Clinical and genetic analysis of MAPT, GRN, and C9orf72
genes in Korean patients with frontotemporal dementia. Neurobiol. Aging. 35,
1213.e13–1213.e17. doi: 10.1016/j.neurobiolaging.2013.11.033
Kim, H.-J., Jeon, B. S., Yun, J. Y., Seong, M.-W., Park, S. S., and Lee,
J.-Y. (2010a). Screening for MAPT and PGRN mutations in Korean
patients with PSP/CBS/FTD. Parkinsonism Relat. Disord. 16, 305–306. doi:
10.1016/j.parkreldis.2010.01.004
Kim, S. H., Shanware, N. P., Bowler, M. J., and Tibbetts, R. S. (2010b). Amyotrophic
lateral sclerosis-associated proteins TDP-43 and FUS/TLS function in a com-
mon biochemical complex to co-regulate HDAC6 mRNA. J. Biol. Chem. 285,
34097–34105. doi: 10.1074/jbc.M110.154831
Kim, V. N. (2004). MicroRNA precursors in motion: exportin-5 mediates
their nuclear export. Trends Cell Biol. 14, 156–159. doi: 10.1016/j.tcb.2004.
02.006
Kimonis, V. E., Mehta, S. G., Fulchiero, E. C., Thomasova, D., Boycott, K., Neilan,
E. G., et al. (2008). Clinical studies in familial VCP myopathy associated with
paget disease of bone and frontotemporal dementia. Am. J. Med. Genet. A. 28,
745–757. doi: 10.1002/ajmg.a.31862
King, I., Yartseva, V., Salas, D., Kumar, A., Heidersbach, A., Ando, D. M., et al.
(2014). The RNA binding protein TDP-43 selectively disruptsMicroRNA-1/206
incorporation into the RNA-induced silencing complex. J. Biol. Chem. 289,
14263–14271. doi: 10.1074/jbc.M114.561902
Kobayashi, T., Ota, S., Tanaka, K., Ito, Y., Hasegawa, M., Umeda, Y., et al.
(2003).Novel L266V mutation of the tau gene causes frontotemporal dementia
with a unique tau pathology. Ann. Neurol. 53, 133–137. doi: 10.1002/ana.10447
Frontiers in Molecular Neuroscience | www.frontiersin.org 25 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
Kouri, N., Carlomagno, Y., Baker, M., Liesinger, A.M., Caselli, R. J., Wszolek, Z. K.,
et al. (2014). Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal
degeneration. Acta Neuropathol. 127, 271–282. doi: 10.1007/s00401-013-
1193-7
Kovach, M. J., Waggoner, B., Leal, S. M., Gelber, D., Khardori, R., Levenstien, M.,
et al. (2001). Clinical delineation and localization to chromosome 9p13.3-p12 of
a unique dominant disorder in four families: hereditary inclusion body myopa-
thy, Paget disease of bone, and frontotemporal dementia. Mol. Genet. Metab.
74, 458–475. doi: 10.1006/mgme.2001.3256
Kovacs, G. G., Murrell, J. R., Horvath, S., Haraszti, L., Majtenyi, K., Molnar, M.
J., et al. (2009). TARDBP variation associated with frontotemporal demen-
tia, supranuclear gaze palsy, and chorea. Mov. Disord. 24, 1843–1847. doi:
10.1002/mds.22697
Kovacs, G. G., Pittman, A., Revesz, T., Luk, C., Lees, A., Kiss, E., et al. (2008).
MAPT S305I mutation: implications for argyrophilic grain disease. Acta Neu-
ropathol. 116, 103–118. doi: 10.1007/s00401-007-0322-6
Kumar, K. R., Needham, M., Mina, K., Davis, M., Brewer, J., Staples, C.,
et al. (2010). Two Australian families with inclusion-body myopathy,
Paget’s disease of bone and frontotemporal dementia: novel clinical and
genetic findings. Neuromuscul. Disord. 20, 330–334. doi: 10.1016/j.nmd.2010.
03.002
Kwiatkowski, T. J., Bosco, D. A., Leclerc, A. L., Tamrazian, E., Vanderburg, C.
R., Russ, C., et al. (2009). Mutations in the FUS/TLS gene on chromosome
16 cause familial amyotrophic lateral sclerosis. Science 323, 1205–1208. doi:
10.1126/science.1166066
Lagier-Tourenne, C., Baughn, M., Rigo, F., Sun, S., Liu, P., Li, H.-R., et al. (2013).
Targeted degradation of sense and antisense C9orf72 RNA foci as therapy
for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. U.S.A. 110,
E4530–E4539. doi: 10.1073/pnas.1318835110
Lagier-Tourenne, C., Polymenidou, M., and Cleveland, D. W. (2010). TDP-43 and
FUS/TLS: emerging roles in RNA processing and neurodegeneration. Hum.
Mol. Genet. 19, R46–R64. doi: 10.1093/hmg/ddq137
Lagier-Tourenne, C., Polymenidou,M., Hutt, K. R., Vu, A. Q., Baughn,M., Huelga,
S. C., et al. (2012). Divergent roles of ALS-linked proteins FUS/TLS and TDP-
43 intersect in processing long pre-mRNAs. Nat. Neurosci. 15, 1488–1497. doi:
10.1038/nn.3230
Lander, E. S., Linton, L. M., Birren, B., Nusbaum, C., Zody, M. C., Baldwin, J.,
et al. (2001). Initial sequencing and analysis of the human genome. Nature 409,
860–921. doi: 10.1038/35057062
Lanska, D. J., Currier, R. D., Cohen, M., Gambetti, P., Smith, E. E., Bebin, J., et al.
(1994). Familial progressive subcortical gliosis. Neurology 44, 1633–1643. doi:
10.1212/WNL.44.9.1633
Law, W. J., Cann, K. L., and Hicks, G. G. (2006). TLS, EWS and TAF15: a
model for transcriptional integration of gene expression. Brief. Funct. Genomic.
Proteomic. 5, 8–14. doi: 10.1093/bfgp/ell015
Le Ber, I., Van der Zee, J., Hannequin, D., Gijselinck, I., Campion, D., Puel,
M., et al. (2007). Progranulin null mutations in both sporadic and familial
frontotemporal dementia.Hum. Mutat. 28, 846–855. doi: 10.1002/humu.20520
Lee, E. B., Lee, V. M.-Y., and Trojanowski, J. Q. (2012). Gains or losses: molecu-
lar mechanisms of TDP43-mediated neurodegeneration.Nat. Rev. Neurosci. 13,
38–50. doi: 10.1038/nrn3121
Lee, H.-G., Perry, G., Moreira, P. I., Garrett, M. R., Liu, Q., Zhu, X., et al. (2005).
Tau phosphorylation in Alzheimer’s disease: pathogen or protector? Trends
Mol. Med. 11, 164–169. doi: 10.1016/j.molmed.2005.02.008
Lee, Y., Ahn, C., Han, J., Choi, H., Kim, J., Yim, J., et al. (2003). The nuclear
RNase III Drosha initiates microRNA processing. Nature 425, 415–419. doi:
10.1038/nature01957
Lee, Y.-B., Chen, H.-J., Peres, J. N., Gomez-Deza, J., Attig, J., Stalekar, M., et al.
(2013). Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci,
sequester RNA binding proteins, and are neurotoxic. Cell Rep. 5, 1178–1186.
doi: 10.1016/j.celrep.2013.10.049
Lee, Y., Kim, M., Han, J., Yeom, K.-H., Lee, S., Baek, S. H., et al. (2004). MicroRNA
genes are transcribed by RNA polymerase II. EMBO J. 23, 4051–4060. doi:
10.1038/sj.emboj.7600385
Ling, S. C., Albuquerque, C. P., Han, J. S., Lagier-Tourenne, C., Tokunaga, S., Zhou,
H., et al. (2010). ALS-associated mutations in TDP-43 increase its stability and
promote TDP-43 complexes with FUS/TLS. Proc. Natl. Acad. Sci. U.S.A. 107,
13318–13323. doi: 10.1073/pnas.1008227107
Ling, S.-C., Polymenidou, M., and Cleveland, D. W. (2013). Converging mecha-
nisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 79,
416–438. doi: 10.1016/j.neuron.2013.07.033
Liu, J., Carmell, M., and Rivas, F. (2004). Argonaute2 is the catalytic engine of
mammalian RNAi. Science 305, 1437–1441. doi: 10.1126/science.1102513
Liu, L., Drouet, V., Wu, J. W., Witter, M. P., Small, S. A., Clelland, C., et al.
(2012). Trans-synaptic spread of tau pathology in vivo. PLoS ONE 7:e31302.
doi: 10.1371/journal.pone.0031302
Lladó, A., Ezquerra,M., Sánchez-Valle, R., Rami, L., Tolosa, E., andMolinuevo, J. L.
(2007). A novelMAPTmutation (P301T) associated with familial frontotempo-
ral dementia. Eur. J. Neurol. 14, e9–e10. doi: 10.1111/j.1468-1331.2007.01763.x
Lopez de Munain, A., Alzualde, A., Gorostidi, A., Otaequi, D., Ruiz-Martinez, J.,
Indakoetxea, B., et al. (2008). Mutations in progranulin gene: clinical, patho-
logical, and ribonucleic acid expression findings. Biol. Psychiatry 63, 946–952.
doi: 10.1016/j.biopsych.2007.08.015
Luna-Muñoz, J., Harrington, C. R., Wischik, C. M., Flores-Rodriìguez, P., Avila,
J., Zamudio, S. R., et al. (2013). “Phosphorylation of tau protein associated as
a protective mechanism in the presence of toxic, C-terminally truncated tau in
Alzheimer’s disease,” in Understanding Alzheimer’s Disease, ed I. Zerr (InTech).
doi: 10.5772/54228
Luquin, N., Yu, B., Saunderson, R. B., Trent, R. J., and Pamphlett, R. (2009).
Genetic variants in the promoter of TARDBP in sporadic amyotrophic lat-
eral sclerosis. Neuromuscul Disord. 19, 696–700. doi: 10.1016/j.nmd.2009.
07.005
Lynch, T., Sano, M., Marder, K. S., Bell, K. L., Foster, N. L., Defendini, R.
F., et al. (1994). Clinical characteristics of a family with chromosome 17-
linked disinhibition-dementia-parkinsonism-amyotrophy complex. Neurology
44, 1878–1884. doi: 10.1212/WNL.44.10.1878
Mackenzie, I. R., Baker, M., Pickering-Brown, S., Hsiung, G.-Y. R., Lindholm, C.,
Dwosh, E., et al. (2006). The neuropathology of frontotemporal lobar degener-
ation caused by mutations in the progranulin gene. Brain 129, 3081–3090. doi:
10.1093/brain/awl271
Mackenzie, I. R. A, Frick, P., and Neumann, M. (2014). The neuropathology asso-
ciated with repeat expansions in the C9ORF72 gene. Acta Neuropathol. 127,
347–357. doi: 10.1007/s00401-013-1232-4
Mackenzie, I. R., Rademakers, R., and Neumann, M. (2010). TDP-43 and FUS in
amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 9,
995–1007. doi: 10.1016/S1474-4422(10)70195-2
Marcon, G., Rossi, G., Giaccone, G., Giovagnoli, A. R., Piccoli, E., Zanini, S., et al.
(2011). Variability of the clinical phenotype in an Italian family with demen-
tia associated with an intronic deletion in the GRN gene. J. Alzheimers Dis. 22,
1123–1133. doi: 10.3233/JAD-2011-110332
Martin-Serrano, J., and Neil, S. J. D. (2011). Host factors involved in retroviral
budding and release.Nat. Rev. Microbiol. 9, 519–531. doi: 10.1038/nrmicro2596
Medina, M., and Avila, J. (2014). The role of extracellular Tau in the
spreading of neurofibrillary pathology. Front. Cell. Neurosci. 8:113. doi:
10.3389/fncel.2014.00113
Mehler,M. F., andMattick, J. S. (2007). Noncoding RNAs and RNA editing in brain
development, functional diversification, and neurological disease. Physiol. Rev.
87, 799–823. doi: 10.1152/physrev.00036.2006
Meissner,M., Lopato, S., Gotzmann, J., Sauermann, G., and Barta, A. (2003). Proto-
oncoprotein tls/fus is associated to the nuclear matrix and complexed with
splicing factors ptb, srm160, and sr proteins. Exp. Cell Res. 283, 184–195. doi:
10.1016/S0014-4827(02)00046-0
Mercer, T. R., Dinger, M. E., Sunkin, S. M., Mehler, M. F., and Mattick, J. S. (2008).
Specific expression of long noncoding RNAs in the mouse brain. Proc. Natl.
Acad. Sci. U.S.A. 105, 716–721. doi: 10.1073/pnas.0706729105
Metcalf, D., and Isaacs, A. M. (2010). The role of ESCRT proteins in fusion events
involving lysosomes, endosomes and autophagosomes. Biochem. Soc. Trans. 38,
1469–1473. doi: 10.1042/BST0381469
Miyamoto, K., Kowalska, A., Hasegawa, M., Tabira, T., Takahashi, K., Araki, W.,
et al. (2001). Familial frontotemporal dementia and parkinsonism with a novel
mutation at an intron 10+11-splice site in the tau gene. Ann. Neurol. 50,
117–120. doi: 10.1002/ana.1083
Mizielinska, S., Lashley, T., Norona, F. E., Clayton, E. L., Ridler, C. E., Fratta, P.,
et al. (2013). C9orf72 frontotemporal lobar degeneration is characterised by fre-
quent neuronal sense and antisense RNA foci. Acta Neuropathol. 126, 845–857.
doi: 10.1007/s00401-013-1200-z
Frontiers in Molecular Neuroscience | www.frontiersin.org 26 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
Mizuno, Y., Hori, S., Kakizuka, A., and Okamoto, K. (2003). Vacuole-creating pro-
tein in neurodegenerative diseases in humans. Neurosci. Lett. 343, 77–80. doi:
10.1016/S0304-3940(03)00280-5
Momeni, P., Rogaeva, E., Van Deerlin, V., Yuan, W., Grafman, J., Tierney, M.,
et al. (2006). Genetic variability in CHMP2B and frontotemporal dementia.
Neurodegener. Dis. 3, 129–133. doi: 10.1159/000094771
Mori, K., Lammich, S., Mackenzie, I. R., Forné, I., Zilow, S., Kretzschmar, H.,
et al. (2013a). hnRNP A3 binds to GGGGCC repeats and is a constituent of
p62-positive/TDP43-negative inclusions in the hippocampus of patients with
C9orf72 mutations. Acta Neuropathol. 125, 413–423. doi: 10.1007/s00401-013-
1088-7
Mori, K., Weng, S.-M., Arzberger, T., May, S., Rentzsch, K., Kremmer, E.,
et al. (2013b). The C9orf72 GGGGCC repeat is translated into aggregat-
ing dipeptide-repeat proteins in FTLD/ALS. Science (New York, NY), 339,
1335–1338. doi: 10.1126/science.1232927
Morita, M., Al-Chalabi, A., Andersen, P. M., Hosler, B., Sapp, P., Englund,
E., et al. (2006). A locus on chromosome 9p confers susceptibil-
ity to ALS and frontotemporal dementia. Neurology 66, 839–844. doi:
10.1212/01.wnl.0000200048.53766.b4
Morlando, M., Dini Modigliani, S., Torrelli, G., Rosa, A., Di Carlo, V., Caf-
farelli, E., et al. (2012). FUS stimulates microRNA biogenesis by facilitat-
ing co-transcriptional Drosha recruitment. EMBO J. 31, 4502–4510. doi:
10.1038/emboj.2012.319
Mukherjee, O., Pastor, P., Cairns, N. J., Chakraverty, S., Kauve, J. S., Shears S., et al.
(2006). HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-
positive, taunegative inclusions caused by a missense mutation in the signal
peptide of progranulin. Ann. Neurol. 60, 314–322. doi: 10.1002/ana.20963
Mukherjee, O., Wang, J., Gitcho, M., Chakraverty, S., Taylor-Reinwald, L.,
Shears, S., et al. (2008). Molecular characterization of novel progranulin
(GRN) mutations in frontotemporal dementia. Hum. Mutat. 29, 512–521. doi:
10.1002/humu.20681
Murrell, J. R., Spillantini, M. G., Zolo, P., Guazzelli, M., Smith, M. J., Hasegawa,
M., et al. (1999). Tau gene mutation G389R causes a tauopathy with abundant
pick body-like inclusions and axonal deposits. J. Neuropathol. Exp. Neurol. 58,
1207–1226. doi: 10.1097/00005072-199912000-00002
Naganuma, T., Nakagawa, S., Tanigawa, A., Sasaki, Y. F., Goshima, N., and
Hirose, T. (2012). Alternative 3′-end processing of long noncoding RNA
initiates construction of nuclear paraspeckles. EMBO J. 31, 4020–4034. doi:
10.1038/emboj.2012.251
Nakagawa, S., and Hirose, T. (2012). Paraspeckle nuclear bodies–useful useless-
ness? Cell. Mol. Life Sci. 69, 3027–3036. doi: 10.1007/s00018-012-0973-x
Nakagawa, S., Naganuma, T., Shioi, G., and Hirose, T. (2011). Paraspeckles are
subpopulation-specific nuclear bodies that are not essential in mice. J. Cell Biol.
193, 31–39. doi: 10.1083/jcb.201011110
Nalbandian, A., Donkervoort, S., Dec, E., Badadani, M., Katheria, V., Rana, P.,
et al. (2011). The multiple faces of valosin-containing protein-associated dis-
eases: inclusion body myopathy with Paget’s disease of bone, frontotemporal
dementia, and amyotrophic lateral sclerosis. J. Mol. Neurosci. 45, 522–531. doi:
10.1007/s12031-011-9627-y
Neumann, M., Diekmann, S., Bertsch, U., Vanmassenhove, B., Bogerts, B., Kret-
zschmar, H. A. (2005). Novel G335V mutation in the tau gene associated
with early onset familial frontotemporal dementia. Neurogenetics 6, 91–95. doi:
10.1007/s10048-005-0210-y
Neumann, M., Kwong, L. K., Lee, E. B., Kremmer, E., Flatley, A., Xu, Y., et al.
(2009a). Phosphorylation of S409/410 of TDP-43 is a consistent feature in all
sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 117,
137–149. doi: 10.1007/s00401-008-0477-9
Neumann, M., Rademakers, R., Roeber, S., Baker, M., Kretzschmar, H. A.,
and Mackenzie, I. R. A. (2009b). A new subtype of frontotemporal
lobar degeneration with FUS pathology. Brain 132(Pt 11), 2922–2931. doi:
10.1093/brain/awp214
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C.,
Chou, T. T., et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degen-
eration and amyotrophic lateral sclerosis. Science (New York, NY) 314, 130–133.
doi: 10.1126/science.1134108
Ng, S. Y., Lin, L., Soh, B. S., and Stanton, L. W. (2013). Long noncoding RNAs
in development and disease of the central nervous system. Trends Genet. 29,
461–468. doi: 10.1016/j.tig.2013.03.002
Nishimoto, Y., Nakagawa, S., Hirose, T., Okano, H. J., Takao, M., Shibata, S.,
et al. (2013). The long non-coding RNA nuclear-enriched abundant tran-
script 1_2 induces paraspeckle formation in the motor neuron during the early
phase of amyotrophic lateral sclerosis. Mol. Brain 6, 31. doi: 10.1186/1756-
6606-6-31
Obita, T., Saksena, S., Ghazi-Tabatabai, S., Gill, D. J., Perisic, O., Emr, S. D.,
et al. (2007). Structural basis for selective recognition of ESCRT-III by theAAA
ATPase Vps4. Nature 449, 735–739. doi: 10.1038/nature06171
O’Rourke, J. R., and Swanson,M. S. (2009). Mechanisms of RNA-mediated disease.
J. Biol. Chem. 284, 7419–7423. doi: 10.1074/jbc.R800025200
Ogaki, K., Li, Y., Takanashi, M., Ishikawa, K.-I., Kobayashi, T., Nonaka, T., et al.
(2013). Analyses of the MAPT, PGRN, and C9orf72 mutations in Japanese
patients with FTLD, PSP, and CBS. Parkinsonism Relat. Disord. 19, 15–20. doi:
10.1016/j.parkreldis.2012.06.019
Okura, H., Yamashita, S., Ohama, T., Saga, A., Yamamoto-Kakuta, A., Hamada,
Y., et al. (2010). HDL/apolipoprotein A-I binds to macrophage-derived
progranulin and suppresses its conversion into proinflammatory granulins.
J. Atheroscler. Thromb. 17, 568–577. doi: 10.5551/jat.3921
Osborne, R. J., and Thornton, C., a. (2006). RNA-dominant diseases. Hum. Mol.
Genet. 15 Spec No(2), R162–R9. doi: 10.1093/hmg/ddl181
Ou, S. H., Wu, F., Harrich, D., García-Martínez, L. F., and Gaynor, R. B. (1995).
Cloning and characterization of a novel cellular protein, TDP-43, that binds to
human immunodeficiency virus type 1 TAR DNA sequence motifs. J. Virol. 69,
3584–3596.
Pandit, S., Wang, D., and Fu, X.-D. (2008). Functional integration of transcrip-
tional and RNA processing machineries. Curr. Opin. Cell Biol. 20, 260–265. doi:
10.1016/j.ceb.2008.03.001
Parkinson, N., Ince, P. G., Smith, M. O., Highley, R., Skibinski, G., Ander-
sen, P. M., et al. (2006). ALS phenotypes with mutations in CHMP2B
(charged multivesicular body protein 2B). Neurology 67, 1074–1077. doi:
10.1212/01.wnl.0000231510.89311.8b
Pasquinelli, A. E. (2012). MicroRNAs and their targets: recognition, regulation
and an emerging reciprocal relationship. Nat. Rev. Genet. 13, 271–282. doi:
10.1038/nrg3162
Pickering-Brown, S., Baker, M., Yen, S. H., Liu, W. K., Hasegawa, M., Cairns, N.,
et al. (2000). Pick’s disease is associated with mutations in the tau gene. Ann.
Neurol. 48, 859–867. doi: 10.1002/1531-8249(200012)48:6<859::AID-ANA6
>3.0.CO;2-1
Pickering-Brown, S. M., Baker, M., Nonaka, T., Ikeda, K., Sharma, S., Mackenzie, J.,
et al. (2004). Frontotemporal dementia with Pick-type histology associated with
Q336R mutation in the tau gene. Brain 127(Pt. 6), 1415–1426. doi: 10.1093/
brain/awh147
Plowman, G. D., Green, J. M., Neubauer, M. G., Buckley, S. D., Mcdonald, V.
L., Todaro, G. J., et al. (1992). The epithelin precursor encodes two pro-
teins with opposing activities on epithelial cell growth. J. Biol. Chem. 267,
13073–13078.
Polymenidou, M., Lagier-Tourenne, C., Hutt, K. R., Huelga, S. C., Moran, J., Liang,
T. Y., et al. (2011). Long pre-mRNA depletion and RNAmissplicing contribute
to neuronal vulnerability from loss of TDP-43. Nat. Neurosci. 14, 459–468. doi:
10.1038/nn.2779
Poorkaj, P., Kas, A., D’Souza, I., Zhou, Y., Pham, Q., Stone, M., et al.
(2001). A genomic sequence analysis of the mouse and human microtubule-
associated protein tau.Mamm. Genome. 12, 700–712. doi: 10.1007/s00335-001-
2044-8
Prasanth, K. V., Prasanth, S. G., Xuan, Z., Hearn, S., Freier, S. M., Bennett, C. F.,
et al. (2005). Regulating gene expression through RNA nuclear retention. Cell
123, 249–263. doi: 10.1016/j.cell.2005.08.033
Pye, V. E., Beuron, F., Keetch, C. A, McKeown, C., Robinson, C. V., Meyer, H. H.,
et al. (2007). Structural insights into the p97-Ufd1-Npl4 complex. Proc. Natl.
Acad. Sci. U.S.A. 104, 467–472. doi: 10.1073/pnas.0603408104
Rademakers, R., Eriksen, J. L., Baker, M., Robinson, T., Ahmed, Z., Lincoln, S. J.,
et al. (2008). Common variation in the miR-659 binding-site of GRN is a major
risk factor for TDP43-positive frontotemporal dementia. Hum. Mol. Genet. 17,
3631–3642. doi: 10.1093/hmg/ddn257
Reddy, K., Zamiri, B., Stanley, S. Y. R., Macgregor, R. B., and Pearson, C. E.
(2013). The disease-associated r(GGGGCC)n repeat from the C9orf72 gene
forms tract length-dependent uni- and multimolecular RNA G-quadruplex
structures. J. Biol. Chem. 288, 9860–9866. doi: 10.1074/jbc.C113.452532
Frontiers in Molecular Neuroscience | www.frontiersin.org 27 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
Reichelt, A. C., Rodgers, R. J., and Clapcote, S. J. (2012). The role of neurex-
ins in schizophrenia and autistic spectrum disorder. Neuropharmacology 62,
1519–1526. doi: 10.1016/j.neuropharm.2011.01.024
Renoux, A., and Todd, P. (2012). Neurodegeneration the RNA way. Prog. Neuro-
biol. 97, 173–189. doi: 10.1016/j.pneurobio.2011.10.006
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs,
J. R., et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is
the cause of chromosome 9p21-linked ALS-FTD. Neuron 72, 257–268. doi:
10.1016/j.neuron.2011.09.010
Rizzini, C., Goedert, M., Hodges, J. R., Smith, M. J., Jakes, R., Hills, R., et al.
(2000).Tau gene mutation K257T causes a tauopathy similar to Pick’s disease.
J. Neuropathol. Exp. Neurol. 59, 990–1001.
Rizzu, P., van Swieten, J. C., Joosse, M., Hasegawa, M., Stevens, M., Tibben, A.,
et al. (1999). High prevalence of mutations in the microtubule-associated pro-
tein tau in a population study of frontotemporal dementia in the Netherlands.
Am. J. Human Genet. 64, 414–421. doi: 10.1086/302256
Rossi, G., Bastone, A., Piccoli, E., Mazzoleni, G., Morbin, M., Uggetti, A., et al.
(2012). New mutations in MAPT gene causing frontotemporal lobar degen-
eration: biochemical and structural characterization. Neurobiol. Aging 33,
834.e1–834.e6. doi: 10.1016/j.neurobiolaging.2011.08.008
Rossi, G., Bastone, A., Piccoli, E., Morbin, M., Mazzoleni, G., Fugnanesi, V.,
et al. (2014). Different mutations at V363 MAPT codon are associated with
atypical clinical phenotypes and show unusual structural and functional
features. Neurobiol. Aging 35, 408–417. doi: 10.1016/j.neurobiolaging.2013.
08.004
Rosso, S. M., Donker, K. L., Baks, T., Joosse, M., de Koning, I., Pijnenburg, Y., et al.
(2003). Frontotemporal dementia in The Netherlands: patient characteristics
and prevalence estimates from a population-based study. Brain 126, 2016–2022.
doi: 10.1093/brain/awg204
Rosso, S. M., van Herpen, E., Deelen, W., Kamphorst, W., Severijnen, L. A.,
Willemsen, R., et al. (2002). A novel tau mutation, S320F, causes a tauopathy
with inclusions similar to those in Pick’s disease. Ann. Neurol. 51, 373–376. doi:
10.1002/ana.10140
Rouiller, I., DeLaBarre, B., May, A. P., Weis, W. I., Brunger, A. T., Milli-
gan, R., et al. (2002). Conformational changes of the multifunction p97AAA
ATPase during its ATPase cycle. Nat. Struct. Biol. 9, 950–957 doi: 10.1038/
nsb872
Rovelet-Lecrux, A., Deramecourt, V., Legallic, S., Maurage, C. A., Le Ber, I., Brice,
A., et al. (2008). Deletion of the progranulin gene in patients with frontotem-
poral lobar degeneration or Parkinson disease. Neurobiol. Dis. 31, 41–45. doi:
10.1016/j.nbd.2008.03.004
Roxrud, I., Stenmark, H., and Malerød, L. (2010). ESCRT and Co. Biol. Cell, 102,
293–318. doi: 10.1042/BC20090161
Saman, S., Kim, W., Raya, M., Visnick, Y., Miro, S., Jackson, B., et al. (2012).
Exosome-associated tau is secreted in tauopathy models and is selectively phos-
phorylated in cerebrospinal fluid in early Alzheimer disease. J. Biol. Chem. 287,
3842–3849. doi: 10.1074/jbc.M111.277061
Sampathu, D. M., Neumann, M., Kwong, L. K., Chou, T. T., Micsenyi, M., Truax,
A., et al. (2006). Pathological heterogeneity of frontotemporal lobar degener-
ation with ubiquitin-positive inclusions delineated by ubiquitin immunohisto-
chemistry and novel monoclonal antibodies.Am. J. Pathol. 169, 1343–1352. doi:
10.2353/ajpath.2006.060438
Sareen, D., O’Rourke, J. G., Meera, P., Muhammad, A. K., Grant, S., Simpkinson,
M., et al. (2013). Targeting RNA foci in iPSC-derived motor neurons from ALS
patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 5, 208ra149. doi:
10.1126/scitranslmed.3007529
Schenk, V. W. (1959). Re-examination of a family with Pick’s disease. Ann. Hum.
Genet. 23, 325–333. doi: 10.1111/j.1469-1809.1959.tb01476.x
Schmidt, O., and Teis, D. (2012). The ESCRT machinery. Curr. Biol. 22,
R116–R120. doi: 10.1016/j.cub.2012.01.028
Schwartz, J. C., Ebmeier, C. C., Podell, E. R., Heimiller, J., Taatjes, D. J., and
Cech, T. R. (2012). FUS binds the CTD of RNA polymerase II and regu-
lates its phosphorylation at Ser2. Genes Dev. 26, 2690–2695. doi: 10.1101/gad.
204602.112
Sephton, C. F., Cenik, C., Kucukural, A., Dammer, E. B., Cenik, B., Han,
Y., et al. (2011). Identification of neuronal RNA targets of TDP-43-
containing ribonucleoprotein complexes. J. Biol. Chem. 286, 1204–1215. doi:
10.1074/jbc.M110.190884
Shan, X., Chiang, P.-M., Price, D. L., and Wong, P. C. (2010). Altered distri-
butions of Gemini of coiled bodies and mitochondria in motor neurons of
TDP-43 transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 107, 16325–16330. doi:
10.1073/pnas.1003459107
Shankaran, S. S., Capell, A., Hruscha, A. T., Fellerer, K., Neumann, M., Schmid, B.,
et al. (2008). Missense mutations in the progranulin gene linked to frontotem-
poral lobar degeneration with ubiquitin-immunoreactive inclusions reduce
progranulin production and secretion. J. Biol. Chem. 283, 1744–1753. doi:
10.1074/jbc.M705115200
Shelkovnikova, T. A., Robinson, H. K., Troakes, C., Ninkina, N., and Buchman,
V. L. (2014). Compromised paraspeckle formation as a pathogenic factor in
FUSopathies. Hum. Mol. Genet. 23, 2298–2312. doi: 10.1093/hmg/ddt622
Shi, Z., Hayashi, Y. K., Mitsuhashi, S., Goto, K., Kaneda, D., Choi, Y.-C., et al.
(2012). Characterization of the Asian myopathy patients with VCP mutations.
Eur. J. Neurol. 19, 501–509. doi: 10.1111/j.1468-1331.2011.03575.x
Shim, S., Kimpler, L. A., and Hanson, P. I. (2007). Structure/function analysis
of four core ESCRT-III proteins reveals common regulatory role for extreme
C-terminal domain. Traffic 8, 1068–1079. doi: 10.1111/j.1600-0854.2007.
00584.x
Simón, D., Garcia-Garcia, E., Royo, F., Falcon-Perez, J. M., and Avila, J. (2012).
Proteostasis of tau. Tau overexpression results in its secretion via membrane
vesicles. FEBS Lett. 586, 47–54. doi: 10.1016/j.febslet.2011.11.022
Skibinski, G., Parkinson, N. J., Brown, J. M., Chakrabarti, L., Lloyd, S. L., Hum-
merich, H., et al. (2005). Mutations in the endosomal ESCRTIII-complex
subunit CHMP2B in frontotemporal dementia. Nat. Genet. 37, 806–808. doi:
10.1038/ng1609
Skoglund, L., Matsui, T., Freeman, S. H., Wallin, A., Blom, E. S., Frosch,
M. P., et al. (2011). Novel progranulin mutation detected in 2
patients with FTLD. Alzheimer Dis. Assoc. Disord. 25, 173–178. doi:
10.1097/WAD.0b013e3181fbc22c
Smith, B. N., Newhouse, S., Shatunov, A., Vance, C., Topp, S., Johnson, L., et al.
(2012). The C9ORF72 expansion mutation is a common cause of ALS+/-FTD
in Europe and has a single founder. Eur. J. Hum. Genet. 21, 102–108. doi:
10.1038/ejhg.2012.98
Snowden, J. S., Rollinson, S., Thompson, J. C., Harris, J. M., Stopford, C. L.,
Richardson, A. M. T., et al. (2012). Distinct clinical and pathological character-
istics of frontotemporal dementia associated with C9ORF72 mutations. Brain
135(Pt 3), 693–708. doi: 10.1093/brain/awr355
Songsrirote, K., Li, Z., Ashford, D., Bateman, A., and Thomas-Oates, J.
(2010). Development and application of mass spectrometric methods for the
analysis of progranulin N-glycosylation. J. Proteomics 73, 1479–1490. doi:
10.1016/j.jprot.2010.02.013
Souquere, S., Beauclair, G., Harper, F., Fox, A., and Pierron, G. (2010). Highly
ordered spatial organization of the structural long noncoding NEAT1 RNAs
within paraspeckle nuclear bodies. Mol. Biol. Cell 21, 4020–4027. doi:
10.1091/mbc.E10-08-0690
Spillantini, M. G., and Goedert, M. (2000). Tau mutations in familial frontotempo-
ral dementia. Brain 123, 857–859. doi: 10.1093/brain/123.5.857
Spillantini, M. G., and Goedert, M. (2013). Tau pathology and neurodegeneration.
Lancet Neurol. 12, 609–622. doi: 10.1016/S1474-4422(13)70090-5
Spillantini, M. G., Goedert, M., Crowther, R. A., Murrell, J. R., Farlow, M. R., and
Ghetti, B. (1997). Familial multiple system tauopathy with presenile dementia:
a disease with abundant neuronal and glial tau filaments. Proc. Natl. Acad. Sci.
U.S.A. 94, 4113–4118. doi: 10.1073/pnas.94.8.4113
Spina, S., Murrell, J. R., Yoshida, H., Ghetti, B., Bermingham, N., Sweeney, B., et al.
(2007). The novel Tau mutation G335S: clinical, neuropathological and molec-
ular characterization. Acta Neuropathol. 113, 461–470. doi: 10.1007/s00401-
006-0182-5
Spina, S., Murrell, J. R., Vidal, R., and Ghetti, B. (2008). Neuropathologic and
genetic characterization of frontotemporal lobar degeneration with Ubiquitin-
and/or Tdp-43-positive inclusions: a large series. Alzheimer’s Dementia 4
(Supp. 2), T431. doi: 10.1016/j.jalz.2008.05.1280
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B., et al. (2008).
TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Sci-
ence 319, 1668–1672. doi: 10.1126/science.1154584
Stallings, N. R., Puttaparthi, K., Luther, C. M., Burns, D. K., and Elliott, E. J. (2010).
Progressive motor weakness in transgenic mice expressing human TDP-43.
Neurobiol. Dis. 40, 404–414. doi: 10.1016/j.nbd.2010.06.017
Frontiers in Molecular Neuroscience | www.frontiersin.org 28 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
Stanford, P. M., Shepherd, C. E., Halliday, G. M., Brooks, W. S., Schofield, P. W.,
Brodaty, H., et al. (2003). Mutations in the tau gene that cause an increase
in three repeat tau and frontotemporal dementia. Brain 126, 814–826 doi:
10.1093/brain/awg090
Stojkovic, T., Hammouda, E. H., Richard, P., Munain, A. L., De Ruiz-Martinez, J.,
Camaño, P., et al. (2009). Clinical outcome in 19 French and Spanish patients
with valosin-containing protein myopathy associated with Paget’s disease of
bone and frontotemporal dementia. Neuromuscul. Disord. 21, 316–323. doi:
10.1016/j.nmd.2009.02.012
Strong, M. J., Volkening, K., Hammond, R., Yang, W., Strong, W., Leystra-
Lantz, C., et al. (2007). TDP43 is a human low molecular weight neurofila-
ment (hNFL) mRNA-binding protein. Mol. Cell. Neurosci. 35, 320–327. doi:
10.1016/j.mcn.2007.03.007
Suárez-Calvet, M., Dols-Icardo, O., Lladó, A., Sánchez-Valle, R., Hernández, I.,
Amer, G., et al. (2014). Plasma phosphorylated TDP-43 levels are elevated
in patients with frontotemporal dementia carrying a C9orf72 repeat expan-
sion or a GRN mutation. J. Neurol. Neurosurg. Psychiatr. 85, 684–691. doi:
10.1136/jnnp-2013-305972
Sunwoo, H., Dinger, M. E., Wilusz, J. E., Amaral, P. P., Mattick, J. S., and Spec-
tor, D. L. (2009). MEN epsilon/beta nuclear-retained non-coding RNAs are
up-regulated upon muscle differentiation and are essential components of
paraspeckles. Genome Res. 19, 347–359. doi: 10.1101/gr.087775.108
Takamatsu, J., Kondo, A., Ikegami, K., Kimura, T., Fujii, H., Mitsuyama, Y., et al.
(1998). Selective expression of Ser 199/202 phosphorylated tau in a case of fron-
totemporal dementia. Dement. Geriatr. Cogn. Disord. 9, 82–89. doi: 10.1159/
000017028
Tan, A. Y., and Manley, J. L. (2009). The TET family of proteins: functions and
roles in disease. J. Mol. Cell Biol. 1, 82–92. doi: 10.1093/jmcb/mjp025
Tang, G., Tang, X., Mendu, V., Tang, X., Jia, X., Chen, Q.-J., et al. (2008). The art of
microRNA: various strategies leading to gene silencing via an ancient pathway.
Biochim. Biophys. Acta 1779, 655–662. doi: 10.1016/j.bbagrm.2008.06.006
Tang, X., Muniappan, L., Tang, G., and Özcan, S. (2009). Identification of glucose-
regulated miRNAs from pancreatic β cells reveals a role for miR-30d in insulin
transcription. RNA 15, 287–293. doi: 10.1261/rna.1211209
Tay, Y., Kats, L., Salmena, L., Weiss, D., Tan, S. M., Ala, U., et al. (2011).
Coding-independent regulation of the tumor suppressor PTEN by competing
endogenous mRNAs. Cell 147, 344–357. doi: 10.1016/j.cell.2011.09.029
Thies, W., and Bleiler, L. (2011). 2011 Alzheimer’s disease facts and figures.
Alzheimers Dement. 7, 208–244. doi: 10.1016/j.jalz.2011.02.004
Todd, P. K., and Paulson, H. L. (2010). RNA-mediated neurodegeneration in repeat
expansion disorders. Ann. Neurol. 67, 291–300. doi: 10.1002/ana.21948
Tollervey, J. R., Curk, T., Rogelj, B., Briese, M., Cereda, M., Kayikci, M., et al.
(2011). Characterizing the RNA targets and position-dependent splicing reg-
ulation by TDP-43. Nat. Neurosci. 14, 452–458. doi: 10.1038/nn.2778
Urwin, H., Authier, A., Nielsen, J. E., Metcalf, D., Powell, C., Froud, K., et al. (2010).
Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B
mutations. Hum. Mol. Genet. 19, 2228–2238. doi: 10.1093/hmg/ddq100
Usami, Y., Popov, S., Popova, E., Inoue,M.,Weissenhorn,W., and, GGöttlinger, H.
(2009). The ESCRT pathway and HIV-1 budding. Biochem. Soc. Trans. 37(Pt 1),
181–184. doi: 10.1042/BST0370181
Valencia-Sanchez, M. A., Liu, J., Hannon, G. J., and Parker, R. (2006). Control of
translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 20,
515–524. doi: 10.1101/gad.1399806
Van Blitterswijk, M., and Landers, J. E. (2010). RNA processing pathways in amy-
otrophic lateral sclerosis. Neurogenetics 11, 275–290. doi: 10.1007/s10048-010-
0239-4
Vance, C., Rogelj, B., Hortobagyi, T., De Vos, K. J., Nishimura, A. L., Sreedha-
ran, J., et al. (2009). Mutations in FUS, an RNA processing protein, cause
familial amyotrophic lateral sclerosis type 6. Science 323, 1208–1211. doi:
10.1126/science.1165942
Van Damme, P., Van Hoecke, A., Lambrechts, D., Vanacker, P., Bogaert, E., van
Swieten, J., et al. (2008). Progranulin functions as a neurotrophic factor to reg-
ulate neurite outgrowth and enhance neuronal survival. J. Cell Biol. 181, 37–41.
doi: 10.1083/jcb.200712039
Van Deerlin, V. M., Leverenz, J. B., Bekris, L. M., Bird, T. D., Yuan, W., Elman, L.
B., et al. (2008). TARDBPmutations in amyotrophic lateral sclerosis with TDP-
43 neuropathology: a genetic and histopathological analysis. Lancet Neurol. 7,
409–416. doi: 10.1016/S1474-4422(08)70071-1
Van der Zee, J., Gijselinck, I., Dillen, L., Van Langenhove, T., Theuns, J., Engel-
borghs, S., et al. (2013). A pan-European study of the C9orf72 repeat associ-
ated with FTLD: geographic prevalence, genomic instability, and intermediate
repeats. Hum. Mutat. 34, 363–373. doi: 10.1002/humu.22244
Van der Zee, J., Rademakers, R., Engelborghs, S., Gijselinck, I., Bogaerts, V., Van-
denberghe, R., et al. (2006). A Belgian ancestral haplotype harbours a highly
prevalent mutation for 17q21-linked tau-negative FTLD. Brain 129(Pt 4),
841–852. doi: 10.1093/brain/awl029
Van der Zee, J., Le Ber, I., Maurer-Stroh, S., Engelborghs, S., Gijselinck, I., Camuzat,
A., et al. (2007). Mutations other than null mutations producing a pathogenic
loss of progranulin in frontotemporal dementia. Hum. Mutat. 28, 416. doi:
10.1002/humu.9484
Van der Zee, J., Urwin, H., Engelborghs, S., Bruyland, M., Vandenberghe,
R., Dermaut, B., et al. (2008). CHMP2B C-truncating mutations in fron-
totemporal lobar degeneration are associated with an aberrant endoso-
mal phenotype in vitro. Hum. Mol. Genet. 17, 313–322. doi: 10.1093/hmg/
ddm309
Van der Zee, J., Van Langenhove, T., Kovacs, G. G., Dillen, L., Deschamps, W.,
Engelborghs, S., et al. (2014). Rare mutations in SQSTM1 modify susceptibil-
ity to frontotemporal lobar degeneration. Acta Neuropathol. 128, 397–410. doi:
10.1007/s00401-014-1298-7
Van Langenhove, T., van der Zee, J., Sleegers, K., Engelborghs, S., Van-
denberghe, R., Gijselinck, I., et al. (2010). Genetic contribution of
FUS to frontotemporal lobar degeneration. Neurology 74, 366–371. doi:
10.1212/WNL.0b013e3181ccc732
Vesa, J., Su, H., Watts, G. D., Krause, S., Walter, M. C., Martin, B., et al. (2009).
Valosin containing protein associated inclusion body myopathy: abnormal
vacuolization, autophagy and cell fusion in myoblasts. Neuromuscul. Disord.
19, 766–772. doi: 10.1016/j.nmd.2009.08.003
Wahid, F., Shehzad, A., Khan, T., and Kim, Y. Y. (2010). MicroRNAs: synthesis,
mechanism, function, and recent clinical trials. Biochim. Biophys. Acta 1803,
1231–1243. doi: 10.1016/j.bbamcr.2010.06.013
Wang, H.-Y., Wang, I.-F., Bose, J., and Shen, C.-K. J. (2004a). Structural diversity
and functional implications of the eukaryotic TDP gene family. Genomics 83,
130–139. doi: 10.1016/S0888-7543(03)00214-3
Wang, Q., Song, C., and Li, C.-C. H. (2004b). Molecular perspectives on p97-
VCP: progress in understanding its structure and diverse biological functions.
J. Struct. Biol. 146, 44–57. doi: 10.1016/j.jsb.2003.11.014
Wang, T., Jiang, X., Chen, G., and Xu, J. (2015). Interaction of amyotrophic lateral
sclerosis/frontotemporal lobar degeneration-associated fused-in-sarcoma with
proteins involved in metabolic and protein degradation pathways. Neurobiol.
Aging 36, 527–535. doi: 10.1016/j.neurobiolaging.2014.07.044
Wang, W. X., Rajeev, B. W., Stromberg, A. J., Ren, N., Tang, G., Huang, Q., et al.
(2008b). The expression of microRNA miR-107 decreases arly in Alzheimer’s
disease and may accelerate disease progression through regulation of beta-site
amyloid precursor protein-cleaving enzyme 1. J. Neurosci. 28, 1213–1223. doi:
10.1523/JNEUROSCI.5065-07.2008
Wang, W.-X., Wilfred, B. R., Madathil, S. K., Tang, G., Hu, Y., Dimayuga, J., et al.
(2010). miR-107 regulates granulin/progranulin with implications for trau-
matic brain injury and neurodegenerative disease. Am. J. Pathol. 177, 334–345.
doi: 10.2353/ajpath.2010.091202
Wang, X., Arai, S., Song, X., Reichart, D., Du, K., Pascual, G., et al. (2008a).
Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit
transcription. Nature 454, 126–130. doi: 10.1038/nature06992
Wang, Y. T., Kuo, P. H., Chiang, C. H., Liang, J. R., Chen, Y. R., Wang, S., et al.
(2013). The Truncated C-terminal RNA recognition motif of TDP-43 pro-
tein plays a key role in forming proteinaceous aggregates. J. Biol. Chem. 288,
9049–9057. doi: 10.1074/jbc.M112.438564
Watts, G. D. J., Thomasova, D., Ramdeen, S. K., Fulchiero, E. C., Mehta, S. G.,
Drachman, D. A., et al. (2007). Novel VCPmutations in inclusion body myopa-
thy associated with Paget disease of bone and frontotemporal dementia. Clin.
Genet. 72, 420–426. doi: 10.1111/j.1399-0004.2007.00887.x
Watts, G. D. J., Wymer, J., Kovach, M. J., Mehta, S. G., Mumm, S., Darvish, D.,
et al. (2004). Inclusion body myopathy associated with Paget disease of bone
and frontotemporal dementia is caused by mutant valosin-containing protein.
Nat. Genet. 36, 377–381. doi: 10.1038/ng1332
Wegorzewska, I., Bell, S., Cairns, N. J., Miller, T. M., and Baloh, R. H. (2009).
TDP-43 mutant transgenic mice develop features of ALS and frontotemporal
Frontiers in Molecular Neuroscience | www.frontiersin.org 29 March 2015 | Volume 8 | Article 9
Fontana et al. A network in frontotemporal dementia
lobar degeneration. Proc. Natl. Acad. Sci. U.S.A. 106, 18809–18814. doi:
10.1073/pnas.0908767106
Weihl, C. C., Dalal, S., Pestronk, A., and Hanson, P. I. (2006). Inclu-
sion body myopathy-associated mutations in p97/VCP impair endoplas-
mic reticulum-associated degradation. Hum. Mol. Genet. 15, 189–199. doi:
10.1093/hmg/ddi426
Weihl, C. C., Miller, S. E., Hanson, P. I., and Pestronk, A. (2007). Transgenic
expression of inclusion body myopathy associated mutant p97/VCP causes
weakness and ubiquitinated protein inclusions in mice. Hum. Mol. Genet. 16,
919–928. doi: 10.1093/hmg/ddm037
Whitley, P., Reaves, B. J., Hashimoto, M., Riley, A. M., Potter, B. V. L., and Hol-
man, G. D. (2003). Identification of mammalian Vps24p as an effector of
phosphatidylinositol 3,5-bisphosphate-dependent endosome compartmental-
ization. J. Biol. Chem. 278, 38786–38795. doi: 10.1074/jbc.M306864200
Wilhelm, B. T., Marguerat, S., Watt, S., Schubert, F., Wood, V., Goodhead, I.,
et al. (2008). Dynamic repertoire of a eukaryotic transcriptome surveyed at
single-nucleotide resolution. Nature 453, 1239–1243. doi: 10.1038/nature07002
Wils, H., Kleinberger, G., Janssens, J., Pereson, S., Joris, G., Cuijt, I., et al. (2010).
TDP-43 transgenicmice develop spastic paralysis and neuronal inclusions char-
acteristic of ALS and frontotemporal lobar degeneration. Proc. Natl. Acad. Sci.
U.S.A. 107, 3858–3863. doi: 10.1073/pnas.0912417107
Wolfe, M. S. (2012). The role of tau in neurodegenerative diseases and its potential
as a therapeutic target. Scientifica 2012:796024. doi: 10.6064/2012/796024
Woodman, P. G. (2003). P97, a protein coping with multiple identities. J. Cell Sci.
116(Pt 21), 4283–4290. doi: 10.1242/jcs.00817
Wszolek, Z. K., Pfeiffer, R. F., Bhatt, M. H., Schelper, R. L., Cordes, M., Snow, B.
J., et al. (1992). Rapidly progressive autosomal dominant parkinsonism and
dementia with pallido-ponto-nigral degeneration. Ann. Neurol. 32, 312–320.
doi: 10.1002/ana.410320303
Wu, H., Huang, M., Lu, M., Zhu, W., Shu, Y., Cao, P., et al. (2013a). Regulation
of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the
chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother. Pharmacol.
71, 1159–1171. doi: 10.1007/s00280-013-2108-y
Wu, P., Zuo, X., Deng, H., Liu, X., Liu, L., and Ji, A. (2013b). Roles of long noncod-
ing RNAs in brain development, functional diversification and neurodegenera-
tive diseases. Brain Res. Bull. 97, 69–80. doi: 10.1016/j.brainresbull.2013.06.001
Xiao, S., Sanelli, T., Dib, S., Sheps, D., Findlater, J., Bilbao, J., et al. (2011). RNA
targets of TDP-43 identified by UV-CLIP are deregulated in ALS. Mol. Cell.
Neurosci. 47, 167–180. doi: 10.1016/j.mcn.2011.02.013
Xu, Y. F., Gendron, T. F., Zhang, Y. J., Lin, W. L., D’Alton, S., Sheng, H., et al.
(2010a).Wild-type human TDP-43 expression causes TDP-43 phosphorylation,
mitochondrial aggregation, motor deficits, and early mortality in transgenic
mice. J. Neurosci. 30, 10851–10859. doi: 10.1523/JNEUROSCI.1630-10.2010
Xu, Y., Suzuki, Y., Ito, K., and Komiyama, M. (2010b). Telomeric repeat-
containing RNA structure in living cells. Proc. Natl. Acad. Sci. U.S.A. 107,
14579–14584. doi: 10.1073/pnas.1001177107
Xu, Z., Poidevin, M., Li, X., and Li, Y. (2013). Expanded GGGGCC repeat RNA
associated with amyotrophic lateral sclerosis and frontotemporal dementia
causes neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 110, 7778–7783. doi:
10.1073/pnas.1219643110
Yamada, S., Inoue, Y., Suga, A., and Iwazaki, M. (2011). Surgical risk of
vessel injury: an unusual anatomical variant of the right medial basal
segmental pulmonary artery. Gen. Thorac. Cardiovasc. Surg. 59, 301–303. doi:
10.1007/s11748-010-0655-2
Yan, J., Deng, H.-X., Siddique, N., Fecto, F., Chen, W., Yang, Y., et al.
(2010). Frameshift and novel mutations in FUS in familial amy-
otrophic lateral sclerosis and ALS/dementia. Neurology 75, 807–814. doi:
10.1212/WNL.0b013e3181f07e0c
Yang, L., Embree, L. J., Tsai, S., andHickstein, D. D. (1998). Oncoprotein TLS inter-
acts with serine-arginine proteins involved in RNA splicing. J. Biol. Chem. 273,
27761–27764. doi: 10.1074/jbc.273.43.27761
Yin, F., Banerjee, R., Thomas, B., Zhou, P., Qian, L., Jia, T., et al. (2010). Exagger-
ated inflammation, impaired host defense, and neuropathology in progranulin-
deficient mice. J. Exp. Med. 207, 117–128. doi: 10.1084/jem.20091568
Zarranz, J. J., Ferrer, I., Lezcano, E., Forcadas, M. I., Eizaguirre, B.,
Atares, B., et al. (2005). A novel mutation (K317M) in the MAPT gene
causes FTDP and motor neuron disease. Neurology 64, 1578–1585. doi:
10.1212/01.WNL.0000160116.65034.12
Zhang, H., Wang, Q., and Kajino Kiichi, G. M. I. (2000). VCP, a weak
ATPase involved in multiple cellular events, interacts physically with
BRCA1 in the nucleus of living cells. DNA Cell Biol. 19, 253–263. doi:
10.1089/10445490050021168
Zhang, Y.-J., Xu, Y., Dickey, C. A., Buratti, E., Baralle, F., Bailey, R., et al.
(2007). Progranulin mediates caspase-dependent cleavage of TAR DNA bind-
ing protein-43. J. Neurosci. 27, 10530–10534. doi: 10.1523/JNEUROSCI.3421-
07.2007
Zheng,M., Liao, M., Cui, T., Tian, H., Fan, D. S., andWan, Q. (2012). Regulation of
nuclear TDP-43 by NR2A-containing NMDA receptors and PTEN. J. Cell Sci.
125(Pt 6), 1556–1567. doi: 10.1242/jcs.095729
Zhu, J., Nathan, C., Jin, W., Sim, D., Ashcroft, G. S., Wahl, S. M., et al. (2002).
Conversion of proepithelin to epithelins: roles of SLPI and elastase in host
defense and wound repair. Cell 111, 867–878. doi: 10.1016/S0092-8674(02)
01141-8
Zinszner, H., Sok, J., Immanuel, D., Yin, Y., and Ron, D. (1997). TLS (FUS) binds
RNA in vivo and engages in nucleo-cytoplasmic shuttling. J. Cell Sci. 110(Pt 1),
1741–1750.
Zovoilis, A., Agbemenyah, H. Y., Agis-Balboa, R. C., Stilling, R. M., Edbauer, D.,
Rao, P., et al. (2011). microRNA-34c is a novel target to treat dementias. EMBO
J. 30, 4299–4308. doi: 10.1038/emboj.2011.327
Zu, T., Liu, Y., and Bañez-Coronel, M. (2013). RAN proteins and RNA foci
from antisense transcripts in C9ORF72 ALS and frontotemporal demen-
tia. Proc. Natl. Acad. Sci. U.S.A. 110, E4968–E4977. doi: 10.1073/pnas.13154
38110
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Fontana, Siva and Denti. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this jour-
nal is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Molecular Neuroscience | www.frontiersin.org 30 March 2015 | Volume 8 | Article 9
 1 
Description of the industrial invention with title: 
“RNA interference mediated therapy for neurodegenerative 
diseases” 
Of: Università degli Studi di Trento, Italian nationality, 
Via Belenzani 12 - 38122 Trento, Italia 
Designated Inventors: Kavitha Siva, Giuseppina Covello, 
Michela Alessandra Denti 
 
Filed on: March 25, 2015 
* * * 
TEXT OF THE DESCRIPTION 
 
FIELD OF THE INVENTION 
 
The present invention concerns RNA interference 
mediated therapy for neurodegenerative diseases associated 
with abnormalities of microtubule-associated protein tau. 
 
BACKGROUND OF THE INVENTION 
  
 Modulation of gene expression by endogenous, non-
coding RNAs have been increasingly appreciated and known to 
play a role in eukaryotic development, and epigenetic 
control. Recently, methods have been developed to trigger 
RNA interference (RNAi) against specific targets in 
mammalian cells by introducing exogenously produced or 
intra-cellularly expressed small interfering RNA (siRNA) 
molecules. 
 These quick, inexpensive and effective methods have 
proven to be effective for knockdown experiments in vitro 
and in vivo. The ability to attain such selective gene 
silencing has led to the hypothesis that siRNAs can be used 
to suppress gene expression for therapeutic benefit. The 
 2 
ideal candidates for such an siRNA approach would be 
dominantly inherited diseases.  
Recent studies by Miller V et al
1
 have shown that 
siRNAs can be used to target untreatable neurodegenerative 
diseases such as polyglutamine (polyQ) neurodegeneration in 
Machado–Joseph disease, spinocerebellar ataxia type 3 
(MJDSCA3) and Frontotemporal dementia with parkinsonism 
linked to chromosome 17 (FTDP-17). These studies have 
focused exclusively on selective silencing of the 
transcript produced by the mutant allele
1
. RNA interference 
has proven to be an efficient strategy for silencing mutant 
tau allele V337M, however, selective depletion of mutant 
allele was not completely achieved in the study because 
there was a partial depletion of the wild type allele of 
tau
1
. More recently, another example of MAPT-targeting 
siRNAs was described
2
, wherein a mix of four siRNAs aimed 
at suppressing all tau isoforms in a mouse model of 
tauopathy was tested. 
 The MAPT (Microtubule associated protein tau) gene 
consists of 16 exons and its expression is regulated by 
complex alternative splicing. This results in the 
production of two types of alternatively spliced 
transcripts: one bearing Exon 10, also known as 4R (Four 
microtubule repeats) isoform and the other that lacks Exon 
10 is called 3R isoform (Three microtubule repeats). Equal 
levels of these two isoforms are expressed in normal human 
adult brain. Though several mutations causing FTDP-17 are 
known in MAPT, a half of these affect alternative splicing 
of Exon 10. These include mis-sense mutations, silent 
mutations and point mutations which are located in Exon 10, 
introns 9 and 10. They are known to implicate an increase 
in Exon 10 causing an excessive accumulation of 4R. This 
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leads to the formation of neurofibrillary tangles, hence 
resulting in neurodegeneration.  
 It is worth mentioning that abnormalities of tau are 
linked to the pathogenesis of neurodegenerative disease 
collectively termed as “tauopathies", and significantly 
elevated levels of tau are present in AD (Alzhiemer’s 
disease) brains. 
 A few approaches have been used for the correction of 
Exon 10 inclusion in FTDP-17:  
 - Small molecules: a screening has been performed 
which yielded cardiotonic steroids as exon 10 splicing 
modulator, albeit non-specific, drugs
3
, and 
- Antisense oligonucleotides for exon skipping: US-A-
2003/0170704 by Stamm et al. relates to substances which 
are capable of controlling the inclusion of MAPT exon 10 
(proteic splicing regulators or their cDNA, polypeptides 
controlling the phosphorylation of splicing regulators, or 
their cDNA, and antisense oligonucleotides which interact 
with the splice junctions of MAPT exon 10). Moreover, work 
by Kalbfuss et al.
4
 has demonstrated that 
oligoribonucleotides binding to Exon 10 splicing junctions 
could suppress the predominant inclusion of Exon 10 in tau 
mRNA in the context of rat PC12 cells. However, recent work 
by Sud R et al
5
 showed that targeting Exon 10 with 
antisense morpholino oligonucleotides did not yield exon-
skipping in neuroblastoma cell lines. These authors claim 
that splicing regulation of exon 10 in cells expressing 
predominantly 4R isoform may vary from the neuroblastoma 
cell line in which the 3R isoform dominates. 
- Trans-splicing of exon 10: RNA reprogramming using 
spliceosome-mediated RNA trans-splicing (SMaRT) was used to 
correct aberrant Exon 10 splicing resulting from FTDP-17 
 4 
mutations in a minigene system in cells in culture
6
. This 
approach, however, is affected by low efficiency. 
  
OBJECT AND SUMMARY OF THE INVENTION 
 
The object of the present invention is to provide a 
therapeutic agent effective in the treatment of 
neurodegenerative diseases associated with abnormalities of 
MAPT gene encoded protein tau. 
According to the invention, the above object is 
achieved thanks to the method specified in the ensuing 
claims, which are understood as forming an integral part of 
the present description. 
In an embodiment, the instant disclosure discloses a 
therapeutic agent for use in the treatment of 
neurodegenerative diseases associated with abnormalities of 
MAPT gene encoded protein tau, wherein said therapeutic 
agent comprises one or more siRNA targeting MAPT gene exon 
10 sequence (SEQ ID No.:1).  
In a further embodiment, the instant disclosure 
provides for a method for the treatment of 
neurodegenerative diseases associated with abnormalities of 
MAPT gene encoded protein tau comprising administering to a 
patient who needs it of one or more siRNA, wherein the one 
or more siRNA comprise a sense strand comprising at least 
19 continuous bases of mRNA corresponding to the MAPT exon 
10 sequence of SEQ ID No.: 1 and an antisense strand 
comprising a sequence complementary thereto in an amount 
sufficient to make said treatment, wherein the one or more 
siRNA induce selective degradation of exon 10-containing 
MAPT transcripts. 
 In a still further embodiment, the instant disclosure 
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concerns a pharmaceutical composition comprising one or 
more siRNA, wherein the one or more siRNA comprise a sense 
strand comprising at least 19 continuous bases of mRNA 
corresponding to the MAPT exon 10 sequence of SEQ ID No.: 1 
and an antisense strand comprising a sequence complementary 
thereto and a pharmaceutically acceptable carrier. 
 
BRIEF DESCRIPTION OF THE DRAWINGS 
 
The invention will now be described, by way of example 
only, with reference to the enclosed figures of drawing, 
wherein: 
 - Figure 1. Semi-quantitative RT-PCR analysis of 
levels of exon 10 in SH-SY5Y cells transfected with wild 
type and N279 mutant plasmid. The gel electrophoresis shows 
the RT-PCR products of transcripts of the minigenes, 
containing exon 10 (E10+, 290 bp) and without exon 10 (E10-
, 210 bp). Histogram represents the densitometric units of 
each treatment condition normalised on ß actin. Values 
represent mean SD± (n=3).  
 - Figure 2. Representative images of SH-SY5Y cell line 
transfected with 0.25 µg of either wild type plasmid or 
mutant plasmid.  A) Wild type and B) Mutant N279 reporter 
plasmids.  
 - Figure 3. Setting up of threshold values based on 
intensities of RFP and GFP. Scatter plots representing 
Green/Red (G/R) values of each cell in a particular well 
bearing one of the dual reporter plasmids (WT and Mut, 
respectively). The indicated thresholds are arbitrarily 
selected to classify the cell population in three different 
classes.  
 - Figure 4. Image based analysis of SHYS5Y cells 
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transfected with Wild type and Mutant reporter plasmids. 
Histogram represents the selected read-outs of the 
quantitative analysis of the two reporters, such as the 
relative percentages of the three sub-populations of SHYS5Y 
cells classified by intensity properties, the transfection 
efficiency and the cell viability.  Values represent 
mean±SD (n=3) 
 - Figure 5. Human tau E10 sequences (capitals) and 
flanking I9 and I10 sequences (lower case). The 5’ and 3’ 
splice sites are denoted by 5’ss and 3’ss, respectively. 
Only FTDP-17 mutations affecting E10 splicing are 
indicated. Deletions are denoted by shaded triangles. The 
sequences and target position of the three designed siRNAs 
are indicated.  
 - Figure 6. An image based screening assay has been 
performed for the different siRNAs and compared to the 
values obtained with a control siRNA. siRNAs were 
cotransfected in SH-SY5Y cells together with 0.25 µg of 
mutant reporter minigene plasmid. The values represent mean 
±SD (n=3) 
 - Figure 7.  An image based screening assay has been 
performed for the different siRNAs and compared to the 
values obtained with a control siRNA. siRNAs were 
cotransfected in SH-SY5Y cells together with 0.5 µg of 
mutant reporter minigene plasmid. The values represent mean 
±SD (n=3). 
 - Figure 8. Semi-quantitative RT-PCR analysis of SH-
SY5Y cells transfected with the minigene reporter plasmid 
and siRNA A. 
 - Figure 9. Semi-quantitative RT-PCR analysis of SH-
SY5Y cells transfected with the minigene reporter plasmid 
and siRNA B. 
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 - Figure 10. Semi-quantitative RT-PCR analysis of SH-
SY5Y cells transfected with the minigene reporter plasmid 
and siRNA C. 
 - Figure 11. Semi-quantitative RT-PCR of NSC34 cells 
transfected with three siRNAs or a control siRNA.  
 - Figure 12. PFLARE 5A MAPT Exon 10 nucleotide 
sequence. 
 - Figure 13. PFLARE 5A MAPT MUT Exon 10 nucleotide 
sequence. 
 
DETAILED DESCRIPTION OF THE INVENTION 
 
The invention will now be described in detail, by way 
of non limiting example, with reference to an RNA 
interference mediated therapy making use of a cell model 
recapitulating the Frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17) disease 
conditions. Nevertheless, the RNA interference mediated 
therapy herein disclosed can be used for the treatment of 
other neurodegenerative diseases associated with 
abnormalities in MAPT gene encoded protein tau, like for 
example Alzheimer’s disease, Huntington’s disease, type 1 
myotonic dystrophy, and Parkinson’s disease. 
In the following description, numerous specific 
details are given to provide a thorough understanding of 
embodiments. The embodiments can be practiced without one 
or more of the specific details, or with other methods, 
components, materials, etc.  In other instances, well-known 
structures, materials, or operations are not shown or 
described in detail to avoid obscuring aspects of the 
embodiments. 
Reference throughout this specification to “one 
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embodiment” or “an embodiment” means that a particular 
feature, structure, or characteristic described in 
connection with the embodiment is included in at least one 
embodiment. Thus, the appearances of the phrases “in one 
embodiment” or “in an embodiment” in various places 
throughout this specification are not necessarily all 
referring to the same embodiment.  Furthermore, the 
particular features, structures, or characteristics may be 
combined in any suitable manner in one or more embodiments. 
The headings provided herein are for convenience only 
and do not interpret the scope or meaning of the 
embodiments. 
 The present description concerns a therapeutic agent 
for use in the treatment of neurodegenerative diseases 
associated with abnormalities of MAPT gene encoded protein 
tau, wherein said therapeutic agent comprises one or more 
siRNAs targeting MAPT gene exon 10. Preferably, the 
therapeutic agent comprise a sense strand comprising at 
least 19 continuous bases of mRNA corresponding to the MAPT 
exon 10 sequence of SEQ ID No.: 1 and an antisense strand 
comprising a sequence complementary thereto. 
 In a further embodiment, the present description 
provides for use in the treatment of neurodegenerative 
diseases associated with abnormalities of MAPT gene encoded 
protein tau one or more siRNAs targeting MAPT gene exon 10, 
wherein the one or more siRNAs comprise a sense strand of 
19-29 continuous bases of mRNA corresponding to the MAPT 
exon 10 sequence set forth in SEQ ID No.: 1 and an 
antisense strand comprising a sequence complementary 
thereto. 
 In a preferred embodiment, the present description 
concerns one or more siRNAs targeting MAPT gene exon 10 
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useful in the treatment of neurodegenerative diseases 
associated with abnormalities of MAPT gene encoded protein 
tau, wherein the one or more siRNAs are selected from i) a 
double strand RNA composed of a sense strand comprising a 
base sequence set forth in SEQ ID No.: 2, 4, 6, and an 
antisense strand comprising a sequence complementary 
thereto, which optionally has an overhang at the terminal 
of the sense strand and/or antisense strand, and ii) a 
double strand RNA composed of a sense strand comprising a 
base sequence wherein one to several bases have been added 
to and/or deleted from the 5’ terminal and/or 3’ terminal 
of the base sequence described in any one of SEQ ID No.: 2, 
4, 6, and an antisense strand comprising a sequence 
complementary thereto, which optionally has an overhang at 
the terminal of the sense strand and/or antisense strand. 
 In a still further preferred embodiment, the instant 
description provides for one or more siRNAs targeting MAPT 
gene exon 10 able to induce selective degradation of exon 
10-containing MAPT transcripts. 
 The neurodegenerative diseases associated with 
abnormalities of MAPT gene encoded protein tau that can 
benefit from the administration of one or more siRNAs 
targeting MAPT gene exon 10 are selected from Alzheimer 
disease, Huntington disease, type 1 myotonic dystrophy, 
Parkinson disease, frontotemporal dementia with 
parkinsonism linked to chromosome 17 (FTDP-17). 
 In a different embodiment, the description provides 
for a method of treatment of a neurodegenerative disease 
associated with abnormalities of MAPT gene encoded protein 
tau comprising administering to a patient who needs it of 
one or more siRNAs targeting MAPT gene exon 10, wherein the 
one or more siRNAs comprise a sense strand comprising at 
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least 19 continuous bases of mRNA corresponding to the MAPT 
exon 10 sequence of SEQ ID No.: 1 and an antisense strand 
comprising a sequence complementary thereto in an amount 
sufficient to make said treatment, wherein the one or more 
siRNA induce selective degradation of exon 10-containing 
MAPT transcripts. 
In a still further embodiment, the present description 
concerns a pharmaceutical composition comprising one or 
more siRNAs targeting MAPT gene exon 10, wherein the one or 
more siRNAs comprise a sense strand comprising at least 19 
continuous bases of mRNA corresponding to the MAPT exon 10 
sequence of SEQ ID No.: 1 and an antisense strand 
comprising a sequence complementary thereto and a 
pharmaceutically acceptable carrier.  
 The present disclosure shows the feasibility of an 
siRNA-based gene therapy to enable post-transcriptional 
gene silencing of Exon 10-containing MAPT transcripts in 
FTDP-17. A panel of siRNAs targeting tau mRNA containing 
Exon 10 have been designed, and tested in SH-SY5Y cells on 
a mutant minigene reporter plasmid in the context of N279 
missense mutation (AAT to AAG) recapitulating FTDP-17 
disease condition. Moreover, the 3 siRNAs were tested on 
NSC34 cells (a motor neuron-like cell line)
1
 to validate 
the effects on endogenous condition with a predominant 
inclusion of Exon 10 (80%). 
 The effect of the siRNAs has been assayed using a high 
content imaging system. The results obtained through the 
screening assay have been further validated using an RT-PCR 
analysis. The effect on the endogenous Exon 10-containing 
MAPT transcripts has been tested using RT-PCR analysis. 
 In the instant description the Inventors designed a 
new approach for the restoration of a normal 4Rtau/3Rtau 
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ratio, based on the use of siRNAs targeting MAPT exon 10 
and inducing the selective degradation of the exon 10-
containing MAPT transcripts. These siRNAs provide 
therapeutic benefit for FTDP-17 patients bearing mutations 
in MAPT exon 10 causing exon 10 inclusion, as the target 
sequences are not affected by the mutations.  
 The three siRNAs herein evaluated have the following 
nucleotide sequences: 
siRNA A’: 
sense strand: 5’AGUCCAAGUGUGGCUCAAA3’ – SEQ ID No.:2, 
antisense strand: 5’UUUGAGCCACACUUGGACU3’ – SEQ ID No.: 3; 
siRNA B’: 
sense strand:  5’GGCUCAAAGGAUAAUAUCA3’ – SEQ ID No.: 4, 
antisense strand: 5’UGAUAUUAUCCUUUGAGCC3’ – SEQ ID No.: 5; 
siRNA C’: 
sense strand: 5’GCAACGUCCAGUCCAAGUG3’ – SEQ ID No.: 6, 
antisense strand: 5’CACUUGGACUGGACGUUGC3’ – SEQ ID No.: 7. 
 Out of the 3 tested siRNAs (A, B and C), siRNA B shows 
maximum efficiency in transcript degradation. These results 
have been validated using a minigene recapitulating 
splicing mutation N279, and a similar effect is exhibited 
on NSC34
7,8
 (a hybrid of mouse spinal cord motor neurons and 
neuroblastoma cell line) cells.  
 A recent review by Rettig and colleagues
9
 has 
summarized the possible delivery approaches of the siRNA 
molecules and their success in clinical trials. The current 
development in the field and ongoing studies establishes 
the significance of these synthetic siRNAs, which may serve 
as potential therapeutics upon suitable delivery and 
administration. 
 Direct CNS (Central nervous system) administration is 
used as a method of choice in neurodegenerative diseases 
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due to restricted entry across the blood brain barrier. 
Options of delivery include intrathecal, intraventricular, 
epidural and direct intratissue injection. Administration 
methods include long term infusions or through the use of 
mini pumps. 
 Chronic intraventricular pumps were used for the 
delivery of siRNAs against Amyloid precursor protein gene 
(App) to study Alzheimers related functions in adult mice. 
Efficient knockdowns were observed through potent siRNAs
10
. 
 By employing naked and unassisted delivery of siRNAs 
in buffered saline, chronic infusion was performed in non-
human primates to suppress levels of α synucein11. This 
protein is known to be associated with Parkinson’s disease. 
Mini osmotic pumps were used for the direct infusion into 
the substantia nigra leading to a decrease in α synucein 
both at mRNA and protein levels. 
 siRNAs with modified PS linkages and 2’F-pyrimidine 
residues near the ends of each strand
12
 were used for 
chronic infusion in to the CNS of SOD1(G93A) mouse model of 
amyotrophic lateral sclerosis (ALS). Significant reduction 
of SOD1 mRNA was observed in the spinal cord. In the 
transgenic mouse model, an infusion over a 28 day period 
led to alleviated the progression of disease. The siRNAs 
were stable over the course of this period.  
 Cholestrol conjugated siRNAs
13
 were used for the 
direct intrastriatal injection to target mutant Huntington 
gene (Htt) in the context of Huntington’s disease.  
 The above mentioned strategies highlight the different 
modes of delivery of siRNAs and demonstrate efficacy in vivo. 
  
Materials and methods 
 siRNAs 
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 The following siRNAs – employed in the present 
experiments - were designed along the stretch of Exon 10 
(SEQ ID No.: 1), and produced by Eurofin Genomics, 
Ebersberg, Germany. 
siRNA A: 
sense strand: 5’AGUCCAAGUGUGGCUCAAAdTdT3’ – SEQ ID No.:19, 
antisense strand: 5’UUUGAGCCACACUUGGACUdTdT3’ – SEQ ID 
No.:20; 
siRNA B: 
sense strand:  5’GGCUCAAAGGAUAAUAUCAdTdT3’ – SEQ ID No.:21, 
antisense strand: 5’UGAUAUUAUCCUUUGAGCCdTdT3’ – SEQ ID 
No.:22; 
siRNA C: 
sense strand: 5’GCAACGUCCAGUCCAAGUGdTdT3’ – SEQ ID No.:23, 
antisense strand: 5’CACUUGGACUGGACGUUGCdTdT3’ – SEQ ID 
No.:24; 
control siRNA: 
sense strand: 5' UAAUGUAUUGGAACGCAUAdTdT3’ – SEQ ID No.:8, 
antisense strand:  5'UAUGCGUUCCAAUACAUUAdTdT3’ – SEQ ID 
No.:9. 
The above siRNAs sequences differ from the SEQ ID NO.: 
2 to 7 for the presence of an overhang consisting of two 
monophosphate deoxyribosylthymine (dT), which were 
introduced in SEQ ID No.: 2 to 7 at the 3’ terminal in 
order to increase siRNA intracellular stability and 
efficiency thereof. 
Figure 5 shows human tau E10 sequence (capitals – 
corresponding to SEQ ID No.: 1) and flanking I9 and I10 
sequences (lower case); the human tau E10 sequence 
comprising flanking I9 (11 bases) and I10 (26 bases) 
sequences is provided in SEQ ID No.: 18. The 5’ and 3’ 
splice sites are denoted by 5’ss and 3’ss, respectively. 
 14 
Only FTDP-17 mutations affecting Exon 10 splicing are 
indicated. Deletions are denoted by shaded triangles. The 
sequences and target position of the three designed siRNAs 
A, B and C are provided. 
  
SHYS5Y cell line 
 The SH-SY5Y cell line (ATCC-LGC standards, Teddington, 
UK; #CRL-2266) used for transfection experiments is a 
thrice cloned (SK-N-SH -> SH-SY -> SH-SY5 -> SH-SY5Y) 
subline of the neuroblastoma cell line SK-N-SH with a 
content of 15% Exon 10+ and 85% of Exon 10- in its 
transcript. The transfection efficiency (25% to 30%) in 
this cell line is comparitively higher than the other 
neuroblastoma cell lines. Therefore, this cell line was 
chosen to test the efficacy of siRNAs against endogenous 
Exon 10+ transcripts and for co-transfections of siRNAs 
with minigene reporter plasmids.  
 
NSC-34 cell line 
 Mouse Motor neuron like hybrid cell line NSC-34 
(Cellutions biosystems, Burlington, Ontario, Canada; # 
CLU140-A) was produced by fusion of motor neuron enriched, 
embryonic mouse spinal cord cells with mouse 
neuroblastoma
7,8
. The cultures contain two populations of 
cells: small, undifferentiated cells that have the capacity 
to undergo cell division and larger, multi-nucleate cells. 
These cells express many properties of motor neurons, 
including choline acetyltransferase, acetylcholine 
synthesis, storage and release and neurofilament triplet 
proteins. These cells can be differentiated using the all 
trans retinoic acid (atRA) thus establishing itself as a 
suitable model for the in vitro study of pathophysiology in 
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motor neurons. 
 
Mutagenesis of fluorescent reporter with Exon 10 
The fluorescent reporter plasmid created by Peter 
Stoilov and colleagues
3
, PFLARE 5A MAPT Exon 10 also 
referred to as the wild-type (WT) plasmid (SEQ ID No.: 10 – 
Figure 12), was mutated using the Quick change II site XL 
site-directed mutagenesis kit (Agilent Technologies, Santa 
Clara, CA, USA; #200521) following the manufacturer’s 
instructions. The following primers were designed such that 
they incorporated the nucleotide change of T to G. 
Forward primer: 
5’CCAAAGGTGCAGATAATTAAGAAG3’ – SEQ ID No.: 11 
 Reverse primer: 
5’GTTGCTAAGATCCAGCTTCTTCTT3’ – SEQ ID No.: 12 
The resulting plasmid PFLARE 5A MAPT MUT Exon 10 (SEQ 
ID No.: 13 – Figure 13) will be referred to as mutant N279 
(Mut) plasmid. 
 
Treatment of siRNA on Endogenous condition 
 1.Transfection of SHYS5Y cells and NSC-34 cells with 
siRNAs 
 The transfection of SHYS5Y cells and NSC34 cells with 
siRNAs were performed using the Lipofectamine 3000 lipid 
based transfection reagent (Life Technologies-Invitrogen, 
Monza, Italy; #L3000-008).  
1.1. Preparation of cells  
 1.1.1) On the day before the experiment, 5 x 10
4
 cells 
were seeded on a 24 well plate in 500 µl of complete medium 
without antibiotics at 37° C in 5% CO2.  
 1.2. Transfection of siRNAs 
 1.2.1) Transfections were performed as instructed by 
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the manufacturer with 2 (µl) Lipofectamine 3000 for a range 
of siRNA concentration starting from 10 nM to 100 nM - in 
Opti-MEM medium without phenol red (Life Technologies-
Gibco, Monza, Italy; #11058-021) - per well in a final 
volume of 500 µl. 
 1.2.2) As controls, cells were treated with 
Lipofectamine 3000 only (Mock) and transfected with Non-
targeting siRNA (Non-specific controls – SEQ ID No.: 8 and 
9).  
1.2.3) Following transfection, the cells are incubated 
at 37° C in 5% CO2 for 48 hours.  
 1.2.4) The wells were then washed with PBS(1X) and 
Trizol reagent (Life Technologies, Monza, Italy; #15596-
026) was used for the extraction of RNA following 
manufacturer’s instructions for downstream analyses. 
 2. Co-transfection of reporter plasmid and siRNAs in 
SHYS5Y cells 
 2.1. Preparation of cells 
 1.1) On the day before the experiment, 5 x 10
4
 cells 
were seeded on a 24 well plate in 500 µl of complete medium 
(i.e. 1:1 mix of EMEM (Lonza #12-125F) and F12 NUTRIENT MIX 
(Life technologies-Gibco #1765-054) with 10% Fetal Bovine 
Serum (FBS)) without antibiotics at 37° C in 5% CO2. The 24 
well plate format has been chosen to allow the recovery of 
a sufficient number of cells at the end of the assay after 
the image-based analysis, in order to perform downstream 
molecular analysis, such as RT-PCR and Western Blot. 
 2.2 Lipid-based DNA and siRNA co-transfection 
 2.2.1) Transfections are performed as instructed by 
the manufacturer with a ratio of DNA (ng):Lipofectamine 
3000 (µl) being 1:2 in Opti-MEM medium (GIBCO 
LIfetechnologies). The plasmids (SEQ ID No.: 10 and 13) are 
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used at a concentration of 0.25 µg and 0.5 µg per well in a 
final volume of 500 µl. 
 2.2.2) Two different plasmid reporters (SEQ ID No.: 
10, 13) are used for transfection namely the wild-type (WT) 
plasmid (SEQ ID No.: 10) and the mutant type (Mut) plasmid 
(SEQ ID No.: 13). 
 2.2.3) siRNAs (SEQ ID No.: 19 to 24) are used at the 
concentrations from 10 nM to 100 nM in a final volume of 
500 µl per well. 
 3. High-content image acquisition and analysis 
 Preparation of cells for image acquisition 
 3.1) Images of transfected cells were captured with a 
High content imaging system (Operetta, Perkin Elmer). 48 
hours after transfection, the cells are incubated for 20 
minutes at 37° C in the presence of 1 mg/ml of Hoechst 
33342 fluorescent dye. This allows counter-staining the 
nuclei which will enable the subsequent analyses.  
 Image acquisition 
 3.2) Images were taken with a 20X LWD objective 
(Perkin Elmer #HH12940107), in combination with different 
filter sets: in particular a filter for Hoechst 3342 stain 
(excitation filter: 360-400 nm (Perkin Elmer #HH12000301); 
emission filter: 410-480 nm (Perkin Elmer #HH12000401)) is 
used to image the stained nuclei at 20 ms exposure time, 
whereas a combination of filters is used to measure the 
reporters’ intensities: GFP (excitation filter: 460-490 nm 
(Perkin Elmer HH1200030); emission filter :500-550 nm 
(Perkin Elmer #HH12000405)) and RFP (excitation filter: 
520-550 nm (Perkin Elmer #HH12000305); emission filter: 
560-630 nm (Perkin Elmer #HH12000410)), both at 200 ms 
exposure time.  
 Image analysis 
 18 
 3.3) For the feature extraction protocol, cells were 
segmented and analyzed using the following workflow: 
 3.3.1) The first step is the identification of Nuclei, 
the primary objects of interest that are segmented by using 
the most suitable algorithm (phenoLOGIC
TM
, PerkinElmer).  
 3.3.2) Assuming a homogeneous distribution of both GFP 
and RFP in the cells, the nuclear region was selected to 
quantify the mean fluorescence intensity in the two 
channels. 
 3.3.3) The sub-population of transfected cells was 
identified using a double-threshold strategy to filter out 
the cells being either positive for G(GFP) or for R(RFP) or 
for both. 
 3.3.4) Restricting the analysis to the transfected 
cells only, the ratio between the fluorescence properties G 
and R mean intensity is calculated on a per-cell basis. G/R 
is a parameter that indicates the prevalence of expression 
of one reporter over the other. Specifically, a low score 
indicates inclusion of the cassette exon, while a high one 
is connected with an efficient splicing of Exon 10.  
 3.3.5) An overview of the numerical properties of the 
cells can be visualized field by field in a scatter plot. 
Alternatively, to get a more complete representation of all 
the cells within a well, scatter plots or histograms of 
single cell properties can be created for representative 
wells of the WT and the Mut plasmid conditions. Such 
graphical representations allow a more accurate selection 
of an upper threshold J and a lower threshold K, 
distinguishing for cells preferentially expressing GFP 
(G/R>J), RFP (G/R<K) or equally expressing both the 
reporters (K<G/R<J) (Fig. 1). Harmony
R
 high content imaging 
software (PerkinElmer) was employed.  
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 3.4.6) The thresholds were then applied in a filter-
based module to classify the cells in three different 
subpopulations. In synthesis, based on intensities emitted 
by the fluorescence signals, 3 read-outs were measured as a 
result of setting specific threshold values:cells 
expressing mainly GFP (G/R>J), cells expressing mainly RFP 
(G/R<K), cells equally expressing both the reporters 
(K<G/R<J). 
 3.4.7) Feature outputs include total cell count, 
transfected cells count and % calculated over the total 
number of cells, G/R median value of all the cells of the 
well, the % of cells preferentially expressing GFP (G/R>J), 
RFP (G/R<K) and equally expressing both the reporters 
(K<G/R<J). 
 3.4.8) Percentage of cell viability was calculated as 
follows: (total number of cells in transfected well/total 
number of cells in Mock)*100 
 4. RNA extractions and RT-PCR 
 4.1) The wells were washed with 1X PBS and RNA was 
extracted from each well using Trizol reagent following 
manufacturer’s instructions. 
 4.2) The extracted RNA was treated with DNase by using 
Turbo DNAse kit (Life technologies-Ambion #AM1907) 
according to the manufacturer’s instructions.  
 4.3) 500 ng of the extracted RNA was reverse 
transcribed to cDNA with Revert Aid First Strand cDNA 
synthesis Kit (Thermoscientific #K1622) by using oligo dT18 
oligonucleotides (a synthetic single-stranded 18-mer 
oligonucleotide with 5'- and 3'-hydroxyl ends, available in 
the kit), following manufacturer’s protocol. 
 4.4) The cDNA obtained serves as a template for semi 
quantitative RT-PCR reactions to evaluate the expression of 
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Exon 10 in these transcripts.  
 PCR CYCLE: 
10 min 95°C 
0:30 seconds 95°C 
0:40 seconds 60°C 
1 min 72°C 
10 min 72°C 
∞ 4°C 
 4.4) The expression levels of Exon 10 containing 
transcripts are analyzed with the following primers: 
Endogenous condition: 
TAUR9F: 5’CTGAAGCACCACCAGCCGGGAGG3’ – SEQ ID No.: 14, 
TAU13R: 5’TGGTCTGTCTTGGCTTTGGC3’ – SEQ ID No.: 15. 
Plasmid reporters: 
Exon 1 Bgl For: 5’AAACAGATCTACCATTGGTGCACCTGACTCC3’ – SEQ 
ID No.: 16, 
EGFP Rev: 5’CGTCGCCGTCCAGCTCGACCAG3’ – SEQ ID No.: 17. 
 4.5) Amplified products are allowed to run with 100bp 
DNA ladder (Fermentas) on a 2% Agarose gel electrophoresis 
(5% Ethidium Bromide) at 100 volts in 1X TBE running buffer 
for 40 minutes. 
 4.6) Densitometric analyses are performed with Image J 
software (an open architecture system using Java plugin) 
after image acquisition with BioDoc–It imaging system (UPV, 
Upland, CA, USA). 
 
Results 
 The siRNAs were tested for their efficacy on 
transfected reporter minigenes. Previous work by Stoilov P 
et al
3
 has shown that the splicing of a two-color 
(Green/Red) fluorescent reporter plasmid with MAPT Exon 10 
can be modulated using bioactive compounds. The reporter 
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plasmid (SEQ ID No.: 10) was produced such that exon 10 
inclusion favors the production of RFP (Red fluorescent 
protein) and exon 10 exclusion produces GFP (Green 
fluorescent protein) (Fig. 1). The reporter plasmid created 
by Stoilov and colleagues and termed as wild type reporter 
(as it recapitulated the endogenous condition of exon 10 
content in the majority of neuroblastoma cell lines) was 
used (Fig. 1). The plasmid was further mutated to 
incorporate the N279 mutation to alter splicing (AAT to 
AAG), recapitulating FTDP-17 disease condition (SEQ ID No.: 
13). This base change creates a purine-rich stretch 
(AAGAAGAAG), and resembles an exon splice-enhancer 
consensus; this alters splicing leading to exon 10 
inclusion and subsequent production of RFP (Fig. 1). 
 With the purpose of analyzing the effects of the 
siRNAs on the reporter minigenes, an image-based analysis 
to quantify the fluorescent reporters, obtaining single 
cell-based read-outs using an High Content Screening 
system, was developed by the present inventors. In brief, 
SH-SY5Y cell line was transfected with either wild type 
plasmid or mutant plasmid. The two plasmids ensure 
different percentages of exon 10 inclusion in the spliced 
transcript, which is evident from the difference in the 
number of red or green cells, and in their intensity (Fig. 
2). The intensity of green and red fluorescence in the 
transfected cells was measured by an Operetta High Content 
Screening instrument, and the cells were grouped in three 
categories: red cells in which the majority of the 
transcript bears exon 10, green cells in which the majority 
of the transcript is devoid of exon 10, and yellow cells in 
which the proportion of the two splicing isoforms is around 
1:1 (Fig. 3). By this analysis the point mutation in the 
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reporter minigene (SEQ ID No.: 13) was assessed to shift 
splicing of Exon 10 thus altering the fluorescent signals 
from a relatively low level of RFP (2%) to a very high 
level (65%) due to Exon 10 inclusion (Fig. 3 and Fig. 4). 
Transfection efficency was about 20% and cell viability 
about 60% (Fig. 4). 
 Three different exon 10-targeting siRNAs (SEQ ID Nos 
19 to 24) spanning the exon 10 sequence have been designed 
on the basis of following rules: stretches of 4 or more 
bases (such as AAAA or CCCC), regions with GC content <30% 
or > 60%, repeats and low complexity sequences, single 
nucleotide polymorphism (SNP) sites were avoided; a BLAST 
homology search was performed to avoid off-target effects 
on other genes or sequences (Fig. 5).  
 The efficacy of the three designed siRNAs was tested 
at increasing concentrations upon their co-transfection 
with either 0.5 µg (Fig. 6) or 0.25 µg of the mutant 
reporter minigene (Fig. 7). In both experimental designs 
siRNA A (SEQ ID No.: 19 and 20), siRNA B (SEQ ID No.: 21 
and 22) and siRNA C (SEQ ID No.: 23 and 24) were effective 
in reducing the exon 10-containing transcript. siRNA B (SEQ 
ID No.: 21 and 22) appeared to be the most efficient siRNA, 
decreasing the red cells from 60% to 15% and increasing the 
yellow cells from 40% to 80% (Fig. 7). Semi-quantitative 
RT-PCR analysis confirmed the reduction of Exon 10 upon 
treatment with siRNA A (SEQ ID No.: 19 and 20, Fig. 8), 
siRNA B (SEQ ID No.: 20 and 22, Fig. 9) and siRNA C (SEQ ID 
No.: 23 and 24, Fig. 10) reaching ~10%, 25% and 20% 
reduction, respectively, upon treatment with a 50 nM 
concentration. 
 The effect of siRNA A (SEQ ID No.: 19 and 20), siRNA B 
(SEQ ID No.: 20 and 22) and siRNA C (SEQ ID No.: 23 and 24) 
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on the endogenous MAPT transcript was tested upon their 
transfection in NSC34 cell line (Fig. 11). In NSC34 cells 
83% of the endogenous MAPT transcript contains exon 10 and 
the remaining 17% is devoid of exon 10, thus serving as a 
suitable model for the study of effects of siRNA on Exon 10 
containing transcripts in endogenous conditions (Fig. 11). 
RT-PCR analysis shows reduction of Exon 10+ endogenous 
transcripts upon treatment with siRNAs A (SEQ ID No.: 19 
and 20)(6%), B (SEQ ID No.: 20 and 22)(28%) and C (SEQ ID 
No.: 23 and 24)(12%) at 50 nM concentration. In this model 
system, therefore, siRNA B appears the most effective siRNA 
in the selective degradation of exon 10-containing 
transcripts.  
Naturally, while the principle of the invention 
remains the same, the details of construction and the 
embodiments may widely vary with respect to what has been 
described and illustrated purely by way of example, without 
departing from the scope of the present invention. 
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CLAIMS 
 
 1. Therapeutic agent for use in the treatment of 
neurodegenerative diseases associated with abnormalities of 
MAPT gene encoded protein tau, wherein said therapeutic 
agent comprises one or more siRNAs targeting MAPT gene exon 
10. 
 
 2. Therapeutic agent for use according to claim 1, 
wherein the one or more siRNAs comprise a sense strand 
comprising at least 19 continuous bases of mRNA 
corresponding to the MAPT gene exon 10 sequence set forth 
in SEQ ID No.: 1 and an antisense strand comprising a 
sequence complementary thereto. 
 
3. Therapeutic agent for use according to claim 1 or 
claim 2, wherein the one or more siRNAs comprise a sense 
strand of 19-29 continuous bases of mRNA corresponding to 
the MAPT gene exon 10 sequence set forth in SEQ ID No.: 1 
and an antisense strand comprising a sequence complementary 
thereto. 
 
 4. Therapeutic agent for use according to any one of 
claims 1 to 3, wherein the one or more siRNAs are selected 
from i) a double strand RNA composed of a sense strand 
comprising a base sequence set forth in SEQ ID No.: 2, 4, 
or 6, and an antisense strand comprising a sequence 
complementary thereto, which optionally has an overhang at 
the terminal of the sense strand and/or antisense strand, 
and ii) a double strand RNA composed of a sense strand 
comprising a base sequence wherein one to several bases 
have been added to and/or deleted from the 5’ terminal 
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and/or 3’ terminal of the base sequence described in any 
one of SEQ ID No.: 2, 4, or 6, and an antisense strand 
comprising a sequence complementary thereto, which 
optionally has an overhang at the terminal of the sense 
strand and/or antisense strand. 
 
 5. Therapeutic agent for use according to any one of 
claims 1 to 4, wherein the one or more siRNAs induce 
selective degradation of exon 10-containing MAPT 
transcripts. 
 
 6. Therapeutic agent for use according to any one of 
claims 1 to 5, wherein the neurodegenerative diseases 
associated with abnormalities of MAPT gene encoded protein 
tau are selected from Alzheimer disease, Huntington 
disease, type 1 myotonic dystrophy, Parkinson disease, and 
frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17). 
 
7. A method for the treatment of a neurodegenerative 
diseases associated with abnormalities of MAPT gene encoded 
protein tau comprising administering to a patient who needs 
it of one or more siRNA, wherein the one or more siRNAs 
comprise a sense strand comprising at least 19 continuous 
bases of mRNA corresponding to the MAPT exon 10 sequence 
set forth in SEQ ID No.: 1 and an antisense strand 
comprising a sequence complementary thereto in an amount 
sufficient to make said treatment, wherein the one or more 
siRNAs induce selective degradation of exon 10-containing 
MAPT transcripts. 
 
8. A pharmaceutical composition comprising one or more 
 28 
siRNAs, wherein the one or more siRNAs comprise a sense 
strand comprising at least 19 continuous bases of mRNA 
corresponding to the MAPT exon 10 sequence set forth in SEQ 
ID No.: 1 and an antisense strand comprising a sequence 
complementary thereto, and a pharmaceutically acceptable 
carrier. 
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ABSTRACT 
 
Therapeutic agent for use in the treatment of 
neurodegenerative diseases associated with abnormalities of 
MAPT gene encoded protein tau, wherein said therapeutic 
agent comprises one or more siRNAs targeting MAPT exon 10 
sequence. 
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WT PFLARE PLASMID 
 
tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg       60 
cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt      120 
gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca      180 
atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc      240 
aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta      300 
catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac      360 
catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg      420 
atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg      480 
ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt      540 
acggtgggag gtctatataa gcagagctgg tttagtgaac cgtcagatcc gctagcgcta      600 
ccggactcag atctaccatt ggtgcacctg actcctgagg agaagtctgc cgttactgcc      660 
ctgtggggca aggtgaacgt ggaagagttg gtggtgaggc cctgggccac cagtaagtat      720 
caaggttaca agacaggttt aaggagacca atagaaactg ggcatgtgga gacagagaag      780 
actcttgggt ttctgaattc ctcatccttt tttctggcta ccaaaggtgc agataattaa      840 
taagaagctg gatcttagca acgtccagtc caagtgtggc tcaaaggata atatcaaaca      900 
cgtcccggga ggcggcagtg tgagtacctt cacacgtccc atgcgccgtg ctgtggcttg      960 
aattattagg aagtggtgtg agtgcgtaca cttgcgagac actgcataga ataaatcctt     1020 
ctggatccac catggtggct tagatccggg catgtggaga cagagaagac tgttgagttt     1080 
gtgataagca ctgactctct ctgcctattg gtctattttc cctccctcag tggcggtcga     1140 
ggacaaactc tacgcggact tgccagtacg cttcgtgagc aagggcgagg agctgttcac     1200 
cggggtggtg cccatcctgg tcgagctgga cggcgacgta aacggccaca agttcagcgt     1260 
gtccggcgag ggcgagggcg acgccaccta cggcaagctg accctgaagt tcatctgcac     1320 
caccggcaag ctgcccgtgc cctggcccac cctcgtgacc accctgacct acggcgtgca     1380 
gtgctttagc cgctaccccg accacctgaa gcagcacgac ttcttcaaga gtgcaatgcc     1440 
cgaaggctac gtccaggagc gcaccatctt cttcaaggac gacggcaact acaagacccg     1500 
cgccgaggtg aagttcgagg gcgacaccct ggtgaaccgc atcgagctga agggcatcga     1560 
cttcaaggag gacggcaaca tcctggggca caagctggag tacaactaca acagccacaa     1620 
cgtctatatc accgccgaca agcagaagaa cggcatcaag gtgaacttca agatccgcca     1680 
caacatcgag gacggcagcg tgcagctcgc cgaccactac cagcagaaca cccccatcgg     1740 
cgacggcccc gtgctgctgc ccgacaacca ctacctgagc acccagtccg ccctgagcaa     1800 
agaccccaac gagaagcgcg atcatatggt cctgctggag ttcgtgaccg ccgccgggat     1860 
cactctcggc accgacgagc tgtacaagta accggtcgcc accatggtga gcaagggcga     1920 
ggagaataac atggccatca tcaaggagtt catgcgcttc aaggtgcgca tggagggctc     1980 
cgtgaacggc cacgagttcg agatcgaggg cgagggcgag ggccgcccct acgagggcac     2040 
ccagaccgcc aagctgaagg tgaccaaggg tggccccctg cccttcgcct gggacatcct     2100 
aacccccaac ttcacctacg gctccaaggc ctacgtgaag caccccgccg acatccccga     2160 
ctacttgaag ctgtccttcc ccgagggctt caagtgggag cgcgtgatga acttcgagga     2220 
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   cggcggcgtg gtgaccgtga cccaggactc ctccctgcag gacggcgagt tcatctacaa     2280 
ggtgaagctg cgcggcacca acttcccctc cgacggcccc gtaatgcaga agaagaccat     2340 
gggctgggag gcctcctccg agcggatgta ccccgaggac ggcgccctga agggcgagat     2400 
caagatgagg ctgaagctga aggacggcgg ccactacgac gctgaggtca agaccaccta     2460 
caaggccaag aagcccgtgc agctgcccgg cgcctacatc gtcggcatca agttggacat     2520 
cacctcccac aacgaggact acaccatcgt ggaactgtac gaacgcgccg agggccgcca     2580 
ctccaccggc ggcatggacg agctgtataa gtaagcggcc gcgactctag atcataatca     2640 
gccataccac atttgtagag gttttacttg ctttaaaaaa cctcccacac ctccccctga     2700 
acctgaaaca taaaatgaat gcaattgttg ttgttaactt gtttattgca gcttataatg     2760 
gttacaaata aagcaatagc atcacaaatt tcacaaataa agcatttttt tcactgcatt     2820 
ctagttgtgg tttgtccaaa ctcatcaatg tatcttaagg cgtaaattgt aagcgttaat     2880 
attttgttaa aattcgcgtt aaatttttgt taaatcagct cattttttaa ccaataggcc     2940 
gaaatcggca aaatccctta taaatcaaaa gaatagaccg agatagggtt gagtgttgtt     3000 
ccagtttgga acaagagtcc actattaaag aacgtggact ccaacgtcaa agggcgaaaa     3060 
accgtctatc agggcgatgg cccactacgt gaaccatcac cctaatcaag ttttttgggg     3120 
tcgaggtgcc gtaaagcact aaatcggaac cctaaaggga gcccccgatt tagagcttga     3180 
cggggaaagc cggcgaacgt ggcgagaaag gaagggaaga aagcgaaagg agcgggcgct     3240 
agggcgctgg caagtgtagc ggtcacgctg cgcgtaacca ccacacccgc cgcgcttaat     3300 
gcgccgctac agggcgcgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt     3360 
tgtttatttt tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa     3420 
atgcttcaat aatattgaaa aaggaagagt cctgaggcgg aaagaaccag ctgtggaatg     3480 
tgtgtcagtt agggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca     3540 
tgcatctcaa ttagtcagca accaggtgtg gaaagtcccc aggctcccca gcaggcagaa     3600 
gtatgcaaag catgcatctc aattagtcag caaccatagt cccgccccta actccgccca     3660 
tcccgcccct aactccgccc agttccgccc attctccgcc ccatggctga ctaatttttt     3720 
ttatttatgc agaggccgag gccgcctcgg cctctgagct attccagaag tagtgaggag     3780 
gcttttttgg aggcctaggc ttttgcaaag atcgatcaag agacaggatg aggatcgttt     3840 
cgcatgattg aacaagatgg attgcacgca ggttctccgg ccgcttgggt ggagaggcta     3900 
ttcggctatg actgggcaca acagacaatc ggctgctctg atgccgccgt gttccggctg     3960 
tcagcgcagg ggcgcccggt tctttttgtc aagaccgacc tgtccggtgc cctgaatgaa     4020 
ctgcaagacg aggcagcgcg gctatcgtgg ctggccacga cgggcgttcc ttgcgcagct     4080 
gtgctcgacg ttgtcactga agcgggaagg gactggctgc tattgggcga agtgccgggg     4140 
caggatctcc tgtcatctca ccttgctcct gccgagaaag tatccatcat ggctgatgca     4200 
atgcggcggc tgcatacgct tgatccggct acctgcccat tcgaccacca agcgaaacat     4260 
cgcatcgagc gagcacgtac tcggatggaa gccggtcttg tcgatcagga tgatctggac     4320 
gaagagcatc aggggctcgc gccagccgaa ctgttcgcca ggctcaaggc gagcatgccc     4380 
gacggcgagg atctcgtcgt gacccatggc gatgcctgct tgccgaatat catggtggaa     4440 
aatggccgct tttctggatt catcgactgt ggccggctgg gtgtggcgga ccgctatcag     4500 
Figure 12 – cont. 
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gacatagcgt tggctacccg tgatattgct gaagagcttg gcggcgaatg ggctgaccgc     4560 
ttcctcgtgc tttacggtat cgccgctccc gattcgcagc gcatcgcctt ctatcgcctt     4620 
cttgacgagt tcttctgagc gggactctgg ggttcgaaat gaccgaccaa gcgacgccca     4680 
acctgccatc acgagatttc gattccaccg ccgccttcta tgaaaggttg ggcttcggaa     4740 
tcgttttccg ggacgccggc tggatgatcc tccagcgcgg ggatctcatg ctggagttct     4800 
tcgcccaccc tagggggagg ctaactgaaa cacggaagga gacaataccg gaaggaaccc     4860 
gcgctatgac ggcaataaaa agacagaata aaacgcacgg tgttgggtcg tttgttcata     4920 
aacgcggggt tcggtcccag ggctggcact ctgtcgatac cccaccgaga ccccattggg     4980 
gccaatacgc ccgcgtttct tccttttccc caccccaccc cccaagttcg ggtgaaggcc     5040 
cagggctcgc agccaacgtc ggggcggcag gccctgccat agcctcaggt tactcatata     5100 
tactttagat tgatttaaaa cttcattttt aatttaaaag gatctaggtg aagatccttt     5160 
ttgataatct catgaccaaa atcccttaac gtgagttttc gttccactga gcgtcagacc     5220 
ccgtagaaaa gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct     5280 
tgcaaacaaa aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa     5340 
ctctttttcc gaaggtaact ggcttcagca gagcgcagat accaaatact gtccttctag     5400 
tgtagccgta gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc     5460 
tgctaatcct gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttgg     5520 
actcaagacg atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca     5580 
cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat     5640 
gagaaagcgc cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg     5700 
tcggaacagg agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc     5760 
ctgtcgggtt tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc     5820 
ggagcctatg gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc     5880 
cttttgctca catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg     5940 
ccatgcat                                                              5948 
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MUT PFLARE PLASMID 
 
tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata tggagttccg       60 
cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc cccgcccatt      120 
gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc attgacgtca      180 
atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt atcatatgcc      240 
aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt atgcccagta      300 
catgacctta tgggactttc ctacttggca gtacatctac gtattagtca tcgctattac      360 
catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg actcacgggg      420 
atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc aaaatcaacg      480 
ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg gtaggcgtgt      540 
acggtgggag gtctatataa gcagagctgg tttagtgaac cgtcagatcc gctagcgcta      600 
ccggactcag atctaccatt ggtgcacctg actcctgagg agaagtctgc cgttactgcc      660 
ctgtggggca aggtgaacgt ggaagagttg gtggtgaggc cctgggccac cagtaagtat      720 
caaggttaca agacaggttt aaggagacca atagaaactg ggcatgtgga gacagagaag      780 
actcttgggt ttctgaattc ctcatccttt tttctggcta ccaaaggtgc agataattaa      840 
gaagaagctg gatcttagca acgtccagtc caagtgtggc tcaaaggata atatcaaaca      900 
cgtcccggga ggcggcagtg tgagtacctt cacacgtccc atgcgccgtg ctgtggcttg      960 
aattattagg aagtggtgtg agtgcgtaca cttgcgagac actgcataga ataaatcctt     1020 
ctggatccac catggtggct tagatccggg catgtggaga cagagaagac tgttgagttt     1080 
gtgataagca ctgactctct ctgcctattg gtctattttc cctccctcag tggcggtcga     1140 
ggacaaactc tacgcggact tgccagtacg cttcgtgagc aagggcgagg agctgttcac     1200 
cggggtggtg cccatcctgg tcgagctgga cggcgacgta aacggccaca agttcagcgt     1260 
gtccggcgag ggcgagggcg acgccaccta cggcaagctg accctgaagt tcatctgcac     1320 
caccggcaag ctgcccgtgc cctggcccac cctcgtgacc accctgacct acggcgtgca     1380 
gtgctttagc cgctaccccg accacctgaa gcagcacgac ttcttcaaga gtgcaatgcc     1440 
cgaaggctac gtccaggagc gcaccatctt cttcaaggac gacggcaact acaagacccg     1500 
cgccgaggtg aagttcgagg gcgacaccct ggtgaaccgc atcgagctga agggcatcga     1560 
cttcaaggag gacggcaaca tcctggggca caagctggag tacaactaca acagccacaa     1620 
cgtctatatc accgccgaca agcagaagaa cggcatcaag gtgaacttca agatccgcca     1680 
caacatcgag gacggcagcg tgcagctcgc cgaccactac cagcagaaca cccccatcgg     1740 
cgacggcccc gtgctgctgc ccgacaacca ctacctgagc acccagtccg ccctgagcaa     1800 
agaccccaac gagaagcgcg atcatatggt cctgctggag ttcgtgaccg ccgccgggat     1860 
cactctcggc accgacgagc tgtacaagta accggtcgcc accatggtga gcaagggcga     1920 
ggagaataac atggccatca tcaaggagtt catgcgcttc aaggtgcgca tggagggctc     1980 
cgtgaacggc cacgagttcg agatcgaggg cgagggcgag ggccgcccct acgagggcac     2040 
ccagaccgcc aagctgaagg tgaccaaggg tggccccctg cccttcgcct gggacatcct     2100 
aacccccaac ttcacctacg gctccaaggc ctacgtgaag caccccgccg acatccccga     2160 
ctacttgaag ctgtccttcc ccgagggctt caagtgggag cgcgtgatga acttcgagga     2220 
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   cggcggcgtg gtgaccgtga cccaggactc ctccctgcag gacggcgagt tcatctacaa     2280 
ggtgaagctg cgcggcacca acttcccctc cgacggcccc gtaatgcaga agaagaccat     2340 
gggctgggag gcctcctccg agcggatgta ccccgaggac ggcgccctga agggcgagat     2400 
caagatgagg ctgaagctga aggacggcgg ccactacgac gctgaggtca agaccaccta     2460 
caaggccaag aagcccgtgc agctgcccgg cgcctacatc gtcggcatca agttggacat     2520 
cacctcccac aacgaggact acaccatcgt ggaactgtac gaacgcgccg agggccgcca     2580 
ctccaccggc ggcatggacg agctgtataa gtaagcggcc gcgactctag atcataatca     2640 
gccataccac atttgtagag gttttacttg ctttaaaaaa cctcccacac ctccccctga     2700 
acctgaaaca taaaatgaat gcaattgttg ttgttaactt gtttattgca gcttataatg     2760 
gttacaaata aagcaatagc atcacaaatt tcacaaataa agcatttttt tcactgcatt     2820 
ctagttgtgg tttgtccaaa ctcatcaatg tatcttaagg cgtaaattgt aagcgttaat     2880 
attttgttaa aattcgcgtt aaatttttgt taaatcagct cattttttaa ccaataggcc     2940 
gaaatcggca aaatccctta taaatcaaaa gaatagaccg agatagggtt gagtgttgtt     3000 
ccagtttgga acaagagtcc actattaaag aacgtggact ccaacgtcaa agggcgaaaa     3060 
accgtctatc agggcgatgg cccactacgt gaaccatcac cctaatcaag ttttttgggg     3120 
tcgaggtgcc gtaaagcact aaatcggaac cctaaaggga gcccccgatt tagagcttga     3180 
cggggaaagc cggcgaacgt ggcgagaaag gaagggaaga aagcgaaagg agcgggcgct     3240 
agggcgctgg caagtgtagc ggtcacgctg cgcgtaacca ccacacccgc cgcgcttaat     3300 
gcgccgctac agggcgcgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt     3360 
tgtttatttt tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa     3420 
atgcttcaat aatattgaaa aaggaagagt cctgaggcgg aaagaaccag ctgtggaatg     3480 
tgtgtcagtt agggtgtgga aagtccccag gctccccagc aggcagaagt atgcaaagca     3540 
tgcatctcaa ttagtcagca accaggtgtg gaaagtcccc aggctcccca gcaggcagaa     3600 
gtatgcaaag catgcatctc aattagtcag caaccatagt cccgccccta actccgccca     3660 
tcccgcccct aactccgccc agttccgccc attctccgcc ccatggctga ctaatttttt     3720 
ttatttatgc agaggccgag gccgcctcgg cctctgagct attccagaag tagtgaggag     3780 
gcttttttgg aggcctaggc ttttgcaaag atcgatcaag agacaggatg aggatcgttt     3840 
cgcatgattg aacaagatgg attgcacgca ggttctccgg ccgcttgggt ggagaggcta     3900 
ttcggctatg actgggcaca acagacaatc ggctgctctg atgccgccgt gttccggctg     3960 
tcagcgcagg ggcgcccggt tctttttgtc aagaccgacc tgtccggtgc cctgaatgaa     4020 
ctgcaagacg aggcagcgcg gctatcgtgg ctggccacga cgggcgttcc ttgcgcagct     4080 
gtgctcgacg ttgtcactga agcgggaagg gactggctgc tattgggcga agtgccgggg     4140 
caggatctcc tgtcatctca ccttgctcct gccgagaaag tatccatcat ggctgatgca     4200 
atgcggcggc tgcatacgct tgatccggct acctgcccat tcgaccacca agcgaaacat     4260 
cgcatcgagc gagcacgtac tcggatggaa gccggtcttg tcgatcagga tgatctggac     4320 
gaagagcatc aggggctcgc gccagccgaa ctgttcgcca ggctcaaggc gagcatgccc     4380 
gacggcgagg atctcgtcgt gacccatggc gatgcctgct tgccgaatat catggtggaa     4440 
aatggccgct tttctggatt catcgactgt ggccggctgg gtgtggcgga ccgctatcag     4500 
gacatagcgt tggctacccg tgatattgct gaagagcttg gcggcgaatg ggctgaccgc     4560 
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ttcctcgtgc tttacggtat cgccgctccc gattcgcagc gcatcgcctt ctatcgcctt     4620 
cttgacgagt tcttctgagc gggactctgg ggttcgaaat gaccgaccaa gcgacgccca     4680 
acctgccatc acgagatttc gattccaccg ccgccttcta tgaaaggttg ggcttcggaa     4740 
tcgttttccg ggacgccggc tggatgatcc tccagcgcgg ggatctcatg ctggagttct     4800 
tcgcccaccc tagggggagg ctaactgaaa cacggaagga gacaataccg gaaggaaccc     4860 
gcgctatgac ggcaataaaa agacagaata aaacgcacgg tgttgggtcg tttgttcata     4920 
aacgcggggt tcggtcccag ggctggcact ctgtcgatac cccaccgaga ccccattggg     4980 
gccaatacgc ccgcgtttct tccttttccc caccccaccc cccaagttcg ggtgaaggcc     5040 
cagggctcgc agccaacgtc ggggcggcag gccctgccat agcctcaggt tactcatata     5100 
tactttagat tgatttaaaa cttcattttt aatttaaaag gatctaggtg aagatccttt     5160 
ttgataatct catgaccaaa atcccttaac gtgagttttc gttccactga gcgtcagacc     5220 
ccgtagaaaa gatcaaagga tcttcttgag atcctttttt tctgcgcgta atctgctgct     5280 
tgcaaacaaa aaaaccaccg ctaccagcgg tggtttgttt gccggatcaa gagctaccaa     5340 
ctctttttcc gaaggtaact ggcttcagca gagcgcagat accaaatact gtccttctag     5400 
tgtagccgta gttaggccac cacttcaaga actctgtagc accgcctaca tacctcgctc     5460 
tgctaatcct gttaccagtg gctgctgcca gtggcgataa gtcgtgtctt accgggttgg     5520 
actcaagacg atagttaccg gataaggcgc agcggtcggg ctgaacgggg ggttcgtgca     5580 
cacagcccag cttggagcga acgacctaca ccgaactgag atacctacag cgtgagctat     5640 
gagaaagcgc cacgcttccc gaagggagaa aggcggacag gtatccggta agcggcaggg     5700 
tcggaacagg agagcgcacg agggagcttc cagggggaaa cgcctggtat ctttatagtc     5760 
ctgtcgggtt tcgccacctc tgacttgagc gtcgattttt gtgatgctcg tcaggggggc     5820 
ggagcctatg gaaaaacgcc agcaacgcgg cctttttacg gttcctggcc ttttgctggc     5880 
cttttgctca catgttcttt cctgcgttat cccctgattc tgtggataac cgtattaccg     5940 
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